Download data/dev.conll from mrojas/shared-task: direct link, hf CLI and curl.
- Browser
- Download file 421 kB
-
https://huggingface.co/datasets/mrojas/shared-task/resolve/ecd7e93e8617c9b0a34bb2d0ea6138327a1fdc87/data/dev.conll
- Command line
-
hf download hf://datasets/mrojas/shared-task@ecd7e93e8617c9b0a34bb2d0ea6138327a1fdc87/data/dev.conll
-
curl -L -o dev.conll https://huggingface.co/datasets/mrojas/shared-task/resolve/ecd7e93e8617c9b0a34bb2d0ea6138327a1fdc87/data/dev.conll
421 kB
Paciente B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
69 I-PRESENT_ILLNESS
a. I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
edad I-PRESENT_ILLNESS
con B-EXPLORATION
un I-EXPLORATION
PSA I-EXPLORATION
en I-EXPLORATION
el I-EXPLORATION
momento I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
consulta I-EXPLORATION
de I-EXPLORATION
22 I-EXPLORATION
ng/ml. I-EXPLORATION
El B-PAST_MEDICAL_HISTORY
paciente I-PAST_MEDICAL_HISTORY
tenía I-PAST_MEDICAL_HISTORY
una I-PAST_MEDICAL_HISTORY
biopsia I-PAST_MEDICAL_HISTORY
previa I-PAST_MEDICAL_HISTORY
por I-PAST_MEDICAL_HISTORY
sextantes I-PAST_MEDICAL_HISTORY
negativa. I-PAST_MEDICAL_HISTORY
Se B-EXPLORATION
practicó I-EXPLORATION
una I-EXPLORATION
E-RME I-EXPLORATION
que I-EXPLORATION
mostró I-EXPLORATION
inicialmente I-EXPLORATION
un I-EXPLORATION
nódulo I-EXPLORATION
situado I-EXPLORATION
en I-EXPLORATION
la I-EXPLORATION
base I-EXPLORATION
prostática I-EXPLORATION
del I-EXPLORATION
lóbulo I-EXPLORATION
izquierdo, I-EXPLORATION
morfológicamente I-EXPLORATION
sugestivo I-EXPLORATION
de I-EXPLORATION
hiperplasia I-EXPLORATION
nodular, I-EXPLORATION
pero I-EXPLORATION
el I-EXPLORATION
estudio I-EXPLORATION
espectroscópico I-EXPLORATION
mostró I-EXPLORATION
una I-EXPLORATION
alteración I-EXPLORATION
metabólica I-EXPLORATION
de I-EXPLORATION
este I-EXPLORATION
nódulo, I-EXPLORATION
con I-EXPLORATION
una I-EXPLORATION
importante I-EXPLORATION
elevación I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
colina I-EXPLORATION
y I-EXPLORATION
una I-EXPLORATION
disminución I-EXPLORATION
del I-EXPLORATION
citrato, I-EXPLORATION
sugerente I-EXPLORATION
de I-EXPLORATION
neoplasia. I-EXPLORATION
<EOS> I-EXPLORATION
Un B-PRESENT_ILLNESS
paciente I-PRESENT_ILLNESS
varón I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
19 I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
acudió I-PRESENT_ILLNESS
al I-PRESENT_ILLNESS
Servicio I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
Urgencias I-PRESENT_ILLNESS
tras I-PRESENT_ILLNESS
un I-PRESENT_ILLNESS
accidente I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
tráfico I-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
vehículo I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
motor. I-PRESENT_ILLNESS
No B-PAST_MEDICAL_HISTORY
presentaba I-PAST_MEDICAL_HISTORY
ningún I-PAST_MEDICAL_HISTORY
antecedente I-PAST_MEDICAL_HISTORY
urológico. I-PAST_MEDICAL_HISTORY
El B-PRESENT_ILLNESS
paciente I-PRESENT_ILLNESS
aquejaba I-PRESENT_ILLNESS
dolor I-PRESENT_ILLNESS
abdominal I-PRESENT_ILLNESS
severo. I-PRESENT_ILLNESS
La B-EXPLORATION
exploración I-EXPLORATION
física I-EXPLORATION
reveló I-EXPLORATION
un I-EXPLORATION
Glasgow I-EXPLORATION
de I-EXPLORATION
15 I-EXPLORATION
puntos, I-EXPLORATION
palpando I-EXPLORATION
una I-EXPLORATION
masa I-EXPLORATION
dolorosa I-EXPLORATION
en I-EXPLORATION
el I-EXPLORATION
hipocondrio/flanco I-EXPLORATION
izquierdo I-EXPLORATION
junto I-EXPLORATION
con I-EXPLORATION
importante I-EXPLORATION
distensión I-EXPLORATION
abdominal. I-EXPLORATION
Presentaba I-EXPLORATION
macrohematuria I-EXPLORATION
a I-EXPLORATION
la I-EXPLORATION
micción I-EXPLORATION
espontánea. I-EXPLORATION
El I-EXPLORATION
paciente I-EXPLORATION
se I-EXPLORATION
mantuvo I-EXPLORATION
hemodinamicamente I-EXPLORATION
estable I-EXPLORATION
en I-EXPLORATION
todo I-EXPLORATION
momento, I-EXPLORATION
pero I-EXPLORATION
durante I-EXPLORATION
la I-EXPLORATION
evaluación I-EXPLORATION
inicial I-EXPLORATION
el I-EXPLORATION
hematocrito I-EXPLORATION
cayó I-EXPLORATION
10 I-EXPLORATION
puntos. I-EXPLORATION
La I-EXPLORATION
tomografía I-EXPLORATION
computerizada I-EXPLORATION
con I-EXPLORATION
contraste I-EXPLORATION
(TC) I-EXPLORATION
evidenció I-EXPLORATION
un I-EXPLORATION
riñón I-EXPLORATION
en I-EXPLORATION
herradura I-EXPLORATION
con I-EXPLORATION
una I-EXPLORATION
fractura I-EXPLORATION
en I-EXPLORATION
la I-EXPLORATION
zona I-EXPLORATION
de I-EXPLORATION
unión I-EXPLORATION
entre I-EXPLORATION
el I-EXPLORATION
polo I-EXPLORATION
inferior I-EXPLORATION
del I-EXPLORATION
riñón I-EXPLORATION
izquierdo I-EXPLORATION
y I-EXPLORATION
el I-EXPLORATION
istmo, I-EXPLORATION
mostrando I-EXPLORATION
hemorragia I-EXPLORATION
activa I-EXPLORATION
y I-EXPLORATION
extenso I-EXPLORATION
hematoma I-EXPLORATION
retroperitoneal I-EXPLORATION
(10x7x23 I-EXPLORATION
cm) I-EXPLORATION
con I-EXPLORATION
ocupación I-EXPLORATION
pélvica, I-EXPLORATION
desplazando I-EXPLORATION
el I-EXPLORATION
riñón I-EXPLORATION
izquierdo I-EXPLORATION
y I-EXPLORATION
el I-EXPLORATION
intestino. I-EXPLORATION
Los I-EXPLORATION
cortes I-EXPLORATION
retardados I-EXPLORATION
mostraron I-EXPLORATION
extravasación I-EXPLORATION
de I-EXPLORATION
contraste I-EXPLORATION
compatible I-EXPLORATION
con I-EXPLORATION
un I-EXPLORATION
importante I-EXPLORATION
urinoma. I-EXPLORATION
<EOS> I-EXPLORATION
Se I-EXPLORATION
realizó I-EXPLORATION
un I-EXPLORATION
arteriografía I-EXPLORATION
que I-EXPLORATION
mostró I-EXPLORATION
un I-EXPLORATION
doble I-EXPLORATION
pedículo I-EXPLORATION
para I-EXPLORATION
cada I-EXPLORATION
riñón I-EXPLORATION
y I-EXPLORATION
un I-EXPLORATION
tronco I-EXPLORATION
lumbo-renal I-EXPLORATION
distal I-EXPLORATION
común I-EXPLORATION
que I-EXPLORATION
daba I-EXPLORATION
ramas I-EXPLORATION
accesorias I-EXPLORATION
a I-EXPLORATION
los I-EXPLORATION
polos I-EXPLORATION
inferiores I-EXPLORATION
de I-EXPLORATION
ambos I-EXPLORATION
riñones I-EXPLORATION
y I-EXPLORATION
al I-EXPLORATION
istmo I-EXPLORATION
con I-EXPLORATION
extravasación I-EXPLORATION
de I-EXPLORATION
contraste I-EXPLORATION
compatible I-EXPLORATION
con I-EXPLORATION
sangrado I-EXPLORATION
activo. I-EXPLORATION
Se B-TREATMENT
cateterizó I-TREATMENT
selectivamente I-TREATMENT
el I-TREATMENT
tronco I-TREATMENT
lumbo-renal, I-TREATMENT
accediendo I-TREATMENT
a I-TREATMENT
la I-TREATMENT
rama I-TREATMENT
del I-TREATMENT
riñón I-TREATMENT
izquierdo I-TREATMENT
e I-TREATMENT
istmo I-TREATMENT
permitiendo I-TREATMENT
su I-TREATMENT
embolización I-TREATMENT
con I-TREATMENT
partículas I-TREATMENT
de I-TREATMENT
polivinilo I-TREATMENT
alcohol, I-TREATMENT
sin I-TREATMENT
complicaciones I-TREATMENT
inmediatas. I-TREATMENT
Se I-TREATMENT
cateterizó I-TREATMENT
la I-TREATMENT
vía I-TREATMENT
urinaria I-TREATMENT
retrógradamente I-TREATMENT
con I-TREATMENT
un I-TREATMENT
catéter I-TREATMENT
ureteral I-TREATMENT
recto I-TREATMENT
para I-TREATMENT
facilitar I-TREATMENT
el I-TREATMENT
drenaje I-TREATMENT
del I-TREATMENT
urinoma. I-TREATMENT
<EOS> I-TREATMENT
En B-EVOLUTION
los I-EVOLUTION
días I-EVOLUTION
posteriores, I-EVOLUTION
el I-EVOLUTION
paciente I-EVOLUTION
permaneció I-EVOLUTION
asintomático I-EVOLUTION
con I-EVOLUTION
una I-EVOLUTION
completa I-EVOLUTION
resolución I-EVOLUTION
del I-EVOLUTION
dolor I-EVOLUTION
y I-EVOLUTION
la I-EVOLUTION
hematuria, I-EVOLUTION
con I-EVOLUTION
hematocritos I-EVOLUTION
estables I-EVOLUTION
y I-EVOLUTION
una I-EVOLUTION
TC I-EVOLUTION
de I-EVOLUTION
control I-EVOLUTION
que I-EVOLUTION
mostró I-EVOLUTION
ausencia I-EVOLUTION
de I-EVOLUTION
signos I-EVOLUTION
de I-EVOLUTION
hemorragia, I-EVOLUTION
con I-EVOLUTION
completa I-EVOLUTION
resolución I-EVOLUTION
del I-EVOLUTION
urinoma I-EVOLUTION
y I-EVOLUTION
sin I-EVOLUTION
signos I-EVOLUTION
de I-EVOLUTION
fuga I-EVOLUTION
urinaria, I-EVOLUTION
por B-TREATMENT
lo I-TREATMENT
que I-TREATMENT
se I-TREATMENT
retiró I-TREATMENT
el I-TREATMENT
tutor I-TREATMENT
ureteral. I-TREATMENT
A B-EVOLUTION
los I-EVOLUTION
3 I-EVOLUTION
meses I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
embolización, I-EVOLUTION
el I-EVOLUTION
TC I-EVOLUTION
de I-EVOLUTION
control I-EVOLUTION
demostró I-EVOLUTION
una I-EVOLUTION
completa I-EVOLUTION
resolución I-EVOLUTION
del I-EVOLUTION
hematoma. I-EVOLUTION
No I-EVOLUTION
presentó I-EVOLUTION
complicaciones I-EVOLUTION
tardías, I-EVOLUTION
manteniendo I-EVOLUTION
un I-EVOLUTION
función I-EVOLUTION
renal I-EVOLUTION
y I-EVOLUTION
una I-EVOLUTION
presión I-EVOLUTION
arterial I-EVOLUTION
completamente I-EVOLUTION
normales I-EVOLUTION
a I-EVOLUTION
los I-EVOLUTION
12 I-EVOLUTION
meses I-EVOLUTION
de I-EVOLUTION
seguimiento. I-EVOLUTION
<EOS> I-EVOLUTION
Varón B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
45 I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
edad, I-PRESENT_ILLNESS
sin B-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
personales I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
interés I-PAST_MEDICAL_HISTORY
que B-PRESENT_ILLNESS
acude I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
la I-PRESENT_ILLNESS
consulta I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
urología I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
dolor I-PRESENT_ILLNESS
testicular I-PRESENT_ILLNESS
bilateral I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
4 I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
evolución. I-PRESENT_ILLNESS
La B-EXPLORATION
exploración I-EXPLORATION
física I-EXPLORATION
es I-EXPLORATION
normal I-EXPLORATION
y I-EXPLORATION
la I-EXPLORATION
ecografía I-EXPLORATION
escrotal I-EXPLORATION
realizada I-EXPLORATION
con I-EXPLORATION
un I-EXPLORATION
transductor I-EXPLORATION
de I-EXPLORATION
alta I-EXPLORATION
frecuencia I-EXPLORATION
(10 I-EXPLORATION
Mhz) I-EXPLORATION
pone I-EXPLORATION
de I-EXPLORATION
manifiesto I-EXPLORATION
la I-EXPLORATION
presencia I-EXPLORATION
de I-EXPLORATION
una I-EXPLORATION
MT I-EXPLORATION
bilateral. I-EXPLORATION
Debido B-TREATMENT
a I-TREATMENT
la I-TREATMENT
no I-TREATMENT
existencia I-TREATMENT
de I-TREATMENT
factores I-TREATMENT
de I-TREATMENT
riesgo I-TREATMENT
(criptorquidia, I-TREATMENT
atrofia, I-TREATMENT
infertilidad, I-TREATMENT
neoplasia I-TREATMENT
intratubular I-TREATMENT
de I-TREATMENT
células I-TREATMENT
germinales, I-TREATMENT
disgenesia I-TREATMENT
gonadal, I-TREATMENT
tumor I-TREATMENT
testicular I-TREATMENT
contralateral, I-TREATMENT
administración I-TREATMENT
exógena I-TREATMENT
de I-TREATMENT
estrógenos) I-TREATMENT
se I-TREATMENT
decide I-TREATMENT
seguimiento I-TREATMENT
con I-TREATMENT
autoexploración I-TREATMENT
física I-TREATMENT
mensual I-TREATMENT
y I-TREATMENT
valoración I-TREATMENT
urológica I-TREATMENT
con I-TREATMENT
ecografía I-TREATMENT
escrotal I-TREATMENT
anual, I-TREATMENT
sin I-TREATMENT
realización I-TREATMENT
de I-TREATMENT
biopsia. I-TREATMENT
A B-EVOLUTION
los I-EVOLUTION
4 I-EVOLUTION
años I-EVOLUTION
de I-EVOLUTION
seguimiento I-EVOLUTION
no I-EVOLUTION
ha I-EVOLUTION
desarrollado I-EVOLUTION
un I-EVOLUTION
tumor I-EVOLUTION
invasivo I-EVOLUTION
de I-EVOLUTION
células I-EVOLUTION
germinales. I-EVOLUTION
<EOS> I-EVOLUTION
Paciente B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
76 I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
edad, I-PRESENT_ILLNESS
varón, I-PRESENT_ILLNESS
blanco, I-PRESENT_ILLNESS
antecedentes B-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
nefrectomía I-PAST_MEDICAL_HISTORY
derecha I-PAST_MEDICAL_HISTORY
por I-PAST_MEDICAL_HISTORY
litiasis I-PAST_MEDICAL_HISTORY
coraliforme I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
dicho I-PAST_MEDICAL_HISTORY
riñón, I-PAST_MEDICAL_HISTORY
hipertensión I-PAST_MEDICAL_HISTORY
arterial I-PAST_MEDICAL_HISTORY
(HTA), I-PAST_MEDICAL_HISTORY
fumador I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
3-4 I-PAST_MEDICAL_HISTORY
puros I-PAST_MEDICAL_HISTORY
al I-PAST_MEDICAL_HISTORY
día. I-PAST_MEDICAL_HISTORY
Comienza B-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
dolor I-PRESENT_ILLNESS
lumbar I-PRESENT_ILLNESS
izquierdo, I-PRESENT_ILLNESS
ascendente, I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
notando I-PRESENT_ILLNESS
disminución I-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
el I-PRESENT_ILLNESS
volumen I-PRESENT_ILLNESS
urinario, I-PRESENT_ILLNESS
es I-PRESENT_ILLNESS
traído I-PRESENT_ILLNESS
al I-PRESENT_ILLNESS
servicio I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
urgencia I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
los I-PRESENT_ILLNESS
familiares I-PRESENT_ILLNESS
porque I-PRESENT_ILLNESS
hace I-PRESENT_ILLNESS
varios I-PRESENT_ILLNESS
días I-PRESENT_ILLNESS
que I-PRESENT_ILLNESS
no I-PRESENT_ILLNESS
orina, I-PRESENT_ILLNESS
astenia, I-PRESENT_ILLNESS
anorexia. I-PRESENT_ILLNESS
Al B-EXPLORATION
examen I-EXPLORATION
físico I-EXPLORATION
se I-EXPLORATION
constata I-EXPLORATION
sequedad I-EXPLORATION
de I-EXPLORATION
piel I-EXPLORATION
y I-EXPLORATION
mucosas, I-EXPLORATION
auscultación I-EXPLORATION
cardíaca: I-EXPLORATION
ruidos I-EXPLORATION
cardíacos I-EXPLORATION
taquicárdicos, I-EXPLORATION
tensión I-EXPLORATION
arterial I-EXPLORATION
165/ I-EXPLORATION
90, I-EXPLORATION
abdomen I-EXPLORATION
blando, I-EXPLORATION
ligeramente I-EXPLORATION
distendido, I-EXPLORATION
doloroso I-EXPLORATION
a I-EXPLORATION
la I-EXPLORATION
palpación I-EXPLORATION
difusamente, I-EXPLORATION
dolor I-EXPLORATION
a I-EXPLORATION
la I-EXPLORATION
compresión I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
fosa I-EXPLORATION
lumbar I-EXPLORATION
izquierda, I-EXPLORATION
tacto I-EXPLORATION
rectal I-EXPLORATION
próstata I-EXPLORATION
aumentada I-EXPLORATION
de I-EXPLORATION
tamaño, I-EXPLORATION
superficie I-EXPLORATION
regular, I-EXPLORATION
bien I-EXPLORATION
delimitada, I-EXPLORATION
fibroadenomatosa, I-EXPLORATION
grado I-EXPLORATION
II, I-EXPLORATION
genitales I-EXPLORATION
externos I-EXPLORATION
normales, I-EXPLORATION
meato I-EXPLORATION
uretral I-EXPLORATION
amplio. I-EXPLORATION
En I-EXPLORATION
la I-EXPLORATION
analítica I-EXPLORATION
sanguínea I-EXPLORATION
destaca I-EXPLORATION
un I-EXPLORATION
aumento I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
creatinina I-EXPLORATION
sérica I-EXPLORATION
de I-EXPLORATION
6 I-EXPLORATION
ng/ml. I-EXPLORATION
<EOS> I-EXPLORATION
Se I-EXPLORATION
le I-EXPLORATION
realiza I-EXPLORATION
ecografía I-EXPLORATION
de I-EXPLORATION
urgencia I-EXPLORATION
donde I-EXPLORATION
se I-EXPLORATION
observa I-EXPLORATION
hidronefrosis I-EXPLORATION
(H) I-EXPLORATION
del I-EXPLORATION
riñón I-EXPLORATION
izquierdo I-EXPLORATION
(RI) I-EXPLORATION
por I-EXPLORATION
compresión I-EXPLORATION
del I-EXPLORATION
uréter I-EXPLORATION
izquierdo I-EXPLORATION
por I-EXPLORATION
una I-EXPLORATION
tumoración I-EXPLORATION
(T?) I-EXPLORATION
posiblemente I-EXPLORATION
aneurismática I-EXPLORATION
izquierda, I-EXPLORATION
lo I-EXPLORATION
que I-EXPLORATION
se I-EXPLORATION
confirma I-EXPLORATION
con I-EXPLORATION
la I-EXPLORATION
toma I-EXPLORATION
de I-EXPLORATION
otras I-EXPLORATION
vistas I-EXPLORATION
ecográficas, I-EXPLORATION
se I-EXPLORATION
realiza I-EXPLORATION
arteriografía I-EXPLORATION
traslumbar I-EXPLORATION
detectándose I-EXPLORATION
aneurisma I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
arteria I-EXPLORATION
ilíaca I-EXPLORATION
externa I-EXPLORATION
izquierda, I-EXPLORATION
que I-EXPLORATION
compromete I-EXPLORATION
y I-EXPLORATION
desplaza I-EXPLORATION
hacia I-EXPLORATION
fuera I-EXPLORATION
al I-EXPLORATION
uréter I-EXPLORATION
izquierdo, I-EXPLORATION
por B-TREATMENT
todo I-TREATMENT
lo I-TREATMENT
anterior I-TREATMENT
se I-TREATMENT
decide I-TREATMENT
realizar I-TREATMENT
nefrostomía I-TREATMENT
derivativa I-TREATMENT
izquierda I-TREATMENT
y I-TREATMENT
posteriormente I-TREATMENT
se I-TREATMENT
interconsulta I-TREATMENT
con I-TREATMENT
Servicio I-TREATMENT
de I-TREATMENT
Angiología I-TREATMENT
los I-TREATMENT
que I-TREATMENT
realizaron I-TREATMENT
reparación I-TREATMENT
del I-TREATMENT
aneurisma. I-TREATMENT
Evolucionó B-EVOLUTION
satisfactoriamente, I-EVOLUTION
con I-EVOLUTION
retirada I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
nefrostomía I-EVOLUTION
y I-EVOLUTION
resolución I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
anuria I-EVOLUTION
obstructiva. I-EVOLUTION
<EOS> I-EVOLUTION
Paciente B-PRESENT_ILLNESS
varón I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
46 I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
edad, I-PRESENT_ILLNESS
sin B-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
patológicos I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
interés I-PAST_MEDICAL_HISTORY
acude B-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
consultas I-PRESENT_ILLNESS
externas I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
nuestro I-PRESENT_ILLNESS
centro I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
presentar I-PRESENT_ILLNESS
bulto I-PRESENT_ILLNESS
peneano I-PRESENT_ILLNESS
ventral I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
12 I-PRESENT_ILLNESS
meses I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
evolución I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
crecimiento I-PRESENT_ILLNESS
progresivo. I-PRESENT_ILLNESS
El I-PRESENT_ILLNESS
paciente I-PRESENT_ILLNESS
refiere I-PRESENT_ILLNESS
salida I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
material I-PRESENT_ILLNESS
blanquecino I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
meato I-PRESENT_ILLNESS
uretral I-PRESENT_ILLNESS
al I-PRESENT_ILLNESS
comprimir I-PRESENT_ILLNESS
la I-PRESENT_ILLNESS
lesión, I-PRESENT_ILLNESS
logrando I-PRESENT_ILLNESS
una I-PRESENT_ILLNESS
leve I-PRESENT_ILLNESS
disminución I-PRESENT_ILLNESS
del I-PRESENT_ILLNESS
volumen I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
la I-PRESENT_ILLNESS
tensión I-PRESENT_ILLNESS
del I-PRESENT_ILLNESS
nódulo, I-PRESENT_ILLNESS
sin I-PRESENT_ILLNESS
síndrome I-PRESENT_ILLNESS
miccional I-PRESENT_ILLNESS
acompañante I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
sensación I-PRESENT_ILLNESS
poco I-PRESENT_ILLNESS
confortable I-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
las I-PRESENT_ILLNESS
relaciones I-PRESENT_ILLNESS
sexuales. I-PRESENT_ILLNESS
<EOS> I-PRESENT_ILLNESS
En B-EXPLORATION
la I-EXPLORATION
exploración I-EXPLORATION
física I-EXPLORATION
se I-EXPLORATION
observa I-EXPLORATION
nódulo I-EXPLORATION
elástico I-EXPLORATION
esferoidal I-EXPLORATION
parauretral I-EXPLORATION
subglandar I-EXPLORATION
ventral I-EXPLORATION
lateralizado I-EXPLORATION
a I-EXPLORATION
la I-EXPLORATION
derecha, I-EXPLORATION
de I-EXPLORATION
1, I-EXPLORATION
5 I-EXPLORATION
cm I-EXPLORATION
de I-EXPLORATION
diámetro, I-EXPLORATION
móvil I-EXPLORATION
y I-EXPLORATION
de I-EXPLORATION
consistencia I-EXPLORATION
quística. I-EXPLORATION
<EOS> I-EXPLORATION
Como I-EXPLORATION
exploraciones I-EXPLORATION
complementarias I-EXPLORATION
se I-EXPLORATION
le I-EXPLORATION
realizan: I-EXPLORATION
<EOS> I-EXPLORATION
- I-EXPLORATION
Resonancia I-EXPLORATION
magnética I-EXPLORATION
nuclear: I-EXPLORATION
imagen I-EXPLORATION
de I-EXPLORATION
características I-EXPLORATION
quísticas I-EXPLORATION
de I-EXPLORATION
2x2x1, I-EXPLORATION
8cm I-EXPLORATION
basal I-EXPLORATION
en I-EXPLORATION
el I-EXPLORATION
extremo I-EXPLORATION
distal I-EXPLORATION
del I-EXPLORATION
pene I-EXPLORATION
con I-EXPLORATION
compresión I-EXPLORATION
y I-EXPLORATION
distorsión I-EXPLORATION
del I-EXPLORATION
cuerpo I-EXPLORATION
cavernoso I-EXPLORATION
del I-EXPLORATION
lado I-EXPLORATION
derecho. I-EXPLORATION
Se I-EXPLORATION
observa I-EXPLORATION
la I-EXPLORATION
existencia I-EXPLORATION
de I-EXPLORATION
una I-EXPLORATION
fina I-EXPLORATION
línea I-EXPLORATION
hiperintensa, I-EXPLORATION
que I-EXPLORATION
se I-EXPLORATION
dirige I-EXPLORATION
a I-EXPLORATION
contactar I-EXPLORATION
con I-EXPLORATION
la I-EXPLORATION
uretra I-EXPLORATION
anterior I-EXPLORATION
peneana I-EXPLORATION
con I-EXPLORATION
posible I-EXPLORATION
comunicación I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
imagen I-EXPLORATION
quística I-EXPLORATION
con I-EXPLORATION
la I-EXPLORATION
uretra. I-EXPLORATION
<EOS> I-EXPLORATION
- I-EXPLORATION
Uretrografía I-EXPLORATION
retrógrada I-EXPLORATION
y I-EXPLORATION
miccional: I-EXPLORATION
con I-EXPLORATION
canal I-EXPLORATION
uretral I-EXPLORATION
anterior I-EXPLORATION
normal. I-EXPLORATION
Elongación I-EXPLORATION
uretra-prostática. I-EXPLORATION
Vejiga I-EXPLORATION
trabeculada I-EXPLORATION
con I-EXPLORATION
apertura I-EXPLORATION
correcta I-EXPLORATION
del I-EXPLORATION
cuello I-EXPLORATION
vesical I-EXPLORATION
y I-EXPLORATION
paso I-EXPLORATION
fácil I-EXPLORATION
de I-EXPLORATION
contraste I-EXPLORATION
por I-EXPLORATION
toda I-EXPLORATION
la I-EXPLORATION
uretra. I-EXPLORATION
Ausencia I-EXPLORATION
de I-EXPLORATION
residuo I-EXPLORATION
potmiccional. I-EXPLORATION
<EOS> I-EXPLORATION
Se B-TREATMENT
decide I-TREATMENT
intervención I-TREATMENT
quirúrgica I-TREATMENT
con I-TREATMENT
exéresis I-TREATMENT
de I-TREATMENT
la I-TREATMENT
formación I-TREATMENT
quística I-TREATMENT
muy I-TREATMENT
fija I-TREATMENT
a I-TREATMENT
cuerpo I-TREATMENT
cavernoso I-TREATMENT
derecho I-TREATMENT
sin I-TREATMENT
observar I-TREATMENT
comunicación I-TREATMENT
alguna I-TREATMENT
con I-TREATMENT
uretra, I-TREATMENT
pero I-TREATMENT
con I-TREATMENT
clara I-TREATMENT
dependencia I-TREATMENT
de I-TREATMENT
la I-TREATMENT
misma. I-TREATMENT
Al I-TREATMENT
abrir I-TREATMENT
el I-TREATMENT
quiste I-TREATMENT
sale I-TREATMENT
un I-TREATMENT
material I-TREATMENT
líquido I-TREATMENT
color I-TREATMENT
blanquecino, I-TREATMENT
no I-TREATMENT
maloliente I-TREATMENT
y I-TREATMENT
con I-TREATMENT
detritus. I-TREATMENT
<EOS> I-TREATMENT
La B-EXPLORATION
anatomía I-EXPLORATION
patológica I-EXPLORATION
informa I-EXPLORATION
de I-EXPLORATION
tejido I-EXPLORATION
conectivo I-EXPLORATION
con I-EXPLORATION
ligero I-EXPLORATION
infiltrado I-EXPLORATION
mononuclear, I-EXPLORATION
revestido I-EXPLORATION
por I-EXPLORATION
epitelio I-EXPLORATION
escamoso I-EXPLORATION
queratinizante. I-EXPLORATION
<EOS> I-EXPLORATION
El B-EVOLUTION
paciente I-EVOLUTION
actualmente I-EVOLUTION
está I-EVOLUTION
asintomático, I-EVOLUTION
con I-EVOLUTION
micción I-EVOLUTION
correcta I-EVOLUTION
y I-EVOLUTION
presencia I-EVOLUTION
de I-EVOLUTION
erecciones I-EVOLUTION
normales I-EVOLUTION
y I-EVOLUTION
satisfactorias. I-EVOLUTION
<EOS> I-EVOLUTION
Paciente B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
67 I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
edad I-PRESENT_ILLNESS
con B-PAST_MEDICAL_HISTORY
diagnóstico I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
adenocarcinoma I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
próstata I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
tratamiento I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
bloqueo I-PAST_MEDICAL_HISTORY
androgénico I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
radioterapia. I-PAST_MEDICAL_HISTORY
Al B-EXPLORATION
año I-EXPLORATION
siguiente I-EXPLORATION
se I-EXPLORATION
aprecia I-EXPLORATION
mediante I-EXPLORATION
exploración I-EXPLORATION
física I-EXPLORATION
una I-EXPLORATION
masa I-EXPLORATION
sólida I-EXPLORATION
extratesticular I-EXPLORATION
localizada I-EXPLORATION
en I-EXPLORATION
saco I-EXPLORATION
escrotal I-EXPLORATION
derecho. I-EXPLORATION
En I-EXPLORATION
la I-EXPLORATION
T.A.C. I-EXPLORATION
se I-EXPLORATION
demuestra I-EXPLORATION
la I-EXPLORATION
existencia I-EXPLORATION
de I-EXPLORATION
una I-EXPLORATION
gran I-EXPLORATION
masa I-EXPLORATION
sólida I-EXPLORATION
extratesticular I-EXPLORATION
localizada I-EXPLORATION
en I-EXPLORATION
saco I-EXPLORATION
escrotal I-EXPLORATION
derecho, I-EXPLORATION
con I-EXPLORATION
componente I-EXPLORATION
graso I-EXPLORATION
y I-EXPLORATION
otro I-EXPLORATION
componente I-EXPLORATION
de I-EXPLORATION
densidad I-EXPLORATION
de I-EXPLORATION
partes I-EXPLORATION
blandas.. I-EXPLORATION
<EOS> I-EXPLORATION
Paciente B-PRESENT_ILLNESS
masculino I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
58 I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
de B-PAST_MEDICAL_HISTORY
edad, I-PAST_MEDICAL_HISTORY
procedencia I-PAST_MEDICAL_HISTORY
urbana I-PAST_MEDICAL_HISTORY
(campesino) I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
raza I-PAST_MEDICAL_HISTORY
blanca. I-PAST_MEDICAL_HISTORY
Que B-PRESENT_ILLNESS
acude I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
nuestra I-PRESENT_ILLNESS
consulta I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
presentar I-PRESENT_ILLNESS
aumento I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
volumen I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
los I-PRESENT_ILLNESS
genitales. I-PRESENT_ILLNESS
Tiene B-PAST_MEDICAL_HISTORY
el I-PAST_MEDICAL_HISTORY
antecedente I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
haber I-PAST_MEDICAL_HISTORY
sido I-PAST_MEDICAL_HISTORY
operado I-PAST_MEDICAL_HISTORY
hace I-PAST_MEDICAL_HISTORY
26 I-PAST_MEDICAL_HISTORY
años I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
una I-PAST_MEDICAL_HISTORY
lesión I-PAST_MEDICAL_HISTORY
maligna I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
pene I-PAST_MEDICAL_HISTORY
(carcinoma I-PAST_MEDICAL_HISTORY
epidermoide), I-PAST_MEDICAL_HISTORY
realizándole I-PAST_MEDICAL_HISTORY
amputación I-PAST_MEDICAL_HISTORY
parcial I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
pene I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
vaciamiento I-PAST_MEDICAL_HISTORY
linfático I-PAST_MEDICAL_HISTORY
inguinal I-PAST_MEDICAL_HISTORY
bilateral. I-PAST_MEDICAL_HISTORY
Pocos B-PRESENT_ILLNESS
meses I-PRESENT_ILLNESS
después I-PRESENT_ILLNESS
comienza I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
presentar I-PRESENT_ILLNESS
aumento I-PRESENT_ILLNESS
progresivo I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
los I-PRESENT_ILLNESS
genitales, I-PRESENT_ILLNESS
tanto I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
las I-PRESENT_ILLNESS
bolsas I-PRESENT_ILLNESS
escrotales I-PRESENT_ILLNESS
como I-PRESENT_ILLNESS
del I-PRESENT_ILLNESS
pene. I-PRESENT_ILLNESS
Por I-PRESENT_ILLNESS
el I-PRESENT_ILLNESS
bajo I-PRESENT_ILLNESS
nivel I-PRESENT_ILLNESS
escolar I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
la I-PRESENT_ILLNESS
lejanía I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
la I-PRESENT_ILLNESS
vivienda I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
los I-PRESENT_ILLNESS
servicios I-PRESENT_ILLNESS
médicos, I-PRESENT_ILLNESS
sumados I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
la I-PRESENT_ILLNESS
gran I-PRESENT_ILLNESS
despreocupación I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
sus I-PRESENT_ILLNESS
familiares, I-PRESENT_ILLNESS
hacen I-PRESENT_ILLNESS
que I-PRESENT_ILLNESS
no I-PRESENT_ILLNESS
acuda I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
consulta, I-PRESENT_ILLNESS
viviendo I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
esta I-PRESENT_ILLNESS
forma I-PRESENT_ILLNESS
durante I-PRESENT_ILLNESS
mucho I-PRESENT_ILLNESS
tiempo, I-PRESENT_ILLNESS
refiriendo I-PRESENT_ILLNESS
que I-PRESENT_ILLNESS
no I-PRESENT_ILLNESS
presentaba I-PRESENT_ILLNESS
trastornos I-PRESENT_ILLNESS
para I-PRESENT_ILLNESS
orinar, I-PRESENT_ILLNESS
ni I-PRESENT_ILLNESS
dolor, I-PRESENT_ILLNESS
sólo I-PRESENT_ILLNESS
un I-PRESENT_ILLNESS
gran I-PRESENT_ILLNESS
volumen I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
los I-PRESENT_ILLNESS
genitales I-PRESENT_ILLNESS
que I-PRESENT_ILLNESS
le I-PRESENT_ILLNESS
imposibilitaba I-PRESENT_ILLNESS
deambular, I-PRESENT_ILLNESS
pues I-PRESENT_ILLNESS
le I-PRESENT_ILLNESS
llegaba I-PRESENT_ILLNESS
casi I-PRESENT_ILLNESS
hasta I-PRESENT_ILLNESS
las I-PRESENT_ILLNESS
rodillas. I-PRESENT_ILLNESS
<EOS> I-PRESENT_ILLNESS
Examen B-EXPLORATION
Físico: I-EXPLORATION
<EOS> I-EXPLORATION
Se I-EXPLORATION
encuentra I-EXPLORATION
gran I-EXPLORATION
tumoración I-EXPLORATION
genital I-EXPLORATION
que I-EXPLORATION
comprende I-EXPLORATION
ambas I-EXPLORATION
bolsas I-EXPLORATION
escrotales I-EXPLORATION
y I-EXPLORATION
el I-EXPLORATION
pene, I-EXPLORATION
este I-EXPLORATION
ultimo I-EXPLORATION
había I-EXPLORATION
sido I-EXPLORATION
amputado I-EXPLORATION
parcialmente I-EXPLORATION
y I-EXPLORATION
presentaba I-EXPLORATION
una I-EXPLORATION
circunferencia I-EXPLORATION
de I-EXPLORATION
ochos I-EXPLORATION
centímetros I-EXPLORATION
de I-EXPLORATION
diámetro, I-EXPLORATION
dividido I-EXPLORATION
en I-EXPLORATION
dos I-EXPLORATION
grandes I-EXPLORATION
labios, I-EXPLORATION
gruesos I-EXPLORATION
y I-EXPLORATION
duros, I-EXPLORATION
que I-EXPLORATION
al I-EXPLORATION
separarlos I-EXPLORATION
dejaba I-EXPLORATION
ver I-EXPLORATION
la I-EXPLORATION
uretra. I-EXPLORATION
Todo I-EXPLORATION
esto I-EXPLORATION
dentro I-EXPLORATION
de I-EXPLORATION
gran I-EXPLORATION
volumen I-EXPLORATION
escrotal I-EXPLORATION
de I-EXPLORATION
cerca I-EXPLORATION
de I-EXPLORATION
cuarenta I-EXPLORATION
centímetros I-EXPLORATION
de I-EXPLORATION
tamaño I-EXPLORATION
transversal, I-EXPLORATION
con I-EXPLORATION
una I-EXPLORATION
piel I-EXPLORATION
muy I-EXPLORATION
gruesa, I-EXPLORATION
rugosa, I-EXPLORATION
de I-EXPLORATION
diferentes I-EXPLORATION
colores I-EXPLORATION
desde I-EXPLORATION
amarillo I-EXPLORATION
grisáceo I-EXPLORATION
hasta I-EXPLORATION
zonas I-EXPLORATION
violáceas, I-EXPLORATION
característico I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
piel I-EXPLORATION
de I-EXPLORATION
un I-EXPLORATION
paquidermo. I-EXPLORATION
En I-EXPLORATION
su I-EXPLORATION
parte I-EXPLORATION
superior I-EXPLORATION
se I-EXPLORATION
estrechaba I-EXPLORATION
de I-EXPLORATION
donde I-EXPLORATION
colgaba I-EXPLORATION
el I-EXPLORATION
resto. I-EXPLORATION
<EOS> I-EXPLORATION
Regiones I-EXPLORATION
inguinales I-EXPLORATION
normales. I-EXPLORATION
<EOS> I-EXPLORATION
Miembros I-EXPLORATION
inferiores I-EXPLORATION
normales, I-EXPLORATION
no I-EXPLORATION
edemas. I-EXPLORATION
Complementarios: I-EXPLORATION
Hematológicos, I-EXPLORATION
normales. I-EXPLORATION
Imagenológicos: I-EXPLORATION
Radiológicos. I-EXPLORATION
Radiografía I-EXPLORATION
simple I-EXPLORATION
de I-EXPLORATION
pelvis I-EXPLORATION
ósea I-EXPLORATION
(masa I-EXPLORATION
de I-EXPLORATION
bordes I-EXPLORATION
bien I-EXPLORATION
definidos, I-EXPLORATION
sin I-EXPLORATION
calcificaciones I-EXPLORATION
en I-EXPLORATION
su I-EXPLORATION
interior). I-EXPLORATION
<EOS> I-EXPLORATION
Ultrasonográficos I-EXPLORATION
y I-EXPLORATION
Tomografía I-EXPLORATION
(No I-EXPLORATION
signos I-EXPLORATION
de I-EXPLORATION
actividad I-EXPLORATION
tumoral). I-EXPLORATION
<EOS> I-EXPLORATION
Material B-TREATMENT
y I-TREATMENT
método I-TREATMENT
<EOS> I-TREATMENT
En I-TREATMENT
estas I-TREATMENT
condiciones I-TREATMENT
se I-TREATMENT
decide I-TREATMENT
llevar I-TREATMENT
al I-TREATMENT
paciente I-TREATMENT
al I-TREATMENT
quirófano I-TREATMENT
y I-TREATMENT
bajo I-TREATMENT
anestesia I-TREATMENT
general, I-TREATMENT
se I-TREATMENT
realiza I-TREATMENT
previamente I-TREATMENT
cistostomía I-TREATMENT
suprapúbica I-TREATMENT
e I-TREATMENT
inmediatamente I-TREATMENT
la I-TREATMENT
extirpación I-TREATMENT
total I-TREATMENT
de I-TREATMENT
ambas I-TREATMENT
bolsas I-TREATMENT
escrotales, I-TREATMENT
con I-TREATMENT
todo I-TREATMENT
su I-TREATMENT
contenido, I-TREATMENT
encontrando I-TREATMENT
los I-TREATMENT
elementos I-TREATMENT
del I-TREATMENT
cordón I-TREATMENT
espermático I-TREATMENT
englobados I-TREATMENT
en I-TREATMENT
un I-TREATMENT
tejido I-TREATMENT
fibroso, I-TREATMENT
encartonado, I-TREATMENT
rugoso, I-TREATMENT
con I-TREATMENT
vasos I-TREATMENT
de I-TREATMENT
neoformación, I-TREATMENT
algunos I-TREATMENT
de I-TREATMENT
ellos I-TREATMENT
de I-TREATMENT
gran I-TREATMENT
calibre. I-TREATMENT
También I-TREATMENT
se I-TREATMENT
le I-TREATMENT
realizó I-TREATMENT
amputación I-TREATMENT
del I-TREATMENT
segmento I-TREATMENT
de I-TREATMENT
pene I-TREATMENT
ya I-TREATMENT
descrita, I-TREATMENT
la I-TREATMENT
uretra I-TREATMENT
se I-TREATMENT
anastomosa I-TREATMENT
a I-TREATMENT
la I-TREATMENT
piel I-TREATMENT
de I-TREATMENT
la I-TREATMENT
raíz I-TREATMENT
del I-TREATMENT
escroto I-TREATMENT
con I-TREATMENT
características I-TREATMENT
normales. I-TREATMENT
<EOS> I-TREATMENT
Descripción B-EXPLORATION
anatómica I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
pieza: I-EXPLORATION
14 I-EXPLORATION
kilogramos I-EXPLORATION
de I-EXPLORATION
peso, I-EXPLORATION
y I-EXPLORATION
mide I-EXPLORATION
39 I-EXPLORATION
x I-EXPLORATION
35 I-EXPLORATION
x I-EXPLORATION
18 I-EXPLORATION
centímetros. I-EXPLORATION
<EOS> I-EXPLORATION
Paciente B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
51 I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
edad I-PRESENT_ILLNESS
sin B-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
dignos I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
mención I-PAST_MEDICAL_HISTORY
que B-PRESENT_ILLNESS
durante I-PRESENT_ILLNESS
una I-PRESENT_ILLNESS
ecografía I-PRESENT_ILLNESS
ginecológica I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
control I-PRESENT_ILLNESS
rutinario I-PRESENT_ILLNESS
nos I-PRESENT_ILLNESS
viene I-PRESENT_ILLNESS
remitida I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
lesión I-PRESENT_ILLNESS
sobreelevada I-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
cara I-PRESENT_ILLNESS
lateral I-PRESENT_ILLNESS
derecha. I-PRESENT_ILLNESS
<EOS> I-PRESENT_ILLNESS
La B-EXPLORATION
enferma I-EXPLORATION
no I-EXPLORATION
presenta I-EXPLORATION
ninguna I-EXPLORATION
sintomatología I-EXPLORATION
urológica I-EXPLORATION
de I-EXPLORATION
interés. I-EXPLORATION
<EOS> I-EXPLORATION
La I-EXPLORATION
cistoscopia I-EXPLORATION
revela I-EXPLORATION
un I-EXPLORATION
crecimiento I-EXPLORATION
de I-EXPLORATION
aproximadamente I-EXPLORATION
2 I-EXPLORATION
cm I-EXPLORATION
de I-EXPLORATION
diámetro I-EXPLORATION
con I-EXPLORATION
mucosa I-EXPLORATION
indemne. I-EXPLORATION
<EOS> I-EXPLORATION
Tras B-TREATMENT
la I-TREATMENT
resección I-TREATMENT
transuretral I-TREATMENT
el I-TREATMENT
diagnóstico I-TREATMENT
fue I-TREATMENT
de I-TREATMENT
leiomioma I-TREATMENT
vesical. I-TREATMENT
<EOS> I-TREATMENT
Al B-EVOLUTION
igual I-EVOLUTION
que I-EVOLUTION
el I-EVOLUTION
caso I-EVOLUTION
anterior I-EVOLUTION
la I-EVOLUTION
enferma I-EVOLUTION
permanece I-EVOLUTION
asintomática I-EVOLUTION
a I-EVOLUTION
los I-EVOLUTION
dos I-EVOLUTION
años I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
cirugía. I-EVOLUTION
<EOS> I-EVOLUTION
Mujer B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
75 I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
edad I-PRESENT_ILLNESS
con B-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
HTA, I-PAST_MEDICAL_HISTORY
síndrome I-PAST_MEDICAL_HISTORY
depresivo I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
estreñimiento I-PAST_MEDICAL_HISTORY
crónico. I-PAST_MEDICAL_HISTORY
Sin I-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
urológicos I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
interés. I-PAST_MEDICAL_HISTORY
<EOS> I-PAST_MEDICAL_HISTORY
Remitida B-DERIVED_FROM/TO
del I-DERIVED_FROM/TO
Servicio I-DERIVED_FROM/TO
de I-DERIVED_FROM/TO
Digestivo, I-DERIVED_FROM/TO
aportando I-DERIVED_FROM/TO
un I-DERIVED_FROM/TO
TAC I-DERIVED_FROM/TO
abdomino-pélvico, I-DERIVED_FROM/TO
realizado I-DERIVED_FROM/TO
durante I-DERIVED_FROM/TO
un I-DERIVED_FROM/TO
estudio I-DERIVED_FROM/TO
de I-DERIVED_FROM/TO
su I-DERIVED_FROM/TO
patología I-DERIVED_FROM/TO
de I-DERIVED_FROM/TO
base, I-DERIVED_FROM/TO
donde I-DERIVED_FROM/TO
se I-DERIVED_FROM/TO
observaba I-DERIVED_FROM/TO
una I-DERIVED_FROM/TO
masa I-DERIVED_FROM/TO
de I-DERIVED_FROM/TO
aspecto I-DERIVED_FROM/TO
sólido I-DERIVED_FROM/TO
en I-DERIVED_FROM/TO
polo I-DERIVED_FROM/TO
superior I-DERIVED_FROM/TO
del I-DERIVED_FROM/TO
riñón I-DERIVED_FROM/TO
izquierdo I-DERIVED_FROM/TO
de I-DERIVED_FROM/TO
4, I-DERIVED_FROM/TO
9 I-DERIVED_FROM/TO
x I-DERIVED_FROM/TO
3, I-DERIVED_FROM/TO
6 I-DERIVED_FROM/TO
cm I-DERIVED_FROM/TO
que I-DERIVED_FROM/TO
infiltraba I-DERIVED_FROM/TO
la I-DERIVED_FROM/TO
grasa I-DERIVED_FROM/TO
perirrenal, I-DERIVED_FROM/TO
con I-DERIVED_FROM/TO
presencia I-DERIVED_FROM/TO
de I-DERIVED_FROM/TO
dos I-DERIVED_FROM/TO
adenopatías I-DERIVED_FROM/TO
en I-DERIVED_FROM/TO
el I-DERIVED_FROM/TO
hilio I-DERIVED_FROM/TO
renal I-DERIVED_FROM/TO
de I-DERIVED_FROM/TO
1, I-DERIVED_FROM/TO
5 I-DERIVED_FROM/TO
cm. I-DERIVED_FROM/TO
Posible I-DERIVED_FROM/TO
afectación I-DERIVED_FROM/TO
de I-DERIVED_FROM/TO
la I-DERIVED_FROM/TO
vena I-DERIVED_FROM/TO
renal I-DERIVED_FROM/TO
izquierda. I-DERIVED_FROM/TO
<EOS> I-DERIVED_FROM/TO
En B-EXPLORATION
el I-EXPLORATION
estudio I-EXPLORATION
de I-EXPLORATION
UIV, I-EXPLORATION
el I-EXPLORATION
riñón I-EXPLORATION
derecho I-EXPLORATION
era I-EXPLORATION
normal; I-EXPLORATION
mientras I-EXPLORATION
el I-EXPLORATION
riñón I-EXPLORATION
izquierdo I-EXPLORATION
mostraba I-EXPLORATION
una I-EXPLORATION
anulación I-EXPLORATION
funcional, I-EXPLORATION
apreciándose I-EXPLORATION
al I-EXPLORATION
cabo I-EXPLORATION
de I-EXPLORATION
2 I-EXPLORATION
horas I-EXPLORATION
un I-EXPLORATION
discreto I-EXPLORATION
nefrograma, I-EXPLORATION
sin I-EXPLORATION
llegar I-EXPLORATION
a I-EXPLORATION
visualizarse I-EXPLORATION
en I-EXPLORATION
ningún I-EXPLORATION
momento I-EXPLORATION
el I-EXPLORATION
polo I-EXPLORATION
superoexterno I-EXPLORATION
del I-EXPLORATION
mismo. I-EXPLORATION
<EOS> I-EXPLORATION
En I-EXPLORATION
la I-EXPLORATION
Angio-RM, I-EXPLORATION
se I-EXPLORATION
apreciaba I-EXPLORATION
una I-EXPLORATION
tumoración I-EXPLORATION
de I-EXPLORATION
4 I-EXPLORATION
cm I-EXPLORATION
que I-EXPLORATION
afectaba I-EXPLORATION
a I-EXPLORATION
1/3 I-EXPLORATION
medio I-EXPLORATION
y I-EXPLORATION
polo I-EXPLORATION
superior I-EXPLORATION
de I-EXPLORATION
riñón I-EXPLORATION
izquierdo, I-EXPLORATION
con I-EXPLORATION
metástasis I-EXPLORATION
en I-EXPLORATION
glándula I-EXPLORATION
suprarrenal I-EXPLORATION
ipsilateral, I-EXPLORATION
adenopatías I-EXPLORATION
locorregionales I-EXPLORATION
y I-EXPLORATION
trombosis I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
vena I-EXPLORATION
renal I-EXPLORATION
izquierda, I-EXPLORATION
sin I-EXPLORATION
afectación I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
vena I-EXPLORATION
cava. I-EXPLORATION
<EOS> I-EXPLORATION
Ante B-TREATMENT
la I-TREATMENT
sospecha I-TREATMENT
diagnóstica I-TREATMENT
de I-TREATMENT
carcinoma I-TREATMENT
renal, I-TREATMENT
se I-TREATMENT
practicó I-TREATMENT
nefrectomía I-TREATMENT
radical I-TREATMENT
izquierda I-TREATMENT
mediante I-TREATMENT
lumbotomía, I-TREATMENT
apreciando I-TREATMENT
la I-TREATMENT
presencia I-TREATMENT
de I-TREATMENT
un I-TREATMENT
bloque I-TREATMENT
adenopático I-TREATMENT
a I-TREATMENT
nivel I-TREATMENT
del I-TREATMENT
hilio I-TREATMENT
renal. I-TREATMENT
<EOS> I-TREATMENT
La B-EXPLORATION
descripción I-EXPLORATION
macroscópica I-EXPLORATION
del I-EXPLORATION
estudio I-EXPLORATION
anatomopatológico, I-EXPLORATION
destacó I-EXPLORATION
una I-EXPLORATION
pieza I-EXPLORATION
de I-EXPLORATION
nefrectomía I-EXPLORATION
de I-EXPLORATION
10 I-EXPLORATION
x I-EXPLORATION
6 I-EXPLORATION
x I-EXPLORATION
7 I-EXPLORATION
cm, I-EXPLORATION
que I-EXPLORATION
su I-EXPLORATION
mayor I-EXPLORATION
parte I-EXPLORATION
se I-EXPLORATION
perdía I-EXPLORATION
la I-EXPLORATION
delimitación I-EXPLORATION
córtico I-EXPLORATION
-medular, I-EXPLORATION
apreciándose I-EXPLORATION
masas I-EXPLORATION
grisáceas I-EXPLORATION
de I-EXPLORATION
consistencia I-EXPLORATION
firme I-EXPLORATION
que I-EXPLORATION
sustituían I-EXPLORATION
de I-EXPLORATION
forma I-EXPLORATION
difusa I-EXPLORATION
e I-EXPLORATION
irregular I-EXPLORATION
gran I-EXPLORATION
parte I-EXPLORATION
del I-EXPLORATION
parénquima I-EXPLORATION
renal. I-EXPLORATION
Por I-EXPLORATION
otro I-EXPLORATION
lado, I-EXPLORATION
la I-EXPLORATION
descripción I-EXPLORATION
microscópica, I-EXPLORATION
apreció I-EXPLORATION
una I-EXPLORATION
neoplasia I-EXPLORATION
maligna I-EXPLORATION
formada I-EXPLORATION
por I-EXPLORATION
estructuras I-EXPLORATION
tubulares I-EXPLORATION
y I-EXPLORATION
ductales I-EXPLORATION
atípicas I-EXPLORATION
que I-EXPLORATION
infiltraba I-EXPLORATION
la I-EXPLORATION
grasa I-EXPLORATION
perirrenal I-EXPLORATION
a I-EXPLORATION
nivel I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
zona I-EXPLORATION
del I-EXPLORATION
seno I-EXPLORATION
renal I-EXPLORATION
y I-EXPLORATION
alcanzando I-EXPLORATION
el I-EXPLORATION
borde I-EXPLORATION
quirúrgico. I-EXPLORATION
Estas I-EXPLORATION
estructuras I-EXPLORATION
mostraron I-EXPLORATION
positividad I-EXPLORATION
inmunohistoquímica I-EXPLORATION
para I-EXPLORATION
keratinas: I-EXPLORATION
CAM I-EXPLORATION
5.2; I-EXPLORATION
AE1 I-EXPLORATION
- I-EXPLORATION
AE2 I-EXPLORATION
y I-EXPLORATION
34 I-EXPLORATION
BE12. I-EXPLORATION
Estableciendo, I-EXPLORATION
de I-EXPLORATION
esta I-EXPLORATION
manera, I-EXPLORATION
el I-EXPLORATION
diagnóstico I-EXPLORATION
definitivo I-EXPLORATION
de I-EXPLORATION
carcinoma I-EXPLORATION
de I-EXPLORATION
ductos I-EXPLORATION
colectores I-EXPLORATION
con I-EXPLORATION
afectación I-EXPLORATION
del I-EXPLORATION
seno I-EXPLORATION
renal I-EXPLORATION
del I-EXPLORATION
borde I-EXPLORATION
quirúrgico. I-EXPLORATION
<EOS> I-EXPLORATION
Tras B-TREATMENT
un I-TREATMENT
mes I-TREATMENT
y I-TREATMENT
medio I-TREATMENT
de I-TREATMENT
la I-TREATMENT
cirugía, I-TREATMENT
una I-TREATMENT
vez I-TREATMENT
valorada I-TREATMENT
por I-TREATMENT
el I-TREATMENT
Servicio I-TREATMENT
de I-TREATMENT
Oncología, I-TREATMENT
se I-TREATMENT
decidió I-TREATMENT
comenzar I-TREATMENT
tratamiento I-TREATMENT
quimioterápico I-TREATMENT
con I-TREATMENT
Carboplatino I-TREATMENT
AUC I-TREATMENT
4 I-TREATMENT
día I-TREATMENT
1º I-TREATMENT
+ I-TREATMENT
Gencitabina I-TREATMENT
1250 I-TREATMENT
mg/m2 I-TREATMENT
días I-TREATMENT
1º I-TREATMENT
y I-TREATMENT
8º I-TREATMENT
cada I-TREATMENT
21 I-TREATMENT
días. I-TREATMENT
No I-TREATMENT
se I-TREATMENT
administró I-TREATMENT
cisplatino I-TREATMENT
debido I-TREATMENT
a I-TREATMENT
su I-TREATMENT
nefrotoxicidad I-TREATMENT
y I-TREATMENT
a I-TREATMENT
tratarse I-TREATMENT
de I-TREATMENT
una I-TREATMENT
paciente I-TREATMENT
monorrena I-TREATMENT
con I-TREATMENT
un I-TREATMENT
ClCr I-TREATMENT
< I-TREATMENT
30. I-TREATMENT
<EOS> I-TREATMENT
Tras B-EXPLORATION
el I-EXPLORATION
4º I-EXPLORATION
ciclo I-EXPLORATION
de I-EXPLORATION
QMT I-EXPLORATION
se I-EXPLORATION
realizó I-EXPLORATION
un I-EXPLORATION
TAC I-EXPLORATION
en I-EXPLORATION
el I-EXPLORATION
que I-EXPLORATION
se I-EXPLORATION
apreció: I-EXPLORATION
lesión I-EXPLORATION
tumoral I-EXPLORATION
en I-EXPLORATION
fosa I-EXPLORATION
renal I-EXPLORATION
izquierda, I-EXPLORATION
que I-EXPLORATION
infiltraba I-EXPLORATION
arteria I-EXPLORATION
mesentérica I-EXPLORATION
superior, I-EXPLORATION
músculo I-EXPLORATION
psoas I-EXPLORATION
izquierdo I-EXPLORATION
y I-EXPLORATION
probablemente I-EXPLORATION
también I-EXPLORATION
aorta, I-EXPLORATION
acompañada I-EXPLORATION
de I-EXPLORATION
una I-EXPLORATION
lesión I-EXPLORATION
hepática I-EXPLORATION
en I-EXPLORATION
segmento I-EXPLORATION
4 I-EXPLORATION
compatible I-EXPLORATION
con I-EXPLORATION
metástasis. I-EXPLORATION
<EOS> I-EXPLORATION
Presentamos B-PRESENT_ILLNESS
el I-PRESENT_ILLNESS
caso I-PRESENT_ILLNESS
clínico I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
una I-PRESENT_ILLNESS
mujer I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
48 I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
edad I-PRESENT_ILLNESS
que I-PRESENT_ILLNESS
es I-PRESENT_ILLNESS
sometida I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
cirugía I-PRESENT_ILLNESS
ginecológica I-PRESENT_ILLNESS
(histerectomía I-PRESENT_ILLNESS
más I-PRESENT_ILLNESS
doble I-PRESENT_ILLNESS
anexectomía). I-PRESENT_ILLNESS
Tras I-PRESENT_ILLNESS
dicha I-PRESENT_ILLNESS
intervención, I-PRESENT_ILLNESS
presenta I-PRESENT_ILLNESS
un I-PRESENT_ILLNESS
cuadro I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
dolor I-PRESENT_ILLNESS
lumbar I-PRESENT_ILLNESS
derecho, I-PRESENT_ILLNESS
motivo I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
el I-PRESENT_ILLNESS
cual I-PRESENT_ILLNESS
es I-PRESENT_ILLNESS
requerido I-PRESENT_ILLNESS
el I-PRESENT_ILLNESS
servicio I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
urología. I-PRESENT_ILLNESS
<EOS> I-PRESENT_ILLNESS
En B-EXPLORATION
la I-EXPLORATION
urografía I-EXPLORATION
intravenosa I-EXPLORATION
observamos I-EXPLORATION
una I-EXPLORATION
concentración I-EXPLORATION
y I-EXPLORATION
eliminación I-EXPLORATION
renal I-EXPLORATION
izquierda I-EXPLORATION
normal, I-EXPLORATION
mientras I-EXPLORATION
que I-EXPLORATION
en I-EXPLORATION
el I-EXPLORATION
lado I-EXPLORATION
derecho I-EXPLORATION
se I-EXPLORATION
objetiva I-EXPLORATION
la I-EXPLORATION
ausencia I-EXPLORATION
de I-EXPLORATION
eliminación I-EXPLORATION
por I-EXPLORATION
el I-EXPLORATION
riñón, I-EXPLORATION
así I-EXPLORATION
mismo I-EXPLORATION
se I-EXPLORATION
visualizan I-EXPLORATION
múltiples I-EXPLORATION
'clips' I-EXPLORATION
quirúrgicos. I-EXPLORATION
<EOS> I-EXPLORATION
Ante B-TREATMENT
la I-TREATMENT
sospecha I-TREATMENT
de I-TREATMENT
una I-TREATMENT
afectación I-TREATMENT
ureteral I-TREATMENT
en I-TREATMENT
la I-TREATMENT
cirugía I-TREATMENT
se I-TREATMENT
decide I-TREATMENT
colocación I-TREATMENT
de I-TREATMENT
catéter I-TREATMENT
doble I-TREATMENT
J I-TREATMENT
derecho, I-TREATMENT
consiguiéndose I-TREATMENT
la I-TREATMENT
misma I-TREATMENT
con I-TREATMENT
cierta I-TREATMENT
dificultad. I-TREATMENT
<EOS> I-TREATMENT
En I-TREATMENT
control I-TREATMENT
intraoperatorio I-TREATMENT
se I-TREATMENT
visualiza I-TREATMENT
correcta I-TREATMENT
colocación I-TREATMENT
del I-TREATMENT
catéter, I-TREATMENT
desapareciendo I-TREATMENT
entonces I-TREATMENT
la I-TREATMENT
clínica I-TREATMENT
de I-TREATMENT
la I-TREATMENT
paciente. I-TREATMENT
<EOS> I-TREATMENT
Diez B-EVOLUTION
días I-EVOLUTION
después I-EVOLUTION
de I-EVOLUTION
dicho I-EVOLUTION
procedimiento I-EVOLUTION
la I-EVOLUTION
enferma I-EVOLUTION
comienza I-EVOLUTION
nuevamente I-EVOLUTION
con I-EVOLUTION
dolor I-EVOLUTION
lumbar I-EVOLUTION
derecho I-EVOLUTION
y I-EVOLUTION
fiebre, I-EVOLUTION
se B-EXPLORATION
realiza I-EXPLORATION
radiografía I-EXPLORATION
simple I-EXPLORATION
de I-EXPLORATION
abdomen I-EXPLORATION
en I-EXPLORATION
la I-EXPLORATION
que I-EXPLORATION
se I-EXPLORATION
confirma I-EXPLORATION
una I-EXPLORATION
migración I-EXPLORATION
proximal I-EXPLORATION
del I-EXPLORATION
catéter I-EXPLORATION
doble I-EXPLORATION
J. I-EXPLORATION
<EOS> I-EXPLORATION
Se B-TREATMENT
decide I-TREATMENT
recolocación I-TREATMENT
del I-TREATMENT
catéter I-TREATMENT
mediante I-TREATMENT
ureteroscopia, I-TREATMENT
siendo I-TREATMENT
imposible I-TREATMENT
realización I-TREATMENT
de I-TREATMENT
la I-TREATMENT
misma, I-TREATMENT
al I-TREATMENT
no I-TREATMENT
poder I-TREATMENT
alcanzar I-TREATMENT
luz I-TREATMENT
ureteral I-TREATMENT
proximal I-TREATMENT
al I-TREATMENT
cruce I-TREATMENT
con I-TREATMENT
la I-TREATMENT
ilíaca. I-TREATMENT
Optándose I-TREATMENT
entonces I-TREATMENT
por I-TREATMENT
colocación I-TREATMENT
de I-TREATMENT
nefrostomía I-TREATMENT
percutánea I-TREATMENT
y I-TREATMENT
retirada I-TREATMENT
por I-TREATMENT
dicha I-TREATMENT
vía I-TREATMENT
del I-TREATMENT
catéter. I-TREATMENT
<EOS> I-TREATMENT
Resuelto I-TREATMENT
el I-TREATMENT
cuadro I-TREATMENT
inicial I-TREATMENT
de I-TREATMENT
la I-TREATMENT
paciente I-TREATMENT
se I-TREATMENT
decide I-TREATMENT
colocación I-TREATMENT
anterógrada I-TREATMENT
de I-TREATMENT
catéter I-TREATMENT
ureteral I-TREATMENT
a I-TREATMENT
través I-TREATMENT
de I-TREATMENT
nefrostomía, I-TREATMENT
permitiendo I-TREATMENT
la I-TREATMENT
retirada I-TREATMENT
de I-TREATMENT
la I-TREATMENT
misma. I-TREATMENT
<EOS> I-TREATMENT
Mujer B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
66 I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
que I-PRESENT_ILLNESS
viene I-PRESENT_ILLNESS
al I-PRESENT_ILLNESS
hospital I-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
dolor I-PRESENT_ILLNESS
abdominal I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
cuadro I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
colelitiasis, I-PRESENT_ILLNESS
antecedentes B-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
hernia I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
hiato I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
tratamiento I-PAST_MEDICAL_HISTORY
por I-PAST_MEDICAL_HISTORY
hipertensión I-PAST_MEDICAL_HISTORY
arterial. I-PAST_MEDICAL_HISTORY
La B-EXPLORATION
analítica I-EXPLORATION
es I-EXPLORATION
irrelevante, I-EXPLORATION
salvo I-EXPLORATION
el I-EXPLORATION
colesterol I-EXPLORATION
total I-EXPLORATION
levemente I-EXPLORATION
elevado. I-EXPLORATION
Marcadores I-EXPLORATION
tumorales I-EXPLORATION
normales. I-EXPLORATION
El I-EXPLORATION
informe I-EXPLORATION
ecográfico I-EXPLORATION
del I-EXPLORATION
abdomen, I-EXPLORATION
sugiere I-EXPLORATION
un I-EXPLORATION
conglomerado I-EXPLORATION
adenopático, I-EXPLORATION
si I-EXPLORATION
bien I-EXPLORATION
no I-EXPLORATION
pueden I-EXPLORATION
descartar I-EXPLORATION
una I-EXPLORATION
neoplasia I-EXPLORATION
de I-EXPLORATION
cabeza I-EXPLORATION
de I-EXPLORATION
páncreas. I-EXPLORATION
Se I-EXPLORATION
le I-EXPLORATION
realiza I-EXPLORATION
un I-EXPLORATION
TAC I-EXPLORATION
abdominopélvico I-EXPLORATION
con I-EXPLORATION
contraste I-EXPLORATION
intravenoso I-EXPLORATION
que I-EXPLORATION
informa I-EXPLORATION
de I-EXPLORATION
una I-EXPLORATION
masa I-EXPLORATION
de I-EXPLORATION
4 I-EXPLORATION
cms I-EXPLORATION
en I-EXPLORATION
cabeza I-EXPLORATION
de I-EXPLORATION
páncreas, I-EXPLORATION
que I-EXPLORATION
capta I-EXPLORATION
el I-EXPLORATION
contraste I-EXPLORATION
intravenoso I-EXPLORATION
de I-EXPLORATION
forma I-EXPLORATION
intensa I-EXPLORATION
en I-EXPLORATION
la I-EXPLORATION
fase I-EXPLORATION
precoz, I-EXPLORATION
sugiriendo I-EXPLORATION
un I-EXPLORATION
tumor I-EXPLORATION
hipervascular, I-EXPLORATION
compatible I-EXPLORATION
con I-EXPLORATION
tumor I-EXPLORATION
endocrino. I-EXPLORATION
La I-EXPLORATION
gammagrafía I-EXPLORATION
ósea I-EXPLORATION
es I-EXPLORATION
normal, I-EXPLORATION
consistente I-EXPLORATION
con I-EXPLORATION
la I-EXPLORATION
edad I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
paciente. I-EXPLORATION
Se B-TREATMENT
le I-TREATMENT
practica I-TREATMENT
una I-TREATMENT
pancreatectomía, I-TREATMENT
colecistectomía I-TREATMENT
y I-TREATMENT
coledocorrafia I-TREATMENT
en I-TREATMENT
Abril I-TREATMENT
de I-TREATMENT
2007. I-TREATMENT
En B-EVOLUTION
la I-EVOLUTION
actualidad, I-EVOLUTION
5 I-EVOLUTION
meses I-EVOLUTION
después, I-EVOLUTION
la I-EVOLUTION
paciente I-EVOLUTION
se I-EVOLUTION
encuentra I-EVOLUTION
bien, I-EVOLUTION
sin I-EVOLUTION
evidencia I-EVOLUTION
de I-EVOLUTION
otras I-EVOLUTION
metástasis. I-EVOLUTION
Ni B-EXPLORATION
en I-EXPLORATION
el I-EXPLORATION
acto I-EXPLORATION
quirúrgico I-EXPLORATION
ni I-EXPLORATION
en I-EXPLORATION
la I-EXPLORATION
disección I-EXPLORATION
macroscópica I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
pieza I-EXPLORATION
se I-EXPLORATION
encuentran I-EXPLORATION
adenopatías. I-EXPLORATION
<EOS> I-EXPLORATION
En I-EXPLORATION
el I-EXPLORATION
páncreas I-EXPLORATION
encontramos I-EXPLORATION
3 I-EXPLORATION
nódulos I-EXPLORATION
bien I-EXPLORATION
delimitados I-EXPLORATION
que I-EXPLORATION
miden I-EXPLORATION
respectivamente I-EXPLORATION
4 I-EXPLORATION
cms., I-EXPLORATION
1 I-EXPLORATION
y I-EXPLORATION
0.7 I-EXPLORATION
cms., I-EXPLORATION
cuyas I-EXPLORATION
superficies I-EXPLORATION
de I-EXPLORATION
corte I-EXPLORATION
son I-EXPLORATION
de I-EXPLORATION
consistencia I-EXPLORATION
blanda, I-EXPLORATION
aspecto I-EXPLORATION
homogéneo I-EXPLORATION
y I-EXPLORATION
coloración I-EXPLORATION
amarillenta. I-EXPLORATION
<EOS> I-EXPLORATION
El I-EXPLORATION
estudio I-EXPLORATION
histológico I-EXPLORATION
de I-EXPLORATION
los I-EXPLORATION
nódulos I-EXPLORATION
tumorales I-EXPLORATION
de I-EXPLORATION
los I-EXPLORATION
dos I-EXPLORATION
pacientes, I-EXPLORATION
mostró I-EXPLORATION
un I-EXPLORATION
cuadro I-EXPLORATION
microscópico I-EXPLORATION
similar I-EXPLORATION
constituido I-EXPLORATION
por I-EXPLORATION
una I-EXPLORATION
población I-EXPLORATION
celular I-EXPLORATION
homogénea, I-EXPLORATION
de I-EXPLORATION
citoplasmas I-EXPLORATION
claros, I-EXPLORATION
con I-EXPLORATION
atipia I-EXPLORATION
nuclear I-EXPLORATION
correspondiente I-EXPLORATION
a I-EXPLORATION
los I-EXPLORATION
grados I-EXPLORATION
3 I-EXPLORATION
(caso I-EXPLORATION
1) I-EXPLORATION
y I-EXPLORATION
1 I-EXPLORATION
(caso I-EXPLORATION
2) I-EXPLORATION
de I-EXPLORATION
Fuhrman, I-EXPLORATION
mostrando I-EXPLORATION
las I-EXPLORATION
tumoraciones I-EXPLORATION
una I-EXPLORATION
marcada I-EXPLORATION
red I-EXPLORATION
vascular. I-EXPLORATION
Los I-EXPLORATION
estudios I-EXPLORATION
inmunohistoquímicos I-EXPLORATION
mostraron I-EXPLORATION
positividad I-EXPLORATION
a I-EXPLORATION
citoqueratina, I-EXPLORATION
vimentina, I-EXPLORATION
antígeno I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
membrana I-EXPLORATION
epitelial I-EXPLORATION
y I-EXPLORATION
a I-EXPLORATION
CD10 I-EXPLORATION
y I-EXPLORATION
negatividad I-EXPLORATION
a I-EXPLORATION
citoqueratinas I-EXPLORATION
7 I-EXPLORATION
y I-EXPLORATION
20, I-EXPLORATION
cromogranina, I-EXPLORATION
tiroglobulina, I-EXPLORATION
sinaptofisina, I-EXPLORATION
HMB45 I-EXPLORATION
y I-EXPLORATION
antígeno I-EXPLORATION
carcinoembrionario. I-EXPLORATION
Se I-EXPLORATION
emitió I-EXPLORATION
un I-EXPLORATION
diagnóstico I-EXPLORATION
de I-EXPLORATION
metástasis I-EXPLORATION
de I-EXPLORATION
carcinoma I-EXPLORATION
renal I-EXPLORATION
de I-EXPLORATION
células I-EXPLORATION
claras I-EXPLORATION
y B-PAST_MEDICAL_HISTORY
al I-PAST_MEDICAL_HISTORY
revisar I-PAST_MEDICAL_HISTORY
las I-PAST_MEDICAL_HISTORY
historias I-PAST_MEDICAL_HISTORY
clínicas I-PAST_MEDICAL_HISTORY
se I-PAST_MEDICAL_HISTORY
encontró I-PAST_MEDICAL_HISTORY
que I-PAST_MEDICAL_HISTORY
ambos I-PAST_MEDICAL_HISTORY
pacientes I-PAST_MEDICAL_HISTORY
habían I-PAST_MEDICAL_HISTORY
sido I-PAST_MEDICAL_HISTORY
diagnosticados I-PAST_MEDICAL_HISTORY
17 I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
16 I-PAST_MEDICAL_HISTORY
años I-PAST_MEDICAL_HISTORY
antes I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
carcinoma I-PAST_MEDICAL_HISTORY
renal I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
células I-PAST_MEDICAL_HISTORY
claras I-PAST_MEDICAL_HISTORY
(hipernefroma), I-PAST_MEDICAL_HISTORY
no I-PAST_MEDICAL_HISTORY
apreciándose I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
ninguno I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
los I-PAST_MEDICAL_HISTORY
casos I-PAST_MEDICAL_HISTORY
infiltración I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
la I-PAST_MEDICAL_HISTORY
vena I-PAST_MEDICAL_HISTORY
renal I-PAST_MEDICAL_HISTORY
ni I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
la I-PAST_MEDICAL_HISTORY
cápsula I-PAST_MEDICAL_HISTORY
del I-PAST_MEDICAL_HISTORY
riñón. I-PAST_MEDICAL_HISTORY
<EOS> I-PAST_MEDICAL_HISTORY
Paciente B-PRESENT_ILLNESS
del I-PRESENT_ILLNESS
sexo I-PRESENT_ILLNESS
femenino I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
74 I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
edad I-PRESENT_ILLNESS
que I-PRESENT_ILLNESS
acude I-PRESENT_ILLNESS
al I-PRESENT_ILLNESS
servicio I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
urgencias I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
hematuria I-PRESENT_ILLNESS
macroscópica, I-PRESENT_ILLNESS
sin I-PRESENT_ILLNESS
otra I-PRESENT_ILLNESS
sintomatología I-PRESENT_ILLNESS
acompañante. I-PRESENT_ILLNESS
Antecedentes B-PAST_MEDICAL_HISTORY
médicos I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
quirúrgicos I-PAST_MEDICAL_HISTORY
irrelevantes. I-PAST_MEDICAL_HISTORY
Ex-fumadora. I-PAST_MEDICAL_HISTORY
La B-EXPLORATION
ecografía I-EXPLORATION
renal I-EXPLORATION
y I-EXPLORATION
vesical I-EXPLORATION
revela I-EXPLORATION
una I-EXPLORATION
ectasia I-EXPLORATION
pielocalicial I-EXPLORATION
moderada I-EXPLORATION
del I-EXPLORATION
riñón I-EXPLORATION
derecho I-EXPLORATION
y I-EXPLORATION
una I-EXPLORATION
masa I-EXPLORATION
sólida, I-EXPLORATION
sésil, I-EXPLORATION
localizada I-EXPLORATION
en I-EXPLORATION
la I-EXPLORATION
pared I-EXPLORATION
lateral I-EXPLORATION
derecha I-EXPLORATION
endovesical I-EXPLORATION
de I-EXPLORATION
4 I-EXPLORATION
cm I-EXPLORATION
de I-EXPLORATION
diámetro. I-EXPLORATION
La I-EXPLORATION
cistoscopia I-EXPLORATION
(se I-EXPLORATION
realiza I-EXPLORATION
en I-EXPLORATION
el I-EXPLORATION
mismo I-EXPLORATION
acto I-EXPLORATION
quirúrgico) I-EXPLORATION
muestra I-EXPLORATION
un I-EXPLORATION
tumor I-EXPLORATION
sésil I-EXPLORATION
de I-EXPLORATION
3, I-EXPLORATION
5 I-EXPLORATION
cm I-EXPLORATION
localizado I-EXPLORATION
en I-EXPLORATION
la I-EXPLORATION
pared I-EXPLORATION
lateral I-EXPLORATION
derecha. I-EXPLORATION
La I-EXPLORATION
palpación I-EXPLORATION
bi-manual I-EXPLORATION
no I-EXPLORATION
existe I-EXPLORATION
fijación. I-EXPLORATION
La I-EXPLORATION
biopsia I-EXPLORATION
del I-EXPLORATION
tumor I-EXPLORATION
revela I-EXPLORATION
adenocarcinoma I-EXPLORATION
invasivo, I-EXPLORATION
no I-EXPLORATION
excluyendo I-EXPLORATION
origen I-EXPLORATION
ginecológico, I-EXPLORATION
por I-EXPLORATION
lo I-EXPLORATION
que I-EXPLORATION
se I-EXPLORATION
realiza I-EXPLORATION
examen I-EXPLORATION
ginecológico I-EXPLORATION
completo I-EXPLORATION
que I-EXPLORATION
se I-EXPLORATION
revela I-EXPLORATION
negativo. I-EXPLORATION
El I-EXPLORATION
estudio I-EXPLORATION
de I-EXPLORATION
extensión I-EXPLORATION
no I-EXPLORATION
muestra I-EXPLORATION
metástasis. I-EXPLORATION
Se B-TREATMENT
le I-TREATMENT
efectúa I-TREATMENT
exanteración I-TREATMENT
pélvica I-TREATMENT
anterior I-TREATMENT
y I-TREATMENT
ureterostomia I-TREATMENT
cutánea I-TREATMENT
transileal I-TREATMENT
tipo I-TREATMENT
Bricker. I-TREATMENT
El B-EXPLORATION
estudio I-EXPLORATION
histológico I-EXPLORATION
describe I-EXPLORATION
un I-EXPLORATION
adenocarcinoma I-EXPLORATION
de I-EXPLORATION
patrón I-EXPLORATION
en I-EXPLORATION
parte I-EXPLORATION
papilar I-EXPLORATION
en I-EXPLORATION
parte I-EXPLORATION
túbulo-quístico I-EXPLORATION
de I-EXPLORATION
alto I-EXPLORATION
grado I-EXPLORATION
citológico, I-EXPLORATION
pT3aN0. I-EXPLORATION
<EOS> I-EXPLORATION
La B-EVOLUTION
paciente I-EVOLUTION
tuvo I-EVOLUTION
una I-EVOLUTION
recuperación I-EVOLUTION
satisfactoria, I-EVOLUTION
sin I-EVOLUTION
complicaciones I-EVOLUTION
per-operatorias. I-EVOLUTION
A I-EVOLUTION
los I-EVOLUTION
6 I-EVOLUTION
meses I-EVOLUTION
de I-EVOLUTION
seguimiento I-EVOLUTION
pos-operatorio I-EVOLUTION
no I-EVOLUTION
revela I-EVOLUTION
evolución I-EVOLUTION
clínica I-EVOLUTION
ni I-EVOLUTION
en I-EVOLUTION
la I-EVOLUTION
imagen I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
neoplasia I-EVOLUTION
o I-EVOLUTION
de I-EVOLUTION
complicaciones I-EVOLUTION
resultantes I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
cirugía. I-EVOLUTION
<EOS> I-EVOLUTION
Varón B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
67 I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
con B-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
personales I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
hipertensión I-PAST_MEDICAL_HISTORY
arterial, I-PAST_MEDICAL_HISTORY
dislipemia, I-PAST_MEDICAL_HISTORY
miocardiopatía I-PAST_MEDICAL_HISTORY
hipertrófica I-PAST_MEDICAL_HISTORY
obstructiva I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
síndrome I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
apnea I-PAST_MEDICAL_HISTORY
obstructiva I-PAST_MEDICAL_HISTORY
del I-PAST_MEDICAL_HISTORY
sueño. I-PAST_MEDICAL_HISTORY
Insuficiencia I-PAST_MEDICAL_HISTORY
renal I-PAST_MEDICAL_HISTORY
crónica I-PAST_MEDICAL_HISTORY
por I-PAST_MEDICAL_HISTORY
nefroangioesclerosis, I-PAST_MEDICAL_HISTORY
siendo I-PAST_MEDICAL_HISTORY
trasplantado I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
el I-PAST_MEDICAL_HISTORY
año I-PAST_MEDICAL_HISTORY
1998 I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
fosa I-PAST_MEDICAL_HISTORY
ilíaca I-PAST_MEDICAL_HISTORY
derecha, I-PAST_MEDICAL_HISTORY
sin I-PAST_MEDICAL_HISTORY
incidencias. I-PAST_MEDICAL_HISTORY
El I-PAST_MEDICAL_HISTORY
paciente I-PAST_MEDICAL_HISTORY
presenta I-PAST_MEDICAL_HISTORY
un I-PAST_MEDICAL_HISTORY
injerto I-PAST_MEDICAL_HISTORY
normofuncionante I-PAST_MEDICAL_HISTORY
(creatinina I-PAST_MEDICAL_HISTORY
sérica: I-PAST_MEDICAL_HISTORY
2, I-PAST_MEDICAL_HISTORY
4 I-PAST_MEDICAL_HISTORY
mg/dL I-PAST_MEDICAL_HISTORY
basal) I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
sigue I-PAST_MEDICAL_HISTORY
tratamiento I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
Prednisona I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
Ciclosporina I-PAST_MEDICAL_HISTORY
A I-PAST_MEDICAL_HISTORY
(CsA). I-PAST_MEDICAL_HISTORY
En I-PAST_MEDICAL_HISTORY
el I-PAST_MEDICAL_HISTORY
año I-PAST_MEDICAL_HISTORY
2006, I-PAST_MEDICAL_HISTORY
se I-PAST_MEDICAL_HISTORY
detecta I-PAST_MEDICAL_HISTORY
lesión I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
labio I-PAST_MEDICAL_HISTORY
inferior I-PAST_MEDICAL_HISTORY
que I-PAST_MEDICAL_HISTORY
es I-PAST_MEDICAL_HISTORY
extirpada, I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
el I-PAST_MEDICAL_HISTORY
resultado I-PAST_MEDICAL_HISTORY
anatomopatológico I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
carcinoma I-PAST_MEDICAL_HISTORY
epidermoide I-PAST_MEDICAL_HISTORY
microinfiltrante. I-PAST_MEDICAL_HISTORY
Se I-PAST_MEDICAL_HISTORY
realiza I-PAST_MEDICAL_HISTORY
modificación I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
la I-PAST_MEDICAL_HISTORY
inmunosupresión, I-PAST_MEDICAL_HISTORY
sustituyéndose I-PAST_MEDICAL_HISTORY
la I-PAST_MEDICAL_HISTORY
CsA I-PAST_MEDICAL_HISTORY
por I-PAST_MEDICAL_HISTORY
Tacrolimus. I-PAST_MEDICAL_HISTORY
<EOS> I-PAST_MEDICAL_HISTORY
En I-PAST_MEDICAL_HISTORY
mayo I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
2007 I-PAST_MEDICAL_HISTORY
se I-PAST_MEDICAL_HISTORY
detecta I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
ecografía I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
rutina I-PAST_MEDICAL_HISTORY
una I-PAST_MEDICAL_HISTORY
masa I-PAST_MEDICAL_HISTORY
sólida I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
cortical I-PAST_MEDICAL_HISTORY
anterior, I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
zona I-PAST_MEDICAL_HISTORY
media I-PAST_MEDICAL_HISTORY
superior, I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
aproximadamente I-PAST_MEDICAL_HISTORY
3 I-PAST_MEDICAL_HISTORY
cm I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
diámetro I-PAST_MEDICAL_HISTORY
mayor. I-PAST_MEDICAL_HISTORY
El I-PAST_MEDICAL_HISTORY
paciente I-PAST_MEDICAL_HISTORY
se I-PAST_MEDICAL_HISTORY
encuentra I-PAST_MEDICAL_HISTORY
asintomático I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
función I-PAST_MEDICAL_HISTORY
del I-PAST_MEDICAL_HISTORY
injerto I-PAST_MEDICAL_HISTORY
conservada. I-PAST_MEDICAL_HISTORY
Se B-EXPLORATION
realiza I-EXPLORATION
TC I-EXPLORATION
de I-EXPLORATION
confirmación, I-EXPLORATION
donde I-EXPLORATION
se I-EXPLORATION
aprecia I-EXPLORATION
lesión I-EXPLORATION
focal I-EXPLORATION
y I-EXPLORATION
sólida I-EXPLORATION
en I-EXPLORATION
zona I-EXPLORATION
media I-EXPLORATION
superior I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
cara I-EXPLORATION
anterior I-EXPLORATION
del I-EXPLORATION
injerto. I-EXPLORATION
Tras B-TREATMENT
punción-aspiración I-TREATMENT
que I-TREATMENT
confirma I-TREATMENT
la I-TREATMENT
lesión I-TREATMENT
como I-TREATMENT
carcinoma I-TREATMENT
de I-TREATMENT
células I-TREATMENT
renales, I-TREATMENT
se I-TREATMENT
decide I-TREATMENT
realización I-TREATMENT
de I-TREATMENT
cirugía I-TREATMENT
conservadora I-TREATMENT
de I-TREATMENT
nefronas I-TREATMENT
ante I-TREATMENT
la I-TREATMENT
buena I-TREATMENT
funcionalidad I-TREATMENT
del I-TREATMENT
injerto I-TREATMENT
y I-TREATMENT
las I-TREATMENT
características I-TREATMENT
favorables I-TREATMENT
de I-TREATMENT
la I-TREATMENT
lesión. I-TREATMENT
Bajo I-TREATMENT
isquemia I-TREATMENT
fría I-TREATMENT
y I-TREATMENT
con I-TREATMENT
control I-TREATMENT
ecográfico I-TREATMENT
intraoperatorio, I-TREATMENT
se I-TREATMENT
realiza I-TREATMENT
nefrectomía I-TREATMENT
parcial I-TREATMENT
con I-TREATMENT
abordaje I-TREATMENT
intracapsular, I-TREATMENT
enviándose B-EXPLORATION
lecho I-EXPLORATION
tumoral I-EXPLORATION
para I-EXPLORATION
análisis I-EXPLORATION
patológico I-EXPLORATION
intraoperatorio I-EXPLORATION
que I-EXPLORATION
confirma I-EXPLORATION
la I-EXPLORATION
negatividad I-EXPLORATION
de I-EXPLORATION
los I-EXPLORATION
márgenes I-EXPLORATION
quirúrgicos. I-EXPLORATION
El I-EXPLORATION
resultado I-EXPLORATION
definitivo I-EXPLORATION
del I-EXPLORATION
análisis I-EXPLORATION
confirmó I-EXPLORATION
un I-EXPLORATION
carcinoma I-EXPLORATION
de I-EXPLORATION
células I-EXPLORATION
renales I-EXPLORATION
estadio I-EXPLORATION
pT1 I-EXPLORATION
G1, I-EXPLORATION
extirpado I-EXPLORATION
en I-EXPLORATION
su I-EXPLORATION
totalidad. I-EXPLORATION
<EOS> I-EXPLORATION
La B-EVOLUTION
evolución I-EVOLUTION
del I-EVOLUTION
paciente I-EVOLUTION
es I-EVOLUTION
satisfactoria, I-EVOLUTION
presentando I-EVOLUTION
una I-EVOLUTION
discreta I-EVOLUTION
elevación I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
creatinina I-EVOLUTION
hasta I-EVOLUTION
4, I-EVOLUTION
2 I-EVOLUTION
mg/dl I-EVOLUTION
con I-EVOLUTION
recuperación I-EVOLUTION
de I-EVOLUTION
ésta I-EVOLUTION
a I-EVOLUTION
los I-EVOLUTION
valores I-EVOLUTION
basales I-EVOLUTION
al I-EVOLUTION
quinto I-EVOLUTION
día I-EVOLUTION
de I-EVOLUTION
postoperatorio. I-EVOLUTION
Actualmente, I-EVOLUTION
tras I-EVOLUTION
un I-EVOLUTION
seguimiento I-EVOLUTION
de I-EVOLUTION
14 I-EVOLUTION
meses, I-EVOLUTION
el I-EVOLUTION
paciente I-EVOLUTION
se I-EVOLUTION
encuentra I-EVOLUTION
asintomático I-EVOLUTION
y I-EVOLUTION
no I-EVOLUTION
existen I-EVOLUTION
datos I-EVOLUTION
de I-EVOLUTION
recidiva I-EVOLUTION
tumoral I-EVOLUTION
ni I-EVOLUTION
metástasis I-EVOLUTION
a I-EVOLUTION
distancia. I-EVOLUTION
La I-EVOLUTION
función I-EVOLUTION
del I-EVOLUTION
injerto I-EVOLUTION
se I-EVOLUTION
encuentra I-EVOLUTION
estable I-EVOLUTION
con I-EVOLUTION
cifras I-EVOLUTION
de I-EVOLUTION
creatinina I-EVOLUTION
de I-EVOLUTION
2, I-EVOLUTION
3 I-EVOLUTION
mg/dl. I-EVOLUTION
Se B-TREATMENT
mantuvo I-TREATMENT
la I-TREATMENT
inmunosupresión I-TREATMENT
previa I-TREATMENT
con I-TREATMENT
Prednisona I-TREATMENT
y I-TREATMENT
se I-TREATMENT
añadió I-TREATMENT
Sirolimus. I-TREATMENT
<EOS> I-TREATMENT
Paciente B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
43 I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
con B-PAST_MEDICAL_HISTORY
antecedente I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
diabetes I-PAST_MEDICAL_HISTORY
conocida I-PAST_MEDICAL_HISTORY
dos I-PAST_MEDICAL_HISTORY
años I-PAST_MEDICAL_HISTORY
atrás I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
tratamiento I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
ADO. I-PAST_MEDICAL_HISTORY
A B-PRESENT_ILLNESS
raiz I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
serle I-PRESENT_ILLNESS
descubierta I-PRESENT_ILLNESS
una I-PRESENT_ILLNESS
HTA, I-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
1975, I-PRESENT_ILLNESS
se I-PRESENT_ILLNESS
iniciaron I-PRESENT_ILLNESS
estudios I-PRESENT_ILLNESS
que I-PRESENT_ILLNESS
incluyeron I-PRESENT_ILLNESS
la I-PRESENT_ILLNESS
práctica I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
una I-PRESENT_ILLNESS
UIV I-PRESENT_ILLNESS
minutada I-PRESENT_ILLNESS
que I-PRESENT_ILLNESS
evidenció I-PRESENT_ILLNESS
una I-PRESENT_ILLNESS
masa I-PRESENT_ILLNESS
renal I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
RI. I-PRESENT_ILLNESS
Siguió B-EXPLORATION
la I-EXPLORATION
realización I-EXPLORATION
de I-EXPLORATION
una I-EXPLORATION
angiografía I-EXPLORATION
que I-EXPLORATION
demostraba I-EXPLORATION
una I-EXPLORATION
importante I-EXPLORATION
masa I-EXPLORATION
de I-EXPLORATION
10 I-EXPLORATION
cm. I-EXPLORATION
que I-EXPLORATION
ocupaba I-EXPLORATION
la I-EXPLORATION
región I-EXPLORATION
mesorrenal I-EXPLORATION
e I-EXPLORATION
hiliar I-EXPLORATION
con I-EXPLORATION
una I-EXPLORATION
importante I-EXPLORATION
fístula I-EXPLORATION
arteriovenosa I-EXPLORATION
que I-EXPLORATION
ocasionaba I-EXPLORATION
una I-EXPLORATION
gran I-EXPLORATION
laguna I-EXPLORATION
vascular I-EXPLORATION
pseudoaneurismática. I-EXPLORATION
En I-EXPLORATION
fases I-EXPLORATION
venosas I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
exploración I-EXPLORATION
se I-EXPLORATION
observaba I-EXPLORATION
una I-EXPLORATION
notable I-EXPLORATION
dilatación I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
arcada I-EXPLORATION
exorrenal. I-EXPLORATION
Con B-TREATMENT
la I-TREATMENT
evidencia I-TREATMENT
de I-TREATMENT
riñón I-TREATMENT
contralateral I-TREATMENT
normal I-TREATMENT
se I-TREATMENT
procedió I-TREATMENT
a I-TREATMENT
la I-TREATMENT
nefrectomía I-TREATMENT
radical I-TREATMENT
izquierda I-TREATMENT
con I-TREATMENT
linfadenectomía I-TREATMENT
reducida I-TREATMENT
renoaórtica. I-TREATMENT
La B-EXPLORATION
anatomía I-EXPLORATION
patológica I-EXPLORATION
demostró I-EXPLORATION
carcinoma I-EXPLORATION
de I-EXPLORATION
células I-EXPLORATION
claras I-EXPLORATION
de I-EXPLORATION
9 I-EXPLORATION
cm., I-EXPLORATION
con I-EXPLORATION
patrón I-EXPLORATION
de I-EXPLORATION
crecimiento I-EXPLORATION
sólido I-EXPLORATION
con I-EXPLORATION
áreas I-EXPLORATION
granulomatosas. I-EXPLORATION
Las I-EXPLORATION
adenopatías I-EXPLORATION
fueron I-EXPLORATION
negativas I-EXPLORATION
presentando I-EXPLORATION
únicamente I-EXPLORATION
histiocitosis I-EXPLORATION
sinusal. I-EXPLORATION
<EOS> I-EXPLORATION
La B-EVOLUTION
paciente I-EVOLUTION
permaneció I-EVOLUTION
asintomática I-EVOLUTION
hasta I-EVOLUTION
que I-EVOLUTION
en I-EVOLUTION
una I-EVOLUTION
exploración I-EVOLUTION
ecográfica, I-EVOLUTION
en I-EVOLUTION
1982, I-EVOLUTION
se I-EVOLUTION
descubre I-EVOLUTION
masa I-EVOLUTION
tumoral I-EVOLUTION
de I-EVOLUTION
polo I-EVOLUTION
superior I-EVOLUTION
del I-EVOLUTION
RD I-EVOLUTION
restante. I-EVOLUTION
Pensando B-EXPLORATION
ya I-EXPLORATION
en I-EXPLORATION
la I-EXPLORATION
imperiosidad I-EXPLORATION
de I-EXPLORATION
realizar I-EXPLORATION
una I-EXPLORATION
cirugía I-EXPLORATION
conservadora I-EXPLORATION
se I-EXPLORATION
solicitó I-EXPLORATION
estudio I-EXPLORATION
angiográfico I-EXPLORATION
completo I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
arquitectura I-EXPLORATION
vascular I-EXPLORATION
del I-EXPLORATION
órgano. I-EXPLORATION
Ello I-EXPLORATION
nos I-EXPLORATION
permitió I-EXPLORATION
ver I-EXPLORATION
como I-EXPLORATION
el I-EXPLORATION
tumor I-EXPLORATION
recibía I-EXPLORATION
dos I-EXPLORATION
ramas I-EXPLORATION
arteriales I-EXPLORATION
directas I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
renal I-EXPLORATION
muy I-EXPLORATION
extrasinusales I-EXPLORATION
y I-EXPLORATION
otras I-EXPLORATION
dos I-EXPLORATION
que I-EXPLORATION
irrigaban I-EXPLORATION
el I-EXPLORATION
tejido I-EXPLORATION
renal I-EXPLORATION
sano I-EXPLORATION
que I-EXPLORATION
limitaba I-EXPLORATION
el I-EXPLORATION
tumor I-EXPLORATION
y I-EXPLORATION
que I-EXPLORATION
deberíamos I-EXPLORATION
sacrificar I-EXPLORATION
en I-EXPLORATION
aras I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
radicalidad I-EXPLORATION
necesaria. I-EXPLORATION
<EOS> I-EXPLORATION
El B-TREATMENT
7.07.82 I-TREATMENT
practicamos, I-TREATMENT
bajo I-TREATMENT
hipotemia I-TREATMENT
in I-TREATMENT
situ I-TREATMENT
y I-TREATMENT
perfusión I-TREATMENT
con I-TREATMENT
Collins, I-TREATMENT
la I-TREATMENT
disección I-TREATMENT
de I-TREATMENT
la I-TREATMENT
arteria I-TREATMENT
renal I-TREATMENT
con I-TREATMENT
ligadura I-TREATMENT
de I-TREATMENT
esas I-TREATMENT
cuatro I-TREATMENT
ramas I-TREATMENT
ya I-TREATMENT
programadas I-TREATMENT
sobre I-TREATMENT
el I-TREATMENT
mapa I-TREATMENT
vascular. I-TREATMENT
La B-EXPLORATION
anatomía I-EXPLORATION
patológica I-EXPLORATION
fue I-EXPLORATION
de I-EXPLORATION
adenocarcinoma I-EXPLORATION
renal I-EXPLORATION
de I-EXPLORATION
células I-EXPLORATION
claras I-EXPLORATION
de I-EXPLORATION
6, I-EXPLORATION
5 I-EXPLORATION
cms, I-EXPLORATION
en I-EXPLORATION
contacto I-EXPLORATION
con I-EXPLORATION
la I-EXPLORATION
grasa I-EXPLORATION
perirrenal I-EXPLORATION
y I-EXPLORATION
con I-EXPLORATION
ganglios I-EXPLORATION
negativos. I-EXPLORATION
<EOS> I-EXPLORATION
En B-EVOLUTION
los I-EVOLUTION
años I-EVOLUTION
siguientes I-EVOLUTION
la I-EVOLUTION
paciente I-EVOLUTION
ingresó I-EVOLUTION
en I-EVOLUTION
Medicina I-EVOLUTION
Interna I-EVOLUTION
por I-EVOLUTION
descompensaciones I-EVOLUTION
diabéticas I-EVOLUTION
sucesivas I-EVOLUTION
aprovechando I-EVOLUTION
para I-EVOLUTION
mantener I-EVOLUTION
control I-EVOLUTION
de I-EVOLUTION
su I-EVOLUTION
patología I-EVOLUTION
renal I-EVOLUTION
mediante I-EVOLUTION
TAC I-EVOLUTION
que I-EVOLUTION
fueron I-EVOLUTION
normales. I-EVOLUTION
<EOS> I-EVOLUTION
En I-EVOLUTION
un I-EVOLUTION
último I-EVOLUTION
reingreso I-EVOLUTION
en I-EVOLUTION
MI I-EVOLUTION
por I-EVOLUTION
anemia I-EVOLUTION
secundaria I-EVOLUTION
a I-EVOLUTION
HDA I-EVOLUTION
por I-EVOLUTION
ulcus I-EVOLUTION
sangrante I-EVOLUTION
y I-EVOLUTION
delgadez I-EVOLUTION
extrema, I-EVOLUTION
se I-EVOLUTION
objetivó I-EVOLUTION
por I-EVOLUTION
TAC I-EVOLUTION
masa I-EVOLUTION
retroperitoneal I-EVOLUTION
pancreática. I-EVOLUTION
No I-EVOLUTION
pudimos I-EVOLUTION
dilucidar I-EVOLUTION
el I-EVOLUTION
origen I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
misma I-EVOLUTION
falleciendo I-EVOLUTION
la I-EVOLUTION
paciente I-EVOLUTION
a I-EVOLUTION
los I-EVOLUTION
18 I-EVOLUTION
y I-EVOLUTION
8 I-EVOLUTION
años I-EVOLUTION
de I-EVOLUTION
sus I-EVOLUTION
respectivas I-EVOLUTION
cirugías I-EVOLUTION
renales. I-EVOLUTION
<EOS> I-EVOLUTION
Hombre B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
65 I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
edad I-PRESENT_ILLNESS
quien I-PRESENT_ILLNESS
consultó I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
polaquiuria, I-PRESENT_ILLNESS
disuria I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
hesitancia. I-PRESENT_ILLNESS
Adicionalmente I-PRESENT_ILLNESS
el I-PRESENT_ILLNESS
paciente I-PRESENT_ILLNESS
informó I-PRESENT_ILLNESS
la I-PRESENT_ILLNESS
pérdida I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
10 I-PRESENT_ILLNESS
Kg. I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
peso I-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
los I-PRESENT_ILLNESS
últimos I-PRESENT_ILLNESS
6 I-PRESENT_ILLNESS
meses, I-PRESENT_ILLNESS
no I-PRESENT_ILLNESS
refirió I-PRESENT_ILLNESS
otros I-PRESENT_ILLNESS
síntomas. I-PRESENT_ILLNESS
Con B-FAMILY_HISTORY
antecedente I-FAMILY_HISTORY
de I-FAMILY_HISTORY
padre I-FAMILY_HISTORY
con I-FAMILY_HISTORY
carcinoma I-FAMILY_HISTORY
de I-FAMILY_HISTORY
próstata, I-FAMILY_HISTORY
no B-PAST_MEDICAL_HISTORY
se I-PAST_MEDICAL_HISTORY
documento I-PAST_MEDICAL_HISTORY
la I-PAST_MEDICAL_HISTORY
presencia I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
historia I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
inmunodeficiencias I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
la I-PAST_MEDICAL_HISTORY
prueba I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
ELISA I-PAST_MEDICAL_HISTORY
para I-PAST_MEDICAL_HISTORY
VIH I-PAST_MEDICAL_HISTORY
fue I-PAST_MEDICAL_HISTORY
negativa I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
dos I-PAST_MEDICAL_HISTORY
oportunidades. I-PAST_MEDICAL_HISTORY
En B-EXPLORATION
el I-EXPLORATION
examen I-EXPLORATION
físico I-EXPLORATION
se I-EXPLORATION
documentó I-EXPLORATION
la I-EXPLORATION
presencia I-EXPLORATION
de I-EXPLORATION
una I-EXPLORATION
próstata I-EXPLORATION
aumentada I-EXPLORATION
de I-EXPLORATION
volumen, I-EXPLORATION
irregular I-EXPLORATION
y I-EXPLORATION
dura, I-EXPLORATION
sin I-EXPLORATION
otras I-EXPLORATION
alteraciones. I-EXPLORATION
Por I-EXPLORATION
lo I-EXPLORATION
cual I-EXPLORATION
se I-EXPLORATION
realizo, I-EXPLORATION
Antígeno I-EXPLORATION
Prostático I-EXPLORATION
Específico I-EXPLORATION
(APE) I-EXPLORATION
(7, I-EXPLORATION
17 I-EXPLORATION
ng/ml), I-EXPLORATION
creatinina I-EXPLORATION
(0, I-EXPLORATION
83 I-EXPLORATION
mg/dl), I-EXPLORATION
y I-EXPLORATION
uroanálisis I-EXPLORATION
en I-EXPLORATION
el I-EXPLORATION
cual I-EXPLORATION
se I-EXPLORATION
evidenciaron I-EXPLORATION
mas I-EXPLORATION
de I-EXPLORATION
10 I-EXPLORATION
eritrocitos I-EXPLORATION
por I-EXPLORATION
campo I-EXPLORATION
de I-EXPLORATION
alto I-EXPLORATION
poder. I-EXPLORATION
La I-EXPLORATION
ecografía I-EXPLORATION
Doppler I-EXPLORATION
prostática I-EXPLORATION
mostró I-EXPLORATION
leve I-EXPLORATION
aumento I-EXPLORATION
de I-EXPLORATION
tamaño, I-EXPLORATION
con I-EXPLORATION
un I-EXPLORATION
volumen I-EXPLORATION
de I-EXPLORATION
39 I-EXPLORATION
cm3 I-EXPLORATION
y I-EXPLORATION
un I-EXPLORATION
peso I-EXPLORATION
estimado I-EXPLORATION
de I-EXPLORATION
34 I-EXPLORATION
gramos, I-EXPLORATION
observándose I-EXPLORATION
adecuado I-EXPLORATION
contraste I-EXPLORATION
entre I-EXPLORATION
la I-EXPLORATION
zona I-EXPLORATION
periférica I-EXPLORATION
y I-EXPLORATION
transicional, I-EXPLORATION
con I-EXPLORATION
ecogenicidad I-EXPLORATION
homogénea I-EXPLORATION
y I-EXPLORATION
bordes I-EXPLORATION
capsulares I-EXPLORATION
normales, I-EXPLORATION
sin I-EXPLORATION
zonas I-EXPLORATION
de I-EXPLORATION
vascularización I-EXPLORATION
anormales. I-EXPLORATION
Teniendo I-EXPLORATION
en I-EXPLORATION
cuenta I-EXPLORATION
los I-EXPLORATION
anteriores I-EXPLORATION
hallazgos I-EXPLORATION
se I-EXPLORATION
realizó I-EXPLORATION
biopsia I-EXPLORATION
por I-EXPLORATION
punción I-EXPLORATION
por I-EXPLORATION
sextantes, I-EXPLORATION
en I-EXPLORATION
la I-EXPLORATION
cual I-EXPLORATION
se I-EXPLORATION
evidenciaron I-EXPLORATION
múltiples I-EXPLORATION
granulomas I-EXPLORATION
constituidos I-EXPLORATION
por I-EXPLORATION
histiocitos I-EXPLORATION
epitelioides, I-EXPLORATION
rodeados I-EXPLORATION
por I-EXPLORATION
un I-EXPLORATION
collar I-EXPLORATION
de I-EXPLORATION
linfocitos I-EXPLORATION
y I-EXPLORATION
acompañados I-EXPLORATION
por I-EXPLORATION
células I-EXPLORATION
gigantes I-EXPLORATION
multinucleadas I-EXPLORATION
tipo I-EXPLORATION
Langhans, I-EXPLORATION
en I-EXPLORATION
algunos I-EXPLORATION
de I-EXPLORATION
estos I-EXPLORATION
granulomas I-EXPLORATION
se I-EXPLORATION
reconoció I-EXPLORATION
la I-EXPLORATION
presencia I-EXPLORATION
de I-EXPLORATION
necrosis I-EXPLORATION
de I-EXPLORATION
caseificación. I-EXPLORATION
La I-EXPLORATION
tinción I-EXPLORATION
de I-EXPLORATION
Ziel-Nielsen I-EXPLORATION
fue I-EXPLORATION
positiva I-EXPLORATION
para I-EXPLORATION
micobacterias. I-EXPLORATION
No I-EXPLORATION
se I-EXPLORATION
observaron I-EXPLORATION
alteraciones I-EXPLORATION
en I-EXPLORATION
el I-EXPLORATION
estudio I-EXPLORATION
radiográfico, I-EXPLORATION
ni I-EXPLORATION
tomográfico I-EXPLORATION
de I-EXPLORATION
tórax I-EXPLORATION
y I-EXPLORATION
no I-EXPLORATION
se I-EXPLORATION
encontró I-EXPLORATION
evidencia I-EXPLORATION
microbiológica I-EXPLORATION
de I-EXPLORATION
micobacterias I-EXPLORATION
en I-EXPLORATION
el I-EXPLORATION
estudio I-EXPLORATION
seriado I-EXPLORATION
del I-EXPLORATION
esputo, I-EXPLORATION
ni I-EXPLORATION
en I-EXPLORATION
el I-EXPLORATION
estudio I-EXPLORATION
del I-EXPLORATION
lavado I-EXPLORATION
broncoalveolar. I-EXPLORATION
Con I-EXPLORATION
los I-EXPLORATION
anteriores I-EXPLORATION
hallazgos I-EXPLORATION
se I-EXPLORATION
realizó I-EXPLORATION
el I-EXPLORATION
diagnostico I-EXPLORATION
de I-EXPLORATION
tuberculosis I-EXPLORATION
prostática I-EXPLORATION
primaria, I-EXPLORATION
iniciando B-TREATMENT
tratamiento I-TREATMENT
antituberculoso I-TREATMENT
con I-TREATMENT
Rifampicina, I-TREATMENT
Isoniazida I-TREATMENT
y I-TREATMENT
Estreptomicina I-TREATMENT
durante I-TREATMENT
6 I-TREATMENT
semanas, I-TREATMENT
posterior I-TREATMENT
al I-TREATMENT
cual I-TREATMENT
presentó I-TREATMENT
mejoría I-TREATMENT
de I-TREATMENT
la I-TREATMENT
sintomatología I-TREATMENT
con I-TREATMENT
solo I-TREATMENT
un I-TREATMENT
episodio I-TREATMENT
de I-TREATMENT
obstrucción I-TREATMENT
miccional I-TREATMENT
al I-TREATMENT
inicio I-TREATMENT
del I-TREATMENT
tratamiento. I-TREATMENT
Actualmente B-EVOLUTION
el I-EVOLUTION
paciente I-EVOLUTION
se I-EVOLUTION
encuentra I-EVOLUTION
asintomático I-EVOLUTION
sin I-EVOLUTION
evidencia I-EVOLUTION
de I-EVOLUTION
enfermedad I-EVOLUTION
tuberculosa I-EVOLUTION
activa. I-EVOLUTION
<EOS> I-EVOLUTION
Estrategia I-EVOLUTION
de I-EVOLUTION
búsqueda I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
literatura I-EVOLUTION
<EOS> I-EVOLUTION
Se I-EVOLUTION
realizó I-EVOLUTION
una I-EVOLUTION
búsqueda I-EVOLUTION
estructurada I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
literatura, I-EVOLUTION
utilizando I-EVOLUTION
la I-EVOLUTION
base I-EVOLUTION
de I-EVOLUTION
datos I-EVOLUTION
MedLine, I-EVOLUTION
a I-EVOLUTION
través I-EVOLUTION
de I-EVOLUTION
su I-EVOLUTION
portal I-EVOLUTION
Web I-EVOLUTION
PubMed, I-EVOLUTION
desde I-EVOLUTION
enero I-EVOLUTION
de I-EVOLUTION
1915 I-EVOLUTION
hasta I-EVOLUTION
Abril I-EVOLUTION
de I-EVOLUTION
2008, I-EVOLUTION
utilizando I-EVOLUTION
inicialmente I-EVOLUTION
los I-EVOLUTION
términos I-EVOLUTION
"Prostate I-EVOLUTION
tuberculosis" I-EVOLUTION
obteniendo I-EVOLUTION
153 I-EVOLUTION
artículos I-EVOLUTION
originales. I-EVOLUTION
Posteriormente I-EVOLUTION
se I-EVOLUTION
adiciono I-EVOLUTION
el I-EVOLUTION
termino I-EVOLUTION
"Primary" I-EVOLUTION
a I-EVOLUTION
los I-EVOLUTION
anteriores I-EVOLUTION
términos, I-EVOLUTION
lo I-EVOLUTION
cual I-EVOLUTION
arrojo I-EVOLUTION
15 I-EVOLUTION
artículos I-EVOLUTION
adicionales, I-EVOLUTION
para I-EVOLUTION
un I-EVOLUTION
total I-EVOLUTION
de I-EVOLUTION
168 I-EVOLUTION
artículos, I-EVOLUTION
de I-EVOLUTION
los I-EVOLUTION
cuales I-EVOLUTION
se I-EVOLUTION
seleccionaron I-EVOLUTION
aquellas I-EVOLUTION
publicaciones I-EVOLUTION
consideradas I-EVOLUTION
relevantes I-EVOLUTION
por I-EVOLUTION
parte I-EVOLUTION
de I-EVOLUTION
los I-EVOLUTION
autores I-EVOLUTION
para I-EVOLUTION
la I-EVOLUTION
discusión I-EVOLUTION
del I-EVOLUTION
tema. I-EVOLUTION
Además I-EVOLUTION
se I-EVOLUTION
tomó I-EVOLUTION
literatura I-EVOLUTION
proveniente I-EVOLUTION
de I-EVOLUTION
libros I-EVOLUTION
y I-EVOLUTION
otras I-EVOLUTION
publicaciones. I-EVOLUTION
<EOS> I-EVOLUTION
Hombre B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
17 I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
sin B-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
mórbidos, I-PAST_MEDICAL_HISTORY
que B-PRESENT_ILLNESS
ingresó I-PRESENT_ILLNESS
el I-PRESENT_ILLNESS
24/07/1992, I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
la I-PRESENT_ILLNESS
Unidad I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
Emergencia I-PRESENT_ILLNESS
del I-PRESENT_ILLNESS
Hospital I-PRESENT_ILLNESS
Clínico I-PRESENT_ILLNESS
Regional I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
Valdivia, I-PRESENT_ILLNESS
20 I-PRESENT_ILLNESS
minutos I-PRESENT_ILLNESS
posterior I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
haber I-PRESENT_ILLNESS
sufrido I-PRESENT_ILLNESS
trauma I-PRESENT_ILLNESS
toracoabdominal I-PRESENT_ILLNESS
cerrado I-PRESENT_ILLNESS
(aplastamiento I-PRESENT_ILLNESS
entre I-PRESENT_ILLNESS
muralla I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
concreto I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
camión). I-PRESENT_ILLNESS
Al B-EXPLORATION
examen, I-EXPLORATION
se I-EXPLORATION
encontró I-EXPLORATION
conciente, I-EXPLORATION
orientado I-EXPLORATION
temporoespacialmente, I-EXPLORATION
pálido, I-EXPLORATION
taquicárdico I-EXPLORATION
(pulso I-EXPLORATION
112x' I-EXPLORATION
débil), I-EXPLORATION
hipotenso I-EXPLORATION
(PA I-EXPLORATION
70/50 I-EXPLORATION
mmHg), I-EXPLORATION
respiración I-EXPLORATION
paradojal, I-EXPLORATION
destacando I-EXPLORATION
múltiples I-EXPLORATION
erosiones I-EXPLORATION
toracoabdominales, I-EXPLORATION
crepitaciones I-EXPLORATION
costales I-EXPLORATION
múltiples, I-EXPLORATION
aumento I-EXPLORATION
de I-EXPLORATION
volumen I-EXPLORATION
y I-EXPLORATION
deformidad I-EXPLORATION
del I-EXPLORATION
antebrazo I-EXPLORATION
izquierdo, I-EXPLORATION
abolición I-EXPLORATION
del I-EXPLORATION
murmullo I-EXPLORATION
pulmonar I-EXPLORATION
en I-EXPLORATION
base I-EXPLORATION
derecha, I-EXPLORATION
abdomen I-EXPLORATION
sensible I-EXPLORATION
y I-EXPLORATION
pérdida I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
matidez I-EXPLORATION
hepática. I-EXPLORATION
Se I-EXPLORATION
efectuó I-EXPLORATION
ecografía I-EXPLORATION
abdominal I-EXPLORATION
que I-EXPLORATION
mostró I-EXPLORATION
líquido I-EXPLORATION
libre, I-EXPLORATION
sin I-EXPLORATION
identificar I-EXPLORATION
lesión I-EXPLORATION
hepática. I-EXPLORATION
<EOS> I-EXPLORATION
Una I-EXPLORATION
vez I-EXPLORATION
estabilizado, I-EXPLORATION
fue I-EXPLORATION
a I-EXPLORATION
pabellón, I-EXPLORATION
a I-EXPLORATION
las I-EXPLORATION
2 I-EXPLORATION
h I-EXPLORATION
después I-EXPLORATION
del I-EXPLORATION
ingreso, I-EXPLORATION
con I-EXPLORATION
los I-EXPLORATION
diagnósticos I-EXPLORATION
de I-EXPLORATION
trauma I-EXPLORATION
toracoabdominal I-EXPLORATION
complicado, I-EXPLORATION
probable I-EXPLORATION
rotura I-EXPLORATION
de I-EXPLORATION
víscera I-EXPLORATION
hueca, I-EXPLORATION
fractura I-EXPLORATION
de I-EXPLORATION
antebrazo I-EXPLORATION
izquierdo, I-EXPLORATION
fractura I-EXPLORATION
esternal, I-EXPLORATION
tórax I-EXPLORATION
volante I-EXPLORATION
y I-EXPLORATION
hemoneumotórax I-EXPLORATION
derecho. I-EXPLORATION
Se B-TREATMENT
instaló I-TREATMENT
pleurostomía I-TREATMENT
derecha, I-TREATMENT
dando I-TREATMENT
salida I-TREATMENT
a I-TREATMENT
aire I-TREATMENT
y I-TREATMENT
sangre. I-TREATMENT
Se I-TREATMENT
abordó I-TREATMENT
vía I-TREATMENT
laparotomía I-TREATMENT
media I-TREATMENT
supraumbilical, I-TREATMENT
encontrando I-TREATMENT
hemoperitoneo I-TREATMENT
de I-TREATMENT
3 I-TREATMENT
l, I-TREATMENT
se I-TREATMENT
identificó I-TREATMENT
lesión I-TREATMENT
hepática I-TREATMENT
única, I-TREATMENT
paralela I-TREATMENT
a I-TREATMENT
ligamento I-TREATMENT
falciforme, I-TREATMENT
que I-TREATMENT
seccionaba I-TREATMENT
al I-TREATMENT
hígado I-TREATMENT
en I-TREATMENT
dos. I-TREATMENT
No I-TREATMENT
se I-TREATMENT
logró I-TREATMENT
control I-TREATMENT
del I-TREATMENT
sangrado I-TREATMENT
con I-TREATMENT
maniobra I-TREATMENT
de I-TREATMENT
Pringle, I-TREATMENT
identificando I-TREATMENT
origen I-TREATMENT
de I-TREATMENT
sangrado I-TREATMENT
en I-TREATMENT
vena I-TREATMENT
cava I-TREATMENT
supra I-TREATMENT
y I-TREATMENT
retrohepática. I-TREATMENT
<EOS> I-TREATMENT
Se I-TREATMENT
decidió I-TREATMENT
realizar I-TREATMENT
shunt I-TREATMENT
atriocava, I-TREATMENT
ampliando I-TREATMENT
incisión I-TREATMENT
a I-TREATMENT
toracofrenolaparotomía I-TREATMENT
derecha I-TREATMENT
y I-TREATMENT
se I-TREATMENT
instaló I-TREATMENT
tubo I-TREATMENT
orotraqueal I-TREATMENT
7, I-TREATMENT
5 I-TREATMENT
a I-TREATMENT
través I-TREATMENT
de I-TREATMENT
aurícula I-TREATMENT
derecha, I-TREATMENT
cediendo I-TREATMENT
el I-TREATMENT
sangrado, I-TREATMENT
identificando I-TREATMENT
2 I-TREATMENT
lesiones I-TREATMENT
en I-TREATMENT
vena I-TREATMENT
cava I-TREATMENT
suprahepática I-TREATMENT
de I-TREATMENT
1 I-TREATMENT
y I-TREATMENT
2 I-TREATMENT
cm I-TREATMENT
y I-TREATMENT
una I-TREATMENT
lesión I-TREATMENT
de I-TREATMENT
1 I-TREATMENT
cm I-TREATMENT
a I-TREATMENT
nivel I-TREATMENT
de I-TREATMENT
cava I-TREATMENT
retrohepática, I-TREATMENT
que I-TREATMENT
se I-TREATMENT
suturan I-TREATMENT
con I-TREATMENT
prolene I-TREATMENT
4/0, I-TREATMENT
completando, I-TREATMENT
posteriormente, I-TREATMENT
hepatectomía I-TREATMENT
izquierda. I-TREATMENT
Durante I-TREATMENT
la I-TREATMENT
cirugía I-TREATMENT
se I-TREATMENT
transfundieron I-TREATMENT
10 I-TREATMENT
U I-TREATMENT
de I-TREATMENT
sangre I-TREATMENT
total, I-TREATMENT
3 I-TREATMENT
U I-TREATMENT
de I-TREATMENT
glóbulos I-TREATMENT
rojos, I-TREATMENT
5 I-TREATMENT
U I-TREATMENT
de I-TREATMENT
crioprecipitados, I-TREATMENT
2 I-TREATMENT
U I-TREATMENT
de I-TREATMENT
plaquetas I-TREATMENT
y I-TREATMENT
6 I-TREATMENT
U I-TREATMENT
de I-TREATMENT
plasma. I-TREATMENT
<EOS> I-TREATMENT
Ingresó B-EVOLUTION
a I-EVOLUTION
la I-EVOLUTION
Unidad I-EVOLUTION
de I-EVOLUTION
Cuidados I-EVOLUTION
Intensivos I-EVOLUTION
(UCI) I-EVOLUTION
con I-EVOLUTION
PA I-EVOLUTION
100/60 I-EVOLUTION
mmHg, I-EVOLUTION
pulso I-EVOLUTION
162 I-EVOLUTION
x', I-EVOLUTION
PVC I-EVOLUTION
16 I-EVOLUTION
cmH2O. I-EVOLUTION
Se B-TREATMENT
conectó I-TREATMENT
a I-TREATMENT
ventilación I-TREATMENT
mecánica I-TREATMENT
que I-TREATMENT
se I-TREATMENT
mantuvo I-TREATMENT
por I-TREATMENT
48 I-TREATMENT
h, I-TREATMENT
cursando I-TREATMENT
posteriormente I-TREATMENT
con I-TREATMENT
coagulación I-TREATMENT
intravascular. I-TREATMENT
Evolucionó B-EVOLUTION
favorablemente, I-EVOLUTION
siendo I-EVOLUTION
trasladado I-EVOLUTION
al I-EVOLUTION
décimo I-EVOLUTION
día I-EVOLUTION
postoperatorio I-EVOLUTION
(03/08/1992) I-EVOLUTION
al I-EVOLUTION
Servicio I-EVOLUTION
de I-EVOLUTION
Cirugía I-EVOLUTION
y I-EVOLUTION
posteriormente I-EVOLUTION
a I-EVOLUTION
mutualidad I-EVOLUTION
el I-EVOLUTION
08/08/1992, I-EVOLUTION
desde I-EVOLUTION
donde I-EVOLUTION
fue I-EVOLUTION
dado I-EVOLUTION
de I-EVOLUTION
alta I-EVOLUTION
en I-EVOLUTION
buenas I-EVOLUTION
condiciones I-EVOLUTION
el I-EVOLUTION
20/08/1992. I-EVOLUTION
<EOS> I-EVOLUTION
Mujer, B-PRESENT_ILLNESS
63 I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
edad, I-PRESENT_ILLNESS
asintomática B-PAST_MEDICAL_HISTORY
cardiovascular. I-PAST_MEDICAL_HISTORY
Mientras B-PRESENT_ILLNESS
realizaba I-PRESENT_ILLNESS
ejercicio I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
moderada I-PRESENT_ILLNESS
intensidad, I-PRESENT_ILLNESS
presentó I-PRESENT_ILLNESS
palpitaciones I-PRESENT_ILLNESS
rápidas, I-PRESENT_ILLNESS
regulares, I-PRESENT_ILLNESS
asociadas I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
compromiso I-PRESENT_ILLNESS
del I-PRESENT_ILLNESS
estado I-PRESENT_ILLNESS
general I-PRESENT_ILLNESS
progresivo. I-PRESENT_ILLNESS
Consultó B-EXPLORATION
en I-EXPLORATION
urgencia, I-EXPLORATION
documentándose I-EXPLORATION
taquicardia I-EXPLORATION
regular, I-EXPLORATION
con I-EXPLORATION
frecuencia I-EXPLORATION
de I-EXPLORATION
180 I-EXPLORATION
latidos I-EXPLORATION
por I-EXPLORATION
minuto I-EXPLORATION
y I-EXPLORATION
complejo I-EXPLORATION
QRS I-EXPLORATION
angosto, I-EXPLORATION
asociada I-EXPLORATION
a I-EXPLORATION
hipotensión, I-EXPLORATION
por B-TREATMENT
lo I-TREATMENT
cual I-TREATMENT
se I-TREATMENT
realizó I-TREATMENT
cardioversión I-TREATMENT
eléctrica. I-TREATMENT
<EOS> I-TREATMENT
Se B-EVOLUTION
hospitalizó I-EVOLUTION
para I-EVOLUTION
monitorización I-EVOLUTION
y I-EVOLUTION
estudio. I-EVOLUTION
Su B-EXPLORATION
ECG I-EXPLORATION
basal I-EXPLORATION
mostró I-EXPLORATION
ritmo I-EXPLORATION
sinusal I-EXPLORATION
con I-EXPLORATION
complejos I-EXPLORATION
QRS I-EXPLORATION
normales. I-EXPLORATION
Se I-EXPLORATION
controlaron I-EXPLORATION
enzimas I-EXPLORATION
cardíacas I-EXPLORATION
seriadas. I-EXPLORATION
<EOS> I-EXPLORATION
Se B-TREATMENT
realizó I-TREATMENT
EEF I-TREATMENT
que I-TREATMENT
mostró I-TREATMENT
HPE I-TREATMENT
lateral I-TREATMENT
izquierdo I-TREATMENT
oculto I-TREATMENT
y I-TREATMENT
taquicardia I-TREATMENT
ortodrómica I-TREATMENT
por I-TREATMENT
éste, I-TREATMENT
realizándose I-TREATMENT
fulguración I-TREATMENT
exitosa. I-TREATMENT
<EOS> I-TREATMENT
Paciente B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
sexo I-PRESENT_ILLNESS
femenino, I-PRESENT_ILLNESS
73 I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
edad. I-PRESENT_ILLNESS
Sin B-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
mórbidos I-PAST_MEDICAL_HISTORY
relevantes. I-PAST_MEDICAL_HISTORY
No I-PAST_MEDICAL_HISTORY
había I-PAST_MEDICAL_HISTORY
sido I-PAST_MEDICAL_HISTORY
sometida I-PAST_MEDICAL_HISTORY
a I-PAST_MEDICAL_HISTORY
cirugías I-PAST_MEDICAL_HISTORY
abdominales I-PAST_MEDICAL_HISTORY
ni I-PAST_MEDICAL_HISTORY
había I-PAST_MEDICAL_HISTORY
presentado I-PAST_MEDICAL_HISTORY
recientemente I-PAST_MEDICAL_HISTORY
algún I-PAST_MEDICAL_HISTORY
cuadro I-PAST_MEDICAL_HISTORY
abdominal I-PAST_MEDICAL_HISTORY
agudo I-PAST_MEDICAL_HISTORY
ni I-PAST_MEDICAL_HISTORY
traumatismos I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
la I-PAST_MEDICAL_HISTORY
zona. I-PAST_MEDICAL_HISTORY
Consultó B-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
molestias I-PRESENT_ILLNESS
digestivas I-PRESENT_ILLNESS
vagas, I-PRESENT_ILLNESS
fundamentalmente I-PRESENT_ILLNESS
del I-PRESENT_ILLNESS
tipo I-PRESENT_ILLNESS
dispéptico, I-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
flatulencia, I-PRESENT_ILLNESS
distensión I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
tendencia I-PRESENT_ILLNESS
fluctuante I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
la I-PRESENT_ILLNESS
estitiquez. I-PRESENT_ILLNESS
El B-EXPLORATION
examen I-EXPLORATION
físico I-EXPLORATION
demostraba I-EXPLORATION
una I-EXPLORATION
paciente I-EXPLORATION
en I-EXPLORATION
buen I-EXPLORATION
estado I-EXPLORATION
general, I-EXPLORATION
con I-EXPLORATION
mucosas I-EXPLORATION
rosadas I-EXPLORATION
y I-EXPLORATION
buen I-EXPLORATION
estado I-EXPLORATION
nutritivo. I-EXPLORATION
La I-EXPLORATION
evaluación I-EXPLORATION
abdominal I-EXPLORATION
descartó I-EXPLORATION
visceromegalia I-EXPLORATION
y I-EXPLORATION
presencia I-EXPLORATION
de I-EXPLORATION
masas. I-EXPLORATION
Sin I-EXPLORATION
soplos I-EXPLORATION
abdominales, I-EXPLORATION
con I-EXPLORATION
buenos I-EXPLORATION
pulsos I-EXPLORATION
inguinales I-EXPLORATION
y I-EXPLORATION
distales. I-EXPLORATION
Se I-EXPLORATION
le I-EXPLORATION
solicitó I-EXPLORATION
hemograma I-EXPLORATION
y I-EXPLORATION
exámenes I-EXPLORATION
bioquímicos, I-EXPLORATION
más I-EXPLORATION
una I-EXPLORATION
exploración I-EXPLORATION
abdominal I-EXPLORATION
por I-EXPLORATION
ultrasonografía I-EXPLORATION
(US). I-EXPLORATION
<EOS> I-EXPLORATION
Los I-EXPLORATION
resultados I-EXPLORATION
demostraron I-EXPLORATION
ausencia I-EXPLORATION
de I-EXPLORATION
anemia I-EXPLORATION
y I-EXPLORATION
funciones I-EXPLORATION
hepática I-EXPLORATION
y I-EXPLORATION
renal I-EXPLORATION
normales. I-EXPLORATION
La I-EXPLORATION
US I-EXPLORATION
puso I-EXPLORATION
en I-EXPLORATION
evidencia I-EXPLORATION
una I-EXPLORATION
lesión I-EXPLORATION
de I-EXPLORATION
aspecto I-EXPLORATION
quístico I-EXPLORATION
de I-EXPLORATION
2, I-EXPLORATION
3 I-EXPLORATION
centímetros I-EXPLORATION
de I-EXPLORATION
diámetro, I-EXPLORATION
en I-EXPLORATION
relación I-EXPLORATION
con I-EXPLORATION
el I-EXPLORATION
cuerpo I-EXPLORATION
del I-EXPLORATION
páncreas. I-EXPLORATION
Este I-EXPLORATION
último I-EXPLORATION
examen I-EXPLORATION
motivó I-EXPLORATION
una I-EXPLORATION
tomografía I-EXPLORATION
axial I-EXPLORATION
computada I-EXPLORATION
(TAC) I-EXPLORATION
del I-EXPLORATION
abdomen, I-EXPLORATION
que I-EXPLORATION
confirmó I-EXPLORATION
la I-EXPLORATION
presencia I-EXPLORATION
de I-EXPLORATION
un I-EXPLORATION
aneurisma I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
arteria I-EXPLORATION
esplénica I-EXPLORATION
de I-EXPLORATION
2, I-EXPLORATION
5 I-EXPLORATION
cm I-EXPLORATION
de I-EXPLORATION
diámetro I-EXPLORATION
a I-EXPLORATION
la I-EXPLORATION
altura I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
región I-EXPLORATION
córporo-caudal I-EXPLORATION
del I-EXPLORATION
páncreas. I-EXPLORATION
<EOS> I-EXPLORATION
Se B-TREATMENT
programó I-TREATMENT
para I-TREATMENT
tratamiento I-TREATMENT
endovascular, I-TREATMENT
efectuándose I-TREATMENT
una I-TREATMENT
exploración I-TREATMENT
por I-TREATMENT
vía I-TREATMENT
femoral I-TREATMENT
derecha I-TREATMENT
según I-TREATMENT
método I-TREATMENT
de I-TREATMENT
Seldinger I-TREATMENT
con I-TREATMENT
técnica I-TREATMENT
coaxial, I-TREATMENT
y I-TREATMENT
embolización I-TREATMENT
mediante I-TREATMENT
coils I-TREATMENT
metálicos, I-TREATMENT
hasta I-TREATMENT
oclusión I-TREATMENT
completa I-TREATMENT
de I-TREATMENT
la I-TREATMENT
cavidad. I-TREATMENT
<EOS> I-TREATMENT
La B-EXPLORATION
TAC I-EXPLORATION
de I-EXPLORATION
control, I-EXPLORATION
efectuada I-EXPLORATION
a I-EXPLORATION
los I-EXPLORATION
30 I-EXPLORATION
días, I-EXPLORATION
mostró I-EXPLORATION
los I-EXPLORATION
coils I-EXPLORATION
en I-EXPLORATION
el I-EXPLORATION
segmento I-EXPLORATION
aneurismático I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
arteria I-EXPLORATION
esplénica I-EXPLORATION
con I-EXPLORATION
permeabilidad I-EXPLORATION
distal. I-EXPLORATION
No I-EXPLORATION
se I-EXPLORATION
visualizó I-EXPLORATION
ninguna I-EXPLORATION
lesión I-EXPLORATION
focal I-EXPLORATION
de I-EXPLORATION
aspecto I-EXPLORATION
isquémico I-EXPLORATION
en I-EXPLORATION
el I-EXPLORATION
parénquima I-EXPLORATION
del I-EXPLORATION
bazo. I-EXPLORATION
A B-EVOLUTION
un I-EVOLUTION
año I-EVOLUTION
del I-EVOLUTION
procedimiento, I-EVOLUTION
la I-EVOLUTION
paciente I-EVOLUTION
se I-EVOLUTION
encuentra I-EVOLUTION
en I-EVOLUTION
buenas I-EVOLUTION
condiciones, I-EVOLUTION
y I-EVOLUTION
sin I-EVOLUTION
síntomas. I-EVOLUTION
<EOS> I-EVOLUTION
Varón, B-PRESENT_ILLNESS
32 I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
edad, I-PRESENT_ILLNESS
deportista, B-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
historia I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
3 I-PAST_MEDICAL_HISTORY
meses I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
evolución I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
claudicación I-PAST_MEDICAL_HISTORY
intermitente. I-PAST_MEDICAL_HISTORY
Consultó, B-PRESENT_ILLNESS
al I-PRESENT_ILLNESS
cabo I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
estos I-PRESENT_ILLNESS
tres I-PRESENT_ILLNESS
meses, I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
necrosis I-PRESENT_ILLNESS
del I-PRESENT_ILLNESS
primer I-PRESENT_ILLNESS
dedo I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
su I-PRESENT_ILLNESS
pie I-PRESENT_ILLNESS
derecho. I-PRESENT_ILLNESS
<EOS> I-PRESENT_ILLNESS
En B-EXPLORATION
el I-EXPLORATION
examen I-EXPLORATION
físico I-EXPLORATION
destacó I-EXPLORATION
ausencia I-EXPLORATION
de I-EXPLORATION
pulsos I-EXPLORATION
poplíteo I-EXPLORATION
y I-EXPLORATION
distales I-EXPLORATION
en I-EXPLORATION
la I-EXPLORATION
extremidad I-EXPLORATION
comprometida I-EXPLORATION
y I-EXPLORATION
necrosis I-EXPLORATION
seca I-EXPLORATION
del I-EXPLORATION
tercio I-EXPLORATION
distal I-EXPLORATION
del I-EXPLORATION
1er I-EXPLORATION
dedo I-EXPLORATION
derecho. I-EXPLORATION
El I-EXPLORATION
examen I-EXPLORATION
de I-EXPLORATION
los I-EXPLORATION
pulsos I-EXPLORATION
en I-EXPLORATION
la I-EXPLORATION
extremidad I-EXPLORATION
contralateral I-EXPLORATION
fue I-EXPLORATION
normal. I-EXPLORATION
<EOS> I-EXPLORATION
Se I-EXPLORATION
realizó I-EXPLORATION
un I-EXPLORATION
registro I-EXPLORATION
de I-EXPLORATION
volumen I-EXPLORATION
de I-EXPLORATION
pulso I-EXPLORATION
en I-EXPLORATION
la I-EXPLORATION
extremidad I-EXPLORATION
derecha, I-EXPLORATION
evidenciándose I-EXPLORATION
alterado I-EXPLORATION
de I-EXPLORATION
rodilla I-EXPLORATION
a I-EXPLORATION
distal. I-EXPLORATION
El I-EXPLORATION
valor I-EXPLORATION
del I-EXPLORATION
índice I-EXPLORATION
tobillo-brazo I-EXPLORATION
fue I-EXPLORATION
0, I-EXPLORATION
64. I-EXPLORATION
<EOS> I-EXPLORATION
Se I-EXPLORATION
realizó I-EXPLORATION
angiografía I-EXPLORATION
por I-EXPLORATION
acceso I-EXPLORATION
femoral I-EXPLORATION
izquierdo, I-EXPLORATION
la I-EXPLORATION
cual I-EXPLORATION
mostró I-EXPLORATION
una I-EXPLORATION
medialización I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
arteria I-EXPLORATION
poplítea I-EXPLORATION
derecha, I-EXPLORATION
asociada I-EXPLORATION
a I-EXPLORATION
estenosis I-EXPLORATION
irregular I-EXPLORATION
del I-EXPLORATION
lumen I-EXPLORATION
arterial I-EXPLORATION
y I-EXPLORATION
dilatación I-EXPLORATION
post-estenótica I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
arteria. I-EXPLORATION
<EOS> I-EXPLORATION
Se B-TREATMENT
procedió I-TREATMENT
a I-TREATMENT
cirugía I-TREATMENT
electiva, I-TREATMENT
abordando I-TREATMENT
el I-TREATMENT
hueco I-TREATMENT
poplíteo I-TREATMENT
por I-TREATMENT
vía I-TREATMENT
posterior. I-TREATMENT
Durante I-TREATMENT
la I-TREATMENT
disección I-TREATMENT
de I-TREATMENT
la I-TREATMENT
estructuras I-TREATMENT
vasculares I-TREATMENT
se I-TREATMENT
observó I-TREATMENT
la I-TREATMENT
arteria I-TREATMENT
poplítea I-TREATMENT
desplazada I-TREATMENT
hacia I-TREATMENT
medial I-TREATMENT
por I-TREATMENT
la I-TREATMENT
cabeza I-TREATMENT
medial I-TREATMENT
del I-TREATMENT
gastrocnemio. I-TREATMENT
Se I-TREATMENT
realizó I-TREATMENT
resección I-TREATMENT
del I-TREATMENT
segmento I-TREATMENT
comprometido I-TREATMENT
(el I-TREATMENT
cual I-TREATMENT
se I-TREATMENT
envió I-TREATMENT
a I-TREATMENT
estudio I-TREATMENT
histológico) I-TREATMENT
y I-TREATMENT
reconstrucción I-TREATMENT
mediante I-TREATMENT
interposición I-TREATMENT
de I-TREATMENT
vena I-TREATMENT
safena I-TREATMENT
externa I-TREATMENT
invertida. I-TREATMENT
En B-EVOLUTION
el I-EVOLUTION
postoperatorio I-EVOLUTION
inmediato I-EVOLUTION
el I-EVOLUTION
paciente I-EVOLUTION
recuperó I-EVOLUTION
los I-EVOLUTION
pulsos I-EVOLUTION
poplíteo I-EVOLUTION
y I-EVOLUTION
tibial I-EVOLUTION
posterior. I-EVOLUTION
<EOS> I-EVOLUTION
El B-EXPLORATION
informe I-EXPLORATION
de I-EXPLORATION
anatomía I-EXPLORATION
patológica I-EXPLORATION
reveló I-EXPLORATION
ateroesclerosis I-EXPLORATION
hialina I-EXPLORATION
con I-EXPLORATION
formación I-EXPLORATION
de I-EXPLORATION
un I-EXPLORATION
aneurisma. I-EXPLORATION
El I-EXPLORATION
estudio I-EXPLORATION
con I-EXPLORATION
angiografía I-EXPLORATION
por I-EXPLORATION
tomografía I-EXPLORATION
axial I-EXPLORATION
computada I-EXPLORATION
(TAC) I-EXPLORATION
no I-EXPLORATION
reveló I-EXPLORATION
atrapamiento I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
arteria I-EXPLORATION
poplítea I-EXPLORATION
contralateral. I-EXPLORATION
<EOS> I-EXPLORATION
El B-EVOLUTION
paciente I-EVOLUTION
evolucionó I-EVOLUTION
favorablemente I-EVOLUTION
sin I-EVOLUTION
progresión I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
necrosis. I-EVOLUTION
Requirió B-TREATMENT
una I-TREATMENT
amputación I-TREATMENT
del I-TREATMENT
primer I-TREATMENT
dedo, I-TREATMENT
a I-TREATMENT
nivel I-TREATMENT
de I-TREATMENT
la I-TREATMENT
falange I-TREATMENT
proximal, I-TREATMENT
a I-TREATMENT
los I-TREATMENT
3 I-TREATMENT
meses I-TREATMENT
del I-TREATMENT
alta. I-TREATMENT
<EOS> I-TREATMENT
Mujer B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
59 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
sin B-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
mórbidos. I-PAST_MEDICAL_HISTORY
Veintiocho B-PRESENT_ILLNESS
meses I-PRESENT_ILLNESS
pretrasplante I-PRESENT_ILLNESS
debutó I-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
edema I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
orina I-PRESENT_ILLNESS
espumosa, I-PRESENT_ILLNESS
objetivándose I-PRESENT_ILLNESS
síndrome I-PRESENT_ILLNESS
nefrótico I-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
proteinuria I-PRESENT_ILLNESS
hasta I-PRESENT_ILLNESS
9 I-PRESENT_ILLNESS
g/día I-PRESENT_ILLNESS
e I-PRESENT_ILLNESS
hipoalbuminemia I-PRESENT_ILLNESS
1, I-PRESENT_ILLNESS
9 I-PRESENT_ILLNESS
g/dL. I-PRESENT_ILLNESS
El B-EXPLORATION
clearance I-EXPLORATION
de I-EXPLORATION
creatinina I-EXPLORATION
y I-EXPLORATION
la I-EXPLORATION
presión I-EXPLORATION
arterial I-EXPLORATION
eran I-EXPLORATION
normales. I-EXPLORATION
El I-EXPLORATION
estudio I-EXPLORATION
etiológico I-EXPLORATION
incluyó I-EXPLORATION
exámenes I-EXPLORATION
de I-EXPLORATION
laboratorio I-EXPLORATION
inmunológico I-EXPLORATION
(anticuerpos I-EXPLORATION
antinucleares, I-EXPLORATION
anticuerpos I-EXPLORATION
antiADN, I-EXPLORATION
anticuerpos I-EXPLORATION
anticitoplasma I-EXPLORATION
de I-EXPLORATION
neutrófilos, I-EXPLORATION
complementemia), I-EXPLORATION
viral I-EXPLORATION
(antígeno I-EXPLORATION
de I-EXPLORATION
superficie I-EXPLORATION
de I-EXPLORATION
virus I-EXPLORATION
hepatitis I-EXPLORATION
B, I-EXPLORATION
anticuerpos I-EXPLORATION
antivirus I-EXPLORATION
hepatitis I-EXPLORATION
C, I-EXPLORATION
virus I-EXPLORATION
de I-EXPLORATION
inmunodeficiencia I-EXPLORATION
humana), I-EXPLORATION
y I-EXPLORATION
electroforesis I-EXPLORATION
de I-EXPLORATION
proteína I-EXPLORATION
en I-EXPLORATION
sangre, I-EXPLORATION
los I-EXPLORATION
que I-EXPLORATION
resultaron I-EXPLORATION
normales. I-EXPLORATION
La I-EXPLORATION
búsqueda I-EXPLORATION
de I-EXPLORATION
una I-EXPLORATION
neoplasia I-EXPLORATION
sólida I-EXPLORATION
resultó I-EXPLORATION
negativa, I-EXPLORATION
incluyendo I-EXPLORATION
mamografía, I-EXPLORATION
radiografía I-EXPLORATION
de I-EXPLORATION
tórax, I-EXPLORATION
ecotomografía I-EXPLORATION
abdominal I-EXPLORATION
y I-EXPLORATION
pelviana, I-EXPLORATION
endoscopia I-EXPLORATION
digestiva I-EXPLORATION
alta I-EXPLORATION
y I-EXPLORATION
colonoscopia. I-EXPLORATION
Se I-EXPLORATION
realizó I-EXPLORATION
biopsia I-EXPLORATION
renal I-EXPLORATION
24 I-EXPLORATION
meses I-EXPLORATION
pretrasplante, I-EXPLORATION
que I-EXPLORATION
reveló I-EXPLORATION
amiloidosis. I-EXPLORATION
La I-EXPLORATION
tinción I-EXPLORATION
con I-EXPLORATION
Rojo I-EXPLORATION
de I-EXPLORATION
Congo, I-EXPLORATION
y I-EXPLORATION
Rojo I-EXPLORATION
de I-EXPLORATION
Congo I-EXPLORATION
con I-EXPLORATION
permanganato I-EXPLORATION
de I-EXPLORATION
potasio I-EXPLORATION
fueron I-EXPLORATION
ambas I-EXPLORATION
muy I-EXPLORATION
tenuemente I-EXPLORATION
positivas I-EXPLORATION
en I-EXPLORATION
glomérulos I-EXPLORATION
y I-EXPLORATION
vasos I-EXPLORATION
sanguíneos. I-EXPLORATION
En I-EXPLORATION
la I-EXPLORATION
microscopia I-EXPLORATION
electrónica I-EXPLORATION
se I-EXPLORATION
observó I-EXPLORATION
desaparición I-EXPLORATION
pedicelar I-EXPLORATION
parcelar I-EXPLORATION
y I-EXPLORATION
depósitos I-EXPLORATION
densos I-EXPLORATION
de I-EXPLORATION
material I-EXPLORATION
amiloideo I-EXPLORATION
en I-EXPLORATION
la I-EXPLORATION
zona I-EXPLORATION
mesangial I-EXPLORATION
y I-EXPLORATION
en I-EXPLORATION
algunas I-EXPLORATION
asas I-EXPLORATION
capilares I-EXPLORATION
libres, I-EXPLORATION
de I-EXPLORATION
aspecto I-EXPLORATION
fibrilar, I-EXPLORATION
con I-EXPLORATION
fibrillas I-EXPLORATION
de I-EXPLORATION
un I-EXPLORATION
espesor I-EXPLORATION
promedio I-EXPLORATION
de I-EXPLORATION
100 I-EXPLORATION
Angström. I-EXPLORATION
Un I-EXPLORATION
estudio I-EXPLORATION
posterior I-EXPLORATION
con I-EXPLORATION
inmunofijación I-EXPLORATION
sérica I-EXPLORATION
y I-EXPLORATION
urinaria I-EXPLORATION
resultó I-EXPLORATION
positivo I-EXPLORATION
para I-EXPLORATION
IgA-lambda I-EXPLORATION
monoclonal. I-EXPLORATION
La I-EXPLORATION
cuantificación I-EXPLORATION
de I-EXPLORATION
inmunoglobulinas I-EXPLORATION
séricas I-EXPLORATION
reveló I-EXPLORATION
IgA I-EXPLORATION
1.000 I-EXPLORATION
mg/dL, I-EXPLORATION
IgG I-EXPLORATION
852 I-EXPLORATION
mg/dL I-EXPLORATION
e I-EXPLORATION
IgM I-EXPLORATION
93 I-EXPLORATION
mg/dL. I-EXPLORATION
El I-EXPLORATION
mielograma I-EXPLORATION
y I-EXPLORATION
la I-EXPLORATION
citometría I-EXPLORATION
de I-EXPLORATION
flujo I-EXPLORATION
de I-EXPLORATION
médula I-EXPLORATION
ósea I-EXPLORATION
descartaron I-EXPLORATION
un I-EXPLORATION
mieloma I-EXPLORATION
múltiple. I-EXPLORATION
Recibió B-TREATMENT
tratamiento I-TREATMENT
con I-TREATMENT
melfalán I-TREATMENT
oral I-TREATMENT
y I-TREATMENT
prednisona I-TREATMENT
durante I-TREATMENT
6 I-TREATMENT
meses, I-TREATMENT
persistiendo I-TREATMENT
la I-TREATMENT
proteinuria I-TREATMENT
nefrótica I-TREATMENT
y I-TREATMENT
la I-TREATMENT
inmunofijación I-TREATMENT
sérica I-TREATMENT
positiva. I-TREATMENT
Posteriormente I-TREATMENT
se I-TREATMENT
mantuvo I-TREATMENT
sólo I-TREATMENT
con I-TREATMENT
terapia I-TREATMENT
inespecífica I-TREATMENT
que I-TREATMENT
incluyó I-TREATMENT
enalapril, I-TREATMENT
espironolactona I-TREATMENT
y I-TREATMENT
atorvastatina. I-TREATMENT
Tres B-EVOLUTION
meses I-EVOLUTION
pretrasplante I-EVOLUTION
se I-EVOLUTION
mantenía I-EVOLUTION
la I-EVOLUTION
presencia I-EVOLUTION
de I-EVOLUTION
proteína I-EVOLUTION
monoclonal I-EVOLUTION
y I-EVOLUTION
de I-EVOLUTION
síndrome I-EVOLUTION
nefrótico, I-EVOLUTION
con I-EVOLUTION
filtración I-EVOLUTION
glomerular I-EVOLUTION
normal. I-EVOLUTION
Un B-EXPLORATION
ecocardiograma I-EXPLORATION
transtorácico I-EXPLORATION
y I-EXPLORATION
una I-EXPLORATION
ventriculografía I-EXPLORATION
isotópica I-EXPLORATION
fueron I-EXPLORATION
normales. I-EXPLORATION
<EOS> I-EXPLORATION
En I-EXPLORATION
enero I-EXPLORATION
de I-EXPLORATION
2004 I-EXPLORATION
se I-EXPLORATION
efectuó I-EXPLORATION
acondicionamiento I-EXPLORATION
medular I-EXPLORATION
con I-EXPLORATION
factor I-EXPLORATION
estimulante I-EXPLORATION
de I-EXPLORATION
colonias I-EXPLORATION
granulocíticas I-EXPLORATION
por I-EXPLORATION
cinco I-EXPLORATION
días, I-EXPLORATION
y I-EXPLORATION
cosecha I-EXPLORATION
mediante I-EXPLORATION
leucoaféresis I-EXPLORATION
de I-EXPLORATION
sangre I-EXPLORATION
periférica I-EXPLORATION
de I-EXPLORATION
2, I-EXPLORATION
6 I-EXPLORATION
x I-EXPLORATION
106 I-EXPLORATION
células I-EXPLORATION
troncales I-EXPLORATION
hematopoyéticas. I-EXPLORATION
Recibió B-TREATMENT
melfalán I-TREATMENT
endovenoso I-TREATMENT
200 I-TREATMENT
mg/m2 I-TREATMENT
de I-TREATMENT
superficie I-TREATMENT
corporal I-TREATMENT
(día I-TREATMENT
0) I-TREATMENT
y I-TREATMENT
al I-TREATMENT
día I-TREATMENT
siguiente I-TREATMENT
se I-TREATMENT
realizó I-TREATMENT
infusión I-TREATMENT
única I-TREATMENT
de I-TREATMENT
las I-TREATMENT
células I-TREATMENT
troncales. I-TREATMENT
A B-EXPLORATION
partir I-EXPLORATION
del I-EXPLORATION
día I-EXPLORATION
2 I-EXPLORATION
desarrolló I-EXPLORATION
IRA I-EXPLORATION
oligúrica, I-EXPLORATION
con I-EXPLORATION
fracción I-EXPLORATION
excretada I-EXPLORATION
de I-EXPLORATION
sodio I-EXPLORATION
2%, I-EXPLORATION
índice I-EXPLORATION
uricosuria/creatininuria I-EXPLORATION
<1, I-EXPLORATION
0 I-EXPLORATION
a I-EXPLORATION
pH I-EXPLORATION
urinario I-EXPLORATION
7, I-EXPLORATION
0, I-EXPLORATION
ecografía-doppler I-EXPLORATION
renal I-EXPLORATION
normal, I-EXPLORATION
creatinquinasa I-EXPLORATION
total I-EXPLORATION
sérica I-EXPLORATION
285 I-EXPLORATION
U/L, I-EXPLORATION
ausencia I-EXPLORATION
de I-EXPLORATION
trombocitopenia I-EXPLORATION
o I-EXPLORATION
esquistocitosis I-EXPLORATION
y I-EXPLORATION
actividad I-EXPLORATION
de I-EXPLORATION
ADAMTS13 I-EXPLORATION
de I-EXPLORATION
20%. I-EXPLORATION
El I-EXPLORATION
deterioro I-EXPLORATION
de I-EXPLORATION
función I-EXPLORATION
renal I-EXPLORATION
se I-EXPLORATION
acompañó I-EXPLORATION
de I-EXPLORATION
evidencias I-EXPLORATION
de I-EXPLORATION
lisis I-EXPLORATION
celular I-EXPLORATION
(láctico-deshidrogenasa I-EXPLORATION
hasta I-EXPLORATION
6.710 I-EXPLORATION
U/L, I-EXPLORATION
fosfatemia I-EXPLORATION
hasta I-EXPLORATION
9, I-EXPLORATION
2 I-EXPLORATION
mg/dL, I-EXPLORATION
uricemia I-EXPLORATION
hasta I-EXPLORATION
13, I-EXPLORATION
2 I-EXPLORATION
mg/dL, I-EXPLORATION
transaminasa I-EXPLORATION
glutámico I-EXPLORATION
oxaloacética I-EXPLORATION
351 I-EXPLORATION
U/L) I-EXPLORATION
y I-EXPLORATION
rápido I-EXPLORATION
ascenso I-EXPLORATION
(hasta I-EXPLORATION
28.000 I-EXPLORATION
células/mm3) I-EXPLORATION
y I-EXPLORATION
posterior I-EXPLORATION
descenso I-EXPLORATION
del I-EXPLORATION
recuento I-EXPLORATION
de I-EXPLORATION
glóbulos I-EXPLORATION
blancos I-EXPLORATION
en I-EXPLORATION
sangre I-EXPLORATION
periférica, I-EXPLORATION
llegando I-EXPLORATION
hasta I-EXPLORATION
una I-EXPLORATION
completa I-EXPLORATION
aplasia I-EXPLORATION
que I-EXPLORATION
se I-EXPLORATION
prolongó I-EXPLORATION
por I-EXPLORATION
12 I-EXPLORATION
días. I-EXPLORATION
En I-EXPLORATION
la I-EXPLORATION
Tabla I-EXPLORATION
1 I-EXPLORATION
se I-EXPLORATION
detalla I-EXPLORATION
la I-EXPLORATION
evolución I-EXPLORATION
de I-EXPLORATION
algunos I-EXPLORATION
parámetros I-EXPLORATION
de I-EXPLORATION
laboratorio I-EXPLORATION
representativos. I-EXPLORATION
La B-TREATMENT
paciente I-TREATMENT
requirió I-TREATMENT
del I-TREATMENT
uso I-TREATMENT
de I-TREATMENT
factor I-TREATMENT
estimulante I-TREATMENT
de I-TREATMENT
colonias I-TREATMENT
granulocíticas I-TREATMENT
entre I-TREATMENT
los I-TREATMENT
días I-TREATMENT
2 I-TREATMENT
y I-TREATMENT
16 I-TREATMENT
y I-TREATMENT
de I-TREATMENT
terapia I-TREATMENT
de I-TREATMENT
sustitución I-TREATMENT
renal I-TREATMENT
con I-TREATMENT
hemodiafiltración I-TREATMENT
veno-venosa I-TREATMENT
intermitente I-TREATMENT
diaria I-TREATMENT
entre I-TREATMENT
los I-TREATMENT
días I-TREATMENT
5 I-TREATMENT
al I-TREATMENT
14. I-TREATMENT
Desde B-EVOLUTION
el I-EVOLUTION
día I-EVOLUTION
13 I-EVOLUTION
recuperó I-EVOLUTION
diuresis I-EVOLUTION
y I-EVOLUTION
fue I-EVOLUTION
dada I-EVOLUTION
de I-EVOLUTION
alta I-EVOLUTION
el I-EVOLUTION
día I-EVOLUTION
23 I-EVOLUTION
post-melfalán, I-EVOLUTION
con I-EVOLUTION
creatininemia I-EVOLUTION
1, I-EVOLUTION
2 I-EVOLUTION
mg/dL I-EVOLUTION
y I-EVOLUTION
recuento I-EVOLUTION
de I-EVOLUTION
glóbulos I-EVOLUTION
blancos I-EVOLUTION
3.000/mm3. I-EVOLUTION
<EOS> I-EVOLUTION
El I-EVOLUTION
control I-EVOLUTION
clínico I-EVOLUTION
al I-EVOLUTION
año I-EVOLUTION
de I-EVOLUTION
seguimiento I-EVOLUTION
reveló I-EVOLUTION
excelente I-EVOLUTION
estado I-EVOLUTION
general, I-EVOLUTION
filtración I-EVOLUTION
glomerular I-EVOLUTION
y I-EVOLUTION
recuentos I-EVOLUTION
hematológicos I-EVOLUTION
normales, I-EVOLUTION
proteinuria I-EVOLUTION
<1 I-EVOLUTION
g/día, I-EVOLUTION
e I-EVOLUTION
inmunofijación I-EVOLUTION
sérica I-EVOLUTION
negativa. I-EVOLUTION
<EOS> I-EVOLUTION
Paciente B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
sexo I-PRESENT_ILLNESS
masculino I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
36 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
con B-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
dispepsia I-PAST_MEDICAL_HISTORY
inespecífica I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
varios I-PAST_MEDICAL_HISTORY
años I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
evolución. I-PAST_MEDICAL_HISTORY
Consultó B-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
estos I-PRESENT_ILLNESS
síntomas. I-PRESENT_ILLNESS
<EOS> B-EXPLORATION
El I-EXPLORATION
examen I-EXPLORATION
físico I-EXPLORATION
no I-EXPLORATION
mostraba I-EXPLORATION
hallazgos I-EXPLORATION
anormales. I-EXPLORATION
La I-EXPLORATION
vesícula I-EXPLORATION
no I-EXPLORATION
era I-EXPLORATION
palpable. I-EXPLORATION
<EOS> I-EXPLORATION
Entre I-EXPLORATION
sus I-EXPLORATION
antecedentes I-EXPLORATION
destacaba I-EXPLORATION
ecotomografía I-EXPLORATION
previa, I-EXPLORATION
años I-EXPLORATION
antes, I-EXPLORATION
que I-EXPLORATION
habría I-EXPLORATION
sido I-EXPLORATION
normal. I-EXPLORATION
Panendoscopia I-EXPLORATION
demostró I-EXPLORATION
gastritis I-EXPLORATION
crónica I-EXPLORATION
erosiva. I-EXPLORATION
<EOS> I-EXPLORATION
Fumador B-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
30 I-PAST_MEDICAL_HISTORY
cigarrillos I-PAST_MEDICAL_HISTORY
diarios, I-PAST_MEDICAL_HISTORY
presentó I-PAST_MEDICAL_HISTORY
neumotórax I-PAST_MEDICAL_HISTORY
izquierdo I-PAST_MEDICAL_HISTORY
tratado I-PAST_MEDICAL_HISTORY
hace I-PAST_MEDICAL_HISTORY
años. I-PAST_MEDICAL_HISTORY
No I-PAST_MEDICAL_HISTORY
usaba I-PAST_MEDICAL_HISTORY
medicamentos I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
forma I-PAST_MEDICAL_HISTORY
habitual. I-PAST_MEDICAL_HISTORY
<EOS> I-PAST_MEDICAL_HISTORY
Fue B-DERIVED_FROM/TO
derivado I-DERIVED_FROM/TO
a I-DERIVED_FROM/TO
nuestro I-DERIVED_FROM/TO
servicio I-DERIVED_FROM/TO
para I-DERIVED_FROM/TO
la I-DERIVED_FROM/TO
realización I-DERIVED_FROM/TO
de I-DERIVED_FROM/TO
ecotomografía I-DERIVED_FROM/TO
abdominal. I-DERIVED_FROM/TO
Examen B-EXPLORATION
que I-EXPLORATION
fue I-EXPLORATION
realizado I-EXPLORATION
en I-EXPLORATION
agosto I-EXPLORATION
de I-EXPLORATION
2000, I-EXPLORATION
donde I-EXPLORATION
se I-EXPLORATION
demostró I-EXPLORATION
tumoración I-EXPLORATION
del I-EXPLORATION
lecho I-EXPLORATION
vesicular I-EXPLORATION
de I-EXPLORATION
aspecto I-EXPLORATION
sólido, I-EXPLORATION
caracterizada I-EXPLORATION
por I-EXPLORATION
engrosamiento I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
pared I-EXPLORATION
de I-EXPLORATION
fondo I-EXPLORATION
y I-EXPLORATION
cuerpo I-EXPLORATION
que I-EXPLORATION
deja I-EXPLORATION
un I-EXPLORATION
lumen I-EXPLORATION
pequeño, I-EXPLORATION
sin I-EXPLORATION
evidencias I-EXPLORATION
de I-EXPLORATION
cálculos. I-EXPLORATION
Había I-EXPLORATION
presencia I-EXPLORATION
de I-EXPLORATION
imágenes I-EXPLORATION
ecogénicas I-EXPLORATION
con I-EXPLORATION
artefacto I-EXPLORATION
en I-EXPLORATION
estalactita I-EXPLORATION
en I-EXPLORATION
su I-EXPLORATION
espesor. I-EXPLORATION
En I-EXPLORATION
conclusión, I-EXPLORATION
se I-EXPLORATION
demostró I-EXPLORATION
tumoración I-EXPLORATION
vesicular I-EXPLORATION
con I-EXPLORATION
signos I-EXPLORATION
que I-EXPLORATION
sugerían I-EXPLORATION
el I-EXPLORATION
diagnóstico I-EXPLORATION
probable I-EXPLORATION
de I-EXPLORATION
extensa I-EXPLORATION
adenomiomatosis I-EXPLORATION
del I-EXPLORATION
fondo I-EXPLORATION
y I-EXPLORATION
cuerpo I-EXPLORATION
vesicular. I-EXPLORATION
<EOS> I-EXPLORATION
Se I-EXPLORATION
complementó I-EXPLORATION
con I-EXPLORATION
tomografía I-EXPLORATION
axial I-EXPLORATION
computarizada I-EXPLORATION
abdominal, I-EXPLORATION
que I-EXPLORATION
confirmó I-EXPLORATION
la I-EXPLORATION
existencia I-EXPLORATION
de I-EXPLORATION
tumoración I-EXPLORATION
del I-EXPLORATION
área I-EXPLORATION
vesicular, I-EXPLORATION
planteando I-EXPLORATION
la I-EXPLORATION
posibilidad I-EXPLORATION
de I-EXPLORATION
neoplasia I-EXPLORATION
vesicular I-EXPLORATION
o I-EXPLORATION
lesión I-EXPLORATION
del I-EXPLORATION
ángulo I-EXPLORATION
esplénico I-EXPLORATION
del I-EXPLORATION
colon. I-EXPLORATION
La I-EXPLORATION
lesión I-EXPLORATION
no I-EXPLORATION
infiltraba I-EXPLORATION
el I-EXPLORATION
hígado. I-EXPLORATION
<EOS> B-TREATMENT
El I-TREATMENT
paciente I-TREATMENT
fue I-TREATMENT
operado I-TREATMENT
el I-TREATMENT
25.08.2000, I-TREATMENT
realizándose I-TREATMENT
colecistectomía. I-TREATMENT
La B-EXPLORATION
exploración I-EXPLORATION
del I-EXPLORATION
resto I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
cavidad I-EXPLORATION
abdominal I-EXPLORATION
fue I-EXPLORATION
negativa. I-EXPLORATION
<EOS> I-EXPLORATION
La I-EXPLORATION
biopsia I-EXPLORATION
confirmó I-EXPLORATION
el I-EXPLORATION
diagnóstico I-EXPLORATION
de I-EXPLORATION
adenomiomatosis I-EXPLORATION
vesicular I-EXPLORATION
difusa. I-EXPLORATION
<EOS> I-EXPLORATION
Paciente B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
sexo I-PRESENT_ILLNESS
femenino, I-PRESENT_ILLNESS
padres B-FAMILY_HISTORY
no I-FAMILY_HISTORY
consanguíneos, I-FAMILY_HISTORY
sin I-FAMILY_HISTORY
antecedentes I-FAMILY_HISTORY
perinatales I-FAMILY_HISTORY
de I-FAMILY_HISTORY
relevancia; I-FAMILY_HISTORY
peso B-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
nacimiento I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
3-450 I-PAST_MEDICAL_HISTORY
g, I-PAST_MEDICAL_HISTORY
talla I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
49, I-PAST_MEDICAL_HISTORY
5 I-PAST_MEDICAL_HISTORY
cm I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
circunferencia I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
cráneo I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
35, I-PAST_MEDICAL_HISTORY
2 I-PAST_MEDICAL_HISTORY
cm. I-PAST_MEDICAL_HISTORY
Apgar I-PAST_MEDICAL_HISTORY
9, I-PAST_MEDICAL_HISTORY
a I-PAST_MEDICAL_HISTORY
los I-PAST_MEDICAL_HISTORY
5 I-PAST_MEDICAL_HISTORY
min. I-PAST_MEDICAL_HISTORY
<EOS> I-PAST_MEDICAL_HISTORY
Al B-PRESENT_ILLNESS
mes I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
medio I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
edad I-PRESENT_ILLNESS
presentó I-PRESENT_ILLNESS
crisis I-PRESENT_ILLNESS
tónico I-PRESENT_ILLNESS
clónicas I-PRESENT_ILLNESS
generalizadas I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
segundos I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
duración, I-PRESENT_ILLNESS
evolucionando I-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
20 I-PRESENT_ILLNESS
mioclonías I-PRESENT_ILLNESS
al I-PRESENT_ILLNESS
día, I-PRESENT_ILLNESS
agregándose I-PRESENT_ILLNESS
espasmos I-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
flexión. I-PRESENT_ILLNESS
Recibió I-PRESENT_ILLNESS
tratamiento I-PRESENT_ILLNESS
farmacológico I-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
ácido I-PRESENT_ILLNESS
valproico, I-PRESENT_ILLNESS
fenobarbital I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
carbamazepina, I-PRESENT_ILLNESS
sin I-PRESENT_ILLNESS
respuesta I-PRESENT_ILLNESS
clínica, I-PRESENT_ILLNESS
desencadenando I-PRESENT_ILLNESS
una I-PRESENT_ILLNESS
reacción I-PRESENT_ILLNESS
adversa I-PRESENT_ILLNESS
al I-PRESENT_ILLNESS
ácido I-PRESENT_ILLNESS
valproico I-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
hiperamonemia I-PRESENT_ILLNESS
sintomática. I-PRESENT_ILLNESS
<EOS> I-PRESENT_ILLNESS
A B-EXPLORATION
los I-EXPLORATION
3 I-EXPLORATION
y I-EXPLORATION
medio I-EXPLORATION
meses I-EXPLORATION
de I-EXPLORATION
edad I-EXPLORATION
se I-EXPLORATION
realizaron I-EXPLORATION
exámenes I-EXPLORATION
para I-EXPLORATION
descartar I-EXPLORATION
una I-EXPLORATION
enfermedad I-EXPLORATION
metabólica, I-EXPLORATION
encontrándose I-EXPLORATION
una I-EXPLORATION
lactacidemia I-EXPLORATION
de I-EXPLORATION
26, I-EXPLORATION
5 I-EXPLORATION
mg/dl I-EXPLORATION
(VN: I-EXPLORATION
5-15), I-EXPLORATION
disminución I-EXPLORATION
del I-EXPLORATION
lactato I-EXPLORATION
en I-EXPLORATION
LCR I-EXPLORATION
de I-EXPLORATION
5, I-EXPLORATION
6 I-EXPLORATION
mg/dl I-EXPLORATION
(VN: I-EXPLORATION
10, I-EXPLORATION
8-18, I-EXPLORATION
9 I-EXPLORATION
mg/dl). I-EXPLORATION
El I-EXPLORATION
ácido I-EXPLORATION
pirúvico I-EXPLORATION
en I-EXPLORATION
plasma I-EXPLORATION
estaba I-EXPLORATION
aumentado I-EXPLORATION
(1, I-EXPLORATION
4 I-EXPLORATION
mg/dl) I-EXPLORATION
(VN: I-EXPLORATION
0, I-EXPLORATION
3-0, I-EXPLORATION
9), I-EXPLORATION
pero I-EXPLORATION
en I-EXPLORATION
LCR I-EXPLORATION
era I-EXPLORATION
normal I-EXPLORATION
(0, I-EXPLORATION
43 I-EXPLORATION
mg/dl) I-EXPLORATION
(VN: I-EXPLORATION
0, I-EXPLORATION
5-1, I-EXPLORATION
7) I-EXPLORATION
y I-EXPLORATION
la I-EXPLORATION
amonemia I-EXPLORATION
fue I-EXPLORATION
de I-EXPLORATION
85 I-EXPLORATION
µg/dl I-EXPLORATION
(35-100 I-EXPLORATION
µg/dl). I-EXPLORATION
La I-EXPLORATION
cuantiñ-cación I-EXPLORATION
de I-EXPLORATION
aminoácidos I-EXPLORATION
en I-EXPLORATION
suero, I-EXPLORATION
acilcarniünas I-EXPLORATION
en I-EXPLORATION
sangre I-EXPLORATION
total, I-EXPLORATION
ácidos I-EXPLORATION
orgánicos I-EXPLORATION
en I-EXPLORATION
orina I-EXPLORATION
y I-EXPLORATION
carnitina I-EXPLORATION
en I-EXPLORATION
suero I-EXPLORATION
fueron I-EXPLORATION
normales. I-EXPLORATION
<EOS> I-EXPLORATION
A I-EXPLORATION
los I-EXPLORATION
5 I-EXPLORATION
meses, I-EXPLORATION
el I-EXPLORATION
electroencefalograma I-EXPLORATION
(EEG) I-EXPLORATION
detectó I-EXPLORATION
una I-EXPLORATION
actividad I-EXPLORATION
theta-delta I-EXPLORATION
polimorfa I-EXPLORATION
continua, I-EXPLORATION
considerada I-EXPLORATION
anormal I-EXPLORATION
para I-EXPLORATION
la I-EXPLORATION
edad I-EXPLORATION
y I-EXPLORATION
la I-EXPLORATION
resonancia I-EXPLORATION
nuclear I-EXPLORATION
magnética I-EXPLORATION
mostró I-EXPLORATION
atrofia I-EXPLORATION
frontal I-EXPLORATION
con I-EXPLORATION
aumento I-EXPLORATION
de I-EXPLORATION
espacios I-EXPLORATION
subaracnoídeos. I-EXPLORATION
Evolucionó B-EVOLUTION
con I-EVOLUTION
retardo I-EVOLUTION
en I-EVOLUTION
el I-EVOLUTION
desarrollo I-EVOLUTION
psicomotor I-EVOLUTION
y I-EVOLUTION
desaceleración I-EVOLUTION
del I-EVOLUTION
crecimiento I-EVOLUTION
craneano, I-EVOLUTION
ataxia I-EVOLUTION
de I-EVOLUTION
tronco I-EVOLUTION
y I-EVOLUTION
síndrome I-EVOLUTION
piramidal I-EVOLUTION
bilateral. I-EVOLUTION
<EOS> I-EVOLUTION
A B-EXPLORATION
los I-EXPLORATION
7 I-EXPLORATION
meses I-EXPLORATION
ingresó I-EXPLORATION
al I-EXPLORATION
Hospital I-EXPLORATION
de I-EXPLORATION
Niños I-EXPLORATION
de I-EXPLORATION
Boston, I-EXPLORATION
de I-EXPLORATION
Estados I-EXPLORATION
Unidos I-EXPLORATION
de I-EXPLORATION
Norteamérica, I-EXPLORATION
donde I-EXPLORATION
se I-EXPLORATION
encontró I-EXPLORATION
disminución I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
glucosa I-EXPLORATION
en I-EXPLORATION
LCR I-EXPLORATION
de I-EXPLORATION
26 I-EXPLORATION
mg/dl I-EXPLORATION
y I-EXPLORATION
normoglucemia I-EXPLORATION
(84 I-EXPLORATION
mg/dl), I-EXPLORATION
obteniéndose I-EXPLORATION
una I-EXPLORATION
razón I-EXPLORATION
entre I-EXPLORATION
ambos I-EXPLORATION
parámetros I-EXPLORATION
de I-EXPLORATION
0, I-EXPLORATION
31 I-EXPLORATION
(valor I-EXPLORATION
normal I-EXPLORATION
sobre I-EXPLORATION
0, I-EXPLORATION
65+0, I-EXPLORATION
01), I-EXPLORATION
concordante I-EXPLORATION
con I-EXPLORATION
una I-EXPLORATION
hipo-glucorraquia, I-EXPLORATION
sugiriéndose I-EXPLORATION
un I-EXPLORATION
SDGLUT-1. I-EXPLORATION
<EOS> I-EXPLORATION
Se I-EXPLORATION
ha I-EXPLORATION
demostrado I-EXPLORATION
que I-EXPLORATION
la I-EXPLORATION
proteína I-EXPLORATION
Glut-1 I-EXPLORATION
en I-EXPLORATION
el I-EXPLORATION
eritrocito I-EXPLORATION
es I-EXPLORATION
idéntica I-EXPLORATION
a I-EXPLORATION
la I-EXPLORATION
proteína I-EXPLORATION
Glut-1 I-EXPLORATION
de I-EXPLORATION
las I-EXPLORATION
células I-EXPLORATION
endoteliales I-EXPLORATION
de I-EXPLORATION
los I-EXPLORATION
capilares I-EXPLORATION
del I-EXPLORATION
cerebro, I-EXPLORATION
tanto I-EXPLORATION
en I-EXPLORATION
la I-EXPLORATION
respuesta I-EXPLORATION
inmunológica I-EXPLORATION
como I-EXPLORATION
química. I-EXPLORATION
Por I-EXPLORATION
esta I-EXPLORATION
razón, I-EXPLORATION
el I-EXPLORATION
transporte I-EXPLORATION
de I-EXPLORATION
glucosa I-EXPLORATION
en I-EXPLORATION
el I-EXPLORATION
eritrocito I-EXPLORATION
es I-EXPLORATION
comparable I-EXPLORATION
con I-EXPLORATION
el I-EXPLORATION
transporte I-EXPLORATION
de I-EXPLORATION
glucosa I-EXPLORATION
a I-EXPLORATION
través I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
barrera I-EXPLORATION
hematoencefálica. I-EXPLORATION
Considerando I-EXPLORATION
este I-EXPLORATION
hallazgo, I-EXPLORATION
se I-EXPLORATION
desarrolló I-EXPLORATION
la I-EXPLORATION
técnica I-EXPLORATION
3-O-metil I-EXPLORATION
D I-EXPLORATION
glucosa, I-EXPLORATION
que I-EXPLORATION
determina I-EXPLORATION
la I-EXPLORATION
captación I-EXPLORATION
de I-EXPLORATION
glucosa I-EXPLORATION
por I-EXPLORATION
el I-EXPLORATION
eritrocito, I-EXPLORATION
lo I-EXPLORATION
que I-EXPLORATION
permite I-EXPLORATION
la I-EXPLORATION
extrapolación I-EXPLORATION
con I-EXPLORATION
el I-EXPLORATION
transporte I-EXPLORATION
de I-EXPLORATION
glucosa I-EXPLORATION
en I-EXPLORATION
la I-EXPLORATION
barrera I-EXPLORATION
hematoencefálica11. I-EXPLORATION
En B-TREATMENT
nuestro I-TREATMENT
caso, I-TREATMENT
se I-TREATMENT
aplicó I-TREATMENT
esta I-TREATMENT
técnica, I-TREATMENT
obteniéndose I-TREATMENT
una I-TREATMENT
captación I-TREATMENT
de I-TREATMENT
glucosa I-TREATMENT
de I-TREATMENT
44% I-TREATMENT
(VN I-TREATMENT
80%-100%), I-TREATMENT
confirmándose I-TREATMENT
un I-TREATMENT
SDGLUT-1. I-TREATMENT
<EOS> I-TREATMENT
En B-EXPLORATION
el I-EXPLORATION
estudio I-EXPLORATION
molecular I-EXPLORATION
se I-EXPLORATION
utilizó I-EXPLORATION
la I-EXPLORATION
reacción I-EXPLORATION
de I-EXPLORATION
polimerasa I-EXPLORATION
en I-EXPLORATION
cadena I-EXPLORATION
(PCR) I-EXPLORATION
y I-EXPLORATION
el I-EXPLORATION
análisis I-EXPLORATION
de I-EXPLORATION
polimorfismos I-EXPLORATION
por I-EXPLORATION
fragmentos I-EXPLORATION
de I-EXPLORATION
restricción I-EXPLORATION
(RFLP) I-EXPLORATION
3, I-EXPLORATION
6 I-EXPLORATION
determinándose I-EXPLORATION
la I-EXPLORATION
mutación I-EXPLORATION
del I-EXPLORATION
upo I-EXPLORATION
deleción I-EXPLORATION
969, I-EXPLORATION
C971T, I-EXPLORATION
ubicada I-EXPLORATION
en I-EXPLORATION
el I-EXPLORATION
exon I-EXPLORATION
6, I-EXPLORATION
de I-EXPLORATION
gen I-EXPLORATION
Glut-1 I-EXPLORATION
(Estudio I-EXPLORATION
molecular I-EXPLORATION
realizado I-EXPLORATION
por I-EXPLORATION
el I-EXPLORATION
Dr. I-EXPLORATION
D. I-EXPLORATION
De I-EXPLORATION
Vivo). I-EXPLORATION
<EOS> I-EXPLORATION
La I-EXPLORATION
tomografía I-EXPLORATION
computada I-EXPLORATION
por I-EXPLORATION
emisión I-EXPLORATION
de I-EXPLORATION
fotón I-EXPLORATION
único I-EXPLORATION
(SPECT) I-EXPLORATION
mostró I-EXPLORATION
hipometabolismo I-EXPLORATION
talámico, I-EXPLORATION
parietal I-EXPLORATION
izquierdo I-EXPLORATION
y I-EXPLORATION
temporal I-EXPLORATION
bilateral. I-EXPLORATION
<EOS> I-EXPLORATION
Inmediatamente B-TREATMENT
se I-TREATMENT
inició I-TREATMENT
la I-TREATMENT
dieta I-TREATMENT
cetogénica, I-TREATMENT
proporcionando I-TREATMENT
90 I-TREATMENT
calorías I-TREATMENT
por I-TREATMENT
kilo I-TREATMENT
de I-TREATMENT
peso, I-TREATMENT
con I-TREATMENT
85% I-TREATMENT
de I-TREATMENT
lípidos, I-TREATMENT
9% I-TREATMENT
de I-TREATMENT
proteínas I-TREATMENT
y I-TREATMENT
6% I-TREATMENT
de I-TREATMENT
carbohidratos, I-TREATMENT
con I-TREATMENT
relación I-TREATMENT
de I-TREATMENT
3: I-TREATMENT
1 I-TREATMENT
entre I-TREATMENT
lípidos I-TREATMENT
y I-TREATMENT
proteínas I-TREATMENT
más I-TREATMENT
carbohidratos, I-TREATMENT
basándose I-TREATMENT
en I-TREATMENT
el I-TREATMENT
protocolo I-TREATMENT
utilizado I-TREATMENT
en I-TREATMENT
el I-TREATMENT
INTA, I-TREATMENT
de I-TREATMENT
la I-TREATMENT
Universidad I-TREATMENT
de I-TREATMENT
Chile9, I-TREATMENT
10. I-TREATMENT
La I-TREATMENT
dieta I-TREATMENT
prohibe I-TREATMENT
alimentos I-TREATMENT
con I-TREATMENT
sacarosa, I-TREATMENT
sorbitol, I-TREATMENT
fructosa I-TREATMENT
y I-TREATMENT
se I-TREATMENT
restringe I-TREATMENT
el I-TREATMENT
consumo I-TREATMENT
de I-TREATMENT
lactosa, I-TREATMENT
razón I-TREATMENT
por I-TREATMENT
lo I-TREATMENT
cual I-TREATMENT
fue I-TREATMENT
necesario I-TREATMENT
suplementar I-TREATMENT
con I-TREATMENT
calcio I-TREATMENT
(450 I-TREATMENT
mg/día), I-TREATMENT
zinc I-TREATMENT
(5 I-TREATMENT
mg/día), I-TREATMENT
vitaminas, I-TREATMENT
especialmente I-TREATMENT
vitamina I-TREATMENT
C I-TREATMENT
(1 I-TREATMENT
g/día) I-TREATMENT
para I-TREATMENT
prevenir I-TREATMENT
oxidación I-TREATMENT
celular, I-TREATMENT
L-carnitina I-TREATMENT
(50 I-TREATMENT
mg/kg/día) I-TREATMENT
y I-TREATMENT
ácido I-TREATMENT
lipóico I-TREATMENT
(200 I-TREATMENT
mg/día). I-TREATMENT
<EOS> I-TREATMENT
Después B-EVOLUTION
de I-EVOLUTION
7 I-EVOLUTION
días I-EVOLUTION
de I-EVOLUTION
iniciada I-EVOLUTION
la I-EVOLUTION
dieta I-EVOLUTION
cetogénica, I-EVOLUTION
desaparecieron I-EVOLUTION
las I-EVOLUTION
crisis, I-EVOLUTION
y B-TREATMENT
conjuntamente I-TREATMENT
se I-TREATMENT
inició I-TREATMENT
la I-TREATMENT
disminución I-TREATMENT
de I-TREATMENT
los I-TREATMENT
anticonvulsivantes. I-TREATMENT
<EOS> I-TREATMENT
Actualmente B-EVOLUTION
tiene I-EVOLUTION
6 I-EVOLUTION
años I-EVOLUTION
de I-EVOLUTION
edad, I-EVOLUTION
mantiene I-EVOLUTION
la I-EVOLUTION
dieta I-EVOLUTION
cetogénica I-EVOLUTION
con I-EVOLUTION
83% I-EVOLUTION
de I-EVOLUTION
lípidos I-EVOLUTION
(27% I-EVOLUTION
de I-EVOLUTION
ellos I-EVOLUTION
corresponde I-EVOLUTION
a I-EVOLUTION
triglicéridos I-EVOLUTION
de I-EVOLUTION
cadena I-EVOLUTION
mediana) I-EVOLUTION
y I-EVOLUTION
17% I-EVOLUTION
de I-EVOLUTION
proteínas I-EVOLUTION
más I-EVOLUTION
carbohidratos I-EVOLUTION
(razón I-EVOLUTION
de I-EVOLUTION
2, I-EVOLUTION
5: I-EVOLUTION
1). I-EVOLUTION
La I-EVOLUTION
suplementación I-EVOLUTION
de I-EVOLUTION
nutrientes I-EVOLUTION
es I-EVOLUTION
la I-EVOLUTION
misma I-EVOLUTION
que I-EVOLUTION
al I-EVOLUTION
inicio, I-EVOLUTION
y I-EVOLUTION
se I-EVOLUTION
han I-EVOLUTION
ido I-EVOLUTION
adecuando I-EVOLUTION
según I-EVOLUTION
edad I-EVOLUTION
y I-EVOLUTION
estado I-EVOLUTION
nutricional. I-EVOLUTION
<EOS> I-EVOLUTION
La B-EXPLORATION
glicemia I-EXPLORATION
se I-EXPLORATION
mantiene I-EXPLORATION
en I-EXPLORATION
valores I-EXPLORATION
de I-EXPLORATION
80 I-EXPLORATION
a I-EXPLORATION
90 I-EXPLORATION
mg/dl, I-EXPLORATION
el I-EXPLORATION
colesterol I-EXPLORATION
total I-EXPLORATION
en I-EXPLORATION
187 I-EXPLORATION
mg/dl, I-EXPLORATION
la I-EXPLORATION
HDL I-EXPLORATION
en I-EXPLORATION
55 I-EXPLORATION
mg/dl I-EXPLORATION
y I-EXPLORATION
LDL I-EXPLORATION
en I-EXPLORATION
121 I-EXPLORATION
mg/dl. I-EXPLORATION
Calciuria I-EXPLORATION
creatininuria, I-EXPLORATION
perfil I-EXPLORATION
bioquímico, I-EXPLORATION
gases I-EXPLORATION
venosos I-EXPLORATION
y I-EXPLORATION
electrolitos I-EXPLORATION
plasmáticos I-EXPLORATION
están I-EXPLORATION
en I-EXPLORATION
rangos I-EXPLORATION
de I-EXPLORATION
normalidad. I-EXPLORATION
El I-EXPLORATION
ácido I-EXPLORATION
beta I-EXPLORATION
hidroxibutirato I-EXPLORATION
en I-EXPLORATION
ayuno I-EXPLORATION
es I-EXPLORATION
de I-EXPLORATION
2, I-EXPLORATION
5 I-EXPLORATION
µM/1 I-EXPLORATION
y I-EXPLORATION
posprandial I-EXPLORATION
de I-EXPLORATION
5, I-EXPLORATION
0 I-EXPLORATION
µM/l, I-EXPLORATION
considerándose I-EXPLORATION
cetogénesis I-EXPLORATION
cuando I-EXPLORATION
este I-EXPLORATION
valor I-EXPLORATION
se I-EXPLORATION
encuentra I-EXPLORATION
sobre I-EXPLORATION
2, I-EXPLORATION
0 I-EXPLORATION
µM/1. I-EXPLORATION
<EOS> I-EXPLORATION
En I-EXPLORATION
el I-EXPLORATION
examen I-EXPLORATION
neurológico I-EXPLORATION
destaca I-EXPLORATION
una I-EXPLORATION
conducta I-EXPLORATION
hiperactiva I-EXPLORATION
en I-EXPLORATION
su I-EXPLORATION
examen I-EXPLORATION
mental. I-EXPLORATION
En I-EXPLORATION
los I-EXPLORATION
pares I-EXPLORATION
craneanos I-EXPLORATION
presenta I-EXPLORATION
disartria I-EXPLORATION
e I-EXPLORATION
hipomimia I-EXPLORATION
facial. I-EXPLORATION
El I-EXPLORATION
examen I-EXPLORATION
motor I-EXPLORATION
muestra I-EXPLORATION
tono I-EXPLORATION
de I-EXPLORATION
tronco I-EXPLORATION
y I-EXPLORATION
extremidades I-EXPLORATION
disminuido, I-EXPLORATION
sin I-EXPLORATION
compromiso I-EXPLORATION
de I-EXPLORATION
fuerza I-EXPLORATION
ni I-EXPLORATION
del I-EXPLORATION
trofismo I-EXPLORATION
muscular. I-EXPLORATION
En I-EXPLORATION
el I-EXPLORATION
examen I-EXPLORATION
cerebeloso I-EXPLORATION
existe I-EXPLORATION
un I-EXPLORATION
temblor I-EXPLORATION
fino I-EXPLORATION
de I-EXPLORATION
intención, I-EXPLORATION
presencia I-EXPLORATION
de I-EXPLORATION
sincinesias, I-EXPLORATION
dismetría I-EXPLORATION
y I-EXPLORATION
discreta I-EXPLORATION
disdiadococinesia. I-EXPLORATION
La I-EXPLORATION
marcha I-EXPLORATION
es I-EXPLORATION
inestable I-EXPLORATION
y I-EXPLORATION
se I-EXPLORATION
caracteriza I-EXPLORATION
por I-EXPLORATION
un I-EXPLORATION
aumento I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
base I-EXPLORATION
de I-EXPLORATION
sustentación, I-EXPLORATION
sin I-EXPLORATION
lateralización. I-EXPLORATION
<EOS> I-EXPLORATION
Su I-EXPLORATION
coeficiente I-EXPLORATION
intelectual I-EXPLORATION
(CI), I-EXPLORATION
evaluado I-EXPLORATION
por I-EXPLORATION
la I-EXPLORATION
prueba I-EXPLORATION
de I-EXPLORATION
inteligencia I-EXPLORATION
para I-EXPLORATION
preescolares I-EXPLORATION
de I-EXPLORATION
Wechs-ler I-EXPLORATION
(WISP) I-EXPLORATION
12, I-EXPLORATION
obtuvo I-EXPLORATION
CI I-EXPLORATION
total I-EXPLORATION
de I-EXPLORATION
103 I-EXPLORATION
puntos, I-EXPLORATION
límite I-EXPLORATION
superior I-EXPLORATION
del I-EXPLORATION
rango I-EXPLORATION
normal I-EXPLORATION
promedio, I-EXPLORATION
corregido I-EXPLORATION
según I-EXPLORATION
normas I-EXPLORATION
norteamericanas. I-EXPLORATION
Presenta, I-EXPLORATION
sin I-EXPLORATION
embargo, I-EXPLORATION
una I-EXPLORATION
discrepancia I-EXPLORATION
significativa I-EXPLORATION
entre I-EXPLORATION
la I-EXPLORATION
escala I-EXPLORATION
verbal I-EXPLORATION
y I-EXPLORATION
manual, I-EXPLORATION
en I-EXPLORATION
desmedro I-EXPLORATION
de I-EXPLORATION
esta I-EXPLORATION
última I-EXPLORATION
(CI I-EXPLORATION
verbal: I-EXPLORATION
119, I-EXPLORATION
normal I-EXPLORATION
alto I-EXPLORATION
y I-EXPLORATION
CI I-EXPLORATION
manual: I-EXPLORATION
85, I-EXPLORATION
normal I-EXPLORATION
lento), I-EXPLORATION
lo I-EXPLORATION
que I-EXPLORATION
se I-EXPLORATION
traduce I-EXPLORATION
en I-EXPLORATION
dificultades I-EXPLORATION
específicas I-EXPLORATION
en I-EXPLORATION
la I-EXPLORATION
organización I-EXPLORATION
visoespacial I-EXPLORATION
y I-EXPLORATION
visomotricidad. I-EXPLORATION
<EOS> I-EXPLORATION
El I-EXPLORATION
estado I-EXPLORATION
nutricional I-EXPLORATION
es I-EXPLORATION
normal: I-EXPLORATION
índice I-EXPLORATION
de I-EXPLORATION
masa I-EXPLORATION
corporal I-EXPLORATION
de I-EXPLORATION
15, I-EXPLORATION
8 I-EXPLORATION
kg/m2 I-EXPLORATION
(VN I-EXPLORATION
entre I-EXPLORATION
15 I-EXPLORATION
y I-EXPLORATION
18 I-EXPLORATION
kg/m2) I-EXPLORATION
13, I-EXPLORATION
con I-EXPLORATION
peso I-EXPLORATION
(21 I-EXPLORATION
kg) I-EXPLORATION
para I-EXPLORATION
la I-EXPLORATION
edad I-EXPLORATION
y I-EXPLORATION
talla I-EXPLORATION
(1, I-EXPLORATION
16 I-EXPLORATION
m) I-EXPLORATION
para I-EXPLORATION
la I-EXPLORATION
edad, I-EXPLORATION
ambos I-EXPLORATION
parámetros I-EXPLORATION
en I-EXPLORATION
el I-EXPLORATION
percentil I-EXPLORATION
75 I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
tabla I-EXPLORATION
de I-EXPLORATION
referencia I-EXPLORATION
(National I-EXPLORATION
Center I-EXPLORATION
for I-EXPLORATION
Health I-EXPLORATION
Statistics) I-EXPLORATION
14. I-EXPLORATION
<EOS> I-EXPLORATION
Mujer B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
35 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
multípara, B-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
epilepsia I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
tratamiento I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
primidona I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
cáncer I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
cuello I-PAST_MEDICAL_HISTORY
uterino I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
etapa I-PAST_MEDICAL_HISTORY
Ib2, I-PAST_MEDICAL_HISTORY
operado I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
diciembre I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
2000 I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
tratado I-PAST_MEDICAL_HISTORY
posteriormente I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
quimioterapia I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
braquiterapia. I-PAST_MEDICAL_HISTORY
En B-PRESENT_ILLNESS
los I-PRESENT_ILLNESS
3 I-PRESENT_ILLNESS
meses I-PRESENT_ILLNESS
posteriores, I-PRESENT_ILLNESS
al I-PRESENT_ILLNESS
finalizar I-PRESENT_ILLNESS
las I-PRESENT_ILLNESS
sesiones I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
radioterapia, I-PRESENT_ILLNESS
presentó I-PRESENT_ILLNESS
sangrado I-PRESENT_ILLNESS
digestivo I-PRESENT_ILLNESS
bajo I-PRESENT_ILLNESS
intermitente, I-PRESENT_ILLNESS
agregándose I-PRESENT_ILLNESS
posteriormente I-PRESENT_ILLNESS
pujo, I-PRESENT_ILLNESS
tenesmo I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
dolor I-PRESENT_ILLNESS
abdominal I-PRESENT_ILLNESS
bajo. I-PRESENT_ILLNESS
El B-EXPLORATION
tacto I-EXPLORATION
rectal I-EXPLORATION
impresionaba I-EXPLORATION
con I-EXPLORATION
mucosa I-EXPLORATION
irregular I-EXPLORATION
y I-EXPLORATION
consistencia I-EXPLORATION
firme, I-EXPLORATION
palpándose I-EXPLORATION
una I-EXPLORATION
zona I-EXPLORATION
ulcerada I-EXPLORATION
de I-EXPLORATION
aproximadamente I-EXPLORATION
2, I-EXPLORATION
5 I-EXPLORATION
cm, I-EXPLORATION
que I-EXPLORATION
se I-EXPLORATION
iniciaba I-EXPLORATION
a I-EXPLORATION
3 I-EXPLORATION
cm I-EXPLORATION
del I-EXPLORATION
esfínter I-EXPLORATION
anorrectal. I-EXPLORATION
Se I-EXPLORATION
diagnosticó I-EXPLORATION
clínicamente I-EXPLORATION
una I-EXPLORATION
rectitis I-EXPLORATION
actínica, I-EXPLORATION
indicándose I-EXPLORATION
una I-EXPLORATION
rectoscopia, I-EXPLORATION
la I-EXPLORATION
que I-EXPLORATION
no I-EXPLORATION
se I-EXPLORATION
realizó I-EXPLORATION
por I-EXPLORATION
rechazo I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
paciente. I-EXPLORATION
Inició B-TREATMENT
tratamiento I-TREATMENT
con I-TREATMENT
enemas I-TREATMENT
con I-TREATMENT
prednisona, I-TREATMENT
que I-TREATMENT
lograron I-TREATMENT
buena I-TREATMENT
respuesta. I-TREATMENT
En B-EXPLORATION
un I-EXPLORATION
examen I-EXPLORATION
ginecológico I-EXPLORATION
8 I-EXPLORATION
meses I-EXPLORATION
post I-EXPLORATION
cirugía I-EXPLORATION
se I-EXPLORATION
apreció I-EXPLORATION
en I-EXPLORATION
el I-EXPLORATION
recto, I-EXPLORATION
a I-EXPLORATION
8 I-EXPLORATION
cm I-EXPLORATION
del I-EXPLORATION
ano, I-EXPLORATION
una I-EXPLORATION
área I-EXPLORATION
densa, I-EXPLORATION
irregular, I-EXPLORATION
que I-EXPLORATION
presentaba I-EXPLORATION
adherencia I-EXPLORATION
a I-EXPLORATION
parametrio I-EXPLORATION
derecho, I-EXPLORATION
que I-EXPLORATION
impresionaba I-EXPLORATION
como I-EXPLORATION
secuela I-EXPLORATION
secundaria I-EXPLORATION
a I-EXPLORATION
fibrosis I-EXPLORATION
post I-EXPLORATION
radioterapia. I-EXPLORATION
No B-EVOLUTION
se I-EVOLUTION
realizaron I-EVOLUTION
exámenes I-EVOLUTION
imagenológicos, I-EVOLUTION
ya I-EVOLUTION
que I-EVOLUTION
presentado I-EVOLUTION
su I-EVOLUTION
caso I-EVOLUTION
al I-EVOLUTION
comité I-EVOLUTION
oncológico, I-EVOLUTION
se I-EVOLUTION
decidió I-EVOLUTION
realizar I-EVOLUTION
sólo I-EVOLUTION
seguimiento I-EVOLUTION
clínico. I-EVOLUTION
La I-EVOLUTION
paciente I-EVOLUTION
se I-EVOLUTION
mantuvo I-EVOLUTION
en I-EVOLUTION
control I-EVOLUTION
ambulatorio I-EVOLUTION
periódico, I-EVOLUTION
describiéndose I-EVOLUTION
asintomática I-EVOLUTION
y I-EVOLUTION
con I-EVOLUTION
tactos I-EVOLUTION
rectales I-EVOLUTION
descritos I-EVOLUTION
como I-EVOLUTION
normales I-EVOLUTION
hasta I-EVOLUTION
su I-EVOLUTION
último I-EVOLUTION
control I-EVOLUTION
en I-EVOLUTION
mayo I-EVOLUTION
de I-EVOLUTION
2005. I-EVOLUTION
El I-EVOLUTION
01/02/2006, I-EVOLUTION
consultó I-EVOLUTION
en I-EVOLUTION
servicio I-EVOLUTION
de I-EVOLUTION
urgencia I-EVOLUTION
por I-EVOLUTION
presentar I-EVOLUTION
un I-EVOLUTION
día I-EVOLUTION
de I-EVOLUTION
dolor I-EVOLUTION
abdominal I-EVOLUTION
cólico I-EVOLUTION
difuso, I-EVOLUTION
con I-EVOLUTION
vómitos I-EVOLUTION
abundantes, I-EVOLUTION
con I-EVOLUTION
abdomen I-EVOLUTION
distendido, I-EVOLUTION
sensible I-EVOLUTION
difusamente. I-EVOLUTION
Al B-EXPLORATION
tacto I-EXPLORATION
rectal I-EXPLORATION
se I-EXPLORATION
detectó I-EXPLORATION
masa I-EXPLORATION
rectal I-EXPLORATION
indurada I-EXPLORATION
(cara I-EXPLORATION
anterior) I-EXPLORATION
con I-EXPLORATION
salida I-EXPLORATION
de I-EXPLORATION
material I-EXPLORATION
purulento. I-EXPLORATION
Ingresó B-EVOLUTION
a I-EVOLUTION
pabellón I-EVOLUTION
con I-EVOLUTION
el I-EVOLUTION
diagnóstico I-EVOLUTION
clínico I-EVOLUTION
de I-EVOLUTION
peritonitis I-EVOLUTION
difusa I-EVOLUTION
y I-EVOLUTION
con I-EVOLUTION
probable I-EVOLUTION
perforación I-EVOLUTION
intestinal. I-EVOLUTION
Durante B-TREATMENT
la I-TREATMENT
cirugía I-TREATMENT
de I-TREATMENT
urgencia I-TREATMENT
se I-TREATMENT
observó I-TREATMENT
segmento I-TREATMENT
rectosigmoideo I-TREATMENT
este-nótico I-TREATMENT
e I-TREATMENT
indurado. I-TREATMENT
Fue I-TREATMENT
interpretado I-TREATMENT
como I-TREATMENT
tumoral, I-TREATMENT
por I-TREATMENT
lo I-TREATMENT
que I-TREATMENT
se I-TREATMENT
realizó I-TREATMENT
resección I-TREATMENT
del I-TREATMENT
segmento I-TREATMENT
afectado I-TREATMENT
y I-TREATMENT
colostomía I-TREATMENT
del I-TREATMENT
cabo I-TREATMENT
proximal. I-TREATMENT
La B-EVOLUTION
paciente I-EVOLUTION
evolucionó I-EVOLUTION
favorablemente I-EVOLUTION
post I-EVOLUTION
cirugía. I-EVOLUTION
<EOS> I-EVOLUTION
En B-EXPLORATION
patología I-EXPLORATION
se I-EXPLORATION
recibió I-EXPLORATION
pieza I-EXPLORATION
quirúrgica I-EXPLORATION
de I-EXPLORATION
intestino I-EXPLORATION
grueso I-EXPLORATION
de I-EXPLORATION
9 I-EXPLORATION
cm I-EXPLORATION
de I-EXPLORATION
longitud I-EXPLORATION
por I-EXPLORATION
8 I-EXPLORATION
y I-EXPLORATION
5 I-EXPLORATION
cm I-EXPLORATION
de I-EXPLORATION
perímetro I-EXPLORATION
en I-EXPLORATION
los I-EXPLORATION
bordes I-EXPLORATION
de I-EXPLORATION
sección. I-EXPLORATION
Al I-EXPLORATION
corte, I-EXPLORATION
la I-EXPLORATION
mucosa I-EXPLORATION
presentaba I-EXPLORATION
zona I-EXPLORATION
cilindrica I-EXPLORATION
estenótica I-EXPLORATION
de I-EXPLORATION
2 I-EXPLORATION
cm I-EXPLORATION
de I-EXPLORATION
longitud I-EXPLORATION
cercana I-EXPLORATION
a I-EXPLORATION
uno I-EXPLORATION
de I-EXPLORATION
los I-EXPLORATION
bordes I-EXPLORATION
de I-EXPLORATION
sección, I-EXPLORATION
con I-EXPLORATION
segmento I-EXPLORATION
proximal I-EXPLORATION
dilatado I-EXPLORATION
que I-EXPLORATION
presentaba I-EXPLORATION
áreas I-EXPLORATION
hemorrágicas I-EXPLORATION
y I-EXPLORATION
con I-EXPLORATION
depósito I-EXPLORATION
superficial I-EXPLORATION
de I-EXPLORATION
fibrina. I-EXPLORATION
<EOS> I-EXPLORATION
El I-EXPLORATION
examen I-EXPLORATION
microscópico I-EXPLORATION
reveló I-EXPLORATION
distorsión I-EXPLORATION
marcada I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
arquitectura I-EXPLORATION
intestinal, I-EXPLORATION
con I-EXPLORATION
fibrosis I-EXPLORATION
de I-EXPLORATION
tipo I-EXPLORATION
cicatricial I-EXPLORATION
asociado I-EXPLORATION
a I-EXPLORATION
proceso I-EXPLORATION
inflamatorio I-EXPLORATION
crónico I-EXPLORATION
con I-EXPLORATION
reagudización I-EXPLORATION
hemorrágica I-EXPLORATION
en I-EXPLORATION
granulación I-EXPLORATION
superficial. I-EXPLORATION
Se I-EXPLORATION
observó I-EXPLORATION
ausencia I-EXPLORATION
parcial I-EXPLORATION
de I-EXPLORATION
lámina I-EXPLORATION
propia I-EXPLORATION
en I-EXPLORATION
un I-EXPLORATION
segmento, I-EXPLORATION
con I-EXPLORATION
glándulas I-EXPLORATION
mucosas I-EXPLORATION
suprayacentes I-EXPLORATION
penetrando I-EXPLORATION
en I-EXPLORATION
la I-EXPLORATION
túnica I-EXPLORATION
muscular I-EXPLORATION
propia, I-EXPLORATION
algunas I-EXPLORATION
dilatadas, I-EXPLORATION
ubicadas I-EXPLORATION
en I-EXPLORATION
su I-EXPLORATION
mitad I-EXPLORATION
externa, I-EXPLORATION
sin I-EXPLORATION
atipias I-EXPLORATION
citológicas I-EXPLORATION
ni I-EXPLORATION
arquitecturales. I-EXPLORATION
Los I-EXPLORATION
vasos I-EXPLORATION
sanguíneos I-EXPLORATION
se I-EXPLORATION
observaban I-EXPLORATION
moderadamente I-EXPLORATION
escleróticos. I-EXPLORATION
En I-EXPLORATION
la I-EXPLORATION
adventicia I-EXPLORATION
se I-EXPLORATION
encontró I-EXPLORATION
área I-EXPLORATION
de I-EXPLORATION
adiponecro-sis I-EXPLORATION
y I-EXPLORATION
esclerosis I-EXPLORATION
de I-EXPLORATION
tipo I-EXPLORATION
cicatricial I-EXPLORATION
con I-EXPLORATION
retracción I-EXPLORATION
del I-EXPLORATION
tejido I-EXPLORATION
adyacente. I-EXPLORATION
No I-EXPLORATION
se I-EXPLORATION
observaron I-EXPLORATION
mitosis I-EXPLORATION
ni I-EXPLORATION
atipias I-EXPLORATION
citológicas. I-EXPLORATION
Los I-EXPLORATION
hallazgos I-EXPLORATION
morfológicos I-EXPLORATION
confirmaron I-EXPLORATION
secuelas I-EXPLORATION
de I-EXPLORATION
una I-EXPLORATION
rectitis I-EXPLORATION
actínica. I-EXPLORATION
<EOS> I-EXPLORATION
Hombre B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
56 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
con B-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
miocar-diopatía I-PAST_MEDICAL_HISTORY
dilatada I-PAST_MEDICAL_HISTORY
avanzada I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
trasplante I-PAST_MEDICAL_HISTORY
cardíaco I-PAST_MEDICAL_HISTORY
ortotópico I-PAST_MEDICAL_HISTORY
biauricular I-PAST_MEDICAL_HISTORY
7 I-PAST_MEDICAL_HISTORY
años I-PAST_MEDICAL_HISTORY
atrás, I-PAST_MEDICAL_HISTORY
procedente I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
un I-PAST_MEDICAL_HISTORY
donante I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
40 I-PAST_MEDICAL_HISTORY
años I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
edad. I-PAST_MEDICAL_HISTORY
Presentó I-PAST_MEDICAL_HISTORY
un I-PAST_MEDICAL_HISTORY
episodio I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
rechazo I-PAST_MEDICAL_HISTORY
humoral I-PAST_MEDICAL_HISTORY
al I-PAST_MEDICAL_HISTORY
cuarto I-PAST_MEDICAL_HISTORY
año I-PAST_MEDICAL_HISTORY
post I-PAST_MEDICAL_HISTORY
trasplante, I-PAST_MEDICAL_HISTORY
que I-PAST_MEDICAL_HISTORY
se I-PAST_MEDICAL_HISTORY
trató I-PAST_MEDICAL_HISTORY
exitosamente I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
metilprednisolona; I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
esa I-PAST_MEDICAL_HISTORY
oportunidad I-PAST_MEDICAL_HISTORY
la I-PAST_MEDICAL_HISTORY
coronariografía I-PAST_MEDICAL_HISTORY
fue I-PAST_MEDICAL_HISTORY
normal. I-PAST_MEDICAL_HISTORY
Tiene I-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
hipertensión I-PAST_MEDICAL_HISTORY
arterial I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
diabetes I-PAST_MEDICAL_HISTORY
mellitus I-PAST_MEDICAL_HISTORY
adquiridas I-PAST_MEDICAL_HISTORY
post I-PAST_MEDICAL_HISTORY
trasplante. I-PAST_MEDICAL_HISTORY
Se I-PAST_MEDICAL_HISTORY
encontraba I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
tratamiento I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
azatioprina I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
ciclosporina, I-PAST_MEDICAL_HISTORY
además I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
pravastatina, I-PAST_MEDICAL_HISTORY
aspirina, I-PAST_MEDICAL_HISTORY
enalapril I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
amlodipino. I-PAST_MEDICAL_HISTORY
Ingresó I-PAST_MEDICAL_HISTORY
por I-PAST_MEDICAL_HISTORY
una I-PAST_MEDICAL_HISTORY
historia I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
2 I-PAST_MEDICAL_HISTORY
meses I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
evolución I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
angina I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
esfuerzos I-PAST_MEDICAL_HISTORY
moderados, I-PAST_MEDICAL_HISTORY
asociado I-PAST_MEDICAL_HISTORY
a I-PAST_MEDICAL_HISTORY
disnea, I-PAST_MEDICAL_HISTORY
que I-PAST_MEDICAL_HISTORY
cedía I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
el I-PAST_MEDICAL_HISTORY
reposo. I-PAST_MEDICAL_HISTORY
Al B-EXPLORATION
examen I-EXPLORATION
físico, I-EXPLORATION
sólo I-EXPLORATION
destacaba I-EXPLORATION
una I-EXPLORATION
frecuencia I-EXPLORATION
cardíaca I-EXPLORATION
de I-EXPLORATION
100 I-EXPLORATION
latidos I-EXPLORATION
por I-EXPLORATION
minuto I-EXPLORATION
y I-EXPLORATION
un I-EXPLORATION
cuarto I-EXPLORATION
ruido I-EXPLORATION
cardíaco. I-EXPLORATION
El I-EXPLORATION
electrocardiograma I-EXPLORATION
de I-EXPLORATION
reposo I-EXPLORATION
mostró I-EXPLORATION
ritmo I-EXPLORATION
sinusal I-EXPLORATION
regular, I-EXPLORATION
imagen I-EXPLORATION
de I-EXPLORATION
bloqueo I-EXPLORATION
completo I-EXPLORATION
de I-EXPLORATION
rama I-EXPLORATION
derecha I-EXPLORATION
con I-EXPLORATION
qS I-EXPLORATION
en I-EXPLORATION
VI, I-EXPLORATION
hemibloqueo I-EXPLORATION
izquierdo I-EXPLORATION
anterior I-EXPLORATION
y I-EXPLORATION
alteraciones I-EXPLORATION
inespecíficas I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
repolarización I-EXPLORATION
ventricular I-EXPLORATION
en I-EXPLORATION
pared I-EXPLORATION
anterior. I-EXPLORATION
Exámenes I-EXPLORATION
de I-EXPLORATION
laboratorio: I-EXPLORATION
glicemia I-EXPLORATION
de I-EXPLORATION
175 I-EXPLORATION
mg/dL, I-EXPLORATION
creatininemia I-EXPLORATION
1.29 I-EXPLORATION
mg/dL, I-EXPLORATION
coleste-rol I-EXPLORATION
LDL I-EXPLORATION
62 I-EXPLORATION
mg/dL. I-EXPLORATION
Se I-EXPLORATION
realizó I-EXPLORATION
una I-EXPLORATION
biopsia I-EXPLORATION
endo-miocárdica I-EXPLORATION
que I-EXPLORATION
fue I-EXPLORATION
negativa I-EXPLORATION
para I-EXPLORATION
rechazo I-EXPLORATION
celular. I-EXPLORATION
La I-EXPLORATION
ventriculografía I-EXPLORATION
angiográfica I-EXPLORATION
reveló I-EXPLORATION
una I-EXPLORATION
disfunción I-EXPLORATION
leve I-EXPLORATION
a I-EXPLORATION
moderada I-EXPLORATION
del I-EXPLORATION
ventrículo I-EXPLORATION
izquierdo I-EXPLORATION
e I-EXPLORATION
hipokinesia I-EXPLORATION
anteroapical. I-EXPLORATION
El I-EXPLORATION
cateterismo I-EXPLORATION
coronario I-EXPLORATION
mostró I-EXPLORATION
una I-EXPLORATION
lesión I-EXPLORATION
crítica I-EXPLORATION
ostial I-EXPLORATION
del I-EXPLORATION
TCI, I-EXPLORATION
la I-EXPLORATION
arteria I-EXPLORATION
descendente I-EXPLORATION
anterior I-EXPLORATION
se I-EXPLORATION
encontraba I-EXPLORATION
ocluida I-EXPLORATION
luego I-EXPLORATION
del I-EXPLORATION
nacimiento I-EXPLORATION
del I-EXPLORATION
primer I-EXPLORATION
ramo I-EXPLORATION
diagonal I-EXPLORATION
y I-EXPLORATION
se I-EXPLORATION
llenaba I-EXPLORATION
por I-EXPLORATION
heterocolaterales I-EXPLORATION
desde I-EXPLORATION
la I-EXPLORATION
arteria I-EXPLORATION
coronaria I-EXPLORATION
derecha. I-EXPLORATION
No I-EXPLORATION
se I-EXPLORATION
encontraron I-EXPLORATION
otras I-EXPLORATION
lesiones I-EXPLORATION
coronarias I-EXPLORATION
significativas. I-EXPLORATION
Luego B-TREATMENT
de I-TREATMENT
discutir I-TREATMENT
las I-TREATMENT
alternativas I-TREATMENT
terapéuticas I-TREATMENT
con I-TREATMENT
el I-TREATMENT
paciente I-TREATMENT
se I-TREATMENT
realizó I-TREATMENT
angioplastia I-TREATMENT
exitosa I-TREATMENT
de I-TREATMENT
la I-TREATMENT
lesión I-TREATMENT
del I-TREATMENT
TCI, I-TREATMENT
con I-TREATMENT
implante I-TREATMENT
directo I-TREATMENT
de I-TREATMENT
sfewíTaxus® I-TREATMENT
3-5 I-TREATMENT
x I-TREATMENT
22 I-TREATMENT
mm I-TREATMENT
con I-TREATMENT
flujo I-TREATMENT
final I-TREATMENT
TIMI I-TREATMENT
3. I-TREATMENT
Un B-EXPLORATION
registro I-EXPLORATION
continuo I-EXPLORATION
del I-EXPLORATION
segmento I-EXPLORATION
ST I-EXPLORATION
en I-EXPLORATION
doce I-EXPLORATION
derivaciones, I-EXPLORATION
detectó I-EXPLORATION
infradesnivel I-EXPLORATION
significativo I-EXPLORATION
y I-EXPLORATION
transitorio I-EXPLORATION
del I-EXPLORATION
segmento I-EXPLORATION
ST I-EXPLORATION
en I-EXPLORATION
la I-EXPLORATION
derivación I-EXPLORATION
V4 I-EXPLORATION
durante I-EXPLORATION
la I-EXPLORATION
angioplastia. I-EXPLORATION
No I-EXPLORATION
se I-EXPLORATION
registraron I-EXPLORATION
otros I-EXPLORATION
incidentes I-EXPLORATION
durante I-EXPLORATION
y I-EXPLORATION
después I-EXPLORATION
del I-EXPLORATION
procedimiento. I-EXPLORATION
Al I-EXPLORATION
séptimo I-EXPLORATION
día I-EXPLORATION
se I-EXPLORATION
realizó I-EXPLORATION
cintigrama I-EXPLORATION
con I-EXPLORATION
I131 I-EXPLORATION
MIBG, I-EXPLORATION
demostrándose I-EXPLORATION
captación I-EXPLORATION
del I-EXPLORATION
radiofármaco I-EXPLORATION
en I-EXPLORATION
la I-EXPLORATION
pared I-EXPLORATION
anterior I-EXPLORATION
del I-EXPLORATION
ventrículo I-EXPLORATION
izquierdo. I-EXPLORATION
El B-EVOLUTION
paciente I-EVOLUTION
fue I-EVOLUTION
dado I-EVOLUTION
de I-EVOLUTION
alta I-EVOLUTION
4 I-EVOLUTION
días I-EVOLUTION
post I-EVOLUTION
angioplastia I-EVOLUTION
en I-EVOLUTION
buenas I-EVOLUTION
condiciones, I-EVOLUTION
se B-TREATMENT
incrementó I-TREATMENT
la I-TREATMENT
dosis I-TREATMENT
de I-TREATMENT
estatina I-TREATMENT
(pravastatina I-TREATMENT
40 I-TREATMENT
mg/día) I-TREATMENT
y I-TREATMENT
se I-TREATMENT
agregó I-TREATMENT
clopidogrel I-TREATMENT
a I-TREATMENT
su I-TREATMENT
terapia I-TREATMENT
habitual. I-TREATMENT
A B-EXPLORATION
los I-EXPLORATION
16 I-EXPLORATION
meses I-EXPLORATION
post I-EXPLORATION
procedimiento, I-EXPLORATION
el I-EXPLORATION
paciente I-EXPLORATION
presentó I-EXPLORATION
disnea I-EXPLORATION
progresiva I-EXPLORATION
realizándose I-EXPLORATION
nueva I-EXPLORATION
coronariografía. I-EXPLORATION
Se I-EXPLORATION
constató I-EXPLORATION
ausencia I-EXPLORATION
de I-EXPLORATION
reestenosis I-EXPLORATION
angiográfica I-EXPLORATION
del I-EXPLORATION
TCI I-EXPLORATION
y I-EXPLORATION
progresión I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
enfermedad I-EXPLORATION
aterosclerótica I-EXPLORATION
de I-EXPLORATION
las I-EXPLORATION
arterias I-EXPLORATION
circunfleja I-EXPLORATION
y I-EXPLORATION
coronaria I-EXPLORATION
derecha, I-EXPLORATION
las I-EXPLORATION
que I-EXPLORATION
presentaban I-EXPLORATION
estenosis I-EXPLORATION
significativas. I-EXPLORATION
Se B-TREATMENT
realizó I-TREATMENT
cirugía I-TREATMENT
de I-TREATMENT
revascularización I-TREATMENT
miocárdica: I-TREATMENT
injerto I-TREATMENT
de I-TREATMENT
arteria I-TREATMENT
mamaria I-TREATMENT
interna I-TREATMENT
izquierda I-TREATMENT
a I-TREATMENT
arteria I-TREATMENT
descendente I-TREATMENT
anterior I-TREATMENT
y I-TREATMENT
puentes I-TREATMENT
venosos I-TREATMENT
sáfenos I-TREATMENT
a I-TREATMENT
arteria I-TREATMENT
descendente I-TREATMENT
anterior, I-TREATMENT
rama I-TREATMENT
posterolateral I-TREATMENT
de I-TREATMENT
la I-TREATMENT
arteria I-TREATMENT
circunfleja I-TREATMENT
y I-TREATMENT
coronaria I-TREATMENT
derecha. I-TREATMENT
El B-EVOLUTION
paciente I-EVOLUTION
evolucionó I-EVOLUTION
con I-EVOLUTION
bloqueo I-EVOLUTION
auriculoventricular I-EVOLUTION
postoperatorio I-EVOLUTION
que I-EVOLUTION
requirió I-EVOLUTION
del I-EVOLUTION
implante I-EVOLUTION
de I-EVOLUTION
marcapaso I-EVOLUTION
definitivo I-EVOLUTION
bicameral. I-EVOLUTION
Su I-EVOLUTION
evolución I-EVOLUTION
fue I-EVOLUTION
satisfactoria I-EVOLUTION
y I-EVOLUTION
fue I-EVOLUTION
dado I-EVOLUTION
de I-EVOLUTION
alta I-EVOLUTION
14 I-EVOLUTION
días I-EVOLUTION
después I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
cirugía I-EVOLUTION
de I-EVOLUTION
revascularización. I-EVOLUTION
<EOS> I-EVOLUTION
Se B-PRESENT_ILLNESS
trata I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
una I-PRESENT_ILLNESS
mujer I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
43 I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
edad I-PRESENT_ILLNESS
con B-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
cefalea I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
crisis I-PAST_MEDICAL_HISTORY
convulsivas I-PAST_MEDICAL_HISTORY
generalizadas I-PAST_MEDICAL_HISTORY
tónico I-PAST_MEDICAL_HISTORY
clónicas I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
reciente I-PAST_MEDICAL_HISTORY
inicio. I-PAST_MEDICAL_HISTORY
Debido B-EXPLORATION
a I-EXPLORATION
su I-EXPLORATION
sintomatología I-EXPLORATION
es I-EXPLORATION
sometida I-EXPLORATION
a I-EXPLORATION
estudio I-EXPLORATION
y I-EXPLORATION
se I-EXPLORATION
diagnóstica I-EXPLORATION
la I-EXPLORATION
presencia I-EXPLORATION
de I-EXPLORATION
una I-EXPLORATION
malformación I-EXPLORATION
arteriovenosa I-EXPLORATION
(MAV) I-EXPLORATION
perirrolándica I-EXPLORATION
(Spetzler I-EXPLORATION
III), I-EXPLORATION
dependiente I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
arteria I-EXPLORATION
cerebral I-EXPLORATION
media I-EXPLORATION
derecha. I-EXPLORATION
Dadas B-TREATMENT
las I-TREATMENT
características I-TREATMENT
de I-TREATMENT
la I-TREATMENT
lesión I-TREATMENT
se I-TREATMENT
decidió I-TREATMENT
realizar I-TREATMENT
tratamiento I-TREATMENT
quirúrgico. I-TREATMENT
La I-TREATMENT
paciente I-TREATMENT
recibía I-TREATMENT
tratamiento I-TREATMENT
anticonvulsivante I-TREATMENT
con I-TREATMENT
ácido I-TREATMENT
valproico I-TREATMENT
debido I-TREATMENT
a I-TREATMENT
que I-TREATMENT
era I-TREATMENT
alérgica I-TREATMENT
a I-TREATMENT
la I-TREATMENT
fenitoína. I-TREATMENT
<EOS> I-TREATMENT
El I-TREATMENT
13 I-TREATMENT
de I-TREATMENT
junio I-TREATMENT
de I-TREATMENT
2006 I-TREATMENT
a I-TREATMENT
las I-TREATMENT
08: I-TREATMENT
00 I-TREATMENT
horas, I-TREATMENT
fue I-TREATMENT
sometida I-TREATMENT
a I-TREATMENT
una I-TREATMENT
craneotomía I-TREATMENT
parietal I-TREATMENT
derecha I-TREATMENT
más I-TREATMENT
resección I-TREATMENT
de I-TREATMENT
la I-TREATMENT
MAV. I-TREATMENT
Durante I-TREATMENT
las I-TREATMENT
7 I-TREATMENT
horas I-TREATMENT
que I-TREATMENT
duró I-TREATMENT
el I-TREATMENT
procedimiento I-TREATMENT
quirúrgico, I-TREATMENT
se I-TREATMENT
administraron I-TREATMENT
7mg/kg/h I-TREATMENT
(117 I-TREATMENT
mg/kg/min) I-TREATMENT
de I-TREATMENT
propofol I-TREATMENT
y I-TREATMENT
0, I-TREATMENT
25 I-TREATMENT
mg/ I-TREATMENT
kg/min I-TREATMENT
de I-TREATMENT
remifentanil. I-TREATMENT
La I-TREATMENT
exéresis I-TREATMENT
de I-TREATMENT
la I-TREATMENT
MAV I-TREATMENT
pudo I-TREATMENT
ser I-TREATMENT
ejecutada I-TREATMENT
en I-TREATMENT
forma I-TREATMENT
satisfactoria I-TREATMENT
y I-TREATMENT
sin I-TREATMENT
incidentes I-TREATMENT
intraoperatorios. I-TREATMENT
En I-TREATMENT
el I-TREATMENT
período I-TREATMENT
postoperatorio I-TREATMENT
inmediato I-TREATMENT
(estando I-TREATMENT
aún I-TREATMENT
en I-TREATMENT
pabellón), I-TREATMENT
la I-TREATMENT
paciente I-TREATMENT
presentó I-TREATMENT
una I-TREATMENT
crisis I-TREATMENT
convulsiva I-TREATMENT
tónico I-TREATMENT
clónica I-TREATMENT
generalizada I-TREATMENT
que I-TREATMENT
cedió I-TREATMENT
con I-TREATMENT
la I-TREATMENT
administración I-TREATMENT
de I-TREATMENT
4 I-TREATMENT
mg I-TREATMENT
de I-TREATMENT
lorazepam I-TREATMENT
por I-TREATMENT
vía I-TREATMENT
endovenosa. I-TREATMENT
<EOS> I-TREATMENT
A B-EVOLUTION
las I-EVOLUTION
16: I-EVOLUTION
00 I-EVOLUTION
horas I-EVOLUTION
del I-EVOLUTION
mismo I-EVOLUTION
día I-EVOLUTION
y I-EVOLUTION
una I-EVOLUTION
vez I-EVOLUTION
estabilizada, I-EVOLUTION
la I-EVOLUTION
paciente I-EVOLUTION
es I-EVOLUTION
trasladada I-EVOLUTION
desde I-EVOLUTION
pabellón I-EVOLUTION
a I-EVOLUTION
la I-EVOLUTION
Unidad I-EVOLUTION
de I-EVOLUTION
Cuidados I-EVOLUTION
Intensivos I-EVOLUTION
(UCI), I-EVOLUTION
donde I-EVOLUTION
se I-EVOLUTION
mantiene I-EVOLUTION
en I-EVOLUTION
ventilación I-EVOLUTION
mecánica I-EVOLUTION
y B-TREATMENT
se I-TREATMENT
continúan I-TREATMENT
las I-TREATMENT
medidas I-TREATMENT
de I-TREATMENT
neuroprotección I-TREATMENT
habituales, I-TREATMENT
incluida I-TREATMENT
la I-TREATMENT
sedo-analgesia I-TREATMENT
(midazolam/ I-TREATMENT
fentanil) I-TREATMENT
y I-TREATMENT
el I-TREATMENT
control I-TREATMENT
de I-TREATMENT
las I-TREATMENT
crisis I-TREATMENT
convulsivas I-TREATMENT
con I-TREATMENT
ácido I-TREATMENT
valproico. I-TREATMENT
<EOS> I-TREATMENT
Los B-EXPLORATION
exámenes I-EXPLORATION
de I-EXPLORATION
química I-EXPLORATION
sanguínea I-EXPLORATION
se I-EXPLORATION
encontraban I-EXPLORATION
dentro I-EXPLORATION
de I-EXPLORATION
rangos I-EXPLORATION
normales, I-EXPLORATION
sin I-EXPLORATION
disfunción I-EXPLORATION
renal, I-EXPLORATION
hepática I-EXPLORATION
o I-EXPLORATION
de I-EXPLORATION
coagulación I-EXPLORATION
y I-EXPLORATION
sin I-EXPLORATION
evidencia I-EXPLORATION
de I-EXPLORATION
infección I-EXPLORATION
activa. I-EXPLORATION
Sin I-EXPLORATION
embargo, I-EXPLORATION
a I-EXPLORATION
las I-EXPLORATION
17: I-EXPLORATION
00 I-EXPLORATION
destacaba I-EXPLORATION
la I-EXPLORATION
presencia I-EXPLORATION
de I-EXPLORATION
una I-EXPLORATION
acidosis I-EXPLORATION
láctica I-EXPLORATION
incipiente I-EXPLORATION
con I-EXPLORATION
pH I-EXPLORATION
7, I-EXPLORATION
34; I-EXPLORATION
PaC02 I-EXPLORATION
36 I-EXPLORATION
mmHg, I-EXPLORATION
Bicarbonato I-EXPLORATION
19 I-EXPLORATION
mmol/L; I-EXPLORATION
BE I-EXPLORATION
- I-EXPLORATION
6, I-EXPLORATION
4 I-EXPLORATION
mmol/L I-EXPLORATION
y I-EXPLORATION
ácido I-EXPLORATION
láctico I-EXPLORATION
4, I-EXPLORATION
1 I-EXPLORATION
mmol/L. I-EXPLORATION
En I-EXPLORATION
ese I-EXPLORATION
momento, I-EXPLORATION
la I-EXPLORATION
paciente I-EXPLORATION
se I-EXPLORATION
encontraba I-EXPLORATION
estable I-EXPLORATION
en I-EXPLORATION
lo I-EXPLORATION
hemodinámico, I-EXPLORATION
con I-EXPLORATION
una I-EXPLORATION
presión I-EXPLORATION
arterial I-EXPLORATION
media I-EXPLORATION
(PAM) I-EXPLORATION
de I-EXPLORATION
80 I-EXPLORATION
mmHg, I-EXPLORATION
frecuencia I-EXPLORATION
cardíaca I-EXPLORATION
de I-EXPLORATION
70 I-EXPLORATION
lat/min I-EXPLORATION
y I-EXPLORATION
una I-EXPLORATION
diuresis I-EXPLORATION
de I-EXPLORATION
60 I-EXPLORATION
a I-EXPLORATION
80 I-EXPLORATION
ml/h, I-EXPLORATION
sin I-EXPLORATION
evidencias I-EXPLORATION
de I-EXPLORATION
hipoperfusión I-EXPLORATION
clínica I-EXPLORATION
(piel I-EXPLORATION
tibia I-EXPLORATION
y I-EXPLORATION
con I-EXPLORATION
adecuado I-EXPLORATION
llene I-EXPLORATION
capilar). I-EXPLORATION
<EOS> I-EXPLORATION
Luego I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
estabilización I-EXPLORATION
inicial, I-EXPLORATION
se I-EXPLORATION
realiza I-EXPLORATION
una I-EXPLORATION
TAC I-EXPLORATION
de I-EXPLORATION
cerebro I-EXPLORATION
de I-EXPLORATION
control, I-EXPLORATION
en I-EXPLORATION
la I-EXPLORATION
que I-EXPLORATION
se I-EXPLORATION
aprecian I-EXPLORATION
cambios I-EXPLORATION
post-quirúrgicos: I-EXPLORATION
lecho I-EXPLORATION
operatorio I-EXPLORATION
sin I-EXPLORATION
hematoma I-EXPLORATION
y I-EXPLORATION
línea I-EXPLORATION
media I-EXPLORATION
conservada. I-EXPLORATION
El I-EXPLORATION
electroencefalograma I-EXPLORATION
descartó I-EXPLORATION
la I-EXPLORATION
existencia I-EXPLORATION
de I-EXPLORATION
actividad I-EXPLORATION
epileptógena I-EXPLORATION
y I-EXPLORATION
evidenció I-EXPLORATION
un I-EXPLORATION
ritmo I-EXPLORATION
lento I-EXPLORATION
generalizado I-EXPLORATION
atribuible I-EXPLORATION
a I-EXPLORATION
la I-EXPLORATION
sedación. I-EXPLORATION
<EOS> I-EXPLORATION
Se B-TREATMENT
mantuvieron I-TREATMENT
las I-TREATMENT
medidas I-TREATMENT
habituales I-TREATMENT
de I-TREATMENT
manejo I-TREATMENT
post-quirúrgico, I-TREATMENT
garantizando I-TREATMENT
una I-TREATMENT
adecuada I-TREATMENT
presión I-TREATMENT
de I-TREATMENT
perfusión I-TREATMENT
cerebral. I-TREATMENT
Durante B-EVOLUTION
las I-EVOLUTION
siguientes I-EVOLUTION
horas I-EVOLUTION
la I-EVOLUTION
paciente I-EVOLUTION
no I-EVOLUTION
presentó I-EVOLUTION
nuevas I-EVOLUTION
crisis I-EVOLUTION
convulsivas I-EVOLUTION
motoras. I-EVOLUTION
<EOS> I-EVOLUTION
A B-EXPLORATION
las I-EXPLORATION
21: I-EXPLORATION
00 I-EXPLORATION
horas, I-EXPLORATION
un I-EXPLORATION
nuevo I-EXPLORATION
control I-EXPLORATION
gasométri-co I-EXPLORATION
pone I-EXPLORATION
en I-EXPLORATION
evidencia I-EXPLORATION
el I-EXPLORATION
agravamiento I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
acidosis I-EXPLORATION
láctica: I-EXPLORATION
pH I-EXPLORATION
7, I-EXPLORATION
12; I-EXPLORATION
PaC02 I-EXPLORATION
31 I-EXPLORATION
mmHg; I-EXPLORATION
bicarbonato I-EXPLORATION
10 I-EXPLORATION
mmol/L; I-EXPLORATION
BE I-EXPLORATION
- I-EXPLORATION
18 I-EXPLORATION
mmol/L I-EXPLORATION
y I-EXPLORATION
ácido I-EXPLORATION
láctico I-EXPLORATION
9, I-EXPLORATION
9 I-EXPLORATION
mmol/L; I-EXPLORATION
pero I-EXPLORATION
con I-EXPLORATION
una I-EXPLORATION
saturación I-EXPLORATION
venosa I-EXPLORATION
central I-EXPLORATION
de I-EXPLORATION
86%. I-EXPLORATION
El I-EXPLORATION
electrocardiograma I-EXPLORATION
no I-EXPLORATION
mostraba I-EXPLORATION
cambios I-EXPLORATION
sugerentes I-EXPLORATION
de I-EXPLORATION
isquemia I-EXPLORATION
miocár-dica I-EXPLORATION
y I-EXPLORATION
las I-EXPLORATION
enzimas I-EXPLORATION
cardiacas I-EXPLORATION
fueron I-EXPLORATION
normales. I-EXPLORATION
<EOS> I-EXPLORATION
En I-EXPLORATION
este I-EXPLORATION
contexto, I-EXPLORATION
se I-EXPLORATION
decide I-EXPLORATION
realizar I-EXPLORATION
monitori-zación I-EXPLORATION
hemodinámica I-EXPLORATION
invasiva I-EXPLORATION
con I-EXPLORATION
un I-EXPLORATION
catéter I-EXPLORATION
de I-EXPLORATION
arteria I-EXPLORATION
pulmonar, I-EXPLORATION
encontrándose I-EXPLORATION
una I-EXPLORATION
presión I-EXPLORATION
de I-EXPLORATION
oclusión I-EXPLORATION
en I-EXPLORATION
la I-EXPLORATION
arteria I-EXPLORATION
pulmonar I-EXPLORATION
(POAP) I-EXPLORATION
de I-EXPLORATION
10 I-EXPLORATION
mmHg, I-EXPLORATION
un I-EXPLORATION
índice I-EXPLORATION
cardíaco I-EXPLORATION
de I-EXPLORATION
5, I-EXPLORATION
2 I-EXPLORATION
L/min/m2, I-EXPLORATION
una I-EXPLORATION
resistencia I-EXPLORATION
vascular I-EXPLORATION
sistémica I-EXPLORATION
indexada I-EXPLORATION
de I-EXPLORATION
1174 I-EXPLORATION
dinassegcm^m2 I-EXPLORATION
y I-EXPLORATION
una I-EXPLORATION
saturación I-EXPLORATION
venosa I-EXPLORATION
mixta I-EXPLORATION
(Satvm) I-EXPLORATION
de I-EXPLORATION
77%. I-EXPLORATION
Se B-TREATMENT
continuó I-TREATMENT
el I-TREATMENT
aporte I-TREATMENT
de I-TREATMENT
fluidos I-TREATMENT
trazándose I-TREATMENT
como I-TREATMENT
meta I-TREATMENT
una I-TREATMENT
POAP I-TREATMENT
de I-TREATMENT
14 I-TREATMENT
a I-TREATMENT
16 I-TREATMENT
mmHg I-TREATMENT
y I-TREATMENT
se I-TREATMENT
asoció I-TREATMENT
noradrenalina I-TREATMENT
con I-TREATMENT
el I-TREATMENT
objeto I-TREATMENT
de I-TREATMENT
mantener I-TREATMENT
una I-TREATMENT
PAM I-TREATMENT
de I-TREATMENT
90 I-TREATMENT
a I-TREATMENT
100 I-TREATMENT
mmHg. I-TREATMENT
Adicionalmente, I-TREATMENT
se I-TREATMENT
incrementó I-TREATMENT
la I-TREATMENT
infusión I-TREATMENT
de I-TREATMENT
midazolam I-TREATMENT
a I-TREATMENT
20 I-TREATMENT
mg/h I-TREATMENT
y I-TREATMENT
se I-TREATMENT
reinició I-TREATMENT
la I-TREATMENT
administración I-TREATMENT
de I-TREATMENT
propofol I-TREATMENT
a I-TREATMENT
3, I-TREATMENT
5 I-TREATMENT
mg/kg/h I-TREATMENT
(58 I-TREATMENT
Lig/kg/min) I-TREATMENT
para I-TREATMENT
alcanzar I-TREATMENT
un I-TREATMENT
nivel I-TREATMENT
de I-TREATMENT
2 I-TREATMENT
en I-TREATMENT
la I-TREATMENT
escala I-TREATMENT
de I-TREATMENT
sedación-agitación I-TREATMENT
descrita I-TREATMENT
por I-TREATMENT
Riker16. I-TREATMENT
<EOS> I-TREATMENT
Sin B-EVOLUTION
embargo, I-EVOLUTION
pese I-EVOLUTION
a I-EVOLUTION
mantenerse I-EVOLUTION
estable I-EVOLUTION
en I-EVOLUTION
lo I-EVOLUTION
macro I-EVOLUTION
y I-EVOLUTION
microhemodinámico I-EVOLUTION
y I-EVOLUTION
sin I-EVOLUTION
presentar I-EVOLUTION
disfunciones I-EVOLUTION
orgánicas, I-EVOLUTION
en I-EVOLUTION
el I-EVOLUTION
control I-EVOLUTION
de I-EVOLUTION
las I-EVOLUTION
00: I-EVOLUTION
20 I-EVOLUTION
se I-EVOLUTION
constató I-EVOLUTION
llamativamente, I-EVOLUTION
un I-EVOLUTION
empeoramiento I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
acidosis I-EVOLUTION
láctica: I-EVOLUTION
pH I-EVOLUTION
7, I-EVOLUTION
0 I-EVOLUTION
y I-EVOLUTION
ácido I-EVOLUTION
láctico I-EVOLUTION
8, I-EVOLUTION
5 I-EVOLUTION
con I-EVOLUTION
Satvm I-EVOLUTION
80%. I-EVOLUTION
No B-TREATMENT
fue I-TREATMENT
posible I-TREATMENT
identificar I-TREATMENT
una I-TREATMENT
causa I-TREATMENT
evidente I-TREATMENT
que I-TREATMENT
explicase I-TREATMENT
la I-TREATMENT
evolución I-TREATMENT
clínica I-TREATMENT
de I-TREATMENT
la I-TREATMENT
paciente, I-TREATMENT
se I-TREATMENT
mantuvo I-TREATMENT
terapia I-TREATMENT
de I-TREATMENT
soporte. I-TREATMENT
En B-EVOLUTION
las I-EVOLUTION
horas I-EVOLUTION
siguientes, I-EVOLUTION
no I-EVOLUTION
se I-EVOLUTION
observó I-EVOLUTION
un I-EVOLUTION
cambio I-EVOLUTION
significativo I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
acidosis I-EVOLUTION
metabólica. I-EVOLUTION
<EOS> I-EVOLUTION
Finalmente, B-TREATMENT
se I-TREATMENT
sospechó I-TREATMENT
que I-TREATMENT
la I-TREATMENT
administración I-TREATMENT
de I-TREATMENT
propofol I-TREATMENT
podría I-TREATMENT
ser I-TREATMENT
la I-TREATMENT
causa I-TREATMENT
desencadenante I-TREATMENT
y I-TREATMENT
la I-TREATMENT
perpetuadora I-TREATMENT
de I-TREATMENT
la I-TREATMENT
acidosis I-TREATMENT
láctica, I-TREATMENT
por I-TREATMENT
lo I-TREATMENT
que I-TREATMENT
se I-TREATMENT
decidió I-TREATMENT
suspender I-TREATMENT
la I-TREATMENT
infusión I-TREATMENT
a I-TREATMENT
las I-TREATMENT
08: I-TREATMENT
30, I-TREATMENT
habiendo I-TREATMENT
completado I-TREATMENT
8 I-TREATMENT
horas I-TREATMENT
adicionales I-TREATMENT
después I-TREATMENT
de I-TREATMENT
la I-TREATMENT
cirugía. I-TREATMENT
La B-EVOLUTION
condición I-EVOLUTION
hemodinámica I-EVOLUTION
continuó I-EVOLUTION
estable I-EVOLUTION
durante I-EVOLUTION
la I-EVOLUTION
mañana. I-EVOLUTION
Cuatro B-EXPLORATION
horas I-EXPLORATION
más I-EXPLORATION
tarde I-EXPLORATION
se I-EXPLORATION
realizó I-EXPLORATION
un I-EXPLORATION
nuevo I-EXPLORATION
control I-EXPLORATION
gasométrico, I-EXPLORATION
en I-EXPLORATION
el I-EXPLORATION
que I-EXPLORATION
se I-EXPLORATION
pudo I-EXPLORATION
apreciar I-EXPLORATION
la I-EXPLORATION
corrección I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
acidosis I-EXPLORATION
láctica: I-EXPLORATION
pH I-EXPLORATION
7, I-EXPLORATION
53 I-EXPLORATION
y I-EXPLORATION
ácido I-EXPLORATION
láctico I-EXPLORATION
2, I-EXPLORATION
9 I-EXPLORATION
mmol/ I-EXPLORATION
L I-EXPLORATION
con I-EXPLORATION
PaC02 I-EXPLORATION
24 I-EXPLORATION
mmHg. I-EXPLORATION
A B-EVOLUTION
las I-EVOLUTION
19: I-EVOLUTION
00, I-EVOLUTION
once I-EVOLUTION
horas I-EVOLUTION
después I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
suspensión I-EVOLUTION
del I-EVOLUTION
propofol, I-EVOLUTION
el I-EVOLUTION
acido I-EVOLUTION
láctico I-EVOLUTION
ya I-EVOLUTION
se I-EVOLUTION
había I-EVOLUTION
normalizado: I-EVOLUTION
1, I-EVOLUTION
6 I-EVOLUTION
mmol/L. I-EVOLUTION
Posteriormente, I-EVOLUTION
la I-EVOLUTION
paciente I-EVOLUTION
tuvo I-EVOLUTION
una I-EVOLUTION
evolución I-EVOLUTION
favorable, I-EVOLUTION
sin I-EVOLUTION
complicaciones I-EVOLUTION
asociadas I-EVOLUTION
a I-EVOLUTION
la I-EVOLUTION
descompensación I-EVOLUTION
metabólica. I-EVOLUTION
No I-EVOLUTION
volvió I-EVOLUTION
a I-EVOLUTION
presentar I-EVOLUTION
crisis I-EVOLUTION
convulsivas, I-EVOLUTION
pudiendo I-EVOLUTION
ser I-EVOLUTION
extuba-da I-EVOLUTION
y I-EVOLUTION
trasladada I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
UCI I-EVOLUTION
en I-EVOLUTION
buenas I-EVOLUTION
condiciones. I-EVOLUTION
<EOS> I-EVOLUTION
En B-DERIVED_FROM/TO
diciembre I-DERIVED_FROM/TO
de I-DERIVED_FROM/TO
2004 I-DERIVED_FROM/TO
fue I-DERIVED_FROM/TO
derivado I-DERIVED_FROM/TO
a I-DERIVED_FROM/TO
la I-DERIVED_FROM/TO
Policlínica I-DERIVED_FROM/TO
Nefrológica I-DERIVED_FROM/TO
del I-DERIVED_FROM/TO
Hospital I-DERIVED_FROM/TO
de I-DERIVED_FROM/TO
Clínicas I-DERIVED_FROM/TO
de I-DERIVED_FROM/TO
Montevideo, I-DERIVED_FROM/TO
un B-PRESENT_ILLNESS
paciente I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
17 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
sexo I-PRESENT_ILLNESS
masculino, I-PRESENT_ILLNESS
raza I-PRESENT_ILLNESS
blanca, I-PRESENT_ILLNESS
con B-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
hepatitis I-PAST_MEDICAL_HISTORY
a I-PAST_MEDICAL_HISTORY
los I-PAST_MEDICAL_HISTORY
3 I-PAST_MEDICAL_HISTORY
años, I-PAST_MEDICAL_HISTORY
para B-DERIVED_FROM/TO
estudio I-DERIVED_FROM/TO
de I-DERIVED_FROM/TO
proteinuria I-DERIVED_FROM/TO
aislada, I-DERIVED_FROM/TO
no I-DERIVED_FROM/TO
nefrótica, I-DERIVED_FROM/TO
detectada I-DERIVED_FROM/TO
en I-DERIVED_FROM/TO
examen I-DERIVED_FROM/TO
preventivo. I-DERIVED_FROM/TO
Fue B-EXPLORATION
descartada I-EXPLORATION
en I-EXPLORATION
el I-EXPLORATION
interrogatorio I-EXPLORATION
la I-EXPLORATION
existencia I-EXPLORATION
de I-EXPLORATION
orinas I-EXPLORATION
espumosas, I-EXPLORATION
edemas I-EXPLORATION
o I-EXPLORATION
disminución I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
diuresis. I-EXPLORATION
El I-EXPLORATION
examen I-EXPLORATION
físico I-EXPLORATION
fue I-EXPLORATION
normal, I-EXPLORATION
con I-EXPLORATION
presión I-EXPLORATION
arterial I-EXPLORATION
de I-EXPLORATION
120/70 I-EXPLORATION
mmHg. I-EXPLORATION
Exámenes I-EXPLORATION
de I-EXPLORATION
laboratorio: I-EXPLORATION
proteinuria I-EXPLORATION
de I-EXPLORATION
2, I-EXPLORATION
2 I-EXPLORATION
g/1, I-EXPLORATION
selectiva, I-EXPLORATION
con I-EXPLORATION
80% I-EXPLORATION
de I-EXPLORATION
albúmina, I-EXPLORATION
no I-EXPLORATION
microhematuria, I-EXPLORATION
creatininemia I-EXPLORATION
de I-EXPLORATION
0, I-EXPLORATION
89 I-EXPLORATION
mm/dl, I-EXPLORATION
azoemia: I-EXPLORATION
0, I-EXPLORATION
12 I-EXPLORATION
g/ I-EXPLORATION
1; I-EXPLORATION
albuminemia: I-EXPLORATION
4, I-EXPLORATION
9 I-EXPLORATION
g/dl; I-EXPLORATION
proteinemia: I-EXPLORATION
7, I-EXPLORATION
8 I-EXPLORATION
g/dl, I-EXPLORATION
gamma I-EXPLORATION
globulina: I-EXPLORATION
1, I-EXPLORATION
3 I-EXPLORATION
g/dl, I-EXPLORATION
colesterol: I-EXPLORATION
166 I-EXPLORATION
mg/dl, I-EXPLORATION
triglicéridos: I-EXPLORATION
35 I-EXPLORATION
mg/dl, I-EXPLORATION
HDL: I-EXPLORATION
39 I-EXPLORATION
mg/dl, I-EXPLORATION
LDL I-EXPLORATION
120 I-EXPLORATION
mg/ I-EXPLORATION
di; I-EXPLORATION
urocultivo: I-EXPLORATION
negativo. I-EXPLORATION
Los I-EXPLORATION
anticuerpos I-EXPLORATION
antinucleares I-EXPLORATION
(ANA) I-EXPLORATION
y I-EXPLORATION
anti-ADN I-EXPLORATION
fueron I-EXPLORATION
negativos I-EXPLORATION
en I-EXPLORATION
2 I-EXPLORATION
oportunidades. I-EXPLORATION
Enzimograma I-EXPLORATION
hepático: I-EXPLORATION
BT I-EXPLORATION
0, I-EXPLORATION
82 I-EXPLORATION
mg/ I-EXPLORATION
di, I-EXPLORATION
TGO I-EXPLORATION
22, I-EXPLORATION
TGP I-EXPLORATION
15, I-EXPLORATION
FA I-EXPLORATION
2, I-EXPLORATION
26, I-EXPLORATION
yGT I-EXPLORATION
28 I-EXPLORATION
(Ul/lt). I-EXPLORATION
La I-EXPLORATION
complementemia I-EXPLORATION
fue I-EXPLORATION
normal. I-EXPLORATION
La I-EXPLORATION
serología I-EXPLORATION
para I-EXPLORATION
ANCA I-EXPLORATION
y I-EXPLORATION
HIV, I-EXPLORATION
Virus I-EXPLORATION
hepatitis I-EXPLORATION
C I-EXPLORATION
y I-EXPLORATION
B I-EXPLORATION
fue I-EXPLORATION
negativa. I-EXPLORATION
La I-EXPLORATION
ecografía I-EXPLORATION
renal I-EXPLORATION
y I-EXPLORATION
abdominal I-EXPLORATION
fue I-EXPLORATION
normal. I-EXPLORATION
El B-TREATMENT
paciente I-TREATMENT
recibió I-TREATMENT
enalapril I-TREATMENT
(40 I-TREATMENT
mg/día) I-TREATMENT
asociado I-TREATMENT
a I-TREATMENT
losartán I-TREATMENT
(50 I-TREATMENT
mg/día). I-TREATMENT
Presentó B-EVOLUTION
una I-EVOLUTION
remisión I-EVOLUTION
progresiva I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
proteinuria, I-EVOLUTION
que I-EVOLUTION
fue I-EVOLUTION
total I-EVOLUTION
a I-EVOLUTION
los I-EVOLUTION
18 I-EVOLUTION
meses I-EVOLUTION
de I-EVOLUTION
iniciado I-EVOLUTION
el I-EVOLUTION
tratamiento. I-EVOLUTION
La I-EVOLUTION
función I-EVOLUTION
renal I-EVOLUTION
se I-EVOLUTION
mantuvo I-EVOLUTION
normal. I-EVOLUTION
Con B-EXPLORATION
el I-EXPLORATION
planteo I-EXPLORATION
clínico I-EXPLORATION
de I-EXPLORATION
una I-EXPLORATION
EFS I-EXPLORATION
se I-EXPLORATION
realizó I-EXPLORATION
biopsia I-EXPLORATION
renal I-EXPLORATION
para I-EXPLORATION
estudio I-EXPLORATION
histopatológico I-EXPLORATION
con I-EXPLORATION
microscopía I-EXPLORATION
de I-EXPLORATION
luz I-EXPLORATION
(ML), I-EXPLORATION
microscopía I-EXPLORATION
electrónica I-EXPLORATION
(ME) I-EXPLORATION
e I-EXPLORATION
inmunofluorescencia I-EXPLORATION
(IF). I-EXPLORATION
<EOS> I-EXPLORATION
Histopatología. I-EXPLORATION
Se I-EXPLORATION
observaron I-EXPLORATION
20 I-EXPLORATION
glomérulos, I-EXPLORATION
1 I-EXPLORATION
de I-EXPLORATION
ellos I-EXPLORATION
con I-EXPLORATION
esclerosis I-EXPLORATION
mayor I-EXPLORATION
a I-EXPLORATION
50% I-EXPLORATION
del I-EXPLORATION
área I-EXPLORATION
del I-EXPLORATION
glomérulo, I-EXPLORATION
en I-EXPLORATION
tanto I-EXPLORATION
que I-EXPLORATION
4 I-EXPLORATION
evidenciaron I-EXPLORATION
esclerosis I-EXPLORATION
segmentaria I-EXPLORATION
leve, I-EXPLORATION
moderado I-EXPLORATION
aumento I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
matriz I-EXPLORATION
mesangial I-EXPLORATION
y I-EXPLORATION
sinequias I-EXPLORATION
entre I-EXPLORATION
asas I-EXPLORATION
capilares I-EXPLORATION
glomerulares I-EXPLORATION
y I-EXPLORATION
cápsula I-EXPLORATION
de I-EXPLORATION
Bowman. I-EXPLORATION
Se I-EXPLORATION
encontraron I-EXPLORATION
escasos I-EXPLORATION
depósitos I-EXPLORATION
fucsinófilos I-EXPLORATION
yux-tamesangiales I-EXPLORATION
con I-EXPLORATION
el I-EXPLORATION
tricrómico I-EXPLORATION
de I-EXPLORATION
Masson. I-EXPLORATION
El I-EXPLORATION
sector I-EXPLORATION
túbulo-intersticial I-EXPLORATION
mostró I-EXPLORATION
un I-EXPLORATION
pequeño I-EXPLORATION
foco I-EXPLORATION
de I-EXPLORATION
necrosis I-EXPLORATION
tubular I-EXPLORATION
y I-EXPLORATION
algunos I-EXPLORATION
cilindros I-EXPLORATION
con I-EXPLORATION
eritrocitos I-EXPLORATION
crenados. I-EXPLORATION
Las I-EXPLORATION
arterias I-EXPLORATION
fueron I-EXPLORATION
normales. I-EXPLORATION
<EOS> I-EXPLORATION
Inmunofluorescencia. I-EXPLORATION
Demostró I-EXPLORATION
positividad I-EXPLORATION
para I-EXPLORATION
Clq I-EXPLORATION
+++, I-EXPLORATION
dominante; I-EXPLORATION
IgA++ I-EXPLORATION
perihiliar; I-EXPLORATION
IgG, I-EXPLORATION
IgM, I-EXPLORATION
C3 I-EXPLORATION
positivas++, I-EXPLORATION
con I-EXPLORATION
patrón I-EXPLORATION
granular I-EXPLORATION
grueso, I-EXPLORATION
de I-EXPLORATION
distribución I-EXPLORATION
a I-EXPLORATION
predominio I-EXPLORATION
mesangial I-EXPLORATION
fibrinógeno: I-EXPLORATION
negativo. I-EXPLORATION
<EOS> I-EXPLORATION
Microscopía I-EXPLORATION
electrónica. I-EXPLORATION
Se I-EXPLORATION
observó I-EXPLORATION
aplanamiento I-EXPLORATION
pedicelar I-EXPLORATION
menor I-EXPLORATION
a I-EXPLORATION
20% I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
superficie I-EXPLORATION
de I-EXPLORATION
las I-EXPLORATION
asas I-EXPLORATION
capilares, I-EXPLORATION
depósitos I-EXPLORATION
electrondensos I-EXPLORATION
granulares I-EXPLORATION
paramesangiales I-EXPLORATION
en I-EXPLORATION
la I-EXPLORATION
región I-EXPLORATION
donde I-EXPLORATION
se I-EXPLORATION
refleja I-EXPLORATION
la I-EXPLORATION
membrana I-EXPLORATION
basal I-EXPLORATION
glomerular I-EXPLORATION
(MBG) I-EXPLORATION
y I-EXPLORATION
moderada I-EXPLORATION
cantidad I-EXPLORATION
de I-EXPLORATION
fibras I-EXPLORATION
colágenas I-EXPLORATION
en I-EXPLORATION
el I-EXPLORATION
mesangio, I-EXPLORATION
en I-EXPLORATION
áreas I-EXPLORATION
de I-EXPLORATION
esclerosis I-EXPLORATION
glomerular. I-EXPLORATION
El I-EXPLORATION
endotelio I-EXPLORATION
capilar I-EXPLORATION
glomerular I-EXPLORATION
no I-EXPLORATION
mostró I-EXPLORATION
inclusiones I-EXPLORATION
túbulo I-EXPLORATION
reticulares I-EXPLORATION
(ITR). I-EXPLORATION
<EOS> I-EXPLORATION
Hombre B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
78 I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
edad, I-PRESENT_ILLNESS
sin B-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
mórbidos, I-PAST_MEDICAL_HISTORY
consultó B-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
aumento I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
volumen I-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
la I-PRESENT_ILLNESS
frente, I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
2 I-PRESENT_ILLNESS
meses I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
evolución, I-PRESENT_ILLNESS
único, I-PRESENT_ILLNESS
sin I-PRESENT_ILLNESS
sintomatología I-PRESENT_ILLNESS
asociada. I-PRESENT_ILLNESS
Al B-EXPLORATION
examen I-EXPLORATION
físico I-EXPLORATION
presentaba I-EXPLORATION
un I-EXPLORATION
tumor I-EXPLORATION
firme, I-EXPLORATION
elástico, I-EXPLORATION
no I-EXPLORATION
adherido I-EXPLORATION
a I-EXPLORATION
planos I-EXPLORATION
profundos, I-EXPLORATION
de I-EXPLORATION
1, I-EXPLORATION
7 I-EXPLORATION
x I-EXPLORATION
0, I-EXPLORATION
6 I-EXPLORATION
cm, I-EXPLORATION
con I-EXPLORATION
algunas I-EXPLORATION
pápulas I-EXPLORATION
eritematosas I-EXPLORATION
levemente I-EXPLORATION
translúcidas I-EXPLORATION
en I-EXPLORATION
la I-EXPLORATION
superficie I-EXPLORATION
y I-EXPLORATION
múltiples I-EXPLORATION
telangiectasias. I-EXPLORATION
Se B-TREATMENT
extrajo I-TREATMENT
la I-TREATMENT
lesión I-TREATMENT
y I-TREATMENT
se I-TREATMENT
envió I-TREATMENT
a I-TREATMENT
anatomía I-TREATMENT
patológica I-TREATMENT
con I-TREATMENT
diagnóstico I-TREATMENT
clínico I-TREATMENT
de I-TREATMENT
carcinoma I-TREATMENT
basocelular I-TREATMENT
sobre I-TREATMENT
quiste I-TREATMENT
epidérmico. I-TREATMENT
Al B-EVOLUTION
momento I-EVOLUTION
del I-EVOLUTION
control I-EVOLUTION
clínico, I-EVOLUTION
una I-EVOLUTION
semana I-EVOLUTION
después, I-EVOLUTION
presentó I-EVOLUTION
otro I-EVOLUTION
tumor I-EVOLUTION
más I-EVOLUTION
pequeño I-EVOLUTION
en I-EVOLUTION
la I-EVOLUTION
región I-EVOLUTION
supraciliar I-EVOLUTION
derecha, I-EVOLUTION
de I-EVOLUTION
similares I-EVOLUTION
características I-EVOLUTION
al I-EVOLUTION
primero. I-EVOLUTION
El B-EXPLORATION
examen I-EXPLORATION
anatomopatológico I-EXPLORATION
del I-EXPLORATION
tumor I-EXPLORATION
frontal I-EXPLORATION
mostró I-EXPLORATION
una I-EXPLORATION
neoplasia I-EXPLORATION
compatible I-EXPLORATION
con I-EXPLORATION
SH. I-EXPLORATION
Estudios I-EXPLORATION
de I-EXPLORATION
imágenes I-EXPLORATION
(tomografía I-EXPLORATION
computada I-EXPLORATION
de I-EXPLORATION
cabeza I-EXPLORATION
y I-EXPLORATION
cuello) I-EXPLORATION
mostraron I-EXPLORATION
múltiples I-EXPLORATION
lesiones I-EXPLORATION
nodulares I-EXPLORATION
en I-EXPLORATION
tejido I-EXPLORATION
celular I-EXPLORATION
subcutáneo I-EXPLORATION
en I-EXPLORATION
ambas I-EXPLORATION
regiones I-EXPLORATION
temporales, I-EXPLORATION
así I-EXPLORATION
como I-EXPLORATION
adenopatías I-EXPLORATION
submandibulares I-EXPLORATION
y I-EXPLORATION
yugulo-digástricas. I-EXPLORATION
También I-EXPLORATION
se I-EXPLORATION
observaron I-EXPLORATION
nodulos I-EXPLORATION
en I-EXPLORATION
ambas I-EXPLORATION
glándulas I-EXPLORATION
parótidas. I-EXPLORATION
Estudios I-EXPLORATION
de I-EXPLORATION
laboratorio I-EXPLORATION
incluyeron I-EXPLORATION
hemograma I-EXPLORATION
que I-EXPLORATION
mostró I-EXPLORATION
los I-EXPLORATION
siguientes I-EXPLORATION
valores: I-EXPLORATION
hemoglobina, I-EXPLORATION
16, I-EXPLORATION
0 I-EXPLORATION
gr/dF I-EXPLORATION
(valores I-EXPLORATION
de I-EXPLORATION
referencia I-EXPLORATION
(VR), I-EXPLORATION
13, I-EXPLORATION
5-17, I-EXPLORATION
5); I-EXPLORATION
hematocrito, I-EXPLORATION
45, I-EXPLORATION
8% I-EXPLORATION
(VR, I-EXPLORATION
41-53); I-EXPLORATION
leucocitos, I-EXPLORATION
5, I-EXPLORATION
0 I-EXPLORATION
x I-EXPLORATION
103 I-EXPLORATION
/mm3 I-EXPLORATION
(VR, I-EXPLORATION
4, I-EXPLORATION
5-11) I-EXPLORATION
y I-EXPLORATION
plaquetas, I-EXPLORATION
200 I-EXPLORATION
x I-EXPLORATION
103/mm3 I-EXPLORATION
(VR, I-EXPLORATION
140-400). I-EXPLORATION
El I-EXPLORATION
recuento I-EXPLORATION
leucocitos I-EXPLORATION
fue: I-EXPLORATION
neutrófilos, I-EXPLORATION
53%; I-EXPLORATION
eosinófilos, I-EXPLORATION
4%; I-EXPLORATION
monocitos, I-EXPLORATION
18% I-EXPLORATION
y I-EXPLORATION
linfocitos, I-EXPLORATION
25%. I-EXPLORATION
Otros I-EXPLORATION
exámenes I-EXPLORATION
de I-EXPLORATION
laboratorio I-EXPLORATION
(perfil I-EXPLORATION
bioquímico I-EXPLORATION
y I-EXPLORATION
pruebas I-EXPLORATION
hepáticas) I-EXPLORATION
estuvieron I-EXPLORATION
dentro I-EXPLORATION
de I-EXPLORATION
rangos I-EXPLORATION
normales. I-EXPLORATION
El B-DERIVED_FROM/TO
paciente I-DERIVED_FROM/TO
fue I-DERIVED_FROM/TO
tratado I-DERIVED_FROM/TO
en I-DERIVED_FROM/TO
otra I-DERIVED_FROM/TO
institución I-DERIVED_FROM/TO
y I-DERIVED_FROM/TO
desafortunadamente I-DERIVED_FROM/TO
se I-DERIVED_FROM/TO
perdió I-DERIVED_FROM/TO
para I-DERIVED_FROM/TO
seguimiento I-DERIVED_FROM/TO
clínico. I-DERIVED_FROM/TO
<EOS> I-DERIVED_FROM/TO
HALLAZGOS B-EXPLORATION
HISTOLÓGICOS I-EXPLORATION
<EOS> I-EXPLORATION
Microscópicamente, I-EXPLORATION
el I-EXPLORATION
tumor I-EXPLORATION
frontal I-EXPLORATION
mostró I-EXPLORATION
una I-EXPLORATION
proliferación I-EXPLORATION
celular I-EXPLORATION
atípica, I-EXPLORATION
difusa, I-EXPLORATION
en I-EXPLORATION
dermis I-EXPLORATION
superficial I-EXPLORATION
y I-EXPLORATION
profunda, I-EXPLORATION
no I-EXPLORATION
epidermotrópica I-EXPLORATION
y I-EXPLORATION
con I-EXPLORATION
zona I-EXPLORATION
de I-EXPLORATION
Grenz. I-EXPLORATION
Constituida I-EXPLORATION
por I-EXPLORATION
células I-EXPLORATION
medianas I-EXPLORATION
a I-EXPLORATION
grandes, I-EXPLORATION
de I-EXPLORATION
aspecto I-EXPLORATION
epiteloideo I-EXPLORATION
y I-EXPLORATION
pleomorfismo I-EXPLORATION
variable, I-EXPLORATION
que I-EXPLORATION
incluye I-EXPLORATION
formas I-EXPLORATION
multinucleadas. I-EXPLORATION
Se I-EXPLORATION
observó I-EXPLORATION
además I-EXPLORATION
un I-EXPLORATION
componente I-EXPLORATION
linfocitario I-EXPLORATION
prominente, I-EXPLORATION
numerosas I-EXPLORATION
mitosis I-EXPLORATION
y I-EXPLORATION
cuerpos I-EXPLORATION
apoptóticos. I-EXPLORATION
<EOS> I-EXPLORATION
Inmunohistoquímicamente, I-EXPLORATION
las I-EXPLORATION
células I-EXPLORATION
neoplásicas I-EXPLORATION
mostraron I-EXPLORATION
reacción I-EXPLORATION
positiva I-EXPLORATION
para I-EXPLORATION
CD43, I-EXPLORATION
CD45, I-EXPLORATION
CD4 I-EXPLORATION
(parcial), I-EXPLORATION
CD30 I-EXPLORATION
(difuso), I-EXPLORATION
CD68, I-EXPLORATION
CD163, I-EXPLORATION
mieloperoxidasa, I-EXPLORATION
lizosima I-EXPLORATION
y I-EXPLORATION
proteína I-EXPLORATION
S-100 I-EXPLORATION
; I-EXPLORATION
y I-EXPLORATION
reacción I-EXPLORATION
negativa I-EXPLORATION
para I-EXPLORATION
TdT, I-EXPLORATION
CD34, I-EXPLORATION
CD117, I-EXPLORATION
CD3, I-EXPLORATION
CD20, I-EXPLORATION
HMB45 I-EXPLORATION
y I-EXPLORATION
citoqueratinas I-EXPLORATION
totales. I-EXPLORATION
<EOS> I-EXPLORATION
Mielograma I-EXPLORATION
y I-EXPLORATION
biopsia I-EXPLORATION
de I-EXPLORATION
médula I-EXPLORATION
ósea I-EXPLORATION
mostraron I-EXPLORATION
una I-EXPLORATION
hipoplasia I-EXPLORATION
medular I-EXPLORATION
con I-EXPLORATION
cambios I-EXPLORATION
displásicos I-EXPLORATION
leves. I-EXPLORATION
Estudio I-EXPLORATION
de I-EXPLORATION
clonalidad I-EXPLORATION
mediante I-EXPLORATION
técnica I-EXPLORATION
de I-EXPLORATION
reacción I-EXPLORATION
de I-EXPLORATION
polimerasa I-EXPLORATION
en I-EXPLORATION
cadena, I-EXPLORATION
mostró I-EXPLORATION
un I-EXPLORATION
reordenamiento I-EXPLORATION
policlonal I-EXPLORATION
de I-EXPLORATION
linfocitos I-EXPLORATION
T I-EXPLORATION
y I-EXPLORATION
B. I-EXPLORATION
<EOS> I-EXPLORATION
Mujer B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
81 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
deterioro I-PRESENT_ILLNESS
cognitivo I-PRESENT_ILLNESS
moderado I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
enfermedad I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
Alzheimer I-PRESENT_ILLNESS
e B-PAST_MEDICAL_HISTORY
historia I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
nodulo I-PAST_MEDICAL_HISTORY
cervical I-PAST_MEDICAL_HISTORY
anterior I-PAST_MEDICAL_HISTORY
pesquisado I-PAST_MEDICAL_HISTORY
3 I-PAST_MEDICAL_HISTORY
meses I-PAST_MEDICAL_HISTORY
previo I-PAST_MEDICAL_HISTORY
al I-PAST_MEDICAL_HISTORY
ingreso, I-PAST_MEDICAL_HISTORY
que I-PAST_MEDICAL_HISTORY
creció I-PAST_MEDICAL_HISTORY
rápidamente I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
las I-PAST_MEDICAL_HISTORY
últimas I-PAST_MEDICAL_HISTORY
tres I-PAST_MEDICAL_HISTORY
semanas, I-PAST_MEDICAL_HISTORY
consultando B-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
disnea I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
reposo, I-PRESENT_ILLNESS
ortopnea I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
disfagia. I-PRESENT_ILLNESS
Fue B-PAST_MEDICAL_HISTORY
estudiada I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
otro I-PAST_MEDICAL_HISTORY
centro, I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
ecografía I-PAST_MEDICAL_HISTORY
cervical I-PAST_MEDICAL_HISTORY
que I-PAST_MEDICAL_HISTORY
mostró I-PAST_MEDICAL_HISTORY
aumento I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
volumen I-PAST_MEDICAL_HISTORY
tiroideo, I-PAST_MEDICAL_HISTORY
TSH I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
32, I-PAST_MEDICAL_HISTORY
4 I-PAST_MEDICAL_HISTORY
mUI/ml I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
anticuerpos I-PAST_MEDICAL_HISTORY
anti I-PAST_MEDICAL_HISTORY
TPO I-PAST_MEDICAL_HISTORY
(++). I-PAST_MEDICAL_HISTORY
Se I-PAST_MEDICAL_HISTORY
realizaron I-PAST_MEDICAL_HISTORY
4 I-PAST_MEDICAL_HISTORY
punciones I-PAST_MEDICAL_HISTORY
tiroideas, I-PAST_MEDICAL_HISTORY
3 I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
ellas I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
muestra I-PAST_MEDICAL_HISTORY
insuficiente I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
la I-PAST_MEDICAL_HISTORY
última I-PAST_MEDICAL_HISTORY
fue I-PAST_MEDICAL_HISTORY
informada I-PAST_MEDICAL_HISTORY
como I-PAST_MEDICAL_HISTORY
tiroiditis I-PAST_MEDICAL_HISTORY
crónica. I-PAST_MEDICAL_HISTORY
La I-PAST_MEDICAL_HISTORY
tomografía I-PAST_MEDICAL_HISTORY
computada I-PAST_MEDICAL_HISTORY
(TC) I-PAST_MEDICAL_HISTORY
cervical I-PAST_MEDICAL_HISTORY
informó I-PAST_MEDICAL_HISTORY
gran I-PAST_MEDICAL_HISTORY
masa I-PAST_MEDICAL_HISTORY
que I-PAST_MEDICAL_HISTORY
reemplaza I-PAST_MEDICAL_HISTORY
el I-PAST_MEDICAL_HISTORY
tiroides, I-PAST_MEDICAL_HISTORY
infiltra I-PAST_MEDICAL_HISTORY
musculatura I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
piel I-PAST_MEDICAL_HISTORY
adyacente I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
rodea I-PAST_MEDICAL_HISTORY
paquete I-PAST_MEDICAL_HISTORY
vascular I-PAST_MEDICAL_HISTORY
cervical I-PAST_MEDICAL_HISTORY
derecho. I-PAST_MEDICAL_HISTORY
<EOS> I-PAST_MEDICAL_HISTORY
En I-PAST_MEDICAL_HISTORY
octubre I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
2004 I-PAST_MEDICAL_HISTORY
consultó I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
urgencia I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
nuestro I-PAST_MEDICAL_HISTORY
centro I-PAST_MEDICAL_HISTORY
por I-PAST_MEDICAL_HISTORY
disnea I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
2 I-PAST_MEDICAL_HISTORY
semanas I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
evolución I-PAST_MEDICAL_HISTORY
que I-PAST_MEDICAL_HISTORY
progresó I-PAST_MEDICAL_HISTORY
hasta I-PAST_MEDICAL_HISTORY
disnea I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
reposo. I-PAST_MEDICAL_HISTORY
<EOS> I-PAST_MEDICAL_HISTORY
Al B-EXPLORATION
examen I-EXPLORATION
físico, I-EXPLORATION
se I-EXPLORATION
observaba I-EXPLORATION
a I-EXPLORATION
la I-EXPLORATION
paciente I-EXPLORATION
ansiosa, I-EXPLORATION
lúcida I-EXPLORATION
y I-EXPLORATION
afebril, I-EXPLORATION
taquipneica, I-EXPLORATION
con I-EXPLORATION
tiraje, I-EXPLORATION
estridor I-EXPLORATION
laríngeo I-EXPLORATION
y I-EXPLORATION
aumento I-EXPLORATION
de I-EXPLORATION
volumen I-EXPLORATION
pétreo I-EXPLORATION
de I-EXPLORATION
10 I-EXPLORATION
cm I-EXPLORATION
en I-EXPLORATION
región I-EXPLORATION
cervical I-EXPLORATION
anterior I-EXPLORATION
y I-EXPLORATION
lateral I-EXPLORATION
derecha I-EXPLORATION
asociado I-EXPLORATION
a I-EXPLORATION
múltiples I-EXPLORATION
adenopatías I-EXPLORATION
cervicales. I-EXPLORATION
Saturación I-EXPLORATION
de I-EXPLORATION
oxígeno I-EXPLORATION
normal. I-EXPLORATION
<EOS> I-EXPLORATION
En I-EXPLORATION
el I-EXPLORATION
laboratorio I-EXPLORATION
destacaba I-EXPLORATION
la I-EXPLORATION
velocidad I-EXPLORATION
de I-EXPLORATION
sedimentación I-EXPLORATION
(VHS) I-EXPLORATION
de I-EXPLORATION
78 I-EXPLORATION
mm/h I-EXPLORATION
y I-EXPLORATION
LDH I-EXPLORATION
de I-EXPLORATION
436 I-EXPLORATION
U/ I-EXPLORATION
L. I-EXPLORATION
Hemograma, I-EXPLORATION
perfil I-EXPLORATION
bioquímico, I-EXPLORATION
función I-EXPLORATION
renal I-EXPLORATION
y I-EXPLORATION
pruebas I-EXPLORATION
de I-EXPLORATION
coagulación I-EXPLORATION
dentro I-EXPLORATION
de I-EXPLORATION
rangos I-EXPLORATION
normales. I-EXPLORATION
<EOS> I-EXPLORATION
Se B-TREATMENT
hospitalizó I-TREATMENT
con I-TREATMENT
diagnóstico I-TREATMENT
de I-TREATMENT
tumor I-TREATMENT
cervical I-TREATMENT
anterior, I-TREATMENT
posiblemente I-TREATMENT
cáncer I-TREATMENT
tiroideo I-TREATMENT
anaplástico I-TREATMENT
y I-TREATMENT
obstrucción I-TREATMENT
secundaria I-TREATMENT
de I-TREATMENT
la I-TREATMENT
vía I-TREATMENT
aérea. I-TREATMENT
Se I-TREATMENT
planteó I-TREATMENT
resección I-TREATMENT
tumoral I-TREATMENT
para I-TREATMENT
manejo I-TREATMENT
de I-TREATMENT
la I-TREATMENT
urgencia I-TREATMENT
obstructiva. I-TREATMENT
<EOS> I-TREATMENT
En I-TREATMENT
pabellón, I-TREATMENT
se I-TREATMENT
realizó I-TREATMENT
nasofibroscopia I-TREATMENT
sin I-TREATMENT
hallazgos I-TREATMENT
patológicos I-TREATMENT
y I-TREATMENT
fibrobroncoscopia I-TREATMENT
(FBC) I-TREATMENT
que I-TREATMENT
constató I-TREATMENT
a I-TREATMENT
nivel I-TREATMENT
tiroideo I-TREATMENT
una I-TREATMENT
estenosis I-TREATMENT
traqueal I-TREATMENT
severa, I-TREATMENT
extrínseca, I-TREATMENT
sin I-TREATMENT
compromiso I-TREATMENT
endoluminal I-TREATMENT
ni I-TREATMENT
de I-TREATMENT
la I-TREATMENT
tráquea I-TREATMENT
distal, I-TREATMENT
procediendo I-TREATMENT
a I-TREATMENT
la I-TREATMENT
intubación I-TREATMENT
nasotraqueal I-TREATMENT
(N° I-TREATMENT
5.5) I-TREATMENT
guiada I-TREATMENT
por I-TREATMENT
FBC. I-TREATMENT
<EOS> I-TREATMENT
En I-TREATMENT
el I-TREATMENT
acto I-TREATMENT
quirúrgico I-TREATMENT
se I-TREATMENT
observó I-TREATMENT
infiltración I-TREATMENT
de I-TREATMENT
musculatura I-TREATMENT
pretlroidea I-TREATMENT
secundaria I-TREATMENT
a I-TREATMENT
tumor I-TREATMENT
subyacente, I-TREATMENT
el I-TREATMENT
cual I-TREATMENT
era I-TREATMENT
de I-TREATMENT
gran I-TREATMENT
tamaño, I-TREATMENT
aspecto I-TREATMENT
encefaloideo, I-TREATMENT
muy I-TREATMENT
vascularizado I-TREATMENT
y I-TREATMENT
mal I-TREATMENT
definido. I-TREATMENT
Se I-TREATMENT
realizó I-TREATMENT
istmectomía I-TREATMENT
tiroidea I-TREATMENT
para I-TREATMENT
ubicar I-TREATMENT
vía I-TREATMENT
aérea I-TREATMENT
e I-TREATMENT
instalar I-TREATMENT
traqueostomía. I-TREATMENT
La I-TREATMENT
tráquea I-TREATMENT
estaba I-TREATMENT
notoriamente I-TREATMENT
desviada I-TREATMENT
a I-TREATMENT
izquierda I-TREATMENT
y I-TREATMENT
muy I-TREATMENT
profunda, I-TREATMENT
12 I-TREATMENT
cm I-TREATMENT
bajo I-TREATMENT
el I-TREATMENT
plano I-TREATMENT
cutáneo, I-TREATMENT
siendo I-TREATMENT
imposible I-TREATMENT
instalar I-TREATMENT
cánula I-TREATMENT
de I-TREATMENT
traqueostomía, I-TREATMENT
por I-TREATMENT
lo I-TREATMENT
que I-TREATMENT
se I-TREATMENT
utilizó I-TREATMENT
un I-TREATMENT
tubo I-TREATMENT
orotraqueal I-TREATMENT
N° I-TREATMENT
5.5 I-TREATMENT
con I-TREATMENT
cuff. I-TREATMENT
<EOS> I-TREATMENT
El B-EXPLORATION
examen I-EXPLORATION
anatomopatológico I-EXPLORATION
informó I-EXPLORATION
"proliferación I-EXPLORATION
celular I-EXPLORATION
linfoide, I-EXPLORATION
dispuesta I-EXPLORATION
en I-EXPLORATION
sábanas I-EXPLORATION
de I-EXPLORATION
mediano I-EXPLORATION
y I-EXPLORATION
gran I-EXPLORATION
tamaño, I-EXPLORATION
con I-EXPLORATION
núcleos I-EXPLORATION
irregulares I-EXPLORATION
e I-EXPLORATION
hipercromáticos, I-EXPLORATION
nucléolo I-EXPLORATION
poco I-EXPLORATION
prominente I-EXPLORATION
y I-EXPLORATION
escaso I-EXPLORATION
citoplasma I-EXPLORATION
eosinófilo I-EXPLORATION
pálido, I-EXPLORATION
asociado I-EXPLORATION
a I-EXPLORATION
tejido I-EXPLORATION
tiroideo, I-EXPLORATION
células I-EXPLORATION
plasmáticas I-EXPLORATION
y I-EXPLORATION
tejido I-EXPLORATION
adiposo I-EXPLORATION
extensamente I-EXPLORATION
infiltrado I-EXPLORATION
por I-EXPLORATION
neoplasia". I-EXPLORATION
<EOS> I-EXPLORATION
La I-EXPLORATION
inmunohistoquímica I-EXPLORATION
señaló I-EXPLORATION
antígeno I-EXPLORATION
leuco-citario I-EXPLORATION
común I-EXPLORATION
(+), I-EXPLORATION
CD20 I-EXPLORATION
(+) I-EXPLORATION
focalmente, I-EXPLORATION
vimentina I-EXPLORATION
(+), I-EXPLORATION
queratina I-EXPLORATION
(-), I-EXPLORATION
BCL2 I-EXPLORATION
(-), I-EXPLORATION
CD10 I-EXPLORATION
(-), I-EXPLORATION
CICLINA I-EXPLORATION
DI I-EXPLORATION
(-), I-EXPLORATION
CD30 I-EXPLORATION
(-), I-EXPLORATION
CD45RO I-EXPLORATION
(-) I-EXPLORATION
en I-EXPLORATION
células I-EXPLORATION
neoplásicas. I-EXPLORATION
Diagnóstico I-EXPLORATION
definitivo: I-EXPLORATION
linfoma I-EXPLORATION
no I-EXPLORATION
Hodgkin I-EXPLORATION
tiroideo I-EXPLORATION
difuso, I-EXPLORATION
estirpe I-EXPLORATION
B, I-EXPLORATION
de I-EXPLORATION
células I-EXPLORATION
grandes. I-EXPLORATION
<EOS> I-EXPLORATION
La B-EVOLUTION
paciente I-EVOLUTION
evolucionó I-EVOLUTION
favorablemente I-EVOLUTION
en I-EVOLUTION
el I-EVOLUTION
postoperatorio, I-EVOLUTION
salvo I-EVOLUTION
broncorrea I-EVOLUTION
purulenta I-EVOLUTION
por I-EVOLUTION
Pseudomona I-EVOLUTION
aeruginosa I-EVOLUTION
multisensible I-EVOLUTION
que I-EVOLUTION
fue I-EVOLUTION
tratada I-EVOLUTION
con I-EVOLUTION
antibióticos. I-EVOLUTION
Se B-TREATMENT
instaló I-TREATMENT
sonda I-TREATMENT
nasoye-yunal I-TREATMENT
para I-TREATMENT
iniciar I-TREATMENT
alimentación I-TREATMENT
progresiva. I-TREATMENT
<EOS> I-TREATMENT
Evaluada B-EXPLORATION
por I-EXPLORATION
hematología, I-EXPLORATION
solicitaron I-EXPLORATION
estudio I-EXPLORATION
de I-EXPLORATION
etapificación I-EXPLORATION
que I-EXPLORATION
descartó I-EXPLORATION
otros I-EXPLORATION
focos I-EXPLORATION
tumora-les, I-EXPLORATION
confirmando I-EXPLORATION
el I-EXPLORATION
origen I-EXPLORATION
primario I-EXPLORATION
tiroideo I-EXPLORATION
del I-EXPLORATION
linfoma. I-EXPLORATION
TC I-EXPLORATION
de I-EXPLORATION
tórax I-EXPLORATION
mostró I-EXPLORATION
tumor I-EXPLORATION
remanente I-EXPLORATION
rodeando I-EXPLORATION
parcialmente I-EXPLORATION
la I-EXPLORATION
tráquea I-EXPLORATION
y I-EXPLORATION
adenopatías I-EXPLORATION
paratraqueales I-EXPLORATION
derechas I-EXPLORATION
de I-EXPLORATION
1-2 I-EXPLORATION
cm I-EXPLORATION
de I-EXPLORATION
diámetro. I-EXPLORATION
<EOS> I-EXPLORATION
Comenzó B-TREATMENT
tratamiento I-TREATMENT
definitivo I-TREATMENT
con I-TREATMENT
esquema I-TREATMENT
CHOP I-TREATMENT
(ciclofosfamida, I-TREATMENT
adriamicina, I-TREATMENT
vincristina I-TREATMENT
y I-TREATMENT
betametasona) I-TREATMENT
al I-TREATMENT
vigésimo I-TREATMENT
día I-TREATMENT
postoperatorio, I-TREATMENT
con I-TREATMENT
respuesta I-TREATMENT
completa I-TREATMENT
tras I-TREATMENT
primer I-TREATMENT
ciclo, I-TREATMENT
lo I-TREATMENT
que I-TREATMENT
permitió I-TREATMENT
reemplazar I-TREATMENT
tubo I-TREATMENT
orotraqueal I-TREATMENT
por I-TREATMENT
cánula I-TREATMENT
de I-TREATMENT
traqueostomía I-TREATMENT
N° I-TREATMENT
7. I-TREATMENT
Se I-TREATMENT
otorgó I-TREATMENT
el I-TREATMENT
alta I-TREATMENT
domiciliaria I-TREATMENT
al I-TREATMENT
finalizar I-TREATMENT
el I-TREATMENT
segundo I-TREATMENT
ciclo. I-TREATMENT
<EOS> I-TREATMENT
Luego I-TREATMENT
del I-TREATMENT
tercer I-TREATMENT
ciclo I-TREATMENT
de I-TREATMENT
quimioterapia, I-TREATMENT
abandonó I-TREATMENT
tratamiento. I-TREATMENT
Familiares B-DERIVED_FROM/TO
la I-DERIVED_FROM/TO
trasladaron I-DERIVED_FROM/TO
a I-DERIVED_FROM/TO
una I-DERIVED_FROM/TO
clínica I-DERIVED_FROM/TO
para I-DERIVED_FROM/TO
adultos I-DERIVED_FROM/TO
mayores, I-DERIVED_FROM/TO
donde I-DERIVED_FROM/TO
falleció I-DERIVED_FROM/TO
en I-DERIVED_FROM/TO
diciembre I-DERIVED_FROM/TO
de I-DERIVED_FROM/TO
2004, I-DERIVED_FROM/TO
aparentemente I-DERIVED_FROM/TO
por I-DERIVED_FROM/TO
insuficiencia I-DERIVED_FROM/TO
respiratoria I-DERIVED_FROM/TO
aguda. I-DERIVED_FROM/TO
<EOS> I-DERIVED_FROM/TO
Primigesta B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
15 I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
edad, I-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
gestación I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
40 I-PRESENT_ILLNESS
semanas, I-PRESENT_ILLNESS
que I-PRESENT_ILLNESS
ingresó I-PRESENT_ILLNESS
al I-PRESENT_ILLNESS
Servicio I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
Obstetricia I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
Ginecología I-PRESENT_ILLNESS
del I-PRESENT_ILLNESS
Hospital I-PRESENT_ILLNESS
Clínico I-PRESENT_ILLNESS
San I-PRESENT_ILLNESS
Borja I-PRESENT_ILLNESS
Arriarán I-PRESENT_ILLNESS
el I-PRESENT_ILLNESS
día I-PRESENT_ILLNESS
11 I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
mayo I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
2008, I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
las I-PRESENT_ILLNESS
05: I-PRESENT_ILLNESS
40 I-PRESENT_ILLNESS
h I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
presentar I-PRESENT_ILLNESS
trabajo I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
parto I-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
fase I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
dilatación I-PRESENT_ILLNESS
rápida I-PRESENT_ILLNESS
(5 I-PRESENT_ILLNESS
cm I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
dilatación) I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
expulsión I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
líquido I-PRESENT_ILLNESS
amniótico I-PRESENT_ILLNESS
(LA) I-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
tinte I-PRESENT_ILLNESS
meconial. I-PRESENT_ILLNESS
Tuvo I-PRESENT_ILLNESS
una I-PRESENT_ILLNESS
rotura I-PRESENT_ILLNESS
precoz I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
membranas I-PRESENT_ILLNESS
1 I-PRESENT_ILLNESS
h I-PRESENT_ILLNESS
20 I-PRESENT_ILLNESS
min I-PRESENT_ILLNESS
antes I-PRESENT_ILLNESS
del I-PRESENT_ILLNESS
ingreso. I-PRESENT_ILLNESS
<EOS> I-PRESENT_ILLNESS
El B-EXPLORATION
embarazo I-EXPLORATION
fue I-EXPLORATION
controlado I-EXPLORATION
regularmente I-EXPLORATION
en I-EXPLORATION
el I-EXPLORATION
Consultorio I-EXPLORATION
de I-EXPLORATION
Maipú I-EXPLORATION
y I-EXPLORATION
fue I-EXPLORATION
considerado I-EXPLORATION
como I-EXPLORATION
fisiológico. I-EXPLORATION
Al I-EXPLORATION
ingreso, I-EXPLORATION
la I-EXPLORATION
paciente I-EXPLORATION
estaba I-EXPLORATION
afebril, I-EXPLORATION
normotensa I-EXPLORATION
y I-EXPLORATION
pulso I-EXPLORATION
de I-EXPLORATION
80 I-EXPLORATION
por I-EXPLORATION
min. I-EXPLORATION
En I-EXPLORATION
el I-EXPLORATION
examen I-EXPLORATION
obstétrico I-EXPLORATION
se I-EXPLORATION
encontró I-EXPLORATION
5 I-EXPLORATION
cm I-EXPLORATION
de I-EXPLORATION
dilatación, I-EXPLORATION
presentación I-EXPLORATION
cefálica I-EXPLORATION
apoyada, I-EXPLORATION
membranas I-EXPLORATION
rotas, I-EXPLORATION
LA I-EXPLORATION
con I-EXPLORATION
tinte I-EXPLORATION
meconial I-EXPLORATION
y I-EXPLORATION
latidos I-EXPLORATION
cardiofetales I-EXPLORATION
(LCF) I-EXPLORATION
normales. I-EXPLORATION
No I-EXPLORATION
se I-EXPLORATION
solicitaron I-EXPLORATION
exámenes I-EXPLORATION
hematológicos I-EXPLORATION
para I-EXPLORATION
pesquisar I-EXPLORATION
infección, I-EXPLORATION
porque I-EXPLORATION
la I-EXPLORATION
paciente I-EXPLORATION
carecía I-EXPLORATION
de I-EXPLORATION
manifestaciones I-EXPLORATION
clínicas I-EXPLORATION
compatibles. I-EXPLORATION
Se I-EXPLORATION
indicó I-EXPLORATION
anestesia I-EXPLORATION
de I-EXPLORATION
conducción I-EXPLORATION
con I-EXPLORATION
peridural I-EXPLORATION
continua I-EXPLORATION
y I-EXPLORATION
monitorización I-EXPLORATION
electrónica I-EXPLORATION
que I-EXPLORATION
reveló I-EXPLORATION
una I-EXPLORATION
variabilidad I-EXPLORATION
menor I-EXPLORATION
de I-EXPLORATION
5 I-EXPLORATION
LCF, I-EXPLORATION
una I-EXPLORATION
frecuencia I-EXPLORATION
cardíaca I-EXPLORATION
fetal I-EXPLORATION
media I-EXPLORATION
de I-EXPLORATION
150 I-EXPLORATION
latidos I-EXPLORATION
por I-EXPLORATION
min I-EXPLORATION
y I-EXPLORATION
una I-EXPLORATION
desaceleración I-EXPLORATION
variable I-EXPLORATION
prolongada I-EXPLORATION
(hasta I-EXPLORATION
120 I-EXPLORATION
LCF I-EXPLORATION
por I-EXPLORATION
minuto I-EXPLORATION
durante I-EXPLORATION
3 I-EXPLORATION
min). I-EXPLORATION
<EOS> I-EXPLORATION
Se I-EXPLORATION
reevaluó I-EXPLORATION
luego I-EXPLORATION
de I-EXPLORATION
nueva I-EXPLORATION
desaceleración I-EXPLORATION
(60 I-EXPLORATION
LCF I-EXPLORATION
por I-EXPLORATION
minuto I-EXPLORATION
durante I-EXPLORATION
7 I-EXPLORATION
min) I-EXPLORATION
y I-EXPLORATION
se I-EXPLORATION
encontró I-EXPLORATION
8 I-EXPLORATION
a I-EXPLORATION
9 I-EXPLORATION
cms I-EXPLORATION
de I-EXPLORATION
dilatación, I-EXPLORATION
presentación I-EXPLORATION
cefálica I-EXPLORATION
en I-EXPLORATION
II I-EXPLORATION
plano I-EXPLORATION
y I-EXPLORATION
LA I-EXPLORATION
con I-EXPLORATION
grumos I-EXPLORATION
de I-EXPLORATION
meconio I-EXPLORATION
con I-EXPLORATION
leve I-EXPLORATION
mal I-EXPLORATION
olor. I-EXPLORATION
Se B-TREATMENT
trasladó I-TREATMENT
inmediatamente I-TREATMENT
a I-TREATMENT
sala I-TREATMENT
de I-TREATMENT
partos I-TREATMENT
con I-TREATMENT
dilatación I-TREATMENT
completa I-TREATMENT
y I-TREATMENT
presentación I-TREATMENT
cefálica I-TREATMENT
en I-TREATMENT
tercer I-TREATMENT
plano. I-TREATMENT
<EOS> I-TREATMENT
El I-TREATMENT
parto I-TREATMENT
vaginal I-TREATMENT
ocurrió I-TREATMENT
a I-TREATMENT
las I-TREATMENT
7: I-TREATMENT
24 I-TREATMENT
h I-TREATMENT
del I-TREATMENT
11 I-TREATMENT
de I-TREATMENT
mayo I-TREATMENT
(1 I-TREATMENT
h I-TREATMENT
44 I-TREATMENT
min I-TREATMENT
desde I-TREATMENT
el I-TREATMENT
ingreso). I-TREATMENT
Se I-TREATMENT
obtuvo I-TREATMENT
un I-TREATMENT
recién I-TREATMENT
nacido I-TREATMENT
(RN) I-TREATMENT
de I-TREATMENT
3-440 I-TREATMENT
g I-TREATMENT
de I-TREATMENT
sexo I-TREATMENT
masculino, I-TREATMENT
con I-TREATMENT
muy I-TREATMENT
mal I-TREATMENT
olor, I-TREATMENT
muy I-TREATMENT
deprimido I-TREATMENT
con I-TREATMENT
Apgar I-TREATMENT
1 I-TREATMENT
al I-TREATMENT
minuto I-TREATMENT
y I-TREATMENT
3 I-TREATMENT
a I-TREATMENT
los I-TREATMENT
5 I-TREATMENT
min. I-TREATMENT
No I-TREATMENT
se I-TREATMENT
describió I-TREATMENT
presencia I-TREATMENT
de I-TREATMENT
meconio I-TREATMENT
en I-TREATMENT
el I-TREATMENT
parto, I-TREATMENT
ni I-TREATMENT
en I-TREATMENT
la I-TREATMENT
aspiración I-TREATMENT
de I-TREATMENT
las I-TREATMENT
secreciones I-TREATMENT
del I-TREATMENT
RN. I-TREATMENT
En I-TREATMENT
la I-TREATMENT
sangre I-TREATMENT
arterial I-TREATMENT
de I-TREATMENT
cordón I-TREATMENT
se I-TREATMENT
encontró I-TREATMENT
pH I-TREATMENT
6, I-TREATMENT
9, I-TREATMENT
BE I-TREATMENT
-25 I-TREATMENT
y I-TREATMENT
C02 I-TREATMENT
35. I-TREATMENT
Ingresó I-TREATMENT
intubado I-TREATMENT
grave I-TREATMENT
a I-TREATMENT
la I-TREATMENT
UCI I-TREATMENT
neonatal, I-TREATMENT
con I-TREATMENT
los I-TREATMENT
diagnósticos: I-TREATMENT
RN I-TREATMENT
de I-TREATMENT
término I-TREATMENT
adecuado I-TREATMENT
para I-TREATMENT
la I-TREATMENT
edad I-TREATMENT
gestacional, I-TREATMENT
de I-TREATMENT
40 I-TREATMENT
semanas, I-TREATMENT
asfixia I-TREATMENT
perinatal I-TREATMENT
severa I-TREATMENT
(criterios I-TREATMENT
de I-TREATMENT
la I-TREATMENT
Asociación I-TREATMENT
Americana I-TREATMENT
de I-TREATMENT
Pediatría) I-TREATMENT
y I-TREATMENT
probable I-TREATMENT
infección I-TREATMENT
connatal. I-TREATMENT
<EOS> I-TREATMENT
El B-EVOLUTION
RN I-EVOLUTION
evolucionó I-EVOLUTION
siempre I-EVOLUTION
grave, I-EVOLUTION
con I-EVOLUTION
compromiso I-EVOLUTION
del I-EVOLUTION
SNC, I-EVOLUTION
encefalopatía I-EVOLUTION
hipóxica I-EVOLUTION
isquémica I-EVOLUTION
grado I-EVOLUTION
III, I-EVOLUTION
asociado I-EVOLUTION
a I-EVOLUTION
shock I-EVOLUTION
séptico I-EVOLUTION
precoz, I-EVOLUTION
con I-EVOLUTION
compromiso I-EVOLUTION
multiorgánico I-EVOLUTION
y I-EVOLUTION
necesidad I-EVOLUTION
de I-EVOLUTION
apoyo I-EVOLUTION
ventilatorio I-EVOLUTION
y I-EVOLUTION
de I-EVOLUTION
drogas I-EVOLUTION
vasoactivas. I-EVOLUTION
<EOS> I-EVOLUTION
A B-TREATMENT
las I-TREATMENT
24 I-TREATMENT
h I-TREATMENT
de I-TREATMENT
vida I-TREATMENT
los I-TREATMENT
hemocultivos I-TREATMENT
tomados I-TREATMENT
al I-TREATMENT
nacer I-TREATMENT
fueron I-TREATMENT
positivos I-TREATMENT
para I-TREATMENT
Morganella I-TREATMENT
morganii I-TREATMENT
cambiándose I-TREATMENT
el I-TREATMENT
esquema I-TREATMENT
antibiótico I-TREATMENT
ampicilina-sulbactam I-TREATMENT
por I-TREATMENT
cefotaxima, I-TREATMENT
según I-TREATMENT
antibiograma. I-TREATMENT
Los B-EXPLORATION
exámenes I-EXPLORATION
demostraron: I-EXPLORATION
hemograma I-EXPLORATION
con I-EXPLORATION
leu-copenia, I-EXPLORATION
proteína I-EXPLORATION
C I-EXPLORATION
reactiva I-EXPLORATION
129 I-EXPLORATION
mg/L, I-EXPLORATION
ácido I-EXPLORATION
láctico I-EXPLORATION
138 I-EXPLORATION
mg/dL. I-EXPLORATION
La I-EXPLORATION
radiografía I-EXPLORATION
de I-EXPLORATION
tórax I-EXPLORATION
reveló I-EXPLORATION
infiltrado I-EXPLORATION
parenquimatoso I-EXPLORATION
bilateral I-EXPLORATION
compatible I-EXPLORATION
con I-EXPLORATION
bronconeumonía. I-EXPLORATION
El I-EXPLORATION
escáner I-EXPLORATION
y I-EXPLORATION
la I-EXPLORATION
ecografía I-EXPLORATION
cerebral I-EXPLORATION
mostraron I-EXPLORATION
edema I-EXPLORATION
cerebral I-EXPLORATION
y I-EXPLORATION
hemorragia I-EXPLORATION
de I-EXPLORATION
fosa I-EXPLORATION
posterior I-EXPLORATION
izquierda I-EXPLORATION
concordante I-EXPLORATION
con I-EXPLORATION
EEG I-EXPLORATION
severamente I-EXPLORATION
alterado, I-EXPLORATION
en I-EXPLORATION
status I-EXPLORATION
convulsivo. I-EXPLORATION
<EOS> I-EXPLORATION
El B-EVOLUTION
neonato I-EVOLUTION
falleció I-EVOLUTION
a I-EVOLUTION
los I-EVOLUTION
17 I-EVOLUTION
días I-EVOLUTION
de I-EVOLUTION
vida. I-EVOLUTION
La B-EXPLORATION
autopsia I-EXPLORATION
reveló: I-EXPLORATION
RN I-EXPLORATION
de I-EXPLORATION
término, I-EXPLORATION
adecuado I-EXPLORATION
para I-EXPLORATION
la I-EXPLORATION
edad I-EXPLORATION
gestacional, I-EXPLORATION
con I-EXPLORATION
signos I-EXPLORATION
morfológicos I-EXPLORATION
de I-EXPLORATION
shock I-EXPLORATION
séptico: I-EXPLORATION
coagulación I-EXPLORATION
intravascular I-EXPLORATION
diseminada, I-EXPLORATION
infarto I-EXPLORATION
hepático, I-EXPLORATION
de I-EXPLORATION
glándulas I-EXPLORATION
suprarrenales I-EXPLORATION
y I-EXPLORATION
congestión I-EXPLORATION
esplénica. I-EXPLORATION
Bronconeumonía I-EXPLORATION
bilateral I-EXPLORATION
descamativa I-EXPLORATION
y I-EXPLORATION
hemorrágica. I-EXPLORATION
Compromiso I-EXPLORATION
cerebral I-EXPLORATION
con I-EXPLORATION
encefalopatía I-EXPLORATION
hipóxica-isquémica. I-EXPLORATION
<EOS> I-EXPLORATION
La I-EXPLORATION
biopsia I-EXPLORATION
placentaria I-EXPLORATION
reveló I-EXPLORATION
corioamnionitis I-EXPLORATION
aguda I-EXPLORATION
abscedada, I-EXPLORATION
funisitis I-EXPLORATION
aguda I-EXPLORATION
y I-EXPLORATION
perivellositis I-EXPLORATION
aguda I-EXPLORATION
focal. I-EXPLORATION
<EOS> I-EXPLORATION
La B-EVOLUTION
madre I-EVOLUTION
evolucionó I-EVOLUTION
afebril, I-EVOLUTION
sin I-EVOLUTION
signos I-EVOLUTION
clínicos I-EVOLUTION
de I-EVOLUTION
infección, I-EVOLUTION
pero I-EVOLUTION
con I-EVOLUTION
cultivo I-EVOLUTION
de I-EVOLUTION
loquios I-EVOLUTION
positivos I-EVOLUTION
para I-EVOLUTION
Morganella I-EVOLUTION
morganii, I-EVOLUTION
muestra I-EVOLUTION
tomada I-EVOLUTION
el I-EVOLUTION
primer I-EVOLUTION
día I-EVOLUTION
de I-EVOLUTION
puerperio I-EVOLUTION
del I-EVOLUTION
fondo I-EVOLUTION
de I-EVOLUTION
saco I-EVOLUTION
vaginal. I-EVOLUTION
Se B-TREATMENT
dio I-TREATMENT
de I-TREATMENT
alta I-TREATMENT
hospitalaria I-TREATMENT
a I-TREATMENT
los I-TREATMENT
tres I-TREATMENT
días I-TREATMENT
del I-TREATMENT
parto I-TREATMENT
y I-TREATMENT
se I-TREATMENT
trató I-TREATMENT
durante I-TREATMENT
5 I-TREATMENT
días I-TREATMENT
con I-TREATMENT
gentamicina I-TREATMENT
l60 I-TREATMENT
mg I-TREATMENT
IM I-TREATMENT
al I-TREATMENT
día. I-TREATMENT
Se I-TREATMENT
controló I-TREATMENT
a I-TREATMENT
los I-TREATMENT
11 I-TREATMENT
días I-TREATMENT
de I-TREATMENT
puerperio I-TREATMENT
en I-TREATMENT
el I-TREATMENT
policlínico I-TREATMENT
del I-TREATMENT
Centro I-TREATMENT
Diagnóstico I-TREATMENT
Terapéutico I-TREATMENT
y I-TREATMENT
se I-TREATMENT
dio I-TREATMENT
de I-TREATMENT
alta I-TREATMENT
definitiva I-TREATMENT
en I-TREATMENT
buenas I-TREATMENT
condiciones I-TREATMENT
físicas. I-TREATMENT
<EOS> I-TREATMENT
Paciente B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
40 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
sexo I-PRESENT_ILLNESS
masculino, I-PRESENT_ILLNESS
procedente B-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
medio I-PAST_MEDICAL_HISTORY
urbano. I-PAST_MEDICAL_HISTORY
Portador B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
linfedema I-PRESENT_ILLNESS
primario I-PRESENT_ILLNESS
tardío I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
miembro I-PRESENT_ILLNESS
inferior I-PRESENT_ILLNESS
derecho I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
tres I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
evolución, I-PRESENT_ILLNESS
valorado I-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
linfocen-tellografia I-PRESENT_ILLNESS
que I-PRESENT_ILLNESS
había I-PRESENT_ILLNESS
evidenciado I-PRESENT_ILLNESS
ausencia I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
drenaje I-PRESENT_ILLNESS
linfático I-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
dicho I-PRESENT_ILLNESS
miembro, I-PRESENT_ILLNESS
tomografía I-PRESENT_ILLNESS
computada I-PRESENT_ILLNESS
(TC) I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
abdomen, I-PRESENT_ILLNESS
pelvis I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
muslo I-PRESENT_ILLNESS
sin I-PRESENT_ILLNESS
alteraciones, I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
eco-Doppler I-PRESENT_ILLNESS
arterial I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
venoso I-PRESENT_ILLNESS
normales. I-PRESENT_ILLNESS
Infecciones I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
piel I-PRESENT_ILLNESS
recurrentes I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
evolución I-PRESENT_ILLNESS
tórpida I-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
dicho I-PRESENT_ILLNESS
miembro. I-PRESENT_ILLNESS
<EOS> I-PRESENT_ILLNESS
Consultó I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
cuadro I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
1 I-PRESENT_ILLNESS
mes I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
medio I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
evolución I-PRESENT_ILLNESS
caracterizado I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
marcada I-PRESENT_ILLNESS
astenia, I-PRESENT_ILLNESS
anorexia, I-PRESENT_ILLNESS
adelgazamiento I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
10 I-PRESENT_ILLNESS
kilos, I-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
fiebre I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
hasta I-PRESENT_ILLNESS
38°C I-PRESENT_ILLNESS
axilar. I-PRESENT_ILLNESS
En I-PRESENT_ILLNESS
la I-PRESENT_ILLNESS
evolución I-PRESENT_ILLNESS
se I-PRESENT_ILLNESS
agregó I-PRESENT_ILLNESS
tos I-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
expectoración I-PRESENT_ILLNESS
hemoptoica. I-PRESENT_ILLNESS
Relataba I-PRESENT_ILLNESS
lesiones I-PRESENT_ILLNESS
sobre I-PRESENT_ILLNESS
linfedema I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
reciente I-PRESENT_ILLNESS
aparición. I-PRESENT_ILLNESS
Del B-EXPLORATION
examen I-EXPLORATION
de I-EXPLORATION
ingreso I-EXPLORATION
destacaba: I-EXPLORATION
severo I-EXPLORATION
adelgazamiento, I-EXPLORATION
sin I-EXPLORATION
palidez I-EXPLORATION
ni I-EXPLORATION
fiebre. I-EXPLORATION
En I-EXPLORATION
miembro I-EXPLORATION
inferior I-EXPLORATION
derecho I-EXPLORATION
presentaba I-EXPLORATION
linfedema I-EXPLORATION
hasta I-EXPLORATION
raíz I-EXPLORATION
de I-EXPLORATION
muslo I-EXPLORATION
con I-EXPLORATION
múltiples I-EXPLORATION
lesiones I-EXPLORATION
nodulares I-EXPLORATION
de I-EXPLORATION
5 I-EXPLORATION
mm I-EXPLORATION
de I-EXPLORATION
diámetro, I-EXPLORATION
firmes, I-EXPLORATION
violáceas, I-EXPLORATION
algunas I-EXPLORATION
descamadas I-EXPLORATION
y I-EXPLORATION
otras I-EXPLORATION
ulceradas I-EXPLORATION
con I-EXPLORATION
mayor I-EXPLORATION
concentración I-EXPLORATION
de I-EXPLORATION
lesiones I-EXPLORATION
en I-EXPLORATION
región I-EXPLORATION
poplítea. I-EXPLORATION
En I-EXPLORATION
muslo I-EXPLORATION
proximal I-EXPLORATION
presentaba I-EXPLORATION
lesión, I-EXPLORATION
pediculada I-EXPLORATION
y I-EXPLORATION
ulcerada. I-EXPLORATION
Lesión I-EXPLORATION
traumática I-EXPLORATION
de I-EXPLORATION
pie I-EXPLORATION
en I-EXPLORATION
vías I-EXPLORATION
de I-EXPLORATION
cicatrización. I-EXPLORATION
Adenomegalias I-EXPLORATION
inguinales I-EXPLORATION
a I-EXPLORATION
derecha, I-EXPLORATION
firmes, I-EXPLORATION
de I-EXPLORATION
2 I-EXPLORATION
cm I-EXPLORATION
de I-EXPLORATION
diámetro I-EXPLORATION
que I-EXPLORATION
no I-EXPLORATION
formaban I-EXPLORATION
conglomerados. I-EXPLORATION
A I-EXPLORATION
nivel I-EXPLORATION
pleuropulmonar I-EXPLORATION
destacaba I-EXPLORATION
la I-EXPLORATION
presencia I-EXPLORATION
de I-EXPLORATION
ruidos I-EXPLORATION
subcrepitantes I-EXPLORATION
bibasales I-EXPLORATION
escasos. I-EXPLORATION
El I-EXPLORATION
resto I-EXPLORATION
del I-EXPLORATION
examen I-EXPLORATION
físico I-EXPLORATION
era I-EXPLORATION
normal. I-EXPLORATION
De I-EXPLORATION
la I-EXPLORATION
analítica I-EXPLORATION
de I-EXPLORATION
laboratorio I-EXPLORATION
destacaba I-EXPLORATION
hemograma, I-EXPLORATION
glicemia, I-EXPLORATION
función I-EXPLORATION
renal I-EXPLORATION
y I-EXPLORATION
pruebas I-EXPLORATION
hepáticas I-EXPLORATION
normales, I-EXPLORATION
VHS I-EXPLORATION
de I-EXPLORATION
50 I-EXPLORATION
mm I-EXPLORATION
en I-EXPLORATION
la I-EXPLORATION
primera I-EXPLORATION
hora, I-EXPLORATION
y I-EXPLORATION
pro I-EXPLORATION
teína I-EXPLORATION
C I-EXPLORATION
reactiva I-EXPLORATION
de I-EXPLORATION
30 I-EXPLORATION
mg/dL. I-EXPLORATION
Serología I-EXPLORATION
para I-EXPLORATION
VIH I-EXPLORATION
negativa. I-EXPLORATION
Baciloscopías I-EXPLORATION
y I-EXPLORATION
prueba I-EXPLORATION
de I-EXPLORATION
Mantoux I-EXPLORATION
negativos. I-EXPLORATION
La I-EXPLORATION
radiografía I-EXPLORATION
de I-EXPLORATION
tórax I-EXPLORATION
mostraba I-EXPLORATION
imagen I-EXPLORATION
nodular I-EXPLORATION
paracardíaca I-EXPLORATION
izquierda. I-EXPLORATION
La I-EXPLORATION
TC I-EXPLORATION
de I-EXPLORATION
tórax, I-EXPLORATION
abdomen I-EXPLORATION
y I-EXPLORATION
pelvis I-EXPLORATION
mostraba I-EXPLORATION
múltiples I-EXPLORATION
nodulos I-EXPLORATION
pulmonares I-EXPLORATION
bilaterales I-EXPLORATION
a I-EXPLORATION
predominio I-EXPLORATION
bibasal, I-EXPLORATION
mal I-EXPLORATION
delimitados I-EXPLORATION
y I-EXPLORATION
adenomegalias I-EXPLORATION
inguinales I-EXPLORATION
e I-EXPLORATION
iliacas I-EXPLORATION
externas I-EXPLORATION
derechas. I-EXPLORATION
Se I-EXPLORATION
realizó I-EXPLORATION
una I-EXPLORATION
biopsia I-EXPLORATION
incisional I-EXPLORATION
de I-EXPLORATION
lesión I-EXPLORATION
pediculada I-EXPLORATION
del I-EXPLORATION
muslo I-EXPLORATION
que I-EXPLORATION
fue I-EXPLORATION
compatible I-EXPLORATION
con I-EXPLORATION
angiosarcoma, I-EXPLORATION
con I-EXPLORATION
inmunohistoquímica I-EXPLORATION
concordante I-EXPLORATION
(positividad I-EXPLORATION
para I-EXPLORATION
marcadores I-EXPLORATION
de I-EXPLORATION
células I-EXPLORATION
endoteliales I-EXPLORATION
CD31 I-EXPLORATION
y I-EXPLORATION
CD34, I-EXPLORATION
el I-EXPLORATION
primero I-EXPLORATION
con I-EXPLORATION
elevada I-EXPLORATION
sensibilidad I-EXPLORATION
y I-EXPLORATION
especificidad12, I-EXPLORATION
13). I-EXPLORATION
Valorado B-TREATMENT
por I-TREATMENT
servicio I-TREATMENT
de I-TREATMENT
oncología I-TREATMENT
clínica I-TREATMENT
se I-TREATMENT
inicio I-TREATMENT
plan I-TREATMENT
de I-TREATMENT
poliquimioterapia. I-TREATMENT
El B-EVOLUTION
paciente I-EVOLUTION
falleció I-EVOLUTION
a I-EVOLUTION
5 I-EVOLUTION
meses I-EVOLUTION
del I-EVOLUTION
diagnóstico. I-EVOLUTION
<EOS> I-EVOLUTION
Hombre B-PRESENT_ILLNESS
chileno, I-PRESENT_ILLNESS
43 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
ingeniero B-PAST_MEDICAL_HISTORY
civil I-PAST_MEDICAL_HISTORY
proveniente I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
Santiago, I-PAST_MEDICAL_HISTORY
residente I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
Valdivia I-PAST_MEDICAL_HISTORY
hace I-PAST_MEDICAL_HISTORY
6 I-PAST_MEDICAL_HISTORY
años. I-PAST_MEDICAL_HISTORY
Portador I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
hemofilia I-PAST_MEDICAL_HISTORY
A I-PAST_MEDICAL_HISTORY
leve I-PAST_MEDICAL_HISTORY
(Factor I-PAST_MEDICAL_HISTORY
VIII I-PAST_MEDICAL_HISTORY
10%) I-PAST_MEDICAL_HISTORY
diagnosticada I-PAST_MEDICAL_HISTORY
a I-PAST_MEDICAL_HISTORY
los I-PAST_MEDICAL_HISTORY
4 I-PAST_MEDICAL_HISTORY
años I-PAST_MEDICAL_HISTORY
por I-PAST_MEDICAL_HISTORY
epistaxis I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
hemartrosis I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
cadera I-PAST_MEDICAL_HISTORY
derecha. I-PAST_MEDICAL_HISTORY
Hasta I-PAST_MEDICAL_HISTORY
1998 I-PAST_MEDICAL_HISTORY
sólo I-PAST_MEDICAL_HISTORY
recibió I-PAST_MEDICAL_HISTORY
transfusiones I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
plasma I-PAST_MEDICAL_HISTORY
fresco I-PAST_MEDICAL_HISTORY
congelado I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
crioprecipitados, I-PAST_MEDICAL_HISTORY
posteriormente I-PAST_MEDICAL_HISTORY
fue I-PAST_MEDICAL_HISTORY
tratado I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
concentrados I-PAST_MEDICAL_HISTORY
liofi I-PAST_MEDICAL_HISTORY
lizados I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
alta I-PAST_MEDICAL_HISTORY
pureza I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
doble I-PAST_MEDICAL_HISTORY
inactivación I-PAST_MEDICAL_HISTORY
viral I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
antifibrinolíticos I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
procedimientos I-PAST_MEDICAL_HISTORY
dentales I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
litotripsia I-PAST_MEDICAL_HISTORY
por I-PAST_MEDICAL_HISTORY
urolitiasis I-PAST_MEDICAL_HISTORY
el I-PAST_MEDICAL_HISTORY
2000 I-PAST_MEDICAL_HISTORY
sin I-PAST_MEDICAL_HISTORY
complicaciones I-PAST_MEDICAL_HISTORY
hemorrágicas. I-PAST_MEDICAL_HISTORY
<EOS> I-PAST_MEDICAL_HISTORY
En B-PRESENT_ILLNESS
agosto I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
2007 I-PRESENT_ILLNESS
presentó I-PRESENT_ILLNESS
epistaxis I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
equimosis I-PRESENT_ILLNESS
sin I-PRESENT_ILLNESS
traumatismos I-PRESENT_ILLNESS
evidentes. I-PRESENT_ILLNESS
Al I-PRESENT_ILLNESS
mes I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
evolución I-PRESENT_ILLNESS
consultó I-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
equimosis I-PRESENT_ILLNESS
múltiples I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
predominio I-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
extremidades I-PRESENT_ILLNESS
inferiores. I-PRESENT_ILLNESS
En B-EXPLORATION
hemograma I-EXPLORATION
trombocitopenia I-EXPLORATION
de I-EXPLORATION
23.000/mm3. I-EXPLORATION
Se I-EXPLORATION
tomó I-EXPLORATION
mielograma I-EXPLORATION
hospitalizado, I-EXPLORATION
previa I-EXPLORATION
transfusión I-EXPLORATION
de I-EXPLORATION
plaquetas I-EXPLORATION
y I-EXPLORATION
concentrado I-EXPLORATION
FVIII, I-EXPLORATION
que I-EXPLORATION
mostró I-EXPLORATION
series I-EXPLORATION
hematopoyéticas I-EXPLORATION
conservadas. I-EXPLORATION
Se B-TREATMENT
iniciaron I-TREATMENT
pulsos I-TREATMENT
de I-TREATMENT
solumedrol I-TREATMENT
125 I-TREATMENT
mg I-TREATMENT
i.v. I-TREATMENT
y I-TREATMENT
luego I-TREATMENT
prednisona I-TREATMENT
60 I-TREATMENT
mg/día I-TREATMENT
p.o., I-TREATMENT
observando I-TREATMENT
aumento I-TREATMENT
de I-TREATMENT
plaquetas I-TREATMENT
hasta I-TREATMENT
50.000/mm3 I-TREATMENT
el I-TREATMENT
cuarto I-TREATMENT
día, I-TREATMENT
siendo I-TREATMENT
dado I-TREATMENT
de I-TREATMENT
alta. I-TREATMENT
<EOS> I-TREATMENT
Dentro B-EXPLORATION
del I-EXPLORATION
estudio I-EXPLORATION
de I-EXPLORATION
laboratorio I-EXPLORATION
destacaba: I-EXPLORATION
elevación I-EXPLORATION
de I-EXPLORATION
transaminasas I-EXPLORATION
(GOT I-EXPLORATION
158/GPT I-EXPLORATION
151), I-EXPLORATION
TTPA, I-EXPLORATION
tiempo I-EXPLORATION
de I-EXPLORATION
protrombina I-EXPLORATION
y I-EXPLORATION
albúmina I-EXPLORATION
normales, I-EXPLORATION
serología I-EXPLORATION
VHC I-EXPLORATION
positivo, I-EXPLORATION
VIH I-EXPLORATION
negativo, I-EXPLORATION
HBAgS I-EXPLORATION
negativo I-EXPLORATION
y I-EXPLORATION
anticuerpos I-EXPLORATION
antiplaquetarios I-EXPLORATION
circulantes I-EXPLORATION
negativos. I-EXPLORATION
<EOS> I-EXPLORATION
Al B-EVOLUTION
tercer I-EVOLUTION
día I-EVOLUTION
posterior I-EVOLUTION
al I-EVOLUTION
alta I-EVOLUTION
las I-EVOLUTION
plaquetas I-EVOLUTION
caen I-EVOLUTION
a I-EVOLUTION
27.000/mm3. I-EVOLUTION
Se B-TREATMENT
mantuvo I-TREATMENT
la I-TREATMENT
prednisona I-TREATMENT
en I-TREATMENT
60 I-TREATMENT
mg/día I-TREATMENT
con I-TREATMENT
persistencia I-TREATMENT
de I-TREATMENT
la I-TREATMENT
trombopenia I-TREATMENT
por I-TREATMENT
cual I-TREATMENT
se I-TREATMENT
decidió I-TREATMENT
nuevo I-TREATMENT
pulso I-TREATMENT
de I-TREATMENT
solumedrol I-TREATMENT
y I-TREATMENT
se I-TREATMENT
asoció I-TREATMENT
azatioprina I-TREATMENT
100 I-TREATMENT
mg/día I-TREATMENT
con I-TREATMENT
buena I-TREATMENT
respuesta. I-TREATMENT
En I-TREATMENT
el I-TREATMENT
transcurso I-TREATMENT
del I-TREATMENT
tratamiento I-TREATMENT
esteroidal I-TREATMENT
desarrolló I-TREATMENT
diabetes I-TREATMENT
requiriendo I-TREATMENT
uso I-TREATMENT
de I-TREATMENT
insulina I-TREATMENT
y I-TREATMENT
luego I-TREATMENT
se I-TREATMENT
estabilizó I-TREATMENT
con I-TREATMENT
régimen. I-TREATMENT
<EOS> I-TREATMENT
Dada I-TREATMENT
la I-TREATMENT
dependencia I-TREATMENT
a I-TREATMENT
corticoides I-TREATMENT
e I-TREATMENT
inmunosupresor I-TREATMENT
en I-TREATMENT
noviembre I-TREATMENT
de I-TREATMENT
2007 I-TREATMENT
se I-TREATMENT
realizó I-TREATMENT
esplenectomía I-TREATMENT
electiva I-TREATMENT
y I-TREATMENT
biopsia I-TREATMENT
hepática I-TREATMENT
bajo I-TREATMENT
terapia I-TREATMENT
de I-TREATMENT
reemplazo I-TREATMENT
del I-TREATMENT
factor I-TREATMENT
deficiente I-TREATMENT
ajustando I-TREATMENT
niveles I-TREATMENT
de I-TREATMENT
FVIII I-TREATMENT
en I-TREATMENT
torno I-TREATMENT
al I-TREATMENT
40% I-TREATMENT
más I-TREATMENT
antifibrinolíticos I-TREATMENT
por I-TREATMENT
diez I-TREATMENT
días I-TREATMENT
presentando I-TREATMENT
dehiscencia I-TREATMENT
de I-TREATMENT
la I-TREATMENT
herida I-TREATMENT
operatoria I-TREATMENT
en I-TREATMENT
el I-TREATMENT
día I-TREATMENT
21 I-TREATMENT
post I-TREATMENT
operatorio I-TREATMENT
debiendo I-TREATMENT
resuturarse. I-TREATMENT
Posterior I-TREATMENT
a I-TREATMENT
cirugía I-TREATMENT
se I-TREATMENT
suspendió I-TREATMENT
prednisona I-TREATMENT
y I-TREATMENT
se I-TREATMENT
mantuvo I-TREATMENT
azatioprina I-TREATMENT
100 I-TREATMENT
mg/día I-TREATMENT
con B-EXPLORATION
lo I-EXPLORATION
cual I-EXPLORATION
logró I-EXPLORATION
recuento I-EXPLORATION
de I-EXPLORATION
plaquetas I-EXPLORATION
alrededor I-EXPLORATION
de I-EXPLORATION
50.000/mm3 I-EXPLORATION
a I-EXPLORATION
los I-EXPLORATION
5 I-EXPLORATION
meses. I-EXPLORATION
<EOS> I-EXPLORATION
La I-EXPLORATION
biopsia I-EXPLORATION
esplénica I-EXPLORATION
demostró I-EXPLORATION
congestión I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
pulpa I-EXPLORATION
roja I-EXPLORATION
y I-EXPLORATION
la I-EXPLORATION
hepática, I-EXPLORATION
hepatitis I-EXPLORATION
crónica I-EXPLORATION
con I-EXPLORATION
moderada I-EXPLORATION
actividad, I-EXPLORATION
colapso I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
trama I-EXPLORATION
reticular I-EXPLORATION
y I-EXPLORATION
formación I-EXPLORATION
de I-EXPLORATION
puentes I-EXPLORATION
porto-portales. I-EXPLORATION
Hepatocitos I-EXPLORATION
con I-EXPLORATION
degeneración I-EXPLORATION
balonada, I-EXPLORATION
esteatosis I-EXPLORATION
microvesicular I-EXPLORATION
y I-EXPLORATION
colestasia I-EXPLORATION
intracelular. I-EXPLORATION
<EOS> I-EXPLORATION
Evaluado I-EXPLORATION
por I-EXPLORATION
gastroenterólogo I-EXPLORATION
se I-EXPLORATION
realizó I-EXPLORATION
endoscopia I-EXPLORATION
digestiva I-EXPLORATION
alta I-EXPLORATION
que I-EXPLORATION
demostró I-EXPLORATION
várices I-EXPLORATION
esofágicas I-EXPLORATION
medianas I-EXPLORATION
y I-EXPLORATION
gastropatía I-EXPLORATION
congestiva, I-EXPLORATION
carga I-EXPLORATION
viral I-EXPLORATION
VHC I-EXPLORATION
(185.120 I-EXPLORATION
UI I-EXPLORATION
RNA/ml), I-EXPLORATION
genotipo I-EXPLORATION
(1b) I-EXPLORATION
y I-EXPLORATION
se I-EXPLORATION
indicó I-EXPLORATION
terapia I-EXPLORATION
con I-EXPLORATION
INF I-EXPLORATION
α I-EXPLORATION
y I-EXPLORATION
ribavirina I-EXPLORATION
que I-EXPLORATION
no I-EXPLORATION
realizó I-EXPLORATION
por I-EXPLORATION
razones I-EXPLORATION
previsionales. I-EXPLORATION
<EOS> I-EXPLORATION
Los B-EVOLUTION
últimos I-EVOLUTION
2 I-EVOLUTION
años I-EVOLUTION
ha I-EVOLUTION
presentado I-EVOLUTION
diversos I-EVOLUTION
episodios I-EVOLUTION
hemorragíparos I-EVOLUTION
como I-EVOLUTION
hemoptisis I-EVOLUTION
asociado I-EVOLUTION
a I-EVOLUTION
cuadro I-EVOLUTION
bronquial, I-EVOLUTION
hematomas I-EVOLUTION
musculares I-EVOLUTION
(antebrazo I-EVOLUTION
y I-EVOLUTION
muslo), I-EVOLUTION
hemartrosis I-EVOLUTION
de I-EVOLUTION
rodilla I-EVOLUTION
y I-EVOLUTION
tobillo I-EVOLUTION
derechos, I-EVOLUTION
a I-EVOLUTION
pesar I-EVOLUTION
de I-EVOLUTION
mantener I-EVOLUTION
recuento I-EVOLUTION
plaquetario I-EVOLUTION
estable I-EVOLUTION
(50.000/mm3). I-EVOLUTION
TTPA I-EVOLUTION
actual I-EVOLUTION
62, I-EVOLUTION
3 I-EVOLUTION
seg I-EVOLUTION
y I-EVOLUTION
FVIII I-EVOLUTION
7%. I-EVOLUTION
<EOS> I-EVOLUTION
Mujer B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
78 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
autovalente, B-PAST_MEDICAL_HISTORY
independiente I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
actividades I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
la I-PAST_MEDICAL_HISTORY
vida I-PAST_MEDICAL_HISTORY
diaria, I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
escolaridad I-PAST_MEDICAL_HISTORY
completa, I-PAST_MEDICAL_HISTORY
tiene I-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
hipertensión I-PAST_MEDICAL_HISTORY
arterial, I-PAST_MEDICAL_HISTORY
hipotiroidismo, I-PAST_MEDICAL_HISTORY
hipoacusia I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
diabetes I-PAST_MEDICAL_HISTORY
mellitus I-PAST_MEDICAL_HISTORY
tipo I-PAST_MEDICAL_HISTORY
2 I-PAST_MEDICAL_HISTORY
(DM I-PAST_MEDICAL_HISTORY
2) I-PAST_MEDICAL_HISTORY
manejada I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
glibenclamida I-PAST_MEDICAL_HISTORY
10 I-PAST_MEDICAL_HISTORY
mg I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
metaformina I-PAST_MEDICAL_HISTORY
1.700 I-PAST_MEDICAL_HISTORY
mg I-PAST_MEDICAL_HISTORY
al I-PAST_MEDICAL_HISTORY
día, I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
lo I-PAST_MEDICAL_HISTORY
cual I-PAST_MEDICAL_HISTORY
lograba I-PAST_MEDICAL_HISTORY
glicemias I-PAST_MEDICAL_HISTORY
capilares I-PAST_MEDICAL_HISTORY
adecuadas. I-PAST_MEDICAL_HISTORY
<EOS> I-PAST_MEDICAL_HISTORY
Fue B-PRESENT_ILLNESS
llevada I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
familiares I-PRESENT_ILLNESS
al I-PRESENT_ILLNESS
Servicio I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
Urgencia, I-PRESENT_ILLNESS
para I-PRESENT_ILLNESS
evaluación I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
compromiso I-PRESENT_ILLNESS
cualitativo I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
conciencia, I-PRESENT_ILLNESS
no I-PRESENT_ILLNESS
fluctuante, I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
más I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
24 I-PRESENT_ILLNESS
hrs I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
evolución, I-PRESENT_ILLNESS
sin I-PRESENT_ILLNESS
signos I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
focalización I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
recuperación I-PRESENT_ILLNESS
espontánea I-PRESENT_ILLNESS
completa. I-PRESENT_ILLNESS
Su I-PRESENT_ILLNESS
familia I-PRESENT_ILLNESS
señaló I-PRESENT_ILLNESS
la I-PRESENT_ILLNESS
ocurrencia I-PRESENT_ILLNESS
cada I-PRESENT_ILLNESS
vez I-PRESENT_ILLNESS
más I-PRESENT_ILLNESS
frecuente I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
episodios I-PRESENT_ILLNESS
similares I-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
los I-PRESENT_ILLNESS
últimos I-PRESENT_ILLNESS
2 I-PRESENT_ILLNESS
meses, I-PRESENT_ILLNESS
indicando I-PRESENT_ILLNESS
además, I-PRESENT_ILLNESS
alteraciones I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
la I-PRESENT_ILLNESS
memoria I-PRESENT_ILLNESS
reciente, I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
la I-PRESENT_ILLNESS
conducta I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
alteraciones I-PRESENT_ILLNESS
autolimitadas I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
la I-PRESENT_ILLNESS
marcha, I-PRESENT_ILLNESS
sin I-PRESENT_ILLNESS
trastorno I-PRESENT_ILLNESS
del I-PRESENT_ILLNESS
control I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
esfínteres, I-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
repercusión I-PRESENT_ILLNESS
funcional I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
pérdida I-PRESENT_ILLNESS
parcial I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
su I-PRESENT_ILLNESS
autovalencia. I-PRESENT_ILLNESS
<EOS> I-PRESENT_ILLNESS
Ingresó B-EXPLORATION
vigil, I-EXPLORATION
orientada I-EXPLORATION
témporo-espacialmente, I-EXPLORATION
atenta, I-EXPLORATION
hemodinámicamente I-EXPLORATION
estable, I-EXPLORATION
afebril, I-EXPLORATION
sin I-EXPLORATION
apremio I-EXPLORATION
respiratorio I-EXPLORATION
y I-EXPLORATION
con I-EXPLORATION
un I-EXPLORATION
examen I-EXPLORATION
neurológico I-EXPLORATION
en I-EXPLORATION
el I-EXPLORATION
que I-EXPLORATION
sólo I-EXPLORATION
destacó I-EXPLORATION
un I-EXPLORATION
rendimiento I-EXPLORATION
anormal I-EXPLORATION
en I-EXPLORATION
el I-EXPLORATION
cuestionario I-EXPLORATION
Mini I-EXPLORATION
Mental, I-EXPLORATION
obteniendo I-EXPLORATION
22 I-EXPLORATION
puntos, I-EXPLORATION
cuyo I-EXPLORATION
resultado I-EXPLORATION
sugiere I-EXPLORATION
la I-EXPLORATION
posibilidad I-EXPLORATION
de I-EXPLORATION
deterioro I-EXPLORATION
cognitivo I-EXPLORATION
(puntaje I-EXPLORATION
esperado I-EXPLORATION
para I-EXPLORATION
nivel I-EXPLORATION
de I-EXPLORATION
escolaridad I-EXPLORATION
> I-EXPLORATION
24 I-EXPLORATION
puntos). I-EXPLORATION
Entre I-EXPLORATION
sus I-EXPLORATION
exámenes I-EXPLORATION
de I-EXPLORATION
laboratorio I-EXPLORATION
destacaron I-EXPLORATION
glicemia, I-EXPLORATION
creatininemia, I-EXPLORATION
natremia, I-EXPLORATION
calcemia, I-EXPLORATION
TSH, I-EXPLORATION
niveles I-EXPLORATION
de I-EXPLORATION
vitamina I-EXPLORATION
B12 I-EXPLORATION
y I-EXPLORATION
hemograma, I-EXPLORATION
normales. I-EXPLORATION
No I-EXPLORATION
presentó I-EXPLORATION
elevación I-EXPLORATION
de I-EXPLORATION
parámetrosinflamatorios, I-EXPLORATION
ELISA I-EXPLORATION
VIH I-EXPLORATION
negativo I-EXPLORATION
y I-EXPLORATION
RPR I-EXPLORATION
no I-EXPLORATION
reactivo. I-EXPLORATION
Se I-EXPLORATION
realizó I-EXPLORATION
una I-EXPLORATION
tomografía I-EXPLORATION
axial I-EXPLORATION
computada I-EXPLORATION
de I-EXPLORATION
cerebro I-EXPLORATION
no I-EXPLORATION
contrastada, I-EXPLORATION
que I-EXPLORATION
pesquisó I-EXPLORATION
un I-EXPLORATION
infarto I-EXPLORATION
lacunar I-EXPLORATION
hemorrágico I-EXPLORATION
putaminal I-EXPLORATION
izquierdo, I-EXPLORATION
probablemente I-EXPLORATION
antiguo. I-EXPLORATION
El I-EXPLORATION
electroencefalograma I-EXPLORATION
mostró I-EXPLORATION
lentitud I-EXPLORATION
intermitente I-EXPLORATION
generalizada. I-EXPLORATION
Eco-Doppler I-EXPLORATION
carotideo I-EXPLORATION
evidenció I-EXPLORATION
ateromatosis I-EXPLORATION
carotídea I-EXPLORATION
derecha I-EXPLORATION
sin I-EXPLORATION
compromiso I-EXPLORATION
hemodinámico. I-EXPLORATION
Ninguno I-EXPLORATION
de I-EXPLORATION
estos I-EXPLORATION
hallazgos I-EXPLORATION
logró I-EXPLORATION
explicar I-EXPLORATION
el I-EXPLORATION
cuadro I-EXPLORATION
clínico. I-EXPLORATION
<EOS> I-EXPLORATION
Se B-TREATMENT
manejó I-TREATMENT
con I-TREATMENT
régimen I-TREATMENT
alimentario I-TREATMENT
diabético, I-TREATMENT
sin I-TREATMENT
hipoglicemiantes I-TREATMENT
orales, I-TREATMENT
evolucionando B-EVOLUTION
en I-EVOLUTION
forma I-EVOLUTION
asintomática I-EVOLUTION
y I-EVOLUTION
con I-EVOLUTION
glicemias I-EVOLUTION
en I-EVOLUTION
rango I-EVOLUTION
adecuado. I-EVOLUTION
La B-EXPLORATION
hemoglobina I-EXPLORATION
glicosilada I-EXPLORATION
A1C I-EXPLORATION
fue I-EXPLORATION
de I-EXPLORATION
5, I-EXPLORATION
2%, I-EXPLORATION
lo I-EXPLORATION
que I-EXPLORATION
hizo I-EXPLORATION
sospechar I-EXPLORATION
la I-EXPLORATION
posibilidad I-EXPLORATION
de I-EXPLORATION
episodios I-EXPLORATION
de I-EXPLORATION
hipoglicemia I-EXPLORATION
recurrentes. I-EXPLORATION
Por B-TREATMENT
ello, I-TREATMENT
se I-TREATMENT
decidió I-TREATMENT
suspender I-TREATMENT
glibenclamida I-TREATMENT
y I-TREATMENT
disminuir I-TREATMENT
la I-TREATMENT
dosis I-TREATMENT
de I-TREATMENT
metformina I-TREATMENT
previo I-TREATMENT
al I-TREATMENT
alta. I-TREATMENT
<EOS> I-TREATMENT
En B-EVOLUTION
controles I-EVOLUTION
ambulatorios, I-EVOLUTION
transcurridos I-EVOLUTION
dos I-EVOLUTION
y I-EVOLUTION
luego I-EVOLUTION
seis I-EVOLUTION
meses I-EVOLUTION
post I-EVOLUTION
alta, I-EVOLUTION
la I-EVOLUTION
paciente I-EVOLUTION
se I-EVOLUTION
encontraba I-EVOLUTION
vigil, I-EVOLUTION
orientada I-EVOLUTION
témporo-espacialmente, I-EVOLUTION
bien I-EVOLUTION
conectada I-EVOLUTION
al I-EVOLUTION
medio, I-EVOLUTION
logrando I-EVOLUTION
26 I-EVOLUTION
puntos I-EVOLUTION
en I-EVOLUTION
Mini I-EVOLUTION
Mental I-EVOLUTION
en I-EVOLUTION
ambas I-EVOLUTION
ocasiones. I-EVOLUTION
Su I-EVOLUTION
familia I-EVOLUTION
no I-EVOLUTION
refrió I-EVOLUTION
nuevos I-EVOLUTION
episodios I-EVOLUTION
de I-EVOLUTION
alteración I-EVOLUTION
de I-EVOLUTION
conciencia, I-EVOLUTION
ni I-EVOLUTION
conductuales, I-EVOLUTION
interpretándose I-EVOLUTION
el I-EVOLUTION
cuadro I-EVOLUTION
original I-EVOLUTION
como I-EVOLUTION
secundario I-EVOLUTION
a I-EVOLUTION
hipoglicemias I-EVOLUTION
subclínicas I-EVOLUTION
frecuentes. I-EVOLUTION
<EOS> I-EVOLUTION
Mujer B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
78 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
autovalente B-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
sin I-PAST_MEDICAL_HISTORY
factores I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
riesgo I-PAST_MEDICAL_HISTORY
coronario I-PAST_MEDICAL_HISTORY
conocidos. I-PAST_MEDICAL_HISTORY
Consultó B-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
Servicio I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
Urgencia I-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
historia I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
dolor I-PRESENT_ILLNESS
torácico I-PRESENT_ILLNESS
izquierdo I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
24 I-PRESENT_ILLNESS
horas I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
evolución I-PRESENT_ILLNESS
que I-PRESENT_ILLNESS
apareció I-PRESENT_ILLNESS
después I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
ejercicio I-PRESENT_ILLNESS
físico I-PRESENT_ILLNESS
moderado, I-PRESENT_ILLNESS
sin I-PRESENT_ILLNESS
estrés I-PRESENT_ILLNESS
emocional I-PRESENT_ILLNESS
aparente. I-PRESENT_ILLNESS
Se I-PRESENT_ILLNESS
asoció I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
disnea I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
fatigabilidad. I-PRESENT_ILLNESS
En B-EXPLORATION
la I-EXPLORATION
evaluación I-EXPLORATION
clínica I-EXPLORATION
inicial I-EXPLORATION
estaba I-EXPLORATION
bien I-EXPLORATION
perfundida, I-EXPLORATION
con I-EXPLORATION
pulso I-EXPLORATION
de I-EXPLORATION
105/min, I-EXPLORATION
presión I-EXPLORATION
arterial I-EXPLORATION
de I-EXPLORATION
98/57 I-EXPLORATION
mmHg. I-EXPLORATION
El I-EXPLORATION
examen I-EXPLORATION
cardiovascular I-EXPLORATION
fue I-EXPLORATION
normal. I-EXPLORATION
En I-EXPLORATION
los I-EXPLORATION
exámenes I-EXPLORATION
de I-EXPLORATION
rutina I-EXPLORATION
destacaron I-EXPLORATION
un I-EXPLORATION
electrocardiograma I-EXPLORATION
que I-EXPLORATION
mostró I-EXPLORATION
supradesnivel I-EXPLORATION
del I-EXPLORATION
segmento I-EXPLORATION
ST I-EXPLORATION
en I-EXPLORATION
pared I-EXPLORATION
anterior I-EXPLORATION
(V2-V4) I-EXPLORATION
y I-EXPLORATION
marcadores I-EXPLORATION
de I-EXPLORATION
daño I-EXPLORATION
miocárdico I-EXPLORATION
elevados I-EXPLORATION
(troponinas I-EXPLORATION
7, I-EXPLORATION
10 I-EXPLORATION
ng/ml, I-EXPLORATION
CK-total I-EXPLORATION
368 I-EXPLORATION
U/L I-EXPLORATION
y I-EXPLORATION
CK-MB I-EXPLORATION
57 I-EXPLORATION
U/L). I-EXPLORATION
Se I-EXPLORATION
realizó I-EXPLORATION
coronariografía I-EXPLORATION
de I-EXPLORATION
urgencia I-EXPLORATION
una I-EXPLORATION
hora I-EXPLORATION
posterior I-EXPLORATION
al I-EXPLORATION
ingreso, I-EXPLORATION
que I-EXPLORATION
reveló I-EXPLORATION
arteria I-EXPLORATION
descendente I-EXPLORATION
anterior I-EXPLORATION
con I-EXPLORATION
lesión I-EXPLORATION
proximal I-EXPLORATION
de I-EXPLORATION
30% I-EXPLORATION
y I-EXPLORATION
flujo I-EXPLORATION
lento, I-EXPLORATION
no I-EXPLORATION
presentando I-EXPLORATION
el I-EXPLORATION
resto I-EXPLORATION
de I-EXPLORATION
las I-EXPLORATION
arterias I-EXPLORATION
coronarias I-EXPLORATION
lesiones I-EXPLORATION
significativas. I-EXPLORATION
En I-EXPLORATION
la I-EXPLORATION
ventriculografía I-EXPLORATION
izquierda I-EXPLORATION
con I-EXPLORATION
contraste I-EXPLORATION
se I-EXPLORATION
observó I-EXPLORATION
balonamiento I-EXPLORATION
apical. I-EXPLORATION
Se B-TREATMENT
planteó I-TREATMENT
como I-TREATMENT
probable I-TREATMENT
diagnóstico I-TREATMENT
STT I-TREATMENT
e I-TREATMENT
ingresó I-TREATMENT
a I-TREATMENT
Unidad I-TREATMENT
Coronaria I-TREATMENT
para I-TREATMENT
tratamiento I-TREATMENT
médico I-TREATMENT
estándar I-TREATMENT
de I-TREATMENT
síndrome I-TREATMENT
coronario I-TREATMENT
agudo I-TREATMENT
(SCA). I-TREATMENT
<EOS> I-TREATMENT
La B-EXPLORATION
ecocardiografía I-EXPLORATION
en I-EXPLORATION
el I-EXPLORATION
segundo I-EXPLORATION
día I-EXPLORATION
de I-EXPLORATION
hospitalización I-EXPLORATION
mostró: I-EXPLORATION
1) I-EXPLORATION
VI I-EXPLORATION
de I-EXPLORATION
dimensiones I-EXPLORATION
básales I-EXPLORATION
en I-EXPLORATION
rangos I-EXPLORATION
normales I-EXPLORATION
con I-EXPLORATION
extensa I-EXPLORATION
akinesia I-EXPLORATION
anteroseptoapical I-EXPLORATION
y I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
punta; I-EXPLORATION
2) I-EXPLORATION
Función I-EXPLORATION
sistólica I-EXPLORATION
global I-EXPLORATION
moderadamente I-EXPLORATION
deprimida I-EXPLORATION
con I-EXPLORATION
una I-EXPLORATION
fracción I-EXPLORATION
de I-EXPLORATION
eyección I-EXPLORATION
del I-EXPLORATION
VI I-EXPLORATION
estimada I-EXPLORATION
en I-EXPLORATION
40%; I-EXPLORATION
3) I-EXPLORATION
Insuficiencia I-EXPLORATION
tricuspídea I-EXPLORATION
severa I-EXPLORATION
e I-EXPLORATION
insuficiencia I-EXPLORATION
mitral I-EXPLORATION
moderada; I-EXPLORATION
4) I-EXPLORATION
Hipertensión I-EXPLORATION
pulmonar I-EXPLORATION
severa I-EXPLORATION
con I-EXPLORATION
presión I-EXPLORATION
sistólica I-EXPLORATION
de I-EXPLORATION
arteria I-EXPLORATION
pulmonar I-EXPLORATION
de I-EXPLORATION
72 I-EXPLORATION
mmHg. I-EXPLORATION
<EOS> I-EXPLORATION
Al I-EXPLORATION
tercer I-EXPLORATION
día, I-EXPLORATION
el I-EXPLORATION
control I-EXPLORATION
electrocardiográfico I-EXPLORATION
reveló I-EXPLORATION
inversión I-EXPLORATION
de I-EXPLORATION
onda I-EXPLORATION
T I-EXPLORATION
de I-EXPLORATION
derivaciones I-EXPLORATION
V2 I-EXPLORATION
a I-EXPLORATION
V6. I-EXPLORATION
<EOS> I-EXPLORATION
La B-EVOLUTION
evolución I-EVOLUTION
posterior I-EVOLUTION
fue I-EVOLUTION
favorable, I-EVOLUTION
con I-EVOLUTION
desaparición I-EVOLUTION
del I-EVOLUTION
dolor I-EVOLUTION
y I-EVOLUTION
disminución I-EVOLUTION
de I-EVOLUTION
los I-EVOLUTION
marcadores I-EVOLUTION
de I-EVOLUTION
daño I-EVOLUTION
miocárdico I-EVOLUTION
por I-EVOLUTION
lo I-EVOLUTION
que I-EVOLUTION
se I-EVOLUTION
decidió I-EVOLUTION
el I-EVOLUTION
alta I-EVOLUTION
al I-EVOLUTION
noveno I-EVOLUTION
día I-EVOLUTION
hospitalización. I-EVOLUTION
El B-EXPLORATION
seguimiento I-EXPLORATION
al I-EXPLORATION
mes I-EXPLORATION
con I-EXPLORATION
ecocardiografía I-EXPLORATION
2-D I-EXPLORATION
mostró: I-EXPLORATION
1) I-EXPLORATION
Función I-EXPLORATION
sistólica I-EXPLORATION
de I-EXPLORATION
VI I-EXPLORATION
conservada; I-EXPLORATION
2) I-EXPLORATION
Insuficiencia I-EXPLORATION
mitral I-EXPLORATION
leve I-EXPLORATION
con I-EXPLORATION
válvula I-EXPLORATION
de I-EXPLORATION
aspecto I-EXPLORATION
normal. I-EXPLORATION
Se I-EXPLORATION
efectuó I-EXPLORATION
estudio I-EXPLORATION
de I-EXPLORATION
perfusión I-EXPLORATION
miocárdica I-EXPLORATION
SPECT I-EXPLORATION
gatillado I-EXPLORATION
para I-EXPLORATION
evaluar I-EXPLORATION
función I-EXPLORATION
ventricular I-EXPLORATION
con I-EXPLORATION
Tecnecio99m-SESTAMIBI I-EXPLORATION
en I-EXPLORATION
estrés I-EXPLORATION
con I-EXPLORATION
protocolo I-EXPLORATION
de I-EXPLORATION
Bruce I-EXPLORATION
y I-EXPLORATION
en I-EXPLORATION
reposo; I-EXPLORATION
concluyó I-EXPLORATION
motilidad I-EXPLORATION
y I-EXPLORATION
engrasamiento I-EXPLORATION
global I-EXPLORATION
y I-EXPLORATION
segmentario I-EXPLORATION
del I-EXPLORATION
VI I-EXPLORATION
conservados, I-EXPLORATION
con I-EXPLORATION
excelente I-EXPLORATION
función I-EXPLORATION
sistólica. I-EXPLORATION
<EOS> I-EXPLORATION
Paciente B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
52 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
hipertensa, B-PAST_MEDICAL_HISTORY
obesa I-PAST_MEDICAL_HISTORY
mórbida, I-PAST_MEDICAL_HISTORY
planificada B-PRESENT_ILLNESS
para I-PRESENT_ILLNESS
bypass I-PRESENT_ILLNESS
gástrico. I-PRESENT_ILLNESS
Durante B-EVOLUTION
la I-EVOLUTION
inducción I-EVOLUTION
anestésica, I-EVOLUTION
sin I-EVOLUTION
haber I-EVOLUTION
modificaciones I-EVOLUTION
de I-EVOLUTION
PA I-EVOLUTION
o I-EVOLUTION
FC, I-EVOLUTION
presentó I-EVOLUTION
alteración I-EVOLUTION
del I-EVOLUTION
segmento I-EVOLUTION
ST I-EVOLUTION
sugerente I-EVOLUTION
de I-EVOLUTION
isquemia. I-EVOLUTION
La B-EXPLORATION
ETE I-EXPLORATION
no I-EXPLORATION
mostró I-EXPLORATION
alteraciones I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
motilidad I-EXPLORATION
ventricular I-EXPLORATION
global I-EXPLORATION
ni I-EXPLORATION
segmentaria. I-EXPLORATION
Se B-TREATMENT
decide I-TREATMENT
realizar I-TREATMENT
la I-TREATMENT
cirugía, I-TREATMENT
la I-TREATMENT
cual I-TREATMENT
transcurre I-TREATMENT
sin I-TREATMENT
incidentes. I-TREATMENT
Post B-EVOLUTION
operatorio I-EVOLUTION
sin I-EVOLUTION
problemas, I-EVOLUTION
dada I-EVOLUTION
de I-EVOLUTION
alta I-EVOLUTION
al I-EVOLUTION
tercer I-EVOLUTION
día. I-EVOLUTION
<EOS> I-EVOLUTION
Hombre B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
26 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
con B-PAST_MEDICAL_HISTORY
antecedente I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
síndrome I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
Down I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
cardiopatía I-PAST_MEDICAL_HISTORY
congénita I-PAST_MEDICAL_HISTORY
consistente I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
canal I-PAST_MEDICAL_HISTORY
aurículo-ventricular I-PAST_MEDICAL_HISTORY
completo, I-PAST_MEDICAL_HISTORY
reparado I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
período I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
lactante, I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
reemplazo I-PAST_MEDICAL_HISTORY
valvular I-PAST_MEDICAL_HISTORY
mitral I-PAST_MEDICAL_HISTORY
biológico I-PAST_MEDICAL_HISTORY
hace I-PAST_MEDICAL_HISTORY
5 I-PAST_MEDICAL_HISTORY
años. I-PAST_MEDICAL_HISTORY
En I-PAST_MEDICAL_HISTORY
abril I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
2010, I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
otra I-PAST_MEDICAL_HISTORY
institución, I-PAST_MEDICAL_HISTORY
debido I-PAST_MEDICAL_HISTORY
a I-PAST_MEDICAL_HISTORY
bradicardia, I-PAST_MEDICAL_HISTORY
se I-PAST_MEDICAL_HISTORY
implantó I-PAST_MEDICAL_HISTORY
un I-PAST_MEDICAL_HISTORY
marcapaso I-PAST_MEDICAL_HISTORY
definitivo I-PAST_MEDICAL_HISTORY
unicameral. I-PAST_MEDICAL_HISTORY
El I-PAST_MEDICAL_HISTORY
implante I-PAST_MEDICAL_HISTORY
se I-PAST_MEDICAL_HISTORY
realizó I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
un I-PAST_MEDICAL_HISTORY
bolsillo I-PAST_MEDICAL_HISTORY
subcutáneo I-PAST_MEDICAL_HISTORY
prepectoral, I-PAST_MEDICAL_HISTORY
utilizando I-PAST_MEDICAL_HISTORY
un I-PAST_MEDICAL_HISTORY
electrodo I-PAST_MEDICAL_HISTORY
transvenoso I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
estimulación I-PAST_MEDICAL_HISTORY
auricular I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
fijación I-PAST_MEDICAL_HISTORY
activa. I-PAST_MEDICAL_HISTORY
El I-PAST_MEDICAL_HISTORY
dispositivo I-PAST_MEDICAL_HISTORY
fue I-PAST_MEDICAL_HISTORY
programado I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
modo I-PAST_MEDICAL_HISTORY
AAI I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
frecuencia I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
estimulación I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
50 I-PAST_MEDICAL_HISTORY
latidos I-PAST_MEDICAL_HISTORY
por I-PAST_MEDICAL_HISTORY
minuto, I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
frecuencia I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
histéresis I-PAST_MEDICAL_HISTORY
a I-PAST_MEDICAL_HISTORY
40 I-PAST_MEDICAL_HISTORY
latidos I-PAST_MEDICAL_HISTORY
por I-PAST_MEDICAL_HISTORY
minuto. I-PAST_MEDICAL_HISTORY
<EOS> I-PAST_MEDICAL_HISTORY
El B-PRESENT_ILLNESS
paciente I-PRESENT_ILLNESS
ingresó I-PRESENT_ILLNESS
electivamente I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
nuestro I-PRESENT_ILLNESS
centro I-PRESENT_ILLNESS
para I-PRESENT_ILLNESS
cirugía I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
hernia I-PRESENT_ILLNESS
abdominal I-PRESENT_ILLNESS
no I-PRESENT_ILLNESS
complicada. I-PRESENT_ILLNESS
Por B-EXPLORATION
rutina, I-EXPLORATION
se I-EXPLORATION
solicitó I-EXPLORATION
evaluación I-EXPLORATION
pre-operatoria I-EXPLORATION
por I-EXPLORATION
electro I-EXPLORATION
fisiología. I-EXPLORATION
En I-EXPLORATION
su I-EXPLORATION
examen I-EXPLORATION
físico I-EXPLORATION
se I-EXPLORATION
constató I-EXPLORATION
contracción I-EXPLORATION
rítmica I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
región I-EXPLORATION
pectoral I-EXPLORATION
izquierda. I-EXPLORATION
Su I-EXPLORATION
electrocardiograma I-EXPLORATION
mostraba I-EXPLORATION
ritmo I-EXPLORATION
sinusal I-EXPLORATION
a I-EXPLORATION
60 I-EXPLORATION
latidos I-EXPLORATION
por I-EXPLORATION
minuto I-EXPLORATION
con I-EXPLORATION
conducción I-EXPLORATION
aurículo-ventricular I-EXPLORATION
normal. I-EXPLORATION
La I-EXPLORATION
interrogación I-EXPLORATION
del I-EXPLORATION
dispositivo I-EXPLORATION
mostró I-EXPLORATION
voltaje I-EXPLORATION
de I-EXPLORATION
batería I-EXPLORATION
normal I-EXPLORATION
(2.79 I-EXPLORATION
V), I-EXPLORATION
con I-EXPLORATION
impedancia I-EXPLORATION
de I-EXPLORATION
estimulación I-EXPLORATION
de I-EXPLORATION
833 I-EXPLORATION
Ohms I-EXPLORATION
y I-EXPLORATION
falla I-EXPLORATION
de I-EXPLORATION
sensado I-EXPLORATION
y I-EXPLORATION
de I-EXPLORATION
captura I-EXPLORATION
auricular I-EXPLORATION
por I-EXPLORATION
el I-EXPLORATION
electrodo. I-EXPLORATION
Se I-EXPLORATION
solicitó I-EXPLORATION
radiografía I-EXPLORATION
de I-EXPLORATION
tórax, I-EXPLORATION
evidenciando I-EXPLORATION
que I-EXPLORATION
el I-EXPLORATION
electrodo I-EXPLORATION
endocavitario I-EXPLORATION
se I-EXPLORATION
encontraba I-EXPLORATION
retraído I-EXPLORATION
fuera I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
silueta I-EXPLORATION
cardiaca, I-EXPLORATION
totalmente I-EXPLORATION
enrollado I-EXPLORATION
alrededor I-EXPLORATION
del I-EXPLORATION
generador I-EXPLORATION
de I-EXPLORATION
pulso I-EXPLORATION
en I-EXPLORATION
la I-EXPLORATION
zona I-EXPLORATION
del I-EXPLORATION
bolsillo I-EXPLORATION
prepectoral. I-EXPLORATION
Se B-TREATMENT
informó I-TREATMENT
a I-TREATMENT
sus I-TREATMENT
tratantes I-TREATMENT
y I-TREATMENT
se I-TREATMENT
optó I-TREATMENT
por I-TREATMENT
abandonar I-TREATMENT
el I-TREATMENT
dispositivo, I-TREATMENT
apagando I-TREATMENT
el I-TREATMENT
marcapaso, I-TREATMENT
dado I-TREATMENT
que I-TREATMENT
el I-TREATMENT
paciente I-TREATMENT
no I-TREATMENT
presentaba I-TREATMENT
síntomas I-TREATMENT
de I-TREATMENT
bradicardia, I-TREATMENT
su I-TREATMENT
Holter I-TREATMENT
ECG I-TREATMENT
no I-TREATMENT
mostró I-TREATMENT
arritmias I-TREATMENT
y I-TREATMENT
la I-TREATMENT
indicación I-TREATMENT
original I-TREATMENT
era I-TREATMENT
cuestionable. I-TREATMENT
Se I-TREATMENT
realizó I-TREATMENT
su I-TREATMENT
herniorrafia I-TREATMENT
abdominal I-TREATMENT
sin I-TREATMENT
complicaciones I-TREATMENT
quirúrgicas I-TREATMENT
ni I-TREATMENT
cardiovasculares, I-TREATMENT
y B-EVOLUTION
se I-EVOLUTION
mantiene I-EVOLUTION
asintomático I-EVOLUTION
a I-EVOLUTION
1 I-EVOLUTION
año I-EVOLUTION
de I-EVOLUTION
seguimiento. I-EVOLUTION
<EOS> I-EVOLUTION
Hombre B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
58 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
tabáquico, B-PAST_MEDICAL_HISTORY
obeso I-PAST_MEDICAL_HISTORY
e I-PAST_MEDICAL_HISTORY
hipertenso I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
tratamiento I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
losartán I-PAST_MEDICAL_HISTORY
50 I-PAST_MEDICAL_HISTORY
mg I-PAST_MEDICAL_HISTORY
al I-PAST_MEDICAL_HISTORY
día. I-PAST_MEDICAL_HISTORY
Consultó B-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
parestesias I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
manos I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
pies I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
una I-PRESENT_ILLNESS
semana I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
evolución I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
debilidad I-PRESENT_ILLNESS
progresiva I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
las I-PRESENT_ILLNESS
cuatro I-PRESENT_ILLNESS
extremidades I-PRESENT_ILLNESS
que I-PRESENT_ILLNESS
le I-PRESENT_ILLNESS
impedían I-PRESENT_ILLNESS
la I-PRESENT_ILLNESS
marcha. I-PRESENT_ILLNESS
Al B-EXPLORATION
ingreso I-EXPLORATION
estaba I-EXPLORATION
consciente I-EXPLORATION
y I-EXPLORATION
orientado, I-EXPLORATION
con I-EXPLORATION
una I-EXPLORATION
tetraparesia I-EXPLORATION
de I-EXPLORATION
predominio I-EXPLORATION
proximal, I-EXPLORATION
arreflexia I-EXPLORATION
generalizada I-EXPLORATION
y I-EXPLORATION
paresia I-EXPLORATION
facial I-EXPLORATION
derecha. I-EXPLORATION
Presión I-EXPLORATION
arterial I-EXPLORATION
(PA) I-EXPLORATION
177/62 I-EXPLORATION
mmHg. I-EXPLORATION
Hemograma, I-EXPLORATION
creatinina, I-EXPLORATION
nitrógeno I-EXPLORATION
ureico, I-EXPLORATION
electrolitos I-EXPLORATION
plasmáticos, I-EXPLORATION
gases I-EXPLORATION
arteriales I-EXPLORATION
y I-EXPLORATION
pruebas I-EXPLORATION
hepáticas I-EXPLORATION
sin I-EXPLORATION
alteraciones. I-EXPLORATION
Inmunoglobulinas I-EXPLORATION
A, I-EXPLORATION
G I-EXPLORATION
y I-EXPLORATION
M I-EXPLORATION
en I-EXPLORATION
rangos I-EXPLORATION
normales. I-EXPLORATION
Con B-TREATMENT
el I-TREATMENT
diagnóstico I-TREATMENT
de I-TREATMENT
Síndrome I-TREATMENT
de I-TREATMENT
Guillain-Barré, I-TREATMENT
se I-TREATMENT
inició I-TREATMENT
la I-TREATMENT
administración I-TREATMENT
de I-TREATMENT
inmunoglobulina I-TREATMENT
endovenosa I-TREATMENT
0, I-TREATMENT
4 I-TREATMENT
g/kg I-TREATMENT
de I-TREATMENT
peso I-TREATMENT
(Inmunoglobulina I-TREATMENT
G I-TREATMENT
endovenosa I-TREATMENT
UNC, I-TREATMENT
Argentina). I-TREATMENT
Dos B-EVOLUTION
horas I-EVOLUTION
después I-EVOLUTION
de I-EVOLUTION
completada I-EVOLUTION
la I-EVOLUTION
primera I-EVOLUTION
infusión, I-EVOLUTION
desarrolló I-EVOLUTION
compromiso I-EVOLUTION
de I-EVOLUTION
conciencia I-EVOLUTION
y I-EVOLUTION
agitación I-EVOLUTION
psicomotora, I-EVOLUTION
que I-EVOLUTION
obligó I-EVOLUTION
a I-EVOLUTION
la I-EVOLUTION
sedación. I-EVOLUTION
Su I-EVOLUTION
PA I-EVOLUTION
era I-EVOLUTION
de I-EVOLUTION
181/90 I-EVOLUTION
mmHg I-EVOLUTION
y I-EVOLUTION
se I-EVOLUTION
notó I-EVOLUTION
una I-EVOLUTION
agravación I-EVOLUTION
motora, I-EVOLUTION
aparición I-EVOLUTION
de I-EVOLUTION
paresia I-EVOLUTION
de I-EVOLUTION
ambos I-EVOLUTION
terceros I-EVOLUTION
pares I-EVOLUTION
y I-EVOLUTION
de I-EVOLUTION
pares I-EVOLUTION
bulbares, I-EVOLUTION
obligando B-TREATMENT
a I-TREATMENT
la I-TREATMENT
intubación I-TREATMENT
orotraqueal I-TREATMENT
y I-TREATMENT
ventilación I-TREATMENT
mecánica. I-TREATMENT
La B-EXPLORATION
tomografía I-EXPLORATION
computada I-EXPLORATION
(TC) I-EXPLORATION
de I-EXPLORATION
cerebro I-EXPLORATION
mostró I-EXPLORATION
borramiento I-EXPLORATION
de I-EXPLORATION
surcos I-EXPLORATION
y I-EXPLORATION
discreto I-EXPLORATION
colapso I-EXPLORATION
ventricular, I-EXPLORATION
sugerentes I-EXPLORATION
de I-EXPLORATION
edema I-EXPLORATION
cerebral. I-EXPLORATION
La I-EXPLORATION
punción I-EXPLORATION
lumbar I-EXPLORATION
dio I-EXPLORATION
salida I-EXPLORATION
a I-EXPLORATION
líquido I-EXPLORATION
cefalorraquídeo I-EXPLORATION
claro. I-EXPLORATION
Su I-EXPLORATION
estudio I-EXPLORATION
reveló I-EXPLORATION
0, I-EXPLORATION
60 I-EXPLORATION
g/l I-EXPLORATION
de I-EXPLORATION
proteínas, I-EXPLORATION
glucosa I-EXPLORATION
0, I-EXPLORATION
75 I-EXPLORATION
g/l I-EXPLORATION
y I-EXPLORATION
1, I-EXPLORATION
6 I-EXPLORATION
leucocitos I-EXPLORATION
por I-EXPLORATION
mm3. I-EXPLORATION
La I-EXPLORATION
electromiografía I-EXPLORATION
definió I-EXPLORATION
una I-EXPLORATION
polineuropatía I-EXPLORATION
desmielinizante I-EXPLORATION
aguda. I-EXPLORATION
Se B-TREATMENT
suspendió I-TREATMENT
la I-TREATMENT
Igev I-TREATMENT
y I-TREATMENT
se I-TREATMENT
inició I-TREATMENT
plasmaféresis I-TREATMENT
ese I-TREATMENT
mismo I-TREATMENT
día. I-TREATMENT
Durante B-EVOLUTION
cuatro I-EVOLUTION
días I-EVOLUTION
permaneció I-EVOLUTION
comprometido I-EVOLUTION
de I-EVOLUTION
conciencia. I-EVOLUTION
Al B-TREATMENT
quinto I-TREATMENT
día I-TREATMENT
fue I-TREATMENT
extubado I-TREATMENT
por I-TREATMENT
la I-TREATMENT
notable I-TREATMENT
recuperación I-TREATMENT
motora, I-TREATMENT
que I-TREATMENT
incluía I-TREATMENT
la I-TREATMENT
oculomotilidad, I-TREATMENT
aunque I-TREATMENT
persistía I-TREATMENT
leve I-TREATMENT
paresia I-TREATMENT
de I-TREATMENT
la I-TREATMENT
aducción I-TREATMENT
y I-TREATMENT
elevación I-TREATMENT
del I-TREATMENT
ojo I-TREATMENT
izquierdo. I-TREATMENT
La B-EXPLORATION
TC I-EXPLORATION
de I-EXPLORATION
cerebro I-EXPLORATION
realizada I-EXPLORATION
al I-EXPLORATION
séptimo I-EXPLORATION
día, I-EXPLORATION
mostró I-EXPLORATION
regresión I-EXPLORATION
del I-EXPLORATION
edema I-EXPLORATION
cerebral I-EXPLORATION
y I-EXPLORATION
el I-EXPLORATION
EEG I-EXPLORATION
realizado I-EXPLORATION
ese I-EXPLORATION
día I-EXPLORATION
fue I-EXPLORATION
normal. I-EXPLORATION
Completó B-TREATMENT
5 I-TREATMENT
sesiones I-TREATMENT
de I-TREATMENT
plasmaféresis I-TREATMENT
logrando B-EVOLUTION
bipedestación I-EVOLUTION
al I-EVOLUTION
décimo I-EVOLUTION
día. I-EVOLUTION
<EOS> I-EVOLUTION
Paciente B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
sexo I-PRESENT_ILLNESS
femenino I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
29 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
procedente B-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
Calama. I-PAST_MEDICAL_HISTORY
Dentro I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
sus I-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
destaca I-PAST_MEDICAL_HISTORY
trombosis I-PAST_MEDICAL_HISTORY
retinal I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
ojo I-PAST_MEDICAL_HISTORY
izquierdo I-PAST_MEDICAL_HISTORY
2 I-PAST_MEDICAL_HISTORY
meses I-PAST_MEDICAL_HISTORY
previo I-PAST_MEDICAL_HISTORY
al I-PAST_MEDICAL_HISTORY
cuadro I-PAST_MEDICAL_HISTORY
actual I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
madre I-PAST_MEDICAL_HISTORY
operada I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
feocromocitoma I-PAST_MEDICAL_HISTORY
a I-PAST_MEDICAL_HISTORY
los I-PAST_MEDICAL_HISTORY
26 I-PAST_MEDICAL_HISTORY
años I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
edad. I-PAST_MEDICAL_HISTORY
Historia I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
10 I-PAST_MEDICAL_HISTORY
años I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
crisis I-PAST_MEDICAL_HISTORY
paroxísticas I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
cefalea, I-PAST_MEDICAL_HISTORY
naúseas, I-PAST_MEDICAL_HISTORY
sudoración, I-PAST_MEDICAL_HISTORY
palpitaciones, I-PAST_MEDICAL_HISTORY
asociadas I-PAST_MEDICAL_HISTORY
a I-PAST_MEDICAL_HISTORY
hipertensión I-PAST_MEDICAL_HISTORY
arterial I-PAST_MEDICAL_HISTORY
severa. I-PAST_MEDICAL_HISTORY
<EOS> I-PAST_MEDICAL_HISTORY
En I-PAST_MEDICAL_HISTORY
tratamiento I-PAST_MEDICAL_HISTORY
hace I-PAST_MEDICAL_HISTORY
6 I-PAST_MEDICAL_HISTORY
años I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
beta I-PAST_MEDICAL_HISTORY
bloqueadores I-PAST_MEDICAL_HISTORY
e I-PAST_MEDICAL_HISTORY
inhibidores I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
enzima I-PAST_MEDICAL_HISTORY
convertidora I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
angiotensina. I-PAST_MEDICAL_HISTORY
Por B-EXPLORATION
aumento I-EXPLORATION
en I-EXPLORATION
la I-EXPLORATION
frecuencia I-EXPLORATION
de I-EXPLORATION
las I-EXPLORATION
crisis I-EXPLORATION
fue I-EXPLORATION
hospitalizada I-EXPLORATION
destacando I-EXPLORATION
al I-EXPLORATION
examen I-EXPLORATION
físico: I-EXPLORATION
presión I-EXPLORATION
arterial I-EXPLORATION
158/111 I-EXPLORATION
mmHg, I-EXPLORATION
pulso I-EXPLORATION
93 I-EXPLORATION
por I-EXPLORATION
minuto, I-EXPLORATION
examen I-EXPLORATION
cardiopulmonar I-EXPLORATION
normal, I-EXPLORATION
abdomen I-EXPLORATION
blando, I-EXPLORATION
depresible, I-EXPLORATION
sin I-EXPLORATION
masas I-EXPLORATION
palpables. I-EXPLORATION
<EOS> I-EXPLORATION
Exámenes I-EXPLORATION
de I-EXPLORATION
ingreso; I-EXPLORATION
creatinina I-EXPLORATION
0, I-EXPLORATION
75 I-EXPLORATION
mg/dL, I-EXPLORATION
calcemia I-EXPLORATION
10, I-EXPLORATION
3 I-EXPLORATION
mg/dL, I-EXPLORATION
fosfemia I-EXPLORATION
3, I-EXPLORATION
5 I-EXPLORATION
mg/dL, I-EXPLORATION
TSH I-EXPLORATION
0, I-EXPLORATION
45 I-EXPLORATION
uUI/mL I-EXPLORATION
(0,4-4,0), I-EXPLORATION
T4 I-EXPLORATION
libre I-EXPLORATION
0, I-EXPLORATION
91 I-EXPLORATION
ng/dL I-EXPLORATION
(0,81,8), I-EXPLORATION
aldosterona I-EXPLORATION
plasmática I-EXPLORATION
22, I-EXPLORATION
7 I-EXPLORATION
ng/dL I-EXPLORATION
(1,0-16), I-EXPLORATION
actividad I-EXPLORATION
renina I-EXPLORATION
plasmática I-EXPLORATION
20 I-EXPLORATION
ng/mL/h I-EXPLORATION
(1, I-EXPLORATION
6 I-EXPLORATION
± I-EXPLORATION
0, I-EXPLORATION
83), I-EXPLORATION
noradrenalina I-EXPLORATION
plasmática I-EXPLORATION
7192 I-EXPLORATION
pg/mL I-EXPLORATION
(41773), I-EXPLORATION
adrenalina I-EXPLORATION
plasmática I-EXPLORATION
< I-EXPLORATION
20 I-EXPLORATION
pg/mL I-EXPLORATION
(20-82), I-EXPLORATION
normetanefrinas I-EXPLORATION
urinarias I-EXPLORATION
4816 I-EXPLORATION
ug/g I-EXPLORATION
creatinina I-EXPLORATION
(46-256), I-EXPLORATION
metanefrinas I-EXPLORATION
urinarias I-EXPLORATION
122 I-EXPLORATION
ug/g I-EXPLORATION
creatinina I-EXPLORATION
(25-155), I-EXPLORATION
calcitonina I-EXPLORATION
plasmática I-EXPLORATION
ultrasensible I-EXPLORATION
< I-EXPLORATION
0, I-EXPLORATION
2 I-EXPLORATION
pg/mL I-EXPLORATION
(< I-EXPLORATION
7, I-EXPLORATION
5), I-EXPLORATION
antígeno I-EXPLORATION
carcinoembrionario I-EXPLORATION
1, I-EXPLORATION
14 I-EXPLORATION
ng/mL I-EXPLORATION
(<4,2). I-EXPLORATION
Las I-EXPLORATION
mediciones I-EXPLORATION
de I-EXPLORATION
estas I-EXPLORATION
hormonas I-EXPLORATION
fueron I-EXPLORATION
realizadas I-EXPLORATION
bajo I-EXPLORATION
tratamiento I-EXPLORATION
con I-EXPLORATION
amlodipino, I-EXPLORATION
el I-EXPLORATION
cual I-EXPLORATION
tiene I-EXPLORATION
mínima I-EXPLORATION
influencia I-EXPLORATION
sobre I-EXPLORATION
el I-EXPLORATION
eje I-EXPLORATION
renina-angiotensina-aldosterona I-EXPLORATION
y I-EXPLORATION
no I-EXPLORATION
afecta I-EXPLORATION
la I-EXPLORATION
medición I-EXPLORATION
de I-EXPLORATION
las I-EXPLORATION
metanefrinas I-EXPLORATION
urinarias2, I-EXPLORATION
3. I-EXPLORATION
<EOS> I-EXPLORATION
Ecografía I-EXPLORATION
tiroidea I-EXPLORATION
evidenció I-EXPLORATION
nódulos I-EXPLORATION
tiroideos I-EXPLORATION
bilaterales I-EXPLORATION
de I-EXPLORATION
aspecto I-EXPLORATION
coloideo, I-EXPLORATION
el I-EXPLORATION
mayor I-EXPLORATION
en I-EXPLORATION
lóbulo I-EXPLORATION
derecho I-EXPLORATION
de I-EXPLORATION
10 I-EXPLORATION
mm. I-EXPLORATION
Tomografía I-EXPLORATION
computada I-EXPLORATION
(TAC) I-EXPLORATION
de I-EXPLORATION
abdomen I-EXPLORATION
y I-EXPLORATION
angioTAC I-EXPLORATION
renal I-EXPLORATION
mostraron I-EXPLORATION
3 I-EXPLORATION
masas I-EXPLORATION
retroperitoneales: I-EXPLORATION
una I-EXPLORATION
pararrenal I-EXPLORATION
izquierda I-EXPLORATION
de I-EXPLORATION
8 I-EXPLORATION
cm, I-EXPLORATION
otra I-EXPLORATION
en I-EXPLORATION
hilio I-EXPLORATION
renal I-EXPLORATION
izquierdo I-EXPLORATION
de I-EXPLORATION
3 I-EXPLORATION
cm I-EXPLORATION
y I-EXPLORATION
la I-EXPLORATION
tercera I-EXPLORATION
paraaórtica I-EXPLORATION
de I-EXPLORATION
4 I-EXPLORATION
cm, I-EXPLORATION
además I-EXPLORATION
de I-EXPLORATION
cierto I-EXPLORATION
grado I-EXPLORATION
de I-EXPLORATION
compresión I-EXPLORATION
de I-EXPLORATION
vena I-EXPLORATION
cava I-EXPLORATION
inferior I-EXPLORATION
y I-EXPLORATION
presencia I-EXPLORATION
de I-EXPLORATION
dos I-EXPLORATION
arterias I-EXPLORATION
renales I-EXPLORATION
izquierda. I-EXPLORATION
Fondo I-EXPLORATION
de I-EXPLORATION
ojo I-EXPLORATION
y I-EXPLORATION
resonancia I-EXPLORATION
magnética I-EXPLORATION
(RM) I-EXPLORATION
de I-EXPLORATION
cerebro I-EXPLORATION
y I-EXPLORATION
cuello I-EXPLORATION
descartaron I-EXPLORATION
presencia I-EXPLORATION
de I-EXPLORATION
hemangiomas I-EXPLORATION
retínales I-EXPLORATION
y I-EXPLORATION
hemangioblastomas I-EXPLORATION
cerebrales. I-EXPLORATION
En I-EXPLORATION
base I-EXPLORATION
a I-EXPLORATION
la I-EXPLORATION
ausencia I-EXPLORATION
de I-EXPLORATION
elementos I-EXPLORATION
clínicos I-EXPLORATION
sugerentes I-EXPLORATION
de I-EXPLORATION
neurofibromatosis I-EXPLORATION
tipo I-EXPLORATION
1 I-EXPLORATION
(NF1), I-EXPLORATION
neoplasia I-EXPLORATION
endocrina I-EXPLORATION
múltiple I-EXPLORATION
tipo I-EXPLORATION
2 I-EXPLORATION
(NEM I-EXPLORATION
2) I-EXPLORATION
y I-EXPLORATION
de I-EXPLORATION
enfermedad I-EXPLORATION
de I-EXPLORATION
von I-EXPLORATION
Hippel-Lindau I-EXPLORATION
(VHL), I-EXPLORATION
la I-EXPLORATION
presencia I-EXPLORATION
de I-EXPLORATION
masas I-EXPLORATION
extraadrenales I-EXPLORATION
y B-FAMILY_HISTORY
considerando I-FAMILY_HISTORY
el I-FAMILY_HISTORY
antecedente I-FAMILY_HISTORY
materno I-FAMILY_HISTORY
de I-FAMILY_HISTORY
feocromocitoma, I-FAMILY_HISTORY
se B-EXPLORATION
planteó I-EXPLORATION
el I-EXPLORATION
diagnóstico I-EXPLORATION
de I-EXPLORATION
síndrome I-EXPLORATION
de I-EXPLORATION
paraganglioma I-EXPLORATION
hereditario. I-EXPLORATION
<EOS> I-EXPLORATION
El I-EXPLORATION
estudio I-EXPLORATION
genético I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
paciente, I-EXPLORATION
realizado I-EXPLORATION
en I-EXPLORATION
el I-EXPLORATION
laboratorio I-EXPLORATION
del I-EXPLORATION
Prof. I-EXPLORATION
Hartmut I-EXPLORATION
P.H. I-EXPLORATION
Neumann I-EXPLORATION
(Universidad I-EXPLORATION
de I-EXPLORATION
Freiburg, I-EXPLORATION
Alemania) I-EXPLORATION
mostró I-EXPLORATION
una I-EXPLORATION
mutación I-EXPLORATION
del I-EXPLORATION
gen I-EXPLORATION
succinato I-EXPLORATION
deshidrogenasa I-EXPLORATION
SDHB I-EXPLORATION
Exon I-EXPLORATION
2 I-EXPLORATION
c.300_304 I-EXPLORATION
del I-EXPLORATION
CCTCA I-EXPLORATION
(p.P56delYfsX5), I-EXPLORATION
siendo I-EXPLORATION
negativo I-EXPLORATION
en I-EXPLORATION
su I-EXPLORATION
hija. I-EXPLORATION
<EOS> I-EXPLORATION
Se B-TREATMENT
realizó I-TREATMENT
cirugía, I-TREATMENT
resecándose I-TREATMENT
3 I-TREATMENT
masas I-TREATMENT
retro-peritoneales I-TREATMENT
que I-TREATMENT
se I-TREATMENT
correspondían I-TREATMENT
en I-TREATMENT
ubicación I-TREATMENT
y I-TREATMENT
tamaño I-TREATMENT
con I-TREATMENT
la I-TREATMENT
TAC I-TREATMENT
abdominal. I-TREATMENT
El B-EXPLORATION
estudio I-EXPLORATION
histológico I-EXPLORATION
informó I-EXPLORATION
paragangliomas. I-EXPLORATION
Las I-EXPLORATION
normetanefrinas I-EXPLORATION
urinarias I-EXPLORATION
se I-EXPLORATION
normalizaron I-EXPLORATION
y I-EXPLORATION
las I-EXPLORATION
resonancias I-EXPLORATION
magnéticas I-EXPLORATION
de I-EXPLORATION
cabeza, I-EXPLORATION
cuello, I-EXPLORATION
abdomen I-EXPLORATION
y I-EXPLORATION
pelvis, I-EXPLORATION
además I-EXPLORATION
de I-EXPLORATION
TAC I-EXPLORATION
de I-EXPLORATION
Tórax I-EXPLORATION
fueron I-EXPLORATION
normales. I-EXPLORATION
<EOS> I-EXPLORATION
Mujer B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
71 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
con B-PAST_MEDICAL_HISTORY
miocardiopatía I-PAST_MEDICAL_HISTORY
dilatada I-PAST_MEDICAL_HISTORY
idiopática I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
fibrilación I-PAST_MEDICAL_HISTORY
auricular I-PAST_MEDICAL_HISTORY
permanente I-PAST_MEDICAL_HISTORY
desde I-PAST_MEDICAL_HISTORY
hace I-PAST_MEDICAL_HISTORY
varios I-PAST_MEDICAL_HISTORY
años. I-PAST_MEDICAL_HISTORY
Evoluciona B-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
insuficiencia I-PRESENT_ILLNESS
cardiaca I-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
capacidad I-PRESENT_ILLNESS
funcional I-PRESENT_ILLNESS
III I-PRESENT_ILLNESS
(NYHA) I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
pesar I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
un I-PRESENT_ILLNESS
tratamiento I-PRESENT_ILLNESS
médico I-PRESENT_ILLNESS
adecuado. I-PRESENT_ILLNESS
Su B-EXPLORATION
ecocardiograma I-EXPLORATION
evidenció I-EXPLORATION
dilatación I-EXPLORATION
moderada I-EXPLORATION
del I-EXPLORATION
ventrículo I-EXPLORATION
izquierdo I-EXPLORATION
(DFDVI I-EXPLORATION
64 I-EXPLORATION
mm), I-EXPLORATION
deterioro I-EXPLORATION
severo I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
función I-EXPLORATION
sistólica I-EXPLORATION
ventricular I-EXPLORATION
izquierda I-EXPLORATION
(FE I-EXPLORATION
30%) I-EXPLORATION
e I-EXPLORATION
importante I-EXPLORATION
dilatación I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
aurícula I-EXPLORATION
izquierda I-EXPLORATION
(diámetro I-EXPLORATION
56 I-EXPLORATION
mm). I-EXPLORATION
Su B-DERIVED_FROM/TO
cardiólogo I-DERIVED_FROM/TO
tratante I-DERIVED_FROM/TO
la I-DERIVED_FROM/TO
derivó I-DERIVED_FROM/TO
a I-DERIVED_FROM/TO
nuestra I-DERIVED_FROM/TO
Institución I-DERIVED_FROM/TO
para I-DERIVED_FROM/TO
terapia I-DERIVED_FROM/TO
de I-DERIVED_FROM/TO
resincronización I-DERIVED_FROM/TO
biventricular. I-DERIVED_FROM/TO
<EOS> I-DERIVED_FROM/TO
Se B-TREATMENT
planificó I-TREATMENT
el I-TREATMENT
implante I-TREATMENT
con I-TREATMENT
abordaje I-TREATMENT
habitual I-TREATMENT
por I-TREATMENT
el I-TREATMENT
lado I-TREATMENT
izquierdo. I-TREATMENT
Se I-TREATMENT
confeccionó I-TREATMENT
un I-TREATMENT
bolsillo I-TREATMENT
subcutáneo I-TREATMENT
prepectoral I-TREATMENT
izquierdo I-TREATMENT
y I-TREATMENT
se I-TREATMENT
realizó I-TREATMENT
punción I-TREATMENT
de I-TREATMENT
la I-TREATMENT
vena I-TREATMENT
axilar I-TREATMENT
izquierda I-TREATMENT
con I-TREATMENT
técnica I-TREATMENT
de I-TREATMENT
Seldinger, I-TREATMENT
sin I-TREATMENT
incidentes. I-TREATMENT
Al I-TREATMENT
avanzar I-TREATMENT
la I-TREATMENT
guía, I-TREATMENT
se I-TREATMENT
observó I-TREATMENT
un I-TREATMENT
trayecto I-TREATMENT
inusual I-TREATMENT
desde I-TREATMENT
la I-TREATMENT
vena I-TREATMENT
subclavia I-TREATMENT
izquierda I-TREATMENT
hacia I-TREATMENT
inferior I-TREATMENT
por I-TREATMENT
la I-TREATMENT
región I-TREATMENT
paravertebral I-TREATMENT
izquierda, I-TREATMENT
compatible I-TREATMENT
con I-TREATMENT
la I-TREATMENT
presencia I-TREATMENT
de I-TREATMENT
una I-TREATMENT
VCSIP. I-TREATMENT
Se B-EXPLORATION
realizó I-EXPLORATION
venograma I-EXPLORATION
que I-EXPLORATION
confirmó I-EXPLORATION
el I-EXPLORATION
diagnóstico I-EXPLORATION
de I-EXPLORATION
VCSIP, I-EXPLORATION
con I-EXPLORATION
ausencia I-EXPLORATION
de I-EXPLORATION
comunicación I-EXPLORATION
con I-EXPLORATION
el I-EXPLORATION
sistema I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
vena I-EXPLORATION
cava I-EXPLORATION
superior I-EXPLORATION
derecha. I-EXPLORATION
Además I-EXPLORATION
el I-EXPLORATION
venograma I-EXPLORATION
permitió I-EXPLORATION
corroborar I-EXPLORATION
drenaje I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
VCSIP I-EXPLORATION
a I-EXPLORATION
la I-EXPLORATION
aurícula I-EXPLORATION
derecha I-EXPLORATION
a I-EXPLORATION
través I-EXPLORATION
del I-EXPLORATION
seno I-EXPLORATION
coronario, I-EXPLORATION
sin I-EXPLORATION
cortocircuito I-EXPLORATION
intracardiaco. I-EXPLORATION
A B-TREATMENT
continuación, I-TREATMENT
se I-TREATMENT
avanzó I-TREATMENT
a I-TREATMENT
través I-TREATMENT
del I-TREATMENT
seno I-TREATMENT
coronario I-TREATMENT
un I-TREATMENT
electrodo I-TREATMENT
ventricular I-TREATMENT
de I-TREATMENT
fijación I-TREATMENT
activa I-TREATMENT
Medtronic® I-TREATMENT
modelo I-TREATMENT
4076 I-TREATMENT
hasta I-TREATMENT
la I-TREATMENT
aurícula I-TREATMENT
derecha, I-TREATMENT
dirigiéndolo I-TREATMENT
a I-TREATMENT
través I-TREATMENT
de I-TREATMENT
la I-TREATMENT
válvula I-TREATMENT
tricúspide I-TREATMENT
hasta I-TREATMENT
la I-TREATMENT
región I-TREATMENT
septo I-TREATMENT
infundibular I-TREATMENT
del I-TREATMENT
ventrículo I-TREATMENT
derecho. I-TREATMENT
Se I-TREATMENT
obtuvo I-TREATMENT
una I-TREATMENT
onda I-TREATMENT
R I-TREATMENT
sensada I-TREATMENT
de I-TREATMENT
12, I-TREATMENT
6 I-TREATMENT
mV, I-TREATMENT
un I-TREATMENT
umbral I-TREATMENT
de I-TREATMENT
estimulación I-TREATMENT
ventricular I-TREATMENT
derecho I-TREATMENT
de I-TREATMENT
0, I-TREATMENT
4 I-TREATMENT
V I-TREATMENT
a I-TREATMENT
0, I-TREATMENT
5 I-TREATMENT
ms, I-TREATMENT
con I-TREATMENT
impedancia I-TREATMENT
de I-TREATMENT
estimulación I-TREATMENT
de I-TREATMENT
550 I-TREATMENT
Ohms. I-TREATMENT
Posteriormente, I-TREATMENT
utilizando I-TREATMENT
un I-TREATMENT
catéter I-TREATMENT
Ber-mann I-TREATMENT
con I-TREATMENT
orificios I-TREATMENT
proximales I-TREATMENT
al I-TREATMENT
balón, I-TREATMENT
se I-TREATMENT
realizó I-TREATMENT
inyección I-TREATMENT
de I-TREATMENT
medio I-TREATMENT
de I-TREATMENT
contraste I-TREATMENT
desde I-TREATMENT
la I-TREATMENT
porción I-TREATMENT
medial I-TREATMENT
del I-TREATMENT
seno I-TREATMENT
coronario, I-TREATMENT
evidenciando I-TREATMENT
un I-TREATMENT
seno I-TREATMENT
coronario I-TREATMENT
dilatado, I-TREATMENT
sin I-TREATMENT
lograr I-TREATMENT
contrastar I-TREATMENT
ramas I-TREATMENT
de I-TREATMENT
venas I-TREATMENT
coronarias I-TREATMENT
laterales. I-TREATMENT
Luego, I-TREATMENT
utilizando I-TREATMENT
una I-TREATMENT
vaina I-TREATMENT
larga I-TREATMENT
y I-TREATMENT
un I-TREATMENT
catéter I-TREATMENT
guía I-TREATMENT
Medtronic® I-TREATMENT
ángulo I-TREATMENT
de I-TREATMENT
130° I-TREATMENT
(modelo I-TREATMENT
6248 I-TREATMENT
del I-TREATMENT
130) I-TREATMENT
se I-TREATMENT
canuló I-TREATMENT
una I-TREATMENT
vena I-TREATMENT
coronaria I-TREATMENT
póstero-lateral I-TREATMENT
izquierda I-TREATMENT
y I-TREATMENT
se I-TREATMENT
avanzó I-TREATMENT
un I-TREATMENT
electrodo I-TREATMENT
de I-TREATMENT
estimulación I-TREATMENT
bipolar I-TREATMENT
Medtronic® I-TREATMENT
modelo I-TREATMENT
4196, I-TREATMENT
logrando I-TREATMENT
una I-TREATMENT
ubicación I-TREATMENT
satisfactoria I-TREATMENT
para I-TREATMENT
estimulación I-TREATMENT
ventricular I-TREATMENT
izquierda, I-TREATMENT
donde I-TREATMENT
se I-TREATMENT
obtuvo I-TREATMENT
una I-TREATMENT
onda I-TREATMENT
R I-TREATMENT
sensada I-TREATMENT
de I-TREATMENT
19, I-TREATMENT
9 I-TREATMENT
mV, I-TREATMENT
un I-TREATMENT
umbral I-TREATMENT
de I-TREATMENT
estimulación I-TREATMENT
ventricular I-TREATMENT
izquierdo I-TREATMENT
de I-TREATMENT
2, I-TREATMENT
0 I-TREATMENT
V I-TREATMENT
a I-TREATMENT
0, I-TREATMENT
5 I-TREATMENT
ms, I-TREATMENT
con I-TREATMENT
impedancia I-TREATMENT
de I-TREATMENT
estimulación I-TREATMENT
de I-TREATMENT
1.200 I-TREATMENT
Ohms. I-TREATMENT
Se I-TREATMENT
fijó I-TREATMENT
ambos I-TREATMENT
electrodos I-TREATMENT
a I-TREATMENT
la I-TREATMENT
fascia I-TREATMENT
prepectoral I-TREATMENT
y I-TREATMENT
se I-TREATMENT
conectaron I-TREATMENT
a I-TREATMENT
los I-TREATMENT
puertos I-TREATMENT
respectivos I-TREATMENT
del I-TREATMENT
generador I-TREATMENT
Medtronic® I-TREATMENT
Insync I-TREATMENT
III I-TREATMENT
modelo I-TREATMENT
8042, I-TREATMENT
ocluyendo I-TREATMENT
el I-TREATMENT
puerto I-TREATMENT
auricular. I-TREATMENT
Finalmente, I-TREATMENT
se I-TREATMENT
completó I-TREATMENT
el I-TREATMENT
procedimiento I-TREATMENT
realizando I-TREATMENT
fulguración I-TREATMENT
del I-TREATMENT
nodo I-TREATMENT
AV I-TREATMENT
compacto. I-TREATMENT
<EOS> I-TREATMENT
La B-EVOLUTION
paciente I-EVOLUTION
evolucionó I-EVOLUTION
en I-EVOLUTION
forma I-EVOLUTION
satisfactoria, I-EVOLUTION
con I-EVOLUTION
mejoría I-EVOLUTION
progresiva I-EVOLUTION
de I-EVOLUTION
su I-EVOLUTION
capacidad I-EVOLUTION
funcional. I-EVOLUTION
A I-EVOLUTION
los I-EVOLUTION
15 I-EVOLUTION
días I-EVOLUTION
se I-EVOLUTION
realizó I-EVOLUTION
control I-EVOLUTION
del I-EVOLUTION
dispositivo I-EVOLUTION
que I-EVOLUTION
confirmó I-EVOLUTION
99% I-EVOLUTION
de I-EVOLUTION
estimulación I-EVOLUTION
biventricular. I-EVOLUTION
Se B-EXPLORATION
midió I-EXPLORATION
una I-EXPLORATION
onda I-EXPLORATION
R I-EXPLORATION
de I-EXPLORATION
11, I-EXPLORATION
2 I-EXPLORATION
-15, I-EXPLORATION
68 I-EXPLORATION
mV I-EXPLORATION
en I-EXPLORATION
ventrículo I-EXPLORATION
derecho, I-EXPLORATION
con I-EXPLORATION
un I-EXPLORATION
umbral I-EXPLORATION
de I-EXPLORATION
estimulación I-EXPLORATION
ventricular I-EXPLORATION
derecho I-EXPLORATION
menor I-EXPLORATION
a I-EXPLORATION
0, I-EXPLORATION
5 I-EXPLORATION
V I-EXPLORATION
a I-EXPLORATION
0, I-EXPLORATION
4 I-EXPLORATION
ms I-EXPLORATION
con I-EXPLORATION
una I-EXPLORATION
impedancia I-EXPLORATION
de I-EXPLORATION
430 I-EXPLORATION
Ohms. I-EXPLORATION
La I-EXPLORATION
onda I-EXPLORATION
R I-EXPLORATION
sensada I-EXPLORATION
en I-EXPLORATION
ventrículo I-EXPLORATION
izquierdo I-EXPLORATION
fue I-EXPLORATION
mayor I-EXPLORATION
a I-EXPLORATION
22, I-EXPLORATION
4 I-EXPLORATION
mV, I-EXPLORATION
el I-EXPLORATION
umbral I-EXPLORATION
de I-EXPLORATION
estimulación I-EXPLORATION
fue I-EXPLORATION
de I-EXPLORATION
1, I-EXPLORATION
5 I-EXPLORATION
V I-EXPLORATION
a I-EXPLORATION
0, I-EXPLORATION
4 I-EXPLORATION
ms I-EXPLORATION
y I-EXPLORATION
la I-EXPLORATION
impedancia I-EXPLORATION
de I-EXPLORATION
776 I-EXPLORATION
Ohms. I-EXPLORATION
<EOS> I-EXPLORATION
A B-EVOLUTION
10 I-EVOLUTION
meses I-EVOLUTION
de I-EVOLUTION
seguimiento, I-EVOLUTION
se I-EVOLUTION
ha I-EVOLUTION
mantenido I-EVOLUTION
en I-EVOLUTION
control I-EVOLUTION
regular I-EVOLUTION
con I-EVOLUTION
su I-EVOLUTION
cardiólogo I-EVOLUTION
y I-EVOLUTION
se I-EVOLUTION
encuentra I-EVOLUTION
en I-EVOLUTION
capacidad I-EVOLUTION
funcional I-EVOLUTION
I-II I-EVOLUTION
(NYHA). I-EVOLUTION
El I-EVOLUTION
último I-EVOLUTION
control I-EVOLUTION
de I-EVOLUTION
su I-EVOLUTION
dispositivo I-EVOLUTION
mostró I-EVOLUTION
99% I-EVOLUTION
de I-EVOLUTION
estimulación I-EVOLUTION
biventricular I-EVOLUTION
y I-EVOLUTION
los I-EVOLUTION
parámetros I-EVOLUTION
de I-EVOLUTION
sensado I-EVOLUTION
y I-EVOLUTION
estimulación I-EVOLUTION
de I-EVOLUTION
ambos I-EVOLUTION
electrodos I-EVOLUTION
son I-EVOLUTION
adecuados. I-EVOLUTION
El B-EXPLORATION
electrodo I-EXPLORATION
ventricular I-EXPLORATION
derecho I-EXPLORATION
sensa I-EXPLORATION
onda I-EXPLORATION
R I-EXPLORATION
mayor I-EXPLORATION
de I-EXPLORATION
8, I-EXPLORATION
0 I-EXPLORATION
mV, I-EXPLORATION
tiene I-EXPLORATION
umbral I-EXPLORATION
de I-EXPLORATION
estimulación I-EXPLORATION
de I-EXPLORATION
1, I-EXPLORATION
0 I-EXPLORATION
V I-EXPLORATION
a I-EXPLORATION
0, I-EXPLORATION
4 I-EXPLORATION
ms, I-EXPLORATION
con I-EXPLORATION
impedancia I-EXPLORATION
de I-EXPLORATION
480 I-EXPLORATION
Ohms. I-EXPLORATION
El I-EXPLORATION
electrodo I-EXPLORATION
ventricular I-EXPLORATION
izquierdo I-EXPLORATION
sensa I-EXPLORATION
una I-EXPLORATION
onda I-EXPLORATION
R I-EXPLORATION
de I-EXPLORATION
12, I-EXPLORATION
0 I-EXPLORATION
mV, I-EXPLORATION
tiene I-EXPLORATION
umbral I-EXPLORATION
de I-EXPLORATION
estimulación I-EXPLORATION
de I-EXPLORATION
1, I-EXPLORATION
5 I-EXPLORATION
V I-EXPLORATION
a I-EXPLORATION
0, I-EXPLORATION
4 I-EXPLORATION
ms, I-EXPLORATION
con I-EXPLORATION
impedancia I-EXPLORATION
de I-EXPLORATION
971 I-EXPLORATION
Ohms. I-EXPLORATION
Mantiene I-EXPLORATION
bloqueo I-EXPLORATION
aurículo-ventricular I-EXPLORATION
completo I-EXPLORATION
con I-EXPLORATION
escape I-EXPLORATION
nodal I-EXPLORATION
a I-EXPLORATION
44 I-EXPLORATION
latidos I-EXPLORATION
por I-EXPLORATION
minuto. I-EXPLORATION
<EOS> I-EXPLORATION
Mujer B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
38 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
domiciliada I-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
sector I-PRESENT_ILLNESS
rural I-PRESENT_ILLNESS
y B-PAST_MEDICAL_HISTORY
sin I-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
mórbidos I-PAST_MEDICAL_HISTORY
conocidos. I-PAST_MEDICAL_HISTORY
Inició B-PRESENT_ILLNESS
cuadro I-PRESENT_ILLNESS
clínico I-PRESENT_ILLNESS
caracterizado I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
deterioro I-PRESENT_ILLNESS
del I-PRESENT_ILLNESS
estado I-PRESENT_ILLNESS
general, I-PRESENT_ILLNESS
baja I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
peso I-PRESENT_ILLNESS
(aproximadamente I-PRESENT_ILLNESS
10 I-PRESENT_ILLNESS
kg I-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
tres I-PRESENT_ILLNESS
meses) I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
edema I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
extremidades I-PRESENT_ILLNESS
inferiores. I-PRESENT_ILLNESS
<EOS> I-PRESENT_ILLNESS
Consultó I-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
varias I-PRESENT_ILLNESS
oportunidades I-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
el I-PRESENT_ILLNESS
centro I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
salud I-PRESENT_ILLNESS
rural I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
su I-PRESENT_ILLNESS
sector I-PRESENT_ILLNESS
donde I-PRESENT_ILLNESS
se I-PRESENT_ILLNESS
trató I-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
forma I-PRESENT_ILLNESS
sintomática. I-PRESENT_ILLNESS
Presentó I-PRESENT_ILLNESS
un I-PRESENT_ILLNESS
episodio I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
hipoglicemia I-PRESENT_ILLNESS
(26 I-PRESENT_ILLNESS
mg/dl) I-PRESENT_ILLNESS
que I-PRESENT_ILLNESS
se I-PRESENT_ILLNESS
trató I-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
infusión I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
solución I-PRESENT_ILLNESS
glucosada I-PRESENT_ILLNESS
al I-PRESENT_ILLNESS
10%. I-PRESENT_ILLNESS
Evolucionó B-DERIVED_FROM/TO
con I-DERIVED_FROM/TO
normalización I-DERIVED_FROM/TO
de I-DERIVED_FROM/TO
la I-DERIVED_FROM/TO
glicemia I-DERIVED_FROM/TO
y I-DERIVED_FROM/TO
fue I-DERIVED_FROM/TO
trasladada I-DERIVED_FROM/TO
a I-DERIVED_FROM/TO
nuestro I-DERIVED_FROM/TO
hospital. I-DERIVED_FROM/TO
<EOS> I-DERIVED_FROM/TO
En B-EXPLORATION
la I-EXPLORATION
radiografía I-EXPLORATION
de I-EXPLORATION
tórax I-EXPLORATION
se I-EXPLORATION
observó I-EXPLORATION
una I-EXPLORATION
ocupación I-EXPLORATION
pleural I-EXPLORATION
derecha I-EXPLORATION
y I-EXPLORATION
desviación I-EXPLORATION
de I-EXPLORATION
las I-EXPLORATION
estructuras I-EXPLORATION
mediastínicas. I-EXPLORATION
En I-EXPLORATION
la I-EXPLORATION
tomografía I-EXPLORATION
computada I-EXPLORATION
de I-EXPLORATION
tórax I-EXPLORATION
se I-EXPLORATION
observó I-EXPLORATION
un I-EXPLORATION
tumor I-EXPLORATION
pleural I-EXPLORATION
derecho, I-EXPLORATION
con I-EXPLORATION
densidad I-EXPLORATION
heterogénea, I-EXPLORATION
que I-EXPLORATION
ocupaba I-EXPLORATION
el I-EXPLORATION
hemitórax I-EXPLORATION
derecho I-EXPLORATION
con I-EXPLORATION
efecto I-EXPLORATION
compresivo, I-EXPLORATION
atelectasia I-EXPLORATION
pulmonar I-EXPLORATION
derecha I-EXPLORATION
y I-EXPLORATION
desplazamiento I-EXPLORATION
del I-EXPLORATION
mediastino. I-EXPLORATION
En I-EXPLORATION
los I-EXPLORATION
otros I-EXPLORATION
exámenes I-EXPLORATION
de I-EXPLORATION
laboratorio I-EXPLORATION
y I-EXPLORATION
de I-EXPLORATION
imagen I-EXPLORATION
no I-EXPLORATION
destacaron I-EXPLORATION
otros I-EXPLORATION
hallazgos I-EXPLORATION
significativos. I-EXPLORATION
<EOS> I-EXPLORATION
Durante B-EVOLUTION
la I-EVOLUTION
hospitalización I-EVOLUTION
presentó I-EVOLUTION
varios I-EVOLUTION
episodios I-EVOLUTION
de I-EVOLUTION
hipoglicemia I-EVOLUTION
sintomática I-EVOLUTION
caracterizada I-EVOLUTION
por I-EVOLUTION
somnolencia, I-EVOLUTION
deterioro I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
agudeza I-EVOLUTION
visual, I-EVOLUTION
debilidad I-EVOLUTION
muscular, I-EVOLUTION
sudoración, I-EVOLUTION
palpitaciones I-EVOLUTION
y I-EVOLUTION
palidez. I-EVOLUTION
Estas I-EVOLUTION
hipoglicemias I-EVOLUTION
fueron I-EVOLUTION
en I-EVOLUTION
días I-EVOLUTION
diferentes I-EVOLUTION
y I-EVOLUTION
se I-EVOLUTION
registraron I-EVOLUTION
al I-EVOLUTION
menos I-EVOLUTION
7 I-EVOLUTION
mediciones I-EVOLUTION
de I-EVOLUTION
glicemia I-EVOLUTION
entre I-EVOLUTION
27 I-EVOLUTION
y I-EVOLUTION
58 I-EVOLUTION
mg/dl, I-EVOLUTION
en I-EVOLUTION
el I-EVOLUTION
segundo I-EVOLUTION
día I-EVOLUTION
de I-EVOLUTION
hospitalización I-EVOLUTION
se I-EVOLUTION
registraron I-EVOLUTION
dos I-EVOLUTION
hipoglicemias. I-EVOLUTION
Fue B-TREATMENT
tratada I-TREATMENT
en I-TREATMENT
cada I-TREATMENT
episodio I-TREATMENT
con I-TREATMENT
infusión I-TREATMENT
de I-TREATMENT
solución I-TREATMENT
glucosada I-TREATMENT
al I-TREATMENT
10%. I-TREATMENT
Debido I-TREATMENT
al I-TREATMENT
difícil I-TREATMENT
control I-TREATMENT
metabólico, I-TREATMENT
se I-TREATMENT
trató I-TREATMENT
y I-TREATMENT
estudió I-TREATMENT
en I-TREATMENT
conjunto I-TREATMENT
con I-TREATMENT
el I-TREATMENT
equipo I-TREATMENT
de I-TREATMENT
endocrinología. I-TREATMENT
Las B-EXPLORATION
mediciones I-EXPLORATION
de I-EXPLORATION
insulinemia I-EXPLORATION
basal, I-EXPLORATION
cortisol, I-EXPLORATION
prolactina I-EXPLORATION
y I-EXPLORATION
hormona I-EXPLORATION
tiroestimulante I-EXPLORATION
(TSH) I-EXPLORATION
estaban I-EXPLORATION
en I-EXPLORATION
rangos I-EXPLORATION
de I-EXPLORATION
normales. I-EXPLORATION
<EOS> I-EXPLORATION
Se I-EXPLORATION
realizó I-EXPLORATION
una I-EXPLORATION
biopsia I-EXPLORATION
por I-EXPLORATION
punción I-EXPLORATION
guiada I-EXPLORATION
por I-EXPLORATION
tomografía I-EXPLORATION
computada, I-EXPLORATION
el I-EXPLORATION
estudio I-EXPLORATION
de I-EXPLORATION
anatomía I-EXPLORATION
patológica I-EXPLORATION
concluyó I-EXPLORATION
que I-EXPLORATION
la I-EXPLORATION
lesión I-EXPLORATION
era I-EXPLORATION
compatible I-EXPLORATION
con I-EXPLORATION
un I-EXPLORATION
TFSP. I-EXPLORATION
<EOS> I-EXPLORATION
Descartada B-TREATMENT
otra I-TREATMENT
causa I-TREATMENT
de I-TREATMENT
hipoglicemia I-TREATMENT
y I-TREATMENT
en I-TREATMENT
el I-TREATMENT
contexto I-TREATMENT
de I-TREATMENT
un I-TREATMENT
TFSP, I-TREATMENT
se I-TREATMENT
decidió I-TREATMENT
tratamiento I-TREATMENT
quirúrgico. I-TREATMENT
<EOS> I-TREATMENT
Procedimiento I-TREATMENT
quirúrgico I-TREATMENT
<EOS> I-TREATMENT
Con I-TREATMENT
intubación I-TREATMENT
monobronquial I-TREATMENT
(tubo I-TREATMENT
endotraqueal I-TREATMENT
de I-TREATMENT
doble I-TREATMENT
lumen) I-TREATMENT
y I-TREATMENT
en I-TREATMENT
decúbito I-TREATMENT
lateral I-TREATMENT
izquierdo. I-TREATMENT
Se I-TREATMENT
abordó I-TREATMENT
por I-TREATMENT
amplia I-TREATMENT
toracotomía I-TREATMENT
posterolateral I-TREATMENT
derecha, I-TREATMENT
se I-TREATMENT
encontró I-TREATMENT
un I-TREATMENT
tumor I-TREATMENT
de I-TREATMENT
aspecto I-TREATMENT
encapsulado I-TREATMENT
que I-TREATMENT
ocupaba I-TREATMENT
toda I-TREATMENT
la I-TREATMENT
cavidad I-TREATMENT
pleural I-TREATMENT
y I-TREATMENT
desplazaba I-TREATMENT
las I-TREATMENT
estructuras I-TREATMENT
mediastínicas I-TREATMENT
sin I-TREATMENT
infiltrarlas. I-TREATMENT
Se I-TREATMENT
encontraba I-TREATMENT
adherido I-TREATMENT
a I-TREATMENT
la I-TREATMENT
pleura I-TREATMENT
parietal, I-TREATMENT
con I-TREATMENT
base I-TREATMENT
de I-TREATMENT
implantación I-TREATMENT
ancha I-TREATMENT
y I-TREATMENT
sin I-TREATMENT
pedículo I-TREATMENT
identificable. I-TREATMENT
Se I-TREATMENT
liberaron I-TREATMENT
las I-TREATMENT
adherencias I-TREATMENT
y I-TREATMENT
se I-TREATMENT
resecó I-TREATMENT
macroscópicamente I-TREATMENT
el I-TREATMENT
tumor I-TREATMENT
en I-TREATMENT
forma I-TREATMENT
completa. I-TREATMENT
Se I-TREATMENT
observó I-TREATMENT
adecuada I-TREATMENT
expansión I-TREATMENT
pulmonar I-TREATMENT
derecha I-TREATMENT
post I-TREATMENT
exéresis I-TREATMENT
del I-TREATMENT
tumor. I-TREATMENT
Se I-TREATMENT
instalaron I-TREATMENT
dos I-TREATMENT
tubos I-TREATMENT
pleurales I-TREATMENT
(28 I-TREATMENT
Fr.) I-TREATMENT
y I-TREATMENT
se I-TREATMENT
cerró I-TREATMENT
la I-TREATMENT
toracotomía I-TREATMENT
en I-TREATMENT
forma I-TREATMENT
habitual. I-TREATMENT
<EOS> I-TREATMENT
Evolución B-EVOLUTION
postoperatoria I-EVOLUTION
<EOS> I-EVOLUTION
La I-EVOLUTION
paciente I-EVOLUTION
evolucionó I-EVOLUTION
en I-EVOLUTION
el I-EVOLUTION
postoperatorio I-EVOLUTION
sin I-EVOLUTION
incidentes. I-EVOLUTION
No I-EVOLUTION
presentó I-EVOLUTION
nuevos I-EVOLUTION
episodios I-EVOLUTION
de I-EVOLUTION
hipoglicemia. I-EVOLUTION
Se I-EVOLUTION
retiraron I-EVOLUTION
los I-EVOLUTION
tubos I-EVOLUTION
pleurales I-EVOLUTION
al I-EVOLUTION
séptimo I-EVOLUTION
día I-EVOLUTION
y I-EVOLUTION
se I-EVOLUTION
dio I-EVOLUTION
el I-EVOLUTION
alta I-EVOLUTION
hospitalaria I-EVOLUTION
al I-EVOLUTION
décimo I-EVOLUTION
día I-EVOLUTION
postoperatorio. I-EVOLUTION
<EOS> I-EVOLUTION
El B-EXPLORATION
estudio I-EXPLORATION
anatomopatológico I-EXPLORATION
concluyó: I-EXPLORATION
TFSP I-EXPLORATION
de I-EXPLORATION
27 I-EXPLORATION
x I-EXPLORATION
25 I-EXPLORATION
x I-EXPLORATION
11, I-EXPLORATION
5 I-EXPLORATION
centímetros I-EXPLORATION
y I-EXPLORATION
peso I-EXPLORATION
de I-EXPLORATION
3.450 I-EXPLORATION
gramos, I-EXPLORATION
con I-EXPLORATION
características I-EXPLORATION
histológicas I-EXPLORATION
de I-EXPLORATION
malignidad. I-EXPLORATION
El I-EXPLORATION
TFSP I-EXPLORATION
tenía I-EXPLORATION
necrosis I-EXPLORATION
tumoral I-EXPLORATION
macro I-EXPLORATION
y I-EXPLORATION
microscópica I-EXPLORATION
extensa, I-EXPLORATION
hasta I-EXPLORATION
2 I-EXPLORATION
mitosis I-EXPLORATION
en I-EXPLORATION
10 I-EXPLORATION
campos I-EXPLORATION
de I-EXPLORATION
aumento I-EXPLORATION
mayor I-EXPLORATION
y I-EXPLORATION
los I-EXPLORATION
bordes I-EXPLORATION
quirúrgicos I-EXPLORATION
estaban I-EXPLORATION
libres I-EXPLORATION
de I-EXPLORATION
lesión. I-EXPLORATION
La I-EXPLORATION
inmunohistoquímica I-EXPLORATION
presentó I-EXPLORATION
positividad I-EXPLORATION
intensa I-EXPLORATION
para I-EXPLORATION
Vimentina I-EXPLORATION
y I-EXPLORATION
CD34. I-EXPLORATION
<EOS> I-EXPLORATION
Actualmente, B-EVOLUTION
a I-EVOLUTION
15 I-EVOLUTION
meses I-EVOLUTION
de I-EVOLUTION
seguimiento, I-EVOLUTION
la I-EVOLUTION
paciente I-EVOLUTION
se I-EVOLUTION
encuentra I-EVOLUTION
con I-EVOLUTION
un I-EVOLUTION
control I-EVOLUTION
metabólico I-EVOLUTION
adecuado, I-EVOLUTION
con I-EVOLUTION
normalización I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
glicemia I-EVOLUTION
y I-EVOLUTION
asintomática I-EVOLUTION
desde I-EVOLUTION
el I-EVOLUTION
punto I-EVOLUTION
de I-EVOLUTION
vista I-EVOLUTION
respiratorio, I-EVOLUTION
sin I-EVOLUTION
evidencias I-EVOLUTION
clínicas I-EVOLUTION
ni I-EVOLUTION
radiológicas I-EVOLUTION
de I-EVOLUTION
recidiva I-EVOLUTION
del I-EVOLUTION
tumor. I-EVOLUTION
<EOS> I-EVOLUTION
Escolar B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
13 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
sexo I-PRESENT_ILLNESS
masculino I-PRESENT_ILLNESS
con B-PAST_MEDICAL_HISTORY
residencia I-PAST_MEDICAL_HISTORY
rural I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
la I-PAST_MEDICAL_HISTORY
IX I-PAST_MEDICAL_HISTORY
región, I-PAST_MEDICAL_HISTORY
sin I-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
mórbidos. I-PAST_MEDICAL_HISTORY
Consultó B-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
presentar I-PRESENT_ILLNESS
déficit I-PRESENT_ILLNESS
motot I-PRESENT_ILLNESS
progresivo I-PRESENT_ILLNESS
(hemiparesia I-PRESENT_ILLNESS
braquiocrural I-PRESENT_ILLNESS
izquierda) I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
cefalea I-PRESENT_ILLNESS
progresiva. I-PRESENT_ILLNESS
La B-EXPLORATION
TC I-EXPLORATION
cerebral I-EXPLORATION
mostró I-EXPLORATION
un I-EXPLORATION
quiste I-EXPLORATION
intraxial I-EXPLORATION
temporal I-EXPLORATION
derecho I-EXPLORATION
de I-EXPLORATION
60 I-EXPLORATION
mm I-EXPLORATION
de I-EXPLORATION
diámetro, I-EXPLORATION
bien I-EXPLORATION
delimitado, I-EXPLORATION
isodenso I-EXPLORATION
respecto I-EXPLORATION
al I-EXPLORATION
LCR, I-EXPLORATION
sin I-EXPLORATION
captación I-EXPLORATION
de I-EXPLORATION
contraste. I-EXPLORATION
Significativo I-EXPLORATION
efecto I-EXPLORATION
de I-EXPLORATION
masa I-EXPLORATION
con I-EXPLORATION
desviación I-EXPLORATION
de I-EXPLORATION
línea I-EXPLORATION
media I-EXPLORATION
de I-EXPLORATION
7 I-EXPLORATION
mm I-EXPLORATION
y I-EXPLORATION
herniación I-EXPLORATION
uncal. I-EXPLORATION
Se B-TREATMENT
planteó I-TREATMENT
el I-TREATMENT
diagnóstico I-TREATMENT
de I-TREATMENT
quiste I-TREATMENT
hidatídico I-TREATMENT
temporal I-TREATMENT
derecho; I-TREATMENT
se I-TREATMENT
realizó I-TREATMENT
la I-TREATMENT
exéresis I-TREATMENT
intacta I-TREATMENT
del I-TREATMENT
quiste I-TREATMENT
y I-TREATMENT
el I-TREATMENT
estudio I-TREATMENT
anatomopatológico I-TREATMENT
confirmó I-TREATMENT
la I-TREATMENT
etiología I-TREATMENT
hidatídica. I-TREATMENT
El B-EXPLORATION
estudio I-EXPLORATION
con I-EXPLORATION
Rx I-EXPLORATION
de I-EXPLORATION
tórax I-EXPLORATION
y I-EXPLORATION
ecotomografía I-EXPLORATION
abdominal I-EXPLORATION
no I-EXPLORATION
mostró I-EXPLORATION
lesiones I-EXPLORATION
quísticas. I-EXPLORATION
<EOS> I-EXPLORATION
El B-EVOLUTION
paciente I-EVOLUTION
evolucionó I-EVOLUTION
favorablemente, I-EVOLUTION
sin I-EVOLUTION
complicaciones I-EVOLUTION
quirúrgicas I-EVOLUTION
ni I-EVOLUTION
déficit I-EVOLUTION
neurológico. I-EVOLUTION
<EOS> I-EVOLUTION
Paciente B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
57 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
sexo I-PRESENT_ILLNESS
masculino, I-PRESENT_ILLNESS
conserje, B-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
antecedente I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
tabaquismo I-PAST_MEDICAL_HISTORY
activo. I-PAST_MEDICAL_HISTORY
Presentaba I-PAST_MEDICAL_HISTORY
historia I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
múltiples I-PAST_MEDICAL_HISTORY
hospitalizaciones I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
distintos I-PAST_MEDICAL_HISTORY
centros I-PAST_MEDICAL_HISTORY
durante I-PAST_MEDICAL_HISTORY
el I-PAST_MEDICAL_HISTORY
año I-PAST_MEDICAL_HISTORY
2010 I-PAST_MEDICAL_HISTORY
para I-PAST_MEDICAL_HISTORY
estudio I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
hemoptisis I-PAST_MEDICAL_HISTORY
autolimitada I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
escasa I-PAST_MEDICAL_HISTORY
cuantía I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
relación I-PAST_MEDICAL_HISTORY
a I-PAST_MEDICAL_HISTORY
esfuerzo I-PAST_MEDICAL_HISTORY
físico. I-PAST_MEDICAL_HISTORY
Al B-PRESENT_ILLNESS
preguntar I-PRESENT_ILLNESS
dirigidamente, I-PRESENT_ILLNESS
refería I-PRESENT_ILLNESS
historia I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
2 I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
astenia, I-PRESENT_ILLNESS
adinamia, I-PRESENT_ILLNESS
disnea I-PRESENT_ILLNESS
leve I-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
relación I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
esfuerzos I-PRESENT_ILLNESS
que I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
través I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
los I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
fue I-PRESENT_ILLNESS
empeorando I-PRESENT_ILLNESS
apareciendo I-PRESENT_ILLNESS
ortopnea I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
disnea I-PRESENT_ILLNESS
ante I-PRESENT_ILLNESS
pequeños I-PRESENT_ILLNESS
esfuerzos, I-PRESENT_ILLNESS
mialgias I-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
piernas I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
rigidez I-PRESENT_ILLNESS
matinal I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
articulaciones I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
manos I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
10-15 I-PRESENT_ILLNESS
minutos I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
duración, I-PRESENT_ILLNESS
sin I-PRESENT_ILLNESS
artralgias. I-PRESENT_ILLNESS
<EOS> I-PRESENT_ILLNESS
Presentaba B-EXPLORATION
radiografía I-EXPLORATION
de I-EXPLORATION
tórax, I-EXPLORATION
ecografía I-EXPLORATION
abdominal, I-EXPLORATION
endoscopía I-EXPLORATION
digestiva I-EXPLORATION
alta, I-EXPLORATION
ecocardio-grama, I-EXPLORATION
perfil I-EXPLORATION
bioquímico, I-EXPLORATION
creatinina I-EXPLORATION
plasmática, I-EXPLORATION
pruebas I-EXPLORATION
hepáticas I-EXPLORATION
y I-EXPLORATION
de I-EXPLORATION
coagulación I-EXPLORATION
normales. I-EXPLORATION
Tuvo I-EXPLORATION
un I-EXPLORATION
hemograma I-EXPLORATION
con I-EXPLORATION
leve I-EXPLORATION
anemia I-EXPLORATION
(hematocrito I-EXPLORATION
35%) I-EXPLORATION
y I-EXPLORATION
VHS I-EXPLORATION
elevada. I-EXPLORATION
En B-EVOLUTION
controles I-EVOLUTION
posteriores I-EVOLUTION
persistió I-EVOLUTION
con I-EVOLUTION
anemia I-EVOLUTION
normocítica-normocrómica I-EVOLUTION
de I-EVOLUTION
carácter I-EVOLUTION
leve, I-EVOLUTION
pero I-EVOLUTION
VHS I-EVOLUTION
se I-EVOLUTION
normalizó. I-EVOLUTION
<EOS> I-EVOLUTION
Presentó B-EXPLORATION
una I-EXPLORATION
tomografía I-EXPLORATION
axial I-EXPLORATION
computarizada I-EXPLORATION
(TAC) I-EXPLORATION
de I-EXPLORATION
tórax, I-EXPLORATION
3 I-EXPLORATION
días I-EXPLORATION
post I-EXPLORATION
hemoptisis, I-EXPLORATION
que I-EXPLORATION
mostró I-EXPLORATION
múltiples I-EXPLORATION
imágenes I-EXPLORATION
de I-EXPLORATION
"vidrio I-EXPLORATION
esmerilado" I-EXPLORATION
difusas I-EXPLORATION
sugerentes I-EXPLORATION
de I-EXPLORATION
hemorragia I-EXPLORATION
alveolar I-EXPLORATION
y I-EXPLORATION
enfisema I-EXPLORATION
pulmonar, I-EXPLORATION
pero I-EXPLORATION
en I-EXPLORATION
TAC I-EXPLORATION
de I-EXPLORATION
control I-EXPLORATION
mostró I-EXPLORATION
sólo I-EXPLORATION
enfisema I-EXPLORATION
leve. I-EXPLORATION
Se I-EXPLORATION
realizó I-EXPLORATION
fibrobroncoscopía I-EXPLORATION
que I-EXPLORATION
resultó I-EXPLORATION
normal, I-EXPLORATION
sin I-EXPLORATION
alteraciones I-EXPLORATION
en I-EXPLORATION
lavado I-EXPLORATION
bronco I-EXPLORATION
alveolar. I-EXPLORATION
Presentaba I-EXPLORATION
exámenes I-EXPLORATION
inmuno-reumatológicos I-EXPLORATION
negativos I-EXPLORATION
(ANA, I-EXPLORATION
AntiDNAds, I-EXPLORATION
ANCA I-EXPLORATION
por I-EXPLORATION
IFI, I-EXPLORATION
Coombs I-EXPLORATION
directo I-EXPLORATION
e I-EXPLORATION
indirecto, I-EXPLORATION
FR). I-EXPLORATION
Radiografía I-EXPLORATION
de I-EXPLORATION
manos I-EXPLORATION
mostraba I-EXPLORATION
leves I-EXPLORATION
cambios I-EXPLORATION
degenerativos I-EXPLORATION
en I-EXPLORATION
articulaciones I-EXPLORATION
interfalángicas I-EXPLORATION
distales. I-EXPLORATION
Al I-EXPLORATION
examen I-EXPLORATION
físico, I-EXPLORATION
se I-EXPLORATION
pesquisó I-EXPLORATION
distrofia I-EXPLORATION
ungueal, I-EXPLORATION
aumento I-EXPLORATION
de I-EXPLORATION
volumen I-EXPLORATION
de I-EXPLORATION
partes I-EXPLORATION
blandas I-EXPLORATION
de I-EXPLORATION
manos I-EXPLORATION
sin I-EXPLORATION
edema, I-EXPLORATION
pigmentación I-EXPLORATION
anaranjada I-EXPLORATION
de I-EXPLORATION
párpados I-EXPLORATION
con I-EXPLORATION
petequias I-EXPLORATION
perioculares I-EXPLORATION
y I-EXPLORATION
leve I-EXPLORATION
macroglosia. I-EXPLORATION
Por I-EXPLORATION
estos I-EXPLORATION
hallazgos I-EXPLORATION
se I-EXPLORATION
sugirió I-EXPLORATION
descartar I-EXPLORATION
enfermedad I-EXPLORATION
de I-EXPLORATION
depósito, I-EXPLORATION
postulando I-EXPLORATION
como I-EXPLORATION
hipótesis I-EXPLORATION
diagnóstica I-EXPLORATION
amiloidosis I-EXPLORATION
sistémica. I-EXPLORATION
Se I-EXPLORATION
realizó I-EXPLORATION
biopsia I-EXPLORATION
incisional I-EXPLORATION
de I-EXPLORATION
párpado, I-EXPLORATION
mejilla I-EXPLORATION
y I-EXPLORATION
mano, I-EXPLORATION
que I-EXPLORATION
mostró I-EXPLORATION
un I-EXPLORATION
infiltrado I-EXPLORATION
amorfo I-EXPLORATION
intersticial I-EXPLORATION
de I-EXPLORATION
material I-EXPLORATION
hialino I-EXPLORATION
eosinofílico I-EXPLORATION
de I-EXPLORATION
tipo I-EXPLORATION
amiloideo, I-EXPLORATION
además I-EXPLORATION
de I-EXPLORATION
focos I-EXPLORATION
de I-EXPLORATION
microhemorragia. I-EXPLORATION
Las I-EXPLORATION
tinciones I-EXPLORATION
de I-EXPLORATION
Cresil I-EXPLORATION
violeta I-EXPLORATION
y I-EXPLORATION
rojo I-EXPLORATION
Congo I-EXPLORATION
fueron I-EXPLORATION
positivas I-EXPLORATION
con I-EXPLORATION
dicroísmo I-EXPLORATION
verde I-EXPLORATION
manzana I-EXPLORATION
positivo I-EXPLORATION
bajo I-EXPLORATION
luz I-EXPLORATION
polarizada I-EXPLORATION
y I-EXPLORATION
resistencia I-EXPLORATION
a I-EXPLORATION
permanganato I-EXPLORATION
de I-EXPLORATION
potasio. I-EXPLORATION
<EOS> I-EXPLORATION
Se I-EXPLORATION
realizó I-EXPLORATION
ecocardiograma I-EXPLORATION
que I-EXPLORATION
mostró I-EXPLORATION
hipertrofia I-EXPLORATION
de I-EXPLORATION
ventrículo I-EXPLORATION
izquierdo, I-EXPLORATION
compatible I-EXPLORATION
con I-EXPLORATION
depósito I-EXPLORATION
amiloideo. I-EXPLORATION
Con I-EXPLORATION
estudio I-EXPLORATION
de I-EXPLORATION
tiroides I-EXPLORATION
y I-EXPLORATION
electroforesis I-EXPLORATION
de I-EXPLORATION
proteínas I-EXPLORATION
normales, I-EXPLORATION
se I-EXPLORATION
planteó I-EXPLORATION
el I-EXPLORATION
diagnóstico I-EXPLORATION
de I-EXPLORATION
una I-EXPLORATION
amiloidosis I-EXPLORATION
AA. I-EXPLORATION
<EOS> I-EXPLORATION
Paciente B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
64 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
hipertenso B-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
tratamiento I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
atenolol I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
lo I-PAST_MEDICAL_HISTORY
que I-PAST_MEDICAL_HISTORY
mantenía I-PAST_MEDICAL_HISTORY
cifras I-PAST_MEDICAL_HISTORY
tensionales I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
140/85 I-PAST_MEDICAL_HISTORY
mm I-PAST_MEDICAL_HISTORY
Hg. I-PAST_MEDICAL_HISTORY
El B-EXPLORATION
ecocardiograma I-EXPLORATION
mostraba I-EXPLORATION
una I-EXPLORATION
buena I-EXPLORATION
función I-EXPLORATION
sistólica I-EXPLORATION
e I-EXPLORATION
hipertrofia I-EXPLORATION
ventricular I-EXPLORATION
izquierda. I-EXPLORATION
Se B-TREATMENT
realizó I-TREATMENT
una I-TREATMENT
lobectomía I-TREATMENT
hepática I-TREATMENT
derecha, I-TREATMENT
sin I-TREATMENT
incidentes I-TREATMENT
de I-TREATMENT
importancia I-TREATMENT
durante I-TREATMENT
el I-TREATMENT
intraoperatorio. I-TREATMENT
Aproximadamente B-EVOLUTION
a I-EVOLUTION
las I-EVOLUTION
12 I-EVOLUTION
h I-EVOLUTION
del I-EVOLUTION
post I-EVOLUTION
operatorio I-EVOLUTION
presentó I-EVOLUTION
disminución I-EVOLUTION
de I-EVOLUTION
presión I-EVOLUTION
arterial I-EVOLUTION
hasta I-EVOLUTION
80/50 I-EVOLUTION
mm I-EVOLUTION
Hg I-EVOLUTION
y I-EVOLUTION
frecuencia I-EVOLUTION
cardiaca I-EVOLUTION
de I-EVOLUTION
135, I-EVOLUTION
sin I-EVOLUTION
respuesta I-EVOLUTION
a B-TREATMENT
la I-TREATMENT
administración I-TREATMENT
de I-TREATMENT
500 I-TREATMENT
ml I-TREATMENT
de I-TREATMENT
Voluven®. I-TREATMENT
Se I-TREATMENT
inició I-TREATMENT
infusión I-TREATMENT
de I-TREATMENT
dobutamina I-TREATMENT
que I-TREATMENT
se I-TREATMENT
aumentó I-TREATMENT
hasta I-TREATMENT
7 I-TREATMENT
ug/kg/min, I-TREATMENT
observándose I-TREATMENT
mayor I-TREATMENT
deterioro I-TREATMENT
de I-TREATMENT
las I-TREATMENT
condiciones I-TREATMENT
hemodinámicas, I-TREATMENT
por I-TREATMENT
lo I-TREATMENT
que I-TREATMENT
se I-TREATMENT
colocó I-TREATMENT
un I-TREATMENT
catéter I-TREATMENT
de I-TREATMENT
arteria I-TREATMENT
pulmonar I-TREATMENT
que I-TREATMENT
mostraba I-TREATMENT
una I-TREATMENT
presión I-TREATMENT
de I-TREATMENT
capilar I-TREATMENT
pulmonar I-TREATMENT
(PCP) I-TREATMENT
de I-TREATMENT
18 I-TREATMENT
mmHg, I-TREATMENT
y I-TREATMENT
un I-TREATMENT
índice I-TREATMENT
cardiaco I-TREATMENT
de I-TREATMENT
1, I-TREATMENT
2 I-TREATMENT
lt/ I-TREATMENT
m2. I-TREATMENT
Se B-EXPLORATION
realizó I-EXPLORATION
un I-EXPLORATION
ETE I-EXPLORATION
que I-EXPLORATION
mostraba I-EXPLORATION
un I-EXPLORATION
ventrículo I-EXPLORATION
izquierdo I-EXPLORATION
hipertrófico, I-EXPLORATION
con I-EXPLORATION
una I-EXPLORATION
cavidad I-EXPLORATION
pequeña, I-EXPLORATION
con I-EXPLORATION
buena I-EXPLORATION
función I-EXPLORATION
global I-EXPLORATION
y I-EXPLORATION
sin I-EXPLORATION
alteraciones I-EXPLORATION
de I-EXPLORATION
motilidad I-EXPLORATION
segmentaria, I-EXPLORATION
y I-EXPLORATION
con I-EXPLORATION
una I-EXPLORATION
válvula I-EXPLORATION
aortica I-EXPLORATION
de I-EXPLORATION
aspecto I-EXPLORATION
y I-EXPLORATION
movilidad I-EXPLORATION
normal. I-EXPLORATION
Durante I-EXPLORATION
el I-EXPLORATION
sístole, I-EXPLORATION
la I-EXPLORATION
valva I-EXPLORATION
anterior I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
válvula I-EXPLORATION
mitral I-EXPLORATION
se I-EXPLORATION
desplaza I-EXPLORATION
obstruyendo I-EXPLORATION
el I-EXPLORATION
70% I-EXPLORATION
del I-EXPLORATION
TSVI, I-EXPLORATION
y I-EXPLORATION
produciendo I-EXPLORATION
una I-EXPLORATION
insuficiencia I-EXPLORATION
mitral I-EXPLORATION
(IM) I-EXPLORATION
moderada. I-EXPLORATION
Se B-TREATMENT
hizo I-TREATMENT
el I-TREATMENT
diagnóstico I-TREATMENT
de I-TREATMENT
SAM, I-TREATMENT
se I-TREATMENT
administraron I-TREATMENT
1.000 I-TREATMENT
ml I-TREATMENT
de I-TREATMENT
Voluven®, I-TREATMENT
se I-TREATMENT
inició I-TREATMENT
infusión I-TREATMENT
de I-TREATMENT
noradrenalina I-TREATMENT
hasta I-TREATMENT
2 I-TREATMENT
ug/kg/min, I-TREATMENT
se I-TREATMENT
suspendió I-TREATMENT
la I-TREATMENT
dobutamina, I-TREATMENT
y I-TREATMENT
se I-TREATMENT
administran I-TREATMENT
3 I-TREATMENT
mg I-TREATMENT
de I-TREATMENT
metoprolol. I-TREATMENT
Dentro B-EVOLUTION
de I-EVOLUTION
los I-EVOLUTION
siguientes I-EVOLUTION
20 I-EVOLUTION
min I-EVOLUTION
se I-EVOLUTION
observa I-EVOLUTION
disminución I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
obstrucción I-EVOLUTION
del I-EVOLUTION
TSVI I-EVOLUTION
y I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
IM, I-EVOLUTION
la I-EVOLUTION
presión I-EVOLUTION
arterial I-EVOLUTION
se I-EVOLUTION
estabilizó I-EVOLUTION
en I-EVOLUTION
100/60 I-EVOLUTION
mm I-EVOLUTION
Hg I-EVOLUTION
y I-EVOLUTION
la I-EVOLUTION
frecuencia I-EVOLUTION
cardiaca I-EVOLUTION
en I-EVOLUTION
100. I-EVOLUTION
Doce I-EVOLUTION
horas I-EVOLUTION
después I-EVOLUTION
se I-EVOLUTION
presentó I-EVOLUTION
nuevo I-EVOLUTION
episodio I-EVOLUTION
de I-EVOLUTION
compromiso I-EVOLUTION
hemodinámico I-EVOLUTION
de I-EVOLUTION
características I-EVOLUTION
similares. I-EVOLUTION
Por B-EXPLORATION
la I-EXPLORATION
posibilidad I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
existencia I-EXPLORATION
de I-EXPLORATION
un I-EXPLORATION
hemoperitoneo I-EXPLORATION
que I-EXPLORATION
pudiera I-EXPLORATION
perpetuar I-EXPLORATION
una I-EXPLORATION
condición I-EXPLORATION
de I-EXPLORATION
hipovolemia I-EXPLORATION
que I-EXPLORATION
favoreciera I-EXPLORATION
el I-EXPLORATION
desarrollo I-EXPLORATION
de I-EXPLORATION
un I-EXPLORATION
SAM, I-EXPLORATION
se I-EXPLORATION
realizó I-EXPLORATION
una I-EXPLORATION
laparotomía I-EXPLORATION
exploradora, I-EXPLORATION
encontrándose I-EXPLORATION
300 I-EXPLORATION
ml I-EXPLORATION
de I-EXPLORATION
sangre I-EXPLORATION
antigua, I-EXPLORATION
sin I-EXPLORATION
identificarse I-EXPLORATION
un I-EXPLORATION
sitio I-EXPLORATION
de I-EXPLORATION
sangrado. I-EXPLORATION
Se B-TREATMENT
aportó I-TREATMENT
volumen, I-TREATMENT
la I-TREATMENT
norepinefrina I-TREATMENT
se I-TREATMENT
aumentó I-TREATMENT
de I-TREATMENT
0, I-TREATMENT
05 I-TREATMENT
a I-TREATMENT
1, I-TREATMENT
5 I-TREATMENT
ug/kg/min, I-TREATMENT
restableciéndose I-TREATMENT
PA I-TREATMENT
de I-TREATMENT
100/70 I-TREATMENT
mm I-TREATMENT
Hg, I-TREATMENT
PCP I-TREATMENT
de I-TREATMENT
22 I-TREATMENT
mm I-TREATMENT
Hg, I-TREATMENT
e I-TREATMENT
IC I-TREATMENT
3, I-TREATMENT
2 I-TREATMENT
lt/m2. I-TREATMENT
No B-EVOLUTION
se I-EVOLUTION
observaron I-EVOLUTION
otros I-EVOLUTION
problemas I-EVOLUTION
hemodinámicos I-EVOLUTION
en I-EVOLUTION
el I-EVOLUTION
post I-EVOLUTION
operatorio. I-EVOLUTION
El I-EVOLUTION
paciente I-EVOLUTION
fue I-EVOLUTION
dado I-EVOLUTION
de I-EVOLUTION
alta I-EVOLUTION
al I-EVOLUTION
día I-EVOLUTION
30 I-EVOLUTION
debido I-EVOLUTION
a I-EVOLUTION
colecciones I-EVOLUTION
intra-abdominales I-EVOLUTION
que B-TREATMENT
requirieron I-TREATMENT
drenaje I-TREATMENT
percutáneo. I-TREATMENT
<EOS> I-TREATMENT
Paciente B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
sexo I-PRESENT_ILLNESS
masculino, I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
74 I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
y B-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
hipertensión I-PAST_MEDICAL_HISTORY
arterial I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
tratamiento. I-PAST_MEDICAL_HISTORY
<EOS> I-PAST_MEDICAL_HISTORY
Consultó B-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
múltiples I-PRESENT_ILLNESS
lesiones I-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
piel I-PRESENT_ILLNESS
del I-PRESENT_ILLNESS
tronco I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
15 I-PRESENT_ILLNESS
días I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
evolución. I-PRESENT_ILLNESS
El B-EXPLORATION
examen I-EXPLORATION
clínico I-EXPLORATION
constató I-EXPLORATION
múltiples I-EXPLORATION
placas I-EXPLORATION
y I-EXPLORATION
nódulos I-EXPLORATION
eritemato-violáceos, I-EXPLORATION
no I-EXPLORATION
dolorosos I-EXPLORATION
ni I-EXPLORATION
pruriginosos, I-EXPLORATION
que I-EXPLORATION
fluctuaban I-EXPLORATION
entre I-EXPLORATION
0, I-EXPLORATION
3 I-EXPLORATION
y I-EXPLORATION
5 I-EXPLORATION
cm, I-EXPLORATION
ubicados I-EXPLORATION
principalmente I-EXPLORATION
en I-EXPLORATION
tronco. I-EXPLORATION
No I-EXPLORATION
se I-EXPLORATION
constataron I-EXPLORATION
linfoadenopatías I-EXPLORATION
ni I-EXPLORATION
visceromegalias. I-EXPLORATION
El I-EXPLORATION
hemograma I-EXPLORATION
mostró I-EXPLORATION
leucopenia I-EXPLORATION
(leucocitos: I-EXPLORATION
3.600/mm3 I-EXPLORATION
[basófilos: I-EXPLORATION
1, I-EXPLORATION
1%, I-EXPLORATION
eosinófilos: I-EXPLORATION
2, I-EXPLORATION
1%, I-EXPLORATION
neutrófilos: I-EXPLORATION
56, I-EXPLORATION
9%, I-EXPLORATION
linfocitos: I-EXPLORATION
33, I-EXPLORATION
2%, I-EXPLORATION
monocitos: I-EXPLORATION
6, I-EXPLORATION
7%], I-EXPLORATION
hematocrito: I-EXPLORATION
46%, I-EXPLORATION
hemoglobina: I-EXPLORATION
15, I-EXPLORATION
8 I-EXPLORATION
g/dL, I-EXPLORATION
plaquetas: I-EXPLORATION
445.000 I-EXPLORATION
mm3, I-EXPLORATION
VHS: I-EXPLORATION
5 I-EXPLORATION
mm/h); I-EXPLORATION
pruebas I-EXPLORATION
hepáticas I-EXPLORATION
y I-EXPLORATION
función I-EXPLORATION
renal I-EXPLORATION
normales. I-EXPLORATION
<EOS> I-EXPLORATION
El I-EXPLORATION
estudio I-EXPLORATION
anátomo-patológico I-EXPLORATION
de I-EXPLORATION
las I-EXPLORATION
lesiones I-EXPLORATION
demostró I-EXPLORATION
fragmento I-EXPLORATION
de I-EXPLORATION
piel I-EXPLORATION
con I-EXPLORATION
denso I-EXPLORATION
infiltrado I-EXPLORATION
nodular I-EXPLORATION
dermo-hipodérmico, I-EXPLORATION
compuesto I-EXPLORATION
por I-EXPLORATION
células I-EXPLORATION
de I-EXPLORATION
tamaño I-EXPLORATION
mediano I-EXPLORATION
y I-EXPLORATION
aspecto I-EXPLORATION
inmaduro, I-EXPLORATION
con I-EXPLORATION
núcleos I-EXPLORATION
irregulares, I-EXPLORATION
nucléolos I-EXPLORATION
inconspicuos, I-EXPLORATION
citoplasma I-EXPLORATION
escaso I-EXPLORATION
y I-EXPLORATION
sin I-EXPLORATION
gránulos I-EXPLORATION
azurófilos. I-EXPLORATION
No I-EXPLORATION
se I-EXPLORATION
observó I-EXPLORATION
epidermotropismo, I-EXPLORATION
necrosis I-EXPLORATION
ni I-EXPLORATION
angioinvasión. I-EXPLORATION
La I-EXPLORATION
inmunohistoquímica I-EXPLORATION
resultó I-EXPLORATION
positiva I-EXPLORATION
para I-EXPLORATION
CD56, I-EXPLORATION
CD4, I-EXPLORATION
CD I-EXPLORATION
123, I-EXPLORATION
CD45, I-EXPLORATION
CD43, I-EXPLORATION
y I-EXPLORATION
TdT; I-EXPLORATION
mientras I-EXPLORATION
que I-EXPLORATION
CD3, I-EXPLORATION
CD45RO, I-EXPLORATION
CD20, I-EXPLORATION
CD79a, I-EXPLORATION
CD5, I-EXPLORATION
CD117 I-EXPLORATION
y I-EXPLORATION
MPO I-EXPLORATION
resultaron I-EXPLORATION
negativos. I-EXPLORATION
Los I-EXPLORATION
hallazgos I-EXPLORATION
clínicos I-EXPLORATION
e I-EXPLORATION
histopatológicos I-EXPLORATION
fueron I-EXPLORATION
concluyentes I-EXPLORATION
con I-EXPLORATION
una I-EXPLORATION
NBCDP. I-EXPLORATION
<EOS> I-EXPLORATION
El I-EXPLORATION
estudio I-EXPLORATION
de I-EXPLORATION
etapificación I-EXPLORATION
con I-EXPLORATION
tomografía I-EXPLORATION
computada I-EXPLORATION
(TC) I-EXPLORATION
de I-EXPLORATION
cuello, I-EXPLORATION
tórax I-EXPLORATION
y I-EXPLORATION
abdomen I-EXPLORATION
mostró I-EXPLORATION
adenopatías I-EXPLORATION
peritraqueales I-EXPLORATION
y I-EXPLORATION
carinales I-EXPLORATION
de I-EXPLORATION
hasta I-EXPLORATION
1, I-EXPLORATION
2 I-EXPLORATION
cm. I-EXPLORATION
No I-EXPLORATION
se I-EXPLORATION
evidenció I-EXPLORATION
compromiso I-EXPLORATION
de I-EXPLORATION
médula I-EXPLORATION
ósea I-EXPLORATION
en I-EXPLORATION
la I-EXPLORATION
biopsia I-EXPLORATION
de I-EXPLORATION
cresta I-EXPLORATION
iliaca. I-EXPLORATION
<EOS> I-EXPLORATION
En B-TREATMENT
la I-TREATMENT
actualidad I-TREATMENT
luego I-TREATMENT
de I-TREATMENT
transcurridos I-TREATMENT
5 I-TREATMENT
meses, I-TREATMENT
el I-TREATMENT
paciente I-TREATMENT
se I-TREATMENT
encuentra I-TREATMENT
en I-TREATMENT
4° I-TREATMENT
ciclo I-TREATMENT
de I-TREATMENT
ciclofosfamida-doxorubicina-vincristina-prednisona I-TREATMENT
(CHOP) I-TREATMENT
con I-TREATMENT
regresión I-TREATMENT
parcial I-TREATMENT
de I-TREATMENT
las I-TREATMENT
lesiones I-TREATMENT
cutáneas. I-TREATMENT
<EOS> I-TREATMENT
Mujer B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
46 I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
hipertensa B-PAST_MEDICAL_HISTORY
controlada, I-PAST_MEDICAL_HISTORY
que B-PRESENT_ILLNESS
presentó I-PRESENT_ILLNESS
cefalea I-PRESENT_ILLNESS
holocránea I-PRESENT_ILLNESS
acompañada I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
náuseas, I-PRESENT_ILLNESS
vómitos I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
fiebre, I-PRESENT_ILLNESS
cuya I-PRESENT_ILLNESS
intensidad I-PRESENT_ILLNESS
llegó I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
10/10 I-PRESENT_ILLNESS
al I-PRESENT_ILLNESS
tercer I-PRESENT_ILLNESS
día I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
evolución. I-PRESENT_ILLNESS
La B-DERIVED_FROM/TO
aparición I-DERIVED_FROM/TO
de I-DERIVED_FROM/TO
compromiso I-DERIVED_FROM/TO
de I-DERIVED_FROM/TO
conciencia I-DERIVED_FROM/TO
obligó I-DERIVED_FROM/TO
a I-DERIVED_FROM/TO
consultar I-DERIVED_FROM/TO
en I-DERIVED_FROM/TO
Servicio I-DERIVED_FROM/TO
de I-DERIVED_FROM/TO
Urgencias. I-DERIVED_FROM/TO
Ingresó B-EXPLORATION
confusa, I-EXPLORATION
lenguaje I-EXPLORATION
poco I-EXPLORATION
fluente, I-EXPLORATION
rigidez I-EXPLORATION
de I-EXPLORATION
nuca, I-EXPLORATION
pupilas I-EXPLORATION
isocoricas I-EXPLORATION
reactivas I-EXPLORATION
y I-EXPLORATION
fondo I-EXPLORATION
de I-EXPLORATION
ojo I-EXPLORATION
con I-EXPLORATION
edema I-EXPLORATION
de I-EXPLORATION
papila I-EXPLORATION
bilateral. I-EXPLORATION
Movilizaba I-EXPLORATION
las I-EXPLORATION
4 I-EXPLORATION
extremidades, I-EXPLORATION
tenía I-EXPLORATION
reflejos I-EXPLORATION
osteotendíneos I-EXPLORATION
vivos I-EXPLORATION
y I-EXPLORATION
Babinski I-EXPLORATION
bilateral. I-EXPLORATION
Presión I-EXPLORATION
arterial I-EXPLORATION
108/64 I-EXPLORATION
mmHg, I-EXPLORATION
frecuencia I-EXPLORATION
cardiaca I-EXPLORATION
56 I-EXPLORATION
lmp, I-EXPLORATION
subfebril I-EXPLORATION
(t° I-EXPLORATION
37, I-EXPLORATION
2°C). I-EXPLORATION
Sin I-EXPLORATION
lesiones I-EXPLORATION
en I-EXPLORATION
mucosas I-EXPLORATION
o I-EXPLORATION
piel I-EXPLORATION
y I-EXPLORATION
ausencia I-EXPLORATION
de I-EXPLORATION
focos I-EXPLORATION
dentarios, I-EXPLORATION
sinusales, I-EXPLORATION
oticos I-EXPLORATION
o I-EXPLORATION
respiratorio. I-EXPLORATION
La I-EXPLORATION
tomografía I-EXPLORATION
cerebral I-EXPLORATION
(TC) I-EXPLORATION
mostró I-EXPLORATION
hipodensidad I-EXPLORATION
frontal I-EXPLORATION
izquierda I-EXPLORATION
redondeada, I-EXPLORATION
con I-EXPLORATION
efecto I-EXPLORATION
de I-EXPLORATION
masa I-EXPLORATION
local I-EXPLORATION
sobre I-EXPLORATION
estructuras I-EXPLORATION
adyacentes. I-EXPLORATION
Líquido I-EXPLORATION
cefalorraquídeo I-EXPLORATION
citrino, I-EXPLORATION
760 I-EXPLORATION
leucocitos I-EXPLORATION
mm3 I-EXPLORATION
(97% I-EXPLORATION
PMN), I-EXPLORATION
proteínas I-EXPLORATION
101, I-EXPLORATION
8 I-EXPLORATION
mg/dL, I-EXPLORATION
glucosa I-EXPLORATION
69 I-EXPLORATION
mg/dL I-EXPLORATION
(hemoglucotest I-EXPLORATION
de I-EXPLORATION
116 I-EXPLORATION
mg/dL), I-EXPLORATION
la I-EXPLORATION
tinción I-EXPLORATION
Gram I-EXPLORATION
fue I-EXPLORATION
negativa. I-EXPLORATION
Hematocrito I-EXPLORATION
29, I-EXPLORATION
9%, I-EXPLORATION
hemoglobina I-EXPLORATION
9, I-EXPLORATION
8 I-EXPLORATION
g/L, I-EXPLORATION
leucocitos I-EXPLORATION
25.800 I-EXPLORATION
k/uL, I-EXPLORATION
(91, I-EXPLORATION
9% I-EXPLORATION
segmentados), I-EXPLORATION
plaquetas I-EXPLORATION
286.000 I-EXPLORATION
uL, I-EXPLORATION
PCR I-EXPLORATION
428 I-EXPLORATION
mg/L, I-EXPLORATION
protrombina I-EXPLORATION
66%, I-EXPLORATION
y I-EXPLORATION
electrolitos I-EXPLORATION
plasmáticos I-EXPLORATION
normales. I-EXPLORATION
VHB, I-EXPLORATION
VHC, I-EXPLORATION
HTLV-1, I-EXPLORATION
Chagas I-EXPLORATION
y I-EXPLORATION
VIH I-EXPLORATION
negativos. I-EXPLORATION
<EOS> I-EXPLORATION
Se B-TREATMENT
inició I-TREATMENT
tratamiento I-TREATMENT
antibiótico I-TREATMENT
endovenoso I-TREATMENT
con I-TREATMENT
ceftriaxona I-TREATMENT
2 I-TREATMENT
g I-TREATMENT
c/12 I-TREATMENT
h, I-TREATMENT
clindamicina I-TREATMENT
600 I-TREATMENT
mg I-TREATMENT
c/8 I-TREATMENT
h, I-TREATMENT
vancomicina I-TREATMENT
1 I-TREATMENT
g I-TREATMENT
c/12 I-TREATMENT
h I-TREATMENT
y I-TREATMENT
betametasona I-TREATMENT
4 I-TREATMENT
mg I-TREATMENT
c/8 I-TREATMENT
h. I-TREATMENT
La B-EVOLUTION
paciente I-EVOLUTION
persistió I-EVOLUTION
comprometida I-EVOLUTION
de I-EVOLUTION
conciencia I-EVOLUTION
(Glasgow I-EVOLUTION
12), I-EVOLUTION
con I-EVOLUTION
rigidez I-EVOLUTION
de I-EVOLUTION
nuca I-EVOLUTION
y I-EVOLUTION
opistótono. I-EVOLUTION
Pupilas B-EXPLORATION
isocóricas I-EXPLORATION
reactivas, I-EXPLORATION
reflejos I-EXPLORATION
oculocefálicos I-EXPLORATION
y I-EXPLORATION
corneales I-EXPLORATION
conservados, I-EXPLORATION
mantenía I-EXPLORATION
el I-EXPLORATION
edema I-EXPLORATION
de I-EXPLORATION
papila, I-EXPLORATION
la I-EXPLORATION
hiperreflexia I-EXPLORATION
generalizada I-EXPLORATION
y I-EXPLORATION
Babinski I-EXPLORATION
bilateral. I-EXPLORATION
La I-EXPLORATION
resonancia I-EXPLORATION
magnética I-EXPLORATION
(RM), I-EXPLORATION
realizada I-EXPLORATION
al I-EXPLORATION
segundo I-EXPLORATION
día I-EXPLORATION
de I-EXPLORATION
hospitalización, I-EXPLORATION
definió I-EXPLORATION
un I-EXPLORATION
proceso I-EXPLORATION
bifrontal I-EXPLORATION
paramediano I-EXPLORATION
anterior, I-EXPLORATION
de I-EXPLORATION
predominio I-EXPLORATION
izquierdo, I-EXPLORATION
con I-EXPLORATION
difusión I-EXPLORATION
restringida I-EXPLORATION
y I-EXPLORATION
edema I-EXPLORATION
vasogénico I-EXPLORATION
perilesional. I-EXPLORATION
Se I-EXPLORATION
observó I-EXPLORATION
captación I-EXPLORATION
de I-EXPLORATION
contraste I-EXPLORATION
leptomeníngeo I-EXPLORATION
y I-EXPLORATION
se I-EXPLORATION
identificó I-EXPLORATION
una I-EXPLORATION
colección I-EXPLORATION
subdural I-EXPLORATION
fronto-temporal I-EXPLORATION
izquierda I-EXPLORATION
de I-EXPLORATION
6 I-EXPLORATION
mm. I-EXPLORATION
La I-EXPLORATION
angioresonancia I-EXPLORATION
no I-EXPLORATION
agregó I-EXPLORATION
elementos I-EXPLORATION
significativos. I-EXPLORATION
El I-EXPLORATION
estudio I-EXPLORATION
se I-EXPLORATION
interpretó I-EXPLORATION
como I-EXPLORATION
cerebritis I-EXPLORATION
bifrontal I-EXPLORATION
abscedada, I-EXPLORATION
empiema I-EXPLORATION
fronto-parietal I-EXPLORATION
izquierdo I-EXPLORATION
y I-EXPLORATION
leptomeningitis. I-EXPLORATION
La I-EXPLORATION
evaluación I-EXPLORATION
neuroquirúrgica I-EXPLORATION
realizada I-EXPLORATION
en I-EXPLORATION
dicho I-EXPLORATION
momento I-EXPLORATION
sugirió I-EXPLORATION
manejo I-EXPLORATION
medico I-EXPLORATION
del I-EXPLORATION
cuadro. I-EXPLORATION
El I-EXPLORATION
ecocardiograma I-EXPLORATION
y I-EXPLORATION
ecografía I-EXPLORATION
abdomino-pélvica I-EXPLORATION
fueron I-EXPLORATION
normales. I-EXPLORATION
Los I-EXPLORATION
hemocultivos, I-EXPLORATION
urocultivos, I-EXPLORATION
cultivo I-EXPLORATION
de I-EXPLORATION
secreción I-EXPLORATION
bronquial I-EXPLORATION
y I-EXPLORATION
cultivo I-EXPLORATION
de I-EXPLORATION
LCR I-EXPLORATION
fueron I-EXPLORATION
negativos. I-EXPLORATION
<EOS> I-EXPLORATION
Al B-EVOLUTION
cuarto I-EVOLUTION
día I-EVOLUTION
de I-EVOLUTION
hospitalización I-EVOLUTION
se I-EVOLUTION
acentuó I-EVOLUTION
el I-EVOLUTION
compromiso I-EVOLUTION
de I-EVOLUTION
conciencia I-EVOLUTION
(Glasgow I-EVOLUTION
4). I-EVOLUTION
TC B-EXPLORATION
cerebral I-EXPLORATION
mostró I-EXPLORATION
significativo I-EXPLORATION
aumento I-EXPLORATION
del I-EXPLORATION
edema I-EXPLORATION
cerebral I-EXPLORATION
sin I-EXPLORATION
cambios I-EXPLORATION
en I-EXPLORATION
las I-EXPLORATION
lesiones I-EXPLORATION
descritas. I-EXPLORATION
La B-TREATMENT
reevaluación I-TREATMENT
neuroquirúrgica I-TREATMENT
decidió I-TREATMENT
evacuar I-TREATMENT
la I-TREATMENT
colección I-TREATMENT
subdural I-TREATMENT
izquierda, I-TREATMENT
dando I-TREATMENT
salida I-TREATMENT
a I-TREATMENT
material I-TREATMENT
purulento. I-TREATMENT
El B-EVOLUTION
procedimiento I-EVOLUTION
se I-EVOLUTION
desarrolló I-EVOLUTION
sin I-EVOLUTION
incidencias. I-EVOLUTION
En I-EVOLUTION
la I-EVOLUTION
etapa I-EVOLUTION
inmediata I-EVOLUTION
post-quirúrgica I-EVOLUTION
necesitó I-EVOLUTION
apoyo I-EVOLUTION
con I-EVOLUTION
drogas I-EVOLUTION
vasoactivas, I-EVOLUTION
no I-EVOLUTION
recuperó I-EVOLUTION
la I-EVOLUTION
conciencia, I-EVOLUTION
quedando I-EVOLUTION
en I-EVOLUTION
coma, I-EVOLUTION
con I-EVOLUTION
pupilas I-EVOLUTION
midriáticas I-EVOLUTION
arreflécticas, I-EVOLUTION
sin I-EVOLUTION
respuestas I-EVOLUTION
de I-EVOLUTION
tronco. I-EVOLUTION
La B-EXPLORATION
TC I-EXPLORATION
mostró I-EXPLORATION
colapso I-EXPLORATION
ventricular, I-EXPLORATION
ausencia I-EXPLORATION
de I-EXPLORATION
surcos I-EXPLORATION
y I-EXPLORATION
borramiento I-EXPLORATION
de I-EXPLORATION
las I-EXPLORATION
cisternas I-EXPLORATION
basales. I-EXPLORATION
Conectada I-EXPLORATION
a I-EXPLORATION
ventilador, I-EXPLORATION
el I-EXPLORATION
electroencefalograma I-EXPLORATION
mostró I-EXPLORATION
trazado I-EXPLORATION
plano. I-EXPLORATION
Se I-EXPLORATION
definió I-EXPLORATION
muerte I-EXPLORATION
cerebral. I-EXPLORATION
<EOS> I-EXPLORATION
El I-EXPLORATION
cultivo I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
colección I-EXPLORATION
subdural I-EXPLORATION
fue I-EXPLORATION
positivo I-EXPLORATION
para I-EXPLORATION
Streptococcus I-EXPLORATION
del I-EXPLORATION
grupo I-EXPLORATION
anginosus I-EXPLORATION
(SAG). I-EXPLORATION
<EOS> I-EXPLORATION
Mujer B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
22 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
sana. B-PAST_MEDICAL_HISTORY
Consultó B-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
aumento I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
volumen I-PRESENT_ILLNESS
cérvico-parotídeo I-PRESENT_ILLNESS
derecho I-PRESENT_ILLNESS
sensible, I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
3 I-PRESENT_ILLNESS
meses I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
evolución I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
refractario I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
antiinflamatorios. I-PRESENT_ILLNESS
Fue B-TREATMENT
interpretado I-TREATMENT
como I-TREATMENT
síndrome I-TREATMENT
de I-TREATMENT
mononucleosis I-TREATMENT
infecciosa I-TREATMENT
y I-TREATMENT
por I-TREATMENT
su I-TREATMENT
persistencia I-TREATMENT
se I-TREATMENT
le I-TREATMENT
indicó I-TREATMENT
empíricamente I-TREATMENT
amoxicilina-ácido I-TREATMENT
clavulánico I-TREATMENT
sin I-TREATMENT
mejoría I-TREATMENT
clínica. I-TREATMENT
Finalmente, I-TREATMENT
le I-TREATMENT
indicaron I-TREATMENT
glucocorticoides I-TREATMENT
con B-EVOLUTION
resolución I-EVOLUTION
completa I-EVOLUTION
del I-EVOLUTION
cuadro. I-EVOLUTION
<EOS> I-EVOLUTION
Dos I-EVOLUTION
meses I-EVOLUTION
después I-EVOLUTION
consultó I-EVOLUTION
nuevamente I-EVOLUTION
por I-EVOLUTION
fiebre I-EVOLUTION
asociado I-EVOLUTION
a I-EVOLUTION
múltiples I-EVOLUTION
adenopatías I-EVOLUTION
submandibulares I-EVOLUTION
sensibles I-EVOLUTION
e I-EVOLUTION
induradas, I-EVOLUTION
con I-EVOLUTION
aumento I-EVOLUTION
de I-EVOLUTION
volumen I-EVOLUTION
parotídeo I-EVOLUTION
ipsilateral. I-EVOLUTION
Presentaba B-EXPLORATION
PCR I-EXPLORATION
de I-EXPLORATION
41 I-EXPLORATION
mg/L I-EXPLORATION
y I-EXPLORATION
hemograma I-EXPLORATION
con I-EXPLORATION
neutro I-EXPLORATION
filia I-EXPLORATION
relativa. I-EXPLORATION
Las I-EXPLORATION
pruebas I-EXPLORATION
hepáticas I-EXPLORATION
y I-EXPLORATION
LDH I-EXPLORATION
estaban I-EXPLORATION
en I-EXPLORATION
rangos I-EXPLORATION
normales. I-EXPLORATION
<EOS> I-EXPLORATION
Se I-EXPLORATION
solicitó I-EXPLORATION
TAC I-EXPLORATION
cervical I-EXPLORATION
que I-EXPLORATION
mostró I-EXPLORATION
aumento I-EXPLORATION
de I-EXPLORATION
volumen I-EXPLORATION
parotídeo I-EXPLORATION
y I-EXPLORATION
de I-EXPLORATION
grupos I-EXPLORATION
ganglionares I-EXPLORATION
cervicales I-EXPLORATION
bilaterales, I-EXPLORATION
ambos I-EXPLORATION
de I-EXPLORATION
predominio I-EXPLORATION
derecho. I-EXPLORATION
Además I-EXPLORATION
se I-EXPLORATION
informó I-EXPLORATION
un I-EXPLORATION
probable I-EXPLORATION
flegmón I-EXPLORATION
cervical. I-EXPLORATION
Se I-EXPLORATION
reiniciaron I-EXPLORATION
los I-EXPLORATION
antibióticos I-EXPLORATION
(ceftriaxona I-EXPLORATION
más I-EXPLORATION
clindamicina) I-EXPLORATION
sin I-EXPLORATION
respuesta. I-EXPLORATION
Dada B-TREATMENT
la I-TREATMENT
persistencia I-TREATMENT
del I-TREATMENT
cuadro, I-TREATMENT
se I-TREATMENT
escaló I-TREATMENT
a I-TREATMENT
esquema I-TREATMENT
antibiótico I-TREATMENT
de I-TREATMENT
segunda I-TREATMENT
línea I-TREATMENT
(vancomicina I-TREATMENT
más I-TREATMENT
levofloxacino) I-TREATMENT
y B-EXPLORATION
se I-EXPLORATION
amplió I-EXPLORATION
estudio I-EXPLORATION
con I-EXPLORATION
TAC I-EXPLORATION
de I-EXPLORATION
tórax-abdomen-pelvis I-EXPLORATION
que I-EXPLORATION
informó I-EXPLORATION
linfonodos I-EXPLORATION
precarinales I-EXPLORATION
de I-EXPLORATION
6 I-EXPLORATION
mm, I-EXPLORATION
sin I-EXPLORATION
otros I-EXPLORATION
hallazgos. I-EXPLORATION
El I-EXPLORATION
estudio I-EXPLORATION
inmunológico I-EXPLORATION
con I-EXPLORATION
ANA I-EXPLORATION
e I-EXPLORATION
infeccioso I-EXPLORATION
para I-EXPLORATION
VEB, I-EXPLORATION
CMV, I-EXPLORATION
VIH, I-EXPLORATION
sífilis, I-EXPLORATION
Toxoplasma I-EXPLORATION
gondii I-EXPLORATION
y I-EXPLORATION
Bartonella I-EXPLORATION
hensenlae I-EXPLORATION
fueron I-EXPLORATION
negativos. I-EXPLORATION
Finalmente, I-EXPLORATION
se I-EXPLORATION
realizó I-EXPLORATION
biopsia I-EXPLORATION
de I-EXPLORATION
ganglio I-EXPLORATION
cervical I-EXPLORATION
que I-EXPLORATION
reveló I-EXPLORATION
hallazgos I-EXPLORATION
compatibles I-EXPLORATION
con I-EXPLORATION
linfadenitis I-EXPLORATION
necrotizante I-EXPLORATION
histiocitaria. I-EXPLORATION
Se B-TREATMENT
suspendieron I-TREATMENT
los I-TREATMENT
antibióticos I-TREATMENT
y I-TREATMENT
se I-TREATMENT
indicó I-TREATMENT
tratamiento I-TREATMENT
con I-TREATMENT
prednisona I-TREATMENT
30 I-TREATMENT
mg I-TREATMENT
al I-TREATMENT
día I-TREATMENT
con I-TREATMENT
disminución I-TREATMENT
progresiva I-TREATMENT
de I-TREATMENT
las I-TREATMENT
dosis I-TREATMENT
a I-TREATMENT
partir I-TREATMENT
de I-TREATMENT
la I-TREATMENT
segunda I-TREATMENT
semana, I-TREATMENT
completando I-TREATMENT
1 I-TREATMENT
mes I-TREATMENT
de I-TREATMENT
tratamiento. I-TREATMENT
La B-EVOLUTION
fiebre I-EVOLUTION
cedió I-EVOLUTION
a I-EVOLUTION
las I-EVOLUTION
24 I-EVOLUTION
h I-EVOLUTION
tras I-EVOLUTION
el I-EVOLUTION
inicio I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
terapia I-EVOLUTION
y I-EVOLUTION
no I-EVOLUTION
ha I-EVOLUTION
presentado I-EVOLUTION
recurrencias I-EVOLUTION
a I-EVOLUTION
los I-EVOLUTION
6 I-EVOLUTION
meses I-EVOLUTION
de I-EVOLUTION
seguimiento. I-EVOLUTION
<EOS> I-EVOLUTION
Paciente B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
60 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
sin B-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
mórbidos, I-PAST_MEDICAL_HISTORY
a B-PRESENT_ILLNESS
quien I-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
una I-PRESENT_ILLNESS
tomografía I-PRESENT_ILLNESS
computada I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
abdomen I-PRESENT_ILLNESS
efectuada I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
dolor I-PRESENT_ILLNESS
abdominal, I-PRESENT_ILLNESS
se I-PRESENT_ILLNESS
le I-PRESENT_ILLNESS
encontró I-PRESENT_ILLNESS
un I-PRESENT_ILLNESS
carcinoma I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
2 I-PRESENT_ILLNESS
cm I-PRESENT_ILLNESS
localizado I-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
la I-PRESENT_ILLNESS
cabeza I-PRESENT_ILLNESS
del I-PRESENT_ILLNESS
páncreas. I-PRESENT_ILLNESS
Fue B-TREATMENT
sometido I-TREATMENT
a I-TREATMENT
una I-TREATMENT
operación I-TREATMENT
de I-TREATMENT
Whipple. I-TREATMENT
Había I-TREATMENT
2 I-TREATMENT
adenopatías I-TREATMENT
regionales I-TREATMENT
con I-TREATMENT
metástasis I-TREATMENT
de I-TREATMENT
carcinoma I-TREATMENT
y I-TREATMENT
no I-TREATMENT
existía I-TREATMENT
diseminación I-TREATMENT
a I-TREATMENT
distancia. I-TREATMENT
Tres I-TREATMENT
meses I-TREATMENT
después I-TREATMENT
de I-TREATMENT
la I-TREATMENT
operación I-TREATMENT
se I-TREATMENT
inició I-TREATMENT
quimioterapia I-TREATMENT
con I-TREATMENT
GEM. I-TREATMENT
Después B-EVOLUTION
de I-EVOLUTION
recibir I-EVOLUTION
11 I-EVOLUTION
dosis I-EVOLUTION
de I-EVOLUTION
GEM, I-EVOLUTION
transcurridos I-EVOLUTION
4 I-EVOLUTION
meses I-EVOLUTION
de I-EVOLUTION
su I-EVOLUTION
inicio I-EVOLUTION
y I-EVOLUTION
habiendo I-EVOLUTION
recibido I-EVOLUTION
una I-EVOLUTION
dosis I-EVOLUTION
total I-EVOLUTION
acumulada I-EVOLUTION
de I-EVOLUTION
16.400 I-EVOLUTION
mg I-EVOLUTION
(9.318 I-EVOLUTION
mg/m2), I-EVOLUTION
presentó I-EVOLUTION
edema I-EVOLUTION
palpebral I-EVOLUTION
y I-EVOLUTION
de I-EVOLUTION
tobillos I-EVOLUTION
e I-EVOLUTION
hipertensión I-EVOLUTION
arterial I-EVOLUTION
de I-EVOLUTION
hasta I-EVOLUTION
160/110 I-EVOLUTION
mmHg. I-EVOLUTION
Los B-EXPLORATION
exámenes I-EXPLORATION
de I-EXPLORATION
laboratorio I-EXPLORATION
mostraron I-EXPLORATION
hematuria I-EXPLORATION
microscópica I-EXPLORATION
(26-50 I-EXPLORATION
hematíes I-EXPLORATION
por I-EXPLORATION
campo), I-EXPLORATION
proteinuria I-EXPLORATION
(1.740 I-EXPLORATION
mg/24 I-EXPLORATION
h), I-EXPLORATION
cilindruria I-EXPLORATION
granulosa, I-EXPLORATION
ascenso I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
creatinina I-EXPLORATION
sérica I-EXPLORATION
hasta I-EXPLORATION
un I-EXPLORATION
máximo I-EXPLORATION
de I-EXPLORATION
2, I-EXPLORATION
0 I-EXPLORATION
mg/dL I-EXPLORATION
con I-EXPLORATION
caída I-EXPLORATION
del I-EXPLORATION
clearance I-EXPLORATION
de I-EXPLORATION
creatinina I-EXPLORATION
a I-EXPLORATION
52 I-EXPLORATION
ml/min/1, I-EXPLORATION
73 I-EXPLORATION
m2 I-EXPLORATION
(medido) I-EXPLORATION
a I-EXPLORATION
los I-EXPLORATION
21 I-EXPLORATION
días I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
última I-EXPLORATION
dosis. I-EXPLORATION
Previo I-EXPLORATION
a I-EXPLORATION
ello I-EXPLORATION
se I-EXPLORATION
había I-EXPLORATION
observado I-EXPLORATION
anemia I-EXPLORATION
progresiva I-EXPLORATION
(hemoglobina I-EXPLORATION
6.0 I-EXPLORATION
g/dL) I-EXPLORATION
y I-EXPLORATION
trombocitopenia I-EXPLORATION
(20.000 I-EXPLORATION
mm3), I-EXPLORATION
que I-EXPLORATION
se I-EXPLORATION
atribuyeron I-EXPLORATION
a I-EXPLORATION
mielodepresión I-EXPLORATION
por I-EXPLORATION
GEM. I-EXPLORATION
La I-EXPLORATION
bilirrubinemia I-EXPLORATION
total I-EXPLORATION
ascendió I-EXPLORATION
a I-EXPLORATION
1, I-EXPLORATION
79 I-EXPLORATION
mg/dL, I-EXPLORATION
la I-EXPLORATION
directa I-EXPLORATION
a I-EXPLORATION
0, I-EXPLORATION
93 I-EXPLORATION
mg/dL I-EXPLORATION
y I-EXPLORATION
la I-EXPLORATION
LDH I-EXPLORATION
a I-EXPLORATION
701 I-EXPLORATION
U/L I-EXPLORATION
(VN: I-EXPLORATION
125-243), I-EXPLORATION
lo I-EXPLORATION
que I-EXPLORATION
se I-EXPLORATION
interpretó I-EXPLORATION
como I-EXPLORATION
secundario I-EXPLORATION
a I-EXPLORATION
toxicidad I-EXPLORATION
hepática I-EXPLORATION
por I-EXPLORATION
GEM. I-EXPLORATION
Se B-TREATMENT
suspendió I-TREATMENT
la I-TREATMENT
administración I-TREATMENT
de I-TREATMENT
nuevas I-TREATMENT
dosis I-TREATMENT
de I-TREATMENT
GEM, I-TREATMENT
se I-TREATMENT
prescribió I-TREATMENT
furosemi-de I-TREATMENT
para I-TREATMENT
controlar I-TREATMENT
el I-TREATMENT
edema I-TREATMENT
y I-TREATMENT
olmesartán I-TREATMENT
para I-TREATMENT
el I-TREATMENT
manejo I-TREATMENT
de I-TREATMENT
la I-TREATMENT
hipertensión I-TREATMENT
arterial. I-TREATMENT
<EOS> I-TREATMENT
Estando B-EXPLORATION
el I-EXPLORATION
recuento I-EXPLORATION
de I-EXPLORATION
plaquetas I-EXPLORATION
sobre I-EXPLORATION
100.000 I-EXPLORATION
mm3 I-EXPLORATION
se I-EXPLORATION
efectuó I-EXPLORATION
una I-EXPLORATION
biopsia I-EXPLORATION
renal I-EXPLORATION
percutánea I-EXPLORATION
que I-EXPLORATION
mostró I-EXPLORATION
hallazgos I-EXPLORATION
característicos I-EXPLORATION
de I-EXPLORATION
una I-EXPLORATION
microangiopatía I-EXPLORATION
trombótica I-EXPLORATION
crónica I-EXPLORATION
activa. I-EXPLORATION
El I-EXPLORATION
examen I-EXPLORATION
de I-EXPLORATION
microscopía I-EXPLORATION
óptica I-EXPLORATION
reveló I-EXPLORATION
la I-EXPLORATION
presencia I-EXPLORATION
de I-EXPLORATION
glomérulos I-EXPLORATION
con I-EXPLORATION
numerosos I-EXPLORATION
dobles I-EXPLORATION
contornos I-EXPLORATION
en I-EXPLORATION
sus I-EXPLORATION
asas I-EXPLORATION
capilares I-EXPLORATION
y I-EXPLORATION
arteriolas, I-EXPLORATION
con I-EXPLORATION
intensa I-EXPLORATION
disminución I-EXPLORATION
de I-EXPLORATION
su I-EXPLORATION
lumen, I-EXPLORATION
hiperplasia I-EXPLORATION
concéntrica I-EXPLORATION
de I-EXPLORATION
miocélulas I-EXPLORATION
y I-EXPLORATION
depósito I-EXPLORATION
hialino I-EXPLORATION
mural I-EXPLORATION
sugerente I-EXPLORATION
de I-EXPLORATION
material I-EXPLORATION
microtrombótico I-EXPLORATION
incorporado I-EXPLORATION
en I-EXPLORATION
su I-EXPLORATION
endotelio I-EXPLORATION
y I-EXPLORATION
pared. I-EXPLORATION
El I-EXPLORATION
examen I-EXPLORATION
de I-EXPLORATION
inmunofluorescencia I-EXPLORATION
no I-EXPLORATION
mostró I-EXPLORATION
presencia I-EXPLORATION
de I-EXPLORATION
complejos I-EXPLORATION
inmunes I-EXPLORATION
en I-EXPLORATION
los I-EXPLORATION
glomérulos. I-EXPLORATION
La I-EXPLORATION
microscopía I-EXPLORATION
electrónica I-EXPLORATION
confirmó I-EXPLORATION
las I-EXPLORATION
alteraciones I-EXPLORATION
glomerulares I-EXPLORATION
encontradas I-EXPLORATION
en I-EXPLORATION
la I-EXPLORATION
microscopía I-EXPLORATION
óptica; I-EXPLORATION
en I-EXPLORATION
especial, I-EXPLORATION
se I-EXPLORATION
demostró I-EXPLORATION
la I-EXPLORATION
presencia I-EXPLORATION
de I-EXPLORATION
múltiples I-EXPLORATION
dobles I-EXPLORATION
contornos I-EXPLORATION
con I-EXPLORATION
interposición I-EXPLORATION
celular I-EXPLORATION
y I-EXPLORATION
expansión I-EXPLORATION
acentuada I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
lámina I-EXPLORATION
rara I-EXPLORATION
interna I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
membrana I-EXPLORATION
basal I-EXPLORATION
por I-EXPLORATION
material I-EXPLORATION
electrón-lúcido I-EXPLORATION
y I-EXPLORATION
detritus I-EXPLORATION
subendotelial. I-EXPLORATION
Todas I-EXPLORATION
estas I-EXPLORATION
alteraciones I-EXPLORATION
se I-EXPLORATION
encontraron I-EXPLORATION
en I-EXPLORATION
ausencia I-EXPLORATION
de I-EXPLORATION
depósitos I-EXPLORATION
densos I-EXPLORATION
de I-EXPLORATION
tipo I-EXPLORATION
complejo I-EXPLORATION
inmune. I-EXPLORATION
La I-EXPLORATION
lesión I-EXPLORATION
pedicelar I-EXPLORATION
fue I-EXPLORATION
moderada. I-EXPLORATION
<EOS> I-EXPLORATION
La B-EVOLUTION
suspensión I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
GEM I-EVOLUTION
se I-EVOLUTION
acompañó I-EVOLUTION
de I-EVOLUTION
una I-EVOLUTION
mejoría I-EVOLUTION
en I-EVOLUTION
la I-EVOLUTION
función I-EVOLUTION
renal I-EVOLUTION
y I-EVOLUTION
de I-EVOLUTION
los I-EVOLUTION
parámetros I-EVOLUTION
hematológicos. I-EVOLUTION
En B-EXPLORATION
el I-EXPLORATION
último I-EXPLORATION
control, I-EXPLORATION
10 I-EXPLORATION
sem I-EXPLORATION
después I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
última I-EXPLORATION
dosis I-EXPLORATION
de I-EXPLORATION
GEM, I-EXPLORATION
la I-EXPLORATION
hemoglobina I-EXPLORATION
fue I-EXPLORATION
12, I-EXPLORATION
3 I-EXPLORATION
g/dL, I-EXPLORATION
plaquetas I-EXPLORATION
147.000 I-EXPLORATION
mm3, I-EXPLORATION
leucocitos I-EXPLORATION
4.700 I-EXPLORATION
mm3, I-EXPLORATION
creatinina I-EXPLORATION
sérica I-EXPLORATION
1, I-EXPLORATION
18 I-EXPLORATION
mg/dl, I-EXPLORATION
clearance I-EXPLORATION
de I-EXPLORATION
creatinina I-EXPLORATION
85 I-EXPLORATION
ml/min/1, I-EXPLORATION
73 I-EXPLORATION
m2 I-EXPLORATION
y I-EXPLORATION
LDH I-EXPLORATION
normal. I-EXPLORATION
El B-TREATMENT
paciente I-TREATMENT
continuó I-TREATMENT
recibiendo I-TREATMENT
olmesartán I-TREATMENT
como I-TREATMENT
terapia I-TREATMENT
antihipertensiva I-TREATMENT
originada I-TREATMENT
por I-TREATMENT
el I-TREATMENT
daño I-TREATMENT
renal I-TREATMENT
por I-TREATMENT
GEM. I-TREATMENT
<EOS> I-TREATMENT
. I-TREATMENT
<EOS> I-TREATMENT
Hombre B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
46 I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
con B-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
infección I-PAST_MEDICAL_HISTORY
respiratoria I-PAST_MEDICAL_HISTORY
la I-PAST_MEDICAL_HISTORY
semana I-PAST_MEDICAL_HISTORY
previa, I-PAST_MEDICAL_HISTORY
luego B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
cinco I-PRESENT_ILLNESS
días I-PRESENT_ILLNESS
comenzó I-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
disartria, I-PRESENT_ILLNESS
diplopía, I-PRESENT_ILLNESS
vértigo I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
ataxia. I-PRESENT_ILLNESS
Al B-EXPLORATION
examen I-EXPLORATION
se I-EXPLORATION
objetivó I-EXPLORATION
disartria, I-EXPLORATION
midriasis I-EXPLORATION
con I-EXPLORATION
reflejos I-EXPLORATION
fotomotores I-EXPLORATION
(RFM) I-EXPLORATION
disminuidos, I-EXPLORATION
paresia I-EXPLORATION
del I-EXPLORATION
recto I-EXPLORATION
superior I-EXPLORATION
izquierdo, I-EXPLORATION
nistagmus I-EXPLORATION
bihorizontal, I-EXPLORATION
ROT I-EXPLORATION
abolidos, I-EXPLORATION
dismetría I-EXPLORATION
bilateral I-EXPLORATION
y I-EXPLORATION
Romberg I-EXPLORATION
positivo. I-EXPLORATION
Se I-EXPLORATION
estudió I-EXPLORATION
con I-EXPLORATION
RM I-EXPLORATION
encéfalo I-EXPLORATION
normal. I-EXPLORATION
La I-EXPLORATION
EMG I-EXPLORATION
presentó I-EXPLORATION
alteración I-EXPLORATION
del I-EXPLORATION
reflejo I-EXPLORATION
de I-EXPLORATION
pestañeo. I-EXPLORATION
Sin I-EXPLORATION
disociación I-EXPLORATION
en I-EXPLORATION
LCR I-EXPLORATION
y I-EXPLORATION
anticuerpos I-EXPLORATION
anti-GQ1b I-EXPLORATION
positivos I-EXPLORATION
en I-EXPLORATION
suero. I-EXPLORATION
Evolucionó B-EVOLUTION
con I-EVOLUTION
sopor, I-EVOLUTION
midriasis I-EVOLUTION
arrefléctica, I-EVOLUTION
biparesia I-EVOLUTION
facial I-EVOLUTION
y I-EVOLUTION
paresia I-EVOLUTION
de I-EVOLUTION
extremidades I-EVOLUTION
superiores. I-EVOLUTION
Requirió B-TREATMENT
intubación I-TREATMENT
para I-TREATMENT
manejo I-TREATMENT
de I-TREATMENT
vía I-TREATMENT
aérea I-TREATMENT
y I-TREATMENT
monitorización I-TREATMENT
por I-TREATMENT
disautonomía. I-TREATMENT
Se I-TREATMENT
establecieron I-TREATMENT
los I-TREATMENT
diagnósticos I-TREATMENT
de I-TREATMENT
SMF, I-TREATMENT
SGB I-TREATMENT
y I-TREATMENT
EB. I-TREATMENT
Recibió I-TREATMENT
IgIV I-TREATMENT
(0, I-TREATMENT
4 I-TREATMENT
gr/kg/día I-TREATMENT
por I-TREATMENT
5 I-TREATMENT
días I-TREATMENT
consecutivos). I-TREATMENT
A B-EVOLUTION
los I-EVOLUTION
6 I-EVOLUTION
meses I-EVOLUTION
tenía I-EVOLUTION
examen I-EVOLUTION
neurológico I-EVOLUTION
normal. I-EVOLUTION
<EOS> I-EVOLUTION
Mujer B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
52 I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
edad, I-PRESENT_ILLNESS
no B-PAST_MEDICAL_HISTORY
fumadora, I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
GPA I-PAST_MEDICAL_HISTORY
diagnosticada I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
1995. I-PAST_MEDICAL_HISTORY
Al B-PRESENT_ILLNESS
diagnóstico I-PRESENT_ILLNESS
presentó I-PRESENT_ILLNESS
compromiso I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
VAS, I-PRESENT_ILLNESS
pulmón I-PRESENT_ILLNESS
(cuya I-PRESENT_ILLNESS
biopsia I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
masa I-PRESENT_ILLNESS
pulmonar I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
videotoracoscopía I-PRESENT_ILLNESS
mostró I-PRESENT_ILLNESS
infamación I-PRESENT_ILLNESS
granulomatosa I-PRESENT_ILLNESS
necrotizante), I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
micro-hematuria I-PRESENT_ILLNESS
asociado I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
astenia, I-PRESENT_ILLNESS
pérdida I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
peso I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
fiebre, I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
lo I-PRESENT_ILLNESS
que I-PRESENT_ILLNESS
se I-PRESENT_ILLNESS
diagnosticó I-PRESENT_ILLNESS
GPA I-PRESENT_ILLNESS
generalizada. I-PRESENT_ILLNESS
Al B-EXPLORATION
diagnóstico I-EXPLORATION
la I-EXPLORATION
VSG I-EXPLORATION
fue I-EXPLORATION
de I-EXPLORATION
113 I-EXPLORATION
mm, I-EXPLORATION
el I-EXPLORATION
ANCA I-EXPLORATION
c I-EXPLORATION
positivos I-EXPLORATION
(no I-EXPLORATION
se I-EXPLORATION
realizó I-EXPLORATION
PR3) I-EXPLORATION
y I-EXPLORATION
la I-EXPLORATION
CFV I-EXPLORATION
normal. I-EXPLORATION
Recibió B-TREATMENT
tratamiento I-TREATMENT
con I-TREATMENT
esteroides I-TREATMENT
y I-TREATMENT
ciclofosfamida I-TREATMENT
con I-TREATMENT
remisión I-TREATMENT
completa I-TREATMENT
de I-TREATMENT
los I-TREATMENT
síntomas, I-TREATMENT
analítica I-TREATMENT
e I-TREATMENT
imágenes. I-TREATMENT
Se I-TREATMENT
realizó I-TREATMENT
mantenimiento I-TREATMENT
con I-TREATMENT
ciclofosfamida. I-TREATMENT
<EOS> I-TREATMENT
A B-EVOLUTION
lo I-EVOLUTION
largo I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
evolución, I-EVOLUTION
presentó I-EVOLUTION
múltiples I-EVOLUTION
recaídas I-EVOLUTION
que I-EVOLUTION
respondieron I-EVOLUTION
a I-EVOLUTION
terapéutica I-EVOLUTION
específica. I-EVOLUTION
Las I-EVOLUTION
recaídas I-EVOLUTION
siempre I-EVOLUTION
fueron I-EVOLUTION
en I-EVOLUTION
VAS, I-EVOLUTION
con I-EVOLUTION
otitis, I-EVOLUTION
sinusitis I-EVOLUTION
y I-EVOLUTION
epistaxis I-EVOLUTION
recurrentes. I-EVOLUTION
Presentó I-EVOLUTION
perforación I-EVOLUTION
del I-EVOLUTION
tabique I-EVOLUTION
nasal I-EVOLUTION
y I-EVOLUTION
mielosupresión I-EVOLUTION
por I-EVOLUTION
ciclofosfamida, I-EVOLUTION
por B-TREATMENT
lo I-TREATMENT
cual I-TREATMENT
se I-TREATMENT
rotó I-TREATMENT
el I-TREATMENT
tratamiento I-TREATMENT
a I-TREATMENT
micofenolato I-TREATMENT
en I-TREATMENT
dosis I-TREATMENT
de I-TREATMENT
tres I-TREATMENT
gramos I-TREATMENT
día. I-TREATMENT
<EOS> I-TREATMENT
Al B-EVOLUTION
año I-EVOLUTION
del I-EVOLUTION
diagnóstico I-EVOLUTION
comenzó I-EVOLUTION
con I-EVOLUTION
disnea I-EVOLUTION
y I-EVOLUTION
estridor I-EVOLUTION
laríngeo. I-EVOLUTION
Se B-EXPLORATION
realizó I-EXPLORATION
EFR I-EXPLORATION
que I-EXPLORATION
evidenció I-EXPLORATION
curva I-EXPLORATION
cajón I-EXPLORATION
y I-EXPLORATION
TAC I-EXPLORATION
de I-EXPLORATION
traquea I-EXPLORATION
y I-EXPLORATION
laringe I-EXPLORATION
que I-EXPLORATION
mostró I-EXPLORATION
una I-EXPLORATION
ESG. I-EXPLORATION
Requirió B-TREATMENT
tratamiento I-TREATMENT
con I-TREATMENT
radiofrecuencia I-TREATMENT
y I-TREATMENT
dilatación. I-TREATMENT
Durante I-TREATMENT
los I-TREATMENT
años I-TREATMENT
2003, I-TREATMENT
2005, I-TREATMENT
2006 I-TREATMENT
se I-TREATMENT
efectuaron I-TREATMENT
dilataciones, I-TREATMENT
llegando I-TREATMENT
a I-TREATMENT
realizar I-TREATMENT
traqueostomía I-TREATMENT
en I-TREATMENT
el I-TREATMENT
2008. I-TREATMENT
Falleció B-EVOLUTION
en I-EVOLUTION
el I-EVOLUTION
año I-EVOLUTION
2009 I-EVOLUTION
en I-EVOLUTION
contexto I-EVOLUTION
de I-EVOLUTION
una I-EVOLUTION
neumonía I-EVOLUTION
nosocomial. I-EVOLUTION
<EOS> I-EVOLUTION
Hombre B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
31 I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
que I-PRESENT_ILLNESS
consultó I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
pérdida I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
fuerzas I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
instalación I-PRESENT_ILLNESS
rápida, I-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
compromiso I-PRESENT_ILLNESS
inicial I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
miembros I-PRESENT_ILLNESS
inferiores I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
progresión I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
miembros I-PRESENT_ILLNESS
superiores I-PRESENT_ILLNESS
determinando I-PRESENT_ILLNESS
cuadriparesia I-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
cefaloparesia. I-PRESENT_ILLNESS
Destacaba B-PAST_MEDICAL_HISTORY
entre I-PAST_MEDICAL_HISTORY
sus I-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
ser I-PAST_MEDICAL_HISTORY
portador I-PAST_MEDICAL_HISTORY
del I-PAST_MEDICAL_HISTORY
virus I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
la I-PAST_MEDICAL_HISTORY
inmunodeficiencia I-PAST_MEDICAL_HISTORY
humana I-PAST_MEDICAL_HISTORY
(VIH) I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
etapa I-PAST_MEDICAL_HISTORY
SIDA I-PAST_MEDICAL_HISTORY
sin I-PAST_MEDICAL_HISTORY
cumplimiento I-PAST_MEDICAL_HISTORY
del I-PAST_MEDICAL_HISTORY
tratamiento I-PAST_MEDICAL_HISTORY
antiretroviral. I-PAST_MEDICAL_HISTORY
Presentaba B-PRESENT_ILLNESS
diarrea I-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
múltiples I-PRESENT_ILLNESS
deposiciones I-PRESENT_ILLNESS
diarias I-PRESENT_ILLNESS
durante I-PRESENT_ILLNESS
los I-PRESENT_ILLNESS
10 I-PRESENT_ILLNESS
días I-PRESENT_ILLNESS
previos I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
la I-PRESENT_ILLNESS
consulta. I-PRESENT_ILLNESS
Al B-EXPLORATION
ingreso I-EXPLORATION
se I-EXPLORATION
encontraba I-EXPLORATION
vigil, I-EXPLORATION
eupneico I-EXPLORATION
y I-EXPLORATION
apirético. I-EXPLORATION
Tenía I-EXPLORATION
aceptable I-EXPLORATION
estado I-EXPLORATION
de I-EXPLORATION
hidratación I-EXPLORATION
y I-EXPLORATION
TA I-EXPLORATION
de I-EXPLORATION
110/70 I-EXPLORATION
mmHg. I-EXPLORATION
En I-EXPLORATION
la I-EXPLORATION
valoración I-EXPLORATION
neuromuscular I-EXPLORATION
se I-EXPLORATION
objetivaba I-EXPLORATION
cuadriparesia I-EXPLORATION
con I-EXPLORATION
cefaloparesia. I-EXPLORATION
El I-EXPLORATION
K+pl I-EXPLORATION
al I-EXPLORATION
momento I-EXPLORATION
del I-EXPLORATION
ingreso I-EXPLORATION
fue I-EXPLORATION
informado I-EXPLORATION
como I-EXPLORATION
indetectable, I-EXPLORATION
con I-EXPLORATION
un I-EXPLORATION
valor I-EXPLORATION
de I-EXPLORATION
K+ I-EXPLORATION
urinario I-EXPLORATION
en I-EXPLORATION
muestra I-EXPLORATION
aislada I-EXPLORATION
de I-EXPLORATION
5 I-EXPLORATION
mEq/L. I-EXPLORATION
Presentaba I-EXPLORATION
elevación I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
CK. I-EXPLORATION
Se B-TREATMENT
inició I-TREATMENT
reposición I-TREATMENT
hidroelectrolítica I-TREATMENT
con I-TREATMENT
mejoría I-TREATMENT
de I-TREATMENT
la I-TREATMENT
cuadriparesia I-TREATMENT
y I-TREATMENT
normalización I-TREATMENT
de I-TREATMENT
los I-TREATMENT
valores I-TREATMENT
de I-TREATMENT
K+pl I-TREATMENT
y I-TREATMENT
CK. I-TREATMENT
Al I-TREATMENT
igual I-TREATMENT
que I-TREATMENT
el I-TREATMENT
caso I-TREATMENT
1, I-TREATMENT
la I-TREATMENT
severa I-TREATMENT
disminución I-TREATMENT
del I-TREATMENT
potasio I-TREATMENT
plasmático I-TREATMENT
se I-TREATMENT
debió I-TREATMENT
a I-TREATMENT
una I-TREATMENT
alteración I-TREATMENT
a I-TREATMENT
nivel I-TREATMENT
del I-TREATMENT
balance I-TREATMENT
externo I-TREATMENT
por I-TREATMENT
pérdidas I-TREATMENT
de I-TREATMENT
origen I-TREATMENT
digestivo, I-TREATMENT
lo I-TREATMENT
que I-TREATMENT
concuerda I-TREATMENT
con I-TREATMENT
el I-TREATMENT
valor I-TREATMENT
de I-TREATMENT
K+ I-TREATMENT
en I-TREATMENT
orina I-TREATMENT
de I-TREATMENT
5 I-TREATMENT
mEq/L. I-TREATMENT
La B-EVOLUTION
reposición I-EVOLUTION
hidroelectrolítica I-EVOLUTION
revirtió I-EVOLUTION
el I-EVOLUTION
cuadro I-EVOLUTION
en I-EVOLUTION
las I-EVOLUTION
primeras I-EVOLUTION
48 I-EVOLUTION
h I-EVOLUTION
de I-EVOLUTION
tratamiento. I-EVOLUTION
<EOS> I-EVOLUTION
Paciente B-PRESENT_ILLNESS
78 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
sexo I-PRESENT_ILLNESS
masculino. I-PRESENT_ILLNESS
Hipertensión I-PRESENT_ILLNESS
arterial I-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
tratamiento, I-PRESENT_ILLNESS
enfermedad I-PRESENT_ILLNESS
arterial I-PRESENT_ILLNESS
oclusiva I-PRESENT_ILLNESS
carotídea I-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
estudio. I-PRESENT_ILLNESS
<EOS> I-PRESENT_ILLNESS
Se I-PRESENT_ILLNESS
presenta I-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
cuadro I-PRESENT_ILLNESS
clínico I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
3 I-PRESENT_ILLNESS
meses I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
baja I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
peso I-PRESENT_ILLNESS
9 I-PRESENT_ILLNESS
kg, I-PRESENT_ILLNESS
disfagia I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
saciedad I-PRESENT_ILLNESS
precoz. I-PRESENT_ILLNESS
Endoscopia B-EXPLORATION
digestiva I-EXPLORATION
compatible I-EXPLORATION
con I-EXPLORATION
lesión I-EXPLORATION
pediculada I-EXPLORATION
subcardial I-EXPLORATION
en I-EXPLORATION
cara I-EXPLORATION
posterior. I-EXPLORATION
Biopsia I-EXPLORATION
endoscópica: I-EXPLORATION
"tumor I-EXPLORATION
estromal I-EXPLORATION
fusocelular I-EXPLORATION
con I-EXPLORATION
> I-EXPLORATION
10 I-EXPLORATION
mitosis I-EXPLORATION
atípicas I-EXPLORATION
por I-EXPLORATION
50 I-EXPLORATION
campos", I-EXPLORATION
compatible I-EXPLORATION
con I-EXPLORATION
GIST. I-EXPLORATION
<EOS> I-EXPLORATION
Tomografía I-EXPLORATION
axial I-EXPLORATION
computada I-EXPLORATION
de I-EXPLORATION
abdomen: I-EXPLORATION
lesión I-EXPLORATION
subcardial I-EXPLORATION
de I-EXPLORATION
6 I-EXPLORATION
cm I-EXPLORATION
diámetro I-EXPLORATION
mayor, I-EXPLORATION
sin I-EXPLORATION
adenopatías I-EXPLORATION
ni I-EXPLORATION
signos I-EXPLORATION
de I-EXPLORATION
diseminación I-EXPLORATION
sistémica, I-EXPLORATION
que I-EXPLORATION
se I-EXPLORATION
confirma I-EXPLORATION
con I-EXPLORATION
un I-EXPLORATION
tránsito I-EXPLORATION
esófago I-EXPLORATION
estómago I-EXPLORATION
y I-EXPLORATION
duodeno I-EXPLORATION
con I-EXPLORATION
sulfato I-EXPLORATION
de I-EXPLORATION
bario: I-EXPLORATION
lesión I-EXPLORATION
pediculada I-EXPLORATION
subcardial. I-EXPLORATION
Se B-TREATMENT
programa I-TREATMENT
resección I-TREATMENT
tumoral I-TREATMENT
laparoscópica: I-TREATMENT
Gastrotomía I-TREATMENT
anterior, I-TREATMENT
resección I-TREATMENT
de I-TREATMENT
tumor I-TREATMENT
con I-TREATMENT
sutura I-TREATMENT
mecánica I-TREATMENT
a I-TREATMENT
pedículo, I-TREATMENT
gastrorrafia, I-TREATMENT
biopsia I-TREATMENT
de I-TREATMENT
serosa I-TREATMENT
gástrica I-TREATMENT
y I-TREATMENT
peritoneo. I-TREATMENT
Postoperatorio B-EXPLORATION
sin I-EXPLORATION
complicaciones. I-EXPLORATION
<EOS> I-EXPLORATION
Biopsia: I-EXPLORATION
Carcinoma I-EXPLORATION
escamoso I-EXPLORATION
fusocelular I-EXPLORATION
sarcomatoide, I-EXPLORATION
polipoide I-EXPLORATION
y I-EXPLORATION
ulcerado I-EXPLORATION
6, I-EXPLORATION
5 I-EXPLORATION
x I-EXPLORATION
5 I-EXPLORATION
x I-EXPLORATION
4 I-EXPLORATION
cm. I-EXPLORATION
Margen I-EXPLORATION
positivo I-EXPLORATION
de I-EXPLORATION
pedículo. I-EXPLORATION
Sin I-EXPLORATION
permeaciones I-EXPLORATION
vasculares, I-EXPLORATION
linfáticas I-EXPLORATION
ni I-EXPLORATION
perineurales. I-EXPLORATION
Peritoneo I-EXPLORATION
y I-EXPLORATION
serosa I-EXPLORATION
gástrica: I-EXPLORATION
sin I-EXPLORATION
neoplasia. I-EXPLORATION
<EOS> I-EXPLORATION
Se B-TREATMENT
programa I-TREATMENT
para I-TREATMENT
gastrectomía I-TREATMENT
total I-TREATMENT
más I-TREATMENT
esofagectomía I-TREATMENT
distal I-TREATMENT
con I-TREATMENT
diagnóstico I-TREATMENT
de I-TREATMENT
carcinoma I-TREATMENT
escamoso I-TREATMENT
de I-TREATMENT
la I-TREATMENT
unión I-TREATMENT
gastroesofágica: I-TREATMENT
en I-TREATMENT
el I-TREATMENT
intraoperatorio I-TREATMENT
se I-TREATMENT
recibió I-TREATMENT
biopsia I-TREATMENT
rápida I-TREATMENT
de I-TREATMENT
límite I-TREATMENT
oral I-TREATMENT
infiltrado I-TREATMENT
por I-TREATMENT
carcinoma, I-TREATMENT
recorte I-TREATMENT
revela I-TREATMENT
compromiso I-TREATMENT
neoplásico I-TREATMENT
proximal I-TREATMENT
por I-TREATMENT
lo I-TREATMENT
que I-TREATMENT
se I-TREATMENT
decidió I-TREATMENT
no I-TREATMENT
reconstituir I-TREATMENT
en I-TREATMENT
un I-TREATMENT
tiempo I-TREATMENT
por I-TREATMENT
las I-TREATMENT
condiciones I-TREATMENT
del I-TREATMENT
paciente I-TREATMENT
en I-TREATMENT
el I-TREATMENT
intraoperatorio, I-TREATMENT
efectuándose I-TREATMENT
esofagogastrectomía I-TREATMENT
total I-TREATMENT
transhiatal, I-TREATMENT
esofagostoma I-TREATMENT
cervical I-TREATMENT
terminal I-TREATMENT
transitorio I-TREATMENT
y I-TREATMENT
yeyunostomía I-TREATMENT
de I-TREATMENT
Wietzel, I-TREATMENT
dejando I-TREATMENT
para I-TREATMENT
un I-TREATMENT
segundo I-TREATMENT
tiempo I-TREATMENT
la I-TREATMENT
reconstitución I-TREATMENT
definitiva I-TREATMENT
del I-TREATMENT
tránsito I-TREATMENT
digestivo. I-TREATMENT
<EOS> I-TREATMENT
Biopsia B-EXPLORATION
definitiva: I-EXPLORATION
Carcinoma I-EXPLORATION
espinocelular I-EXPLORATION
fusocelular I-EXPLORATION
sarcomatoide I-EXPLORATION
esofágico I-EXPLORATION
con I-EXPLORATION
extensión I-EXPLORATION
hasta I-EXPLORATION
submucosa, I-EXPLORATION
compromiso I-EXPLORATION
de I-EXPLORATION
grupo I-EXPLORATION
1 I-EXPLORATION
y I-EXPLORATION
5 I-EXPLORATION
(4/37), I-EXPLORATION
sin I-EXPLORATION
adenopatías I-EXPLORATION
mediastínicas. I-EXPLORATION
Nódulo I-EXPLORATION
metastásico I-EXPLORATION
en I-EXPLORATION
epiplón I-EXPLORATION
menor I-EXPLORATION
correspondiente I-EXPLORATION
a I-EXPLORATION
ganglio I-EXPLORATION
N° I-EXPLORATION
5. I-EXPLORATION
Márgenes I-EXPLORATION
quirúrgicos I-EXPLORATION
sin I-EXPLORATION
neoplasia. I-EXPLORATION
<EOS> I-EXPLORATION
Al B-TREATMENT
mes I-TREATMENT
postoperatorio I-TREATMENT
se I-TREATMENT
realizó I-TREATMENT
reconstrucción I-TREATMENT
con I-TREATMENT
ascenso I-TREATMENT
de I-TREATMENT
colon I-TREATMENT
derecho I-TREATMENT
e I-TREATMENT
íleon I-TREATMENT
terminal I-TREATMENT
vía I-TREATMENT
retroesternal: I-TREATMENT
esófago-íleo I-TREATMENT
anastomosis I-TREATMENT
cervical I-TREATMENT
terminolateral, I-TREATMENT
transverso-duodeno I-TREATMENT
anastomosis I-TREATMENT
laterolateral, I-TREATMENT
íleo-transverso I-TREATMENT
anastomosis I-TREATMENT
latero-lateral I-TREATMENT
y I-TREATMENT
yeyunostomía I-TREATMENT
de I-TREATMENT
Wietzel. I-TREATMENT
<EOS> I-TREATMENT
Evolucionó B-EVOLUTION
con I-EVOLUTION
fístula I-EVOLUTION
cervical I-EVOLUTION
de I-EVOLUTION
bajo I-EVOLUTION
débito I-EVOLUTION
sin I-EVOLUTION
repercusión I-EVOLUTION
clínica, I-EVOLUTION
alta I-EVOLUTION
al I-EVOLUTION
día I-EVOLUTION
21 I-EVOLUTION
postoperatorio I-EVOLUTION
con I-EVOLUTION
régimen I-EVOLUTION
líquido I-EVOLUTION
y I-EVOLUTION
aporte I-EVOLUTION
por I-EVOLUTION
yeyunostomía. I-EVOLUTION
<EOS> I-EVOLUTION
Paciente I-EVOLUTION
en I-EVOLUTION
excelentes I-EVOLUTION
condiciones I-EVOLUTION
a I-EVOLUTION
los I-EVOLUTION
18 I-EVOLUTION
meses I-EVOLUTION
postoperatorios, I-EVOLUTION
autovalente, I-EVOLUTION
requirió I-EVOLUTION
dilatación I-EVOLUTION
endoscópica I-EVOLUTION
de I-EVOLUTION
anastomosis I-EVOLUTION
cervical, I-EVOLUTION
sin I-EVOLUTION
incidentes. I-EVOLUTION
<EOS> I-EVOLUTION
Hombre B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
41 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
fumador. B-PAST_MEDICAL_HISTORY
Historia B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
2 I-PRESENT_ILLNESS
meses I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
dolor I-PRESENT_ILLNESS
dorsal I-PRESENT_ILLNESS
irradiado I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
hombro I-PRESENT_ILLNESS
izquierdo, I-PRESENT_ILLNESS
intensidad I-PRESENT_ILLNESS
8/10 I-PRESENT_ILLNESS
sin I-PRESENT_ILLNESS
respuesta I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
analgésicos, I-PRESENT_ILLNESS
tos I-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
expectoración I-PRESENT_ILLNESS
mucosa, I-PRESENT_ILLNESS
baja I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
peso I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
sudoración I-PRESENT_ILLNESS
nocturna. I-PRESENT_ILLNESS
Examen B-EXPLORATION
físico I-EXPLORATION
inicial I-EXPLORATION
normal. I-EXPLORATION
Presentó I-EXPLORATION
anemia I-EXPLORATION
leve, I-EXPLORATION
VHS: I-EXPLORATION
96 I-EXPLORATION
mm/h, I-EXPLORATION
examen I-EXPLORATION
de I-EXPLORATION
orina, I-EXPLORATION
función I-EXPLORATION
renal, I-EXPLORATION
pruebas I-EXPLORATION
hepáticas I-EXPLORATION
y I-EXPLORATION
perfil I-EXPLORATION
lipídico I-EXPLORATION
normales. I-EXPLORATION
Tomografía I-EXPLORATION
computada I-EXPLORATION
de I-EXPLORATION
columna I-EXPLORATION
dorsal I-EXPLORATION
sin I-EXPLORATION
hallazgos I-EXPLORATION
significativos. I-EXPLORATION
Radiografía I-EXPLORATION
de I-EXPLORATION
tórax: I-EXPLORATION
nódulos I-EXPLORATION
subpleurales I-EXPLORATION
en I-EXPLORATION
vértices I-EXPLORATION
pulmonares I-EXPLORATION
y I-EXPLORATION
lóbulo I-EXPLORATION
superior I-EXPLORATION
izquierdo. I-EXPLORATION
Hemocultivos I-EXPLORATION
negativos. I-EXPLORATION
Ecotomografía I-EXPLORATION
abdominal I-EXPLORATION
normal, I-EXPLORATION
aTAC I-EXPLORATION
de I-EXPLORATION
tórax I-EXPLORATION
ateromatosis I-EXPLORATION
aórtica I-EXPLORATION
segmentaria I-EXPLORATION
en I-EXPLORATION
aorta I-EXPLORATION
descendente, I-EXPLORATION
con I-EXPLORATION
engrosamiento I-EXPLORATION
extraintimal, I-EXPLORATION
estenosis I-EXPLORATION
significativa I-EXPLORATION
de I-EXPLORATION
ostium I-EXPLORATION
en I-EXPLORATION
tronco I-EXPLORATION
celíaco. I-EXPLORATION
Nodulos I-EXPLORATION
pulmonares I-EXPLORATION
y I-EXPLORATION
condensaciones I-EXPLORATION
apicales I-EXPLORATION
bilaterales. I-EXPLORATION
VDRL: I-EXPLORATION
No I-EXPLORATION
reactivo, I-EXPLORATION
VIH I-EXPLORATION
negativo, I-EXPLORATION
PPD: I-EXPLORATION
10 I-EXPLORATION
mm. I-EXPLORATION
Quatiferon I-EXPLORATION
(-). I-EXPLORATION
El I-EXPLORATION
paciente I-EXPLORATION
evolucionó I-EXPLORATION
con I-EXPLORATION
escleritis I-EXPLORATION
bilateral I-EXPLORATION
y I-EXPLORATION
fiebre I-EXPLORATION
hasta I-EXPLORATION
37, I-EXPLORATION
8 I-EXPLORATION
°C. I-EXPLORATION
Se I-EXPLORATION
sospecha I-EXPLORATION
vasculitis I-EXPLORATION
de I-EXPLORATION
grandes I-EXPLORATION
vasos. I-EXPLORATION
Nuevos I-EXPLORATION
estudios I-EXPLORATION
demostraron I-EXPLORATION
ANCA I-EXPLORATION
citoplasmático I-EXPLORATION
(C): I-EXPLORATION
positivo, I-EXPLORATION
anti I-EXPLORATION
proteinasa I-EXPLORATION
3 I-EXPLORATION
(PR3) I-EXPLORATION
+6, I-EXPLORATION
5 I-EXPLORATION
(VN I-EXPLORATION
< I-EXPLORATION
1, I-EXPLORATION
2), I-EXPLORATION
C3 I-EXPLORATION
y I-EXPLORATION
C4 I-EXPLORATION
normales, I-EXPLORATION
ANA, I-EXPLORATION
anticuerpos I-EXPLORATION
anti-ADN I-EXPLORATION
y I-EXPLORATION
ENA I-EXPLORATION
negativos. I-EXPLORATION
Biopsia I-EXPLORATION
pulmonar: I-EXPLORATION
Nodulo I-EXPLORATION
con I-EXPLORATION
centro I-EXPLORATION
fibroso, I-EXPLORATION
necrosis I-EXPLORATION
y I-EXPLORATION
reacción I-EXPLORATION
histiocitaria, I-EXPLORATION
con I-EXPLORATION
células I-EXPLORATION
gigantes. I-EXPLORATION
Se I-EXPLORATION
reconoce I-EXPLORATION
neumonía I-EXPLORATION
organizativa I-EXPLORATION
periférica, I-EXPLORATION
signos I-EXPLORATION
de I-EXPLORATION
hemorragia I-EXPLORATION
antigua, I-EXPLORATION
concordante I-EXPLORATION
con I-EXPLORATION
PG. I-EXPLORATION
Recibió B-TREATMENT
corticoterapia I-TREATMENT
y I-TREATMENT
ciclofosfamida I-TREATMENT
oral I-TREATMENT
por I-TREATMENT
un I-TREATMENT
año I-TREATMENT
y I-TREATMENT
posteriormente I-TREATMENT
mantención I-TREATMENT
con I-TREATMENT
azatioprina. I-TREATMENT
Presentó B-EVOLUTION
buena I-EVOLUTION
respuesta I-EVOLUTION
clínica, I-EVOLUTION
normalización I-EVOLUTION
de I-EVOLUTION
los I-EVOLUTION
parámetros I-EVOLUTION
inflamatorios, I-EVOLUTION
radiografía I-EVOLUTION
y I-EVOLUTION
aTAC I-EVOLUTION
de I-EVOLUTION
tórax. I-EVOLUTION
Anti I-EVOLUTION
PR3 I-EVOLUTION
(-) I-EVOLUTION
a I-EVOLUTION
los I-EVOLUTION
6 I-EVOLUTION
meses. I-EVOLUTION
<EOS> I-EVOLUTION
Presentamos B-PRESENT_ILLNESS
el I-PRESENT_ILLNESS
caso I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
una I-PRESENT_ILLNESS
paciente I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
sexo I-PRESENT_ILLNESS
femenino, I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
75 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
con B-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
hipertensión I-PAST_MEDICAL_HISTORY
e I-PAST_MEDICAL_HISTORY
hipotiroidismo I-PAST_MEDICAL_HISTORY
postquirúrgico I-PAST_MEDICAL_HISTORY
(por I-PAST_MEDICAL_HISTORY
bocio I-PAST_MEDICAL_HISTORY
nodular). I-PAST_MEDICAL_HISTORY
Consultó B-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
agosto I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
2008 I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
un I-PRESENT_ILLNESS
cuadro I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
9 I-PRESENT_ILLNESS
meses I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
evolución I-PRESENT_ILLNESS
caracterizado I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
fatigabilidad, I-PRESENT_ILLNESS
síncopes I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
repetición I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
disnea I-PRESENT_ILLNESS
progresiva. I-PRESENT_ILLNESS
Dentro B-EXPLORATION
del I-EXPLORATION
estudio I-EXPLORATION
se I-EXPLORATION
pesquisó I-EXPLORATION
anemia I-EXPLORATION
severa I-EXPLORATION
normocítica I-EXPLORATION
normocrómica, I-EXPLORATION
con I-EXPLORATION
hemoglobina I-EXPLORATION
de I-EXPLORATION
6, I-EXPLORATION
8 I-EXPLORATION
g/dL, I-EXPLORATION
leucocitos I-EXPLORATION
y I-EXPLORATION
plaquetas I-EXPLORATION
normales. I-EXPLORATION
Además I-EXPLORATION
destacó I-EXPLORATION
una I-EXPLORATION
VHS I-EXPLORATION
de I-EXPLORATION
140 I-EXPLORATION
mm/h. I-EXPLORATION
Por I-EXPLORATION
sospecha I-EXPLORATION
de I-EXPLORATION
MM I-EXPLORATION
se I-EXPLORATION
continuó I-EXPLORATION
estudio I-EXPLORATION
destacando I-EXPLORATION
proteínas I-EXPLORATION
totales I-EXPLORATION
14, I-EXPLORATION
6 I-EXPLORATION
g/dL, I-EXPLORATION
albúmina I-EXPLORATION
2 I-EXPLORATION
g/dL, I-EXPLORATION
calcio I-EXPLORATION
corregido I-EXPLORATION
10, I-EXPLORATION
8 I-EXPLORATION
mg/dL, I-EXPLORATION
creatinina: I-EXPLORATION
0, I-EXPLORATION
8 I-EXPLORATION
mg/dL, I-EXPLORATION
B2 I-EXPLORATION
microglobulina I-EXPLORATION
10, I-EXPLORATION
2 I-EXPLORATION
mg/L. I-EXPLORATION
La I-EXPLORATION
electroforesis I-EXPLORATION
de I-EXPLORATION
proteínas I-EXPLORATION
reveló I-EXPLORATION
un I-EXPLORATION
peak I-EXPLORATION
monoclonal I-EXPLORATION
en I-EXPLORATION
gamma I-EXPLORATION
y I-EXPLORATION
se I-EXPLORATION
vio I-EXPLORATION
un I-EXPLORATION
aumento I-EXPLORATION
de I-EXPLORATION
inmunoglobulina I-EXPLORATION
IgG I-EXPLORATION
de I-EXPLORATION
3.450 I-EXPLORATION
mg/dl, I-EXPLORATION
siendo I-EXPLORATION
el I-EXPLORATION
resto I-EXPLORATION
de I-EXPLORATION
las I-EXPLORATION
Ig I-EXPLORATION
menores I-EXPLORATION
al I-EXPLORATION
rango I-EXPLORATION
normal. I-EXPLORATION
Se I-EXPLORATION
realizó I-EXPLORATION
un I-EXPLORATION
mielograma I-EXPLORATION
que I-EXPLORATION
mostró I-EXPLORATION
25% I-EXPLORATION
de I-EXPLORATION
plasmoblastos I-EXPLORATION
y I-EXPLORATION
plasmocitos, I-EXPLORATION
algunos I-EXPLORATION
binucleados. I-EXPLORATION
La I-EXPLORATION
serie I-EXPLORATION
radiológica I-EXPLORATION
reveló I-EXPLORATION
imágenes I-EXPLORATION
líticas I-EXPLORATION
en I-EXPLORATION
calota I-EXPLORATION
y I-EXPLORATION
en I-EXPLORATION
columna I-EXPLORATION
lumbar. I-EXPLORATION
Por I-EXPLORATION
lo I-EXPLORATION
tanto, I-EXPLORATION
se I-EXPLORATION
hizo I-EXPLORATION
el I-EXPLORATION
diagnóstico I-EXPLORATION
de I-EXPLORATION
MM I-EXPLORATION
IgG, I-EXPLORATION
con I-EXPLORATION
índices I-EXPLORATION
pronósticos I-EXPLORATION
de I-EXPLORATION
Durie I-EXPLORATION
Salmon I-EXPLORATION
IIIA I-EXPLORATION
e I-EXPLORATION
ISS I-EXPLORATION
de I-EXPLORATION
3 I-EXPLORATION
puntos. I-EXPLORATION
<EOS> I-EXPLORATION
Se B-TREATMENT
inició I-TREATMENT
tratamiento I-TREATMENT
con I-TREATMENT
hidratación, I-TREATMENT
pamidronato I-TREATMENT
y I-TREATMENT
melfalán/prednisona, I-TREATMENT
recuperándose I-TREATMENT
la I-TREATMENT
hipercalcemia. I-TREATMENT
Recibió I-TREATMENT
tratamiento I-TREATMENT
con I-TREATMENT
melfalán/prednisona I-TREATMENT
por I-TREATMENT
6 I-TREATMENT
ciclos I-TREATMENT
y I-TREATMENT
radioterapia I-TREATMENT
de I-TREATMENT
columna I-TREATMENT
lumbar, I-TREATMENT
destacando I-TREATMENT
en I-TREATMENT
los I-TREATMENT
controles I-TREATMENT
ambulatorios I-TREATMENT
mejoría I-TREATMENT
en I-TREATMENT
albúmina I-TREATMENT
y I-TREATMENT
calcemia, I-TREATMENT
pero I-TREATMENT
pancitopenia I-TREATMENT
progresiva I-TREATMENT
e I-TREATMENT
infecciones I-TREATMENT
urinarias I-TREATMENT
a I-TREATMENT
repetición. I-TREATMENT
En B-EVOLUTION
marzo I-EVOLUTION
de I-EVOLUTION
2009 I-EVOLUTION
estuvo I-EVOLUTION
hospitalizada I-EVOLUTION
por I-EVOLUTION
neumonía. I-EVOLUTION
En I-EVOLUTION
noviembre I-EVOLUTION
de I-EVOLUTION
2009 I-EVOLUTION
evolucionó I-EVOLUTION
con I-EVOLUTION
mayor I-EVOLUTION
dolor I-EVOLUTION
óseo I-EVOLUTION
y I-EVOLUTION
postración. I-EVOLUTION
Además, I-EVOLUTION
llamó I-EVOLUTION
la I-EVOLUTION
atención I-EVOLUTION
la I-EVOLUTION
aparición I-EVOLUTION
de I-EVOLUTION
lesiones I-EVOLUTION
cutáneas I-EVOLUTION
nodulares, I-EVOLUTION
violáceas, I-EVOLUTION
dolorosas I-EVOLUTION
de I-EVOLUTION
1, I-EVOLUTION
5 I-EVOLUTION
a I-EVOLUTION
2 I-EVOLUTION
cm I-EVOLUTION
en I-EVOLUTION
cuero I-EVOLUTION
cabelludo, I-EVOLUTION
ángulo I-EVOLUTION
mandibular I-EVOLUTION
izquierdo, I-EVOLUTION
cuello I-EVOLUTION
y I-EVOLUTION
dorso. I-EVOLUTION
Se B-EXPLORATION
realizó I-EXPLORATION
una I-EXPLORATION
punción I-EXPLORATION
de I-EXPLORATION
las I-EXPLORATION
lesiones I-EXPLORATION
que I-EXPLORATION
mostró I-EXPLORATION
una I-EXPLORATION
celularidad I-EXPLORATION
constituida I-EXPLORATION
exclusivamente I-EXPLORATION
por I-EXPLORATION
células I-EXPLORATION
plasmáticas I-EXPLORATION
predominando I-EXPLORATION
proplasmocitos. I-EXPLORATION
La I-EXPLORATION
biopsia I-EXPLORATION
mostró I-EXPLORATION
igualmente I-EXPLORATION
infiltración I-EXPLORATION
por I-EXPLORATION
células I-EXPLORATION
plasmáticas. I-EXPLORATION
Debido B-TREATMENT
a I-TREATMENT
progresión I-TREATMENT
de I-TREATMENT
la I-TREATMENT
enfermedad I-TREATMENT
se I-TREATMENT
cambió I-TREATMENT
el I-TREATMENT
tratamiento I-TREATMENT
a I-TREATMENT
talidomida/dexametasona, I-TREATMENT
sin I-TREATMENT
resultados. I-TREATMENT
Se B-EVOLUTION
derivó I-EVOLUTION
a I-EVOLUTION
cuidados I-EVOLUTION
paliativos I-EVOLUTION
y I-EVOLUTION
la I-EVOLUTION
paciente I-EVOLUTION
falleció I-EVOLUTION
2 I-EVOLUTION
meses I-EVOLUTION
después, I-EVOLUTION
por I-EVOLUTION
infección I-EVOLUTION
en I-EVOLUTION
mieloma I-EVOLUTION
refractario. I-EVOLUTION
<EOS> I-EVOLUTION
Paciente B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
sexo I-PRESENT_ILLNESS
masculino I-PRESENT_ILLNESS
con B-PAST_MEDICAL_HISTORY
antecedente I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
transfusión I-PAST_MEDICAL_HISTORY
sanguínea I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
1972, I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
el I-PAST_MEDICAL_HISTORY
contexto I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
sangrado I-PAST_MEDICAL_HISTORY
por I-PAST_MEDICAL_HISTORY
úlcera I-PAST_MEDICAL_HISTORY
duodenal. I-PAST_MEDICAL_HISTORY
Además, I-PAST_MEDICAL_HISTORY
cáncer I-PAST_MEDICAL_HISTORY
testicular I-PAST_MEDICAL_HISTORY
a I-PAST_MEDICAL_HISTORY
los I-PAST_MEDICAL_HISTORY
15 I-PAST_MEDICAL_HISTORY
años I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
hemicolectomía I-PAST_MEDICAL_HISTORY
izquierda I-PAST_MEDICAL_HISTORY
por I-PAST_MEDICAL_HISTORY
cáncer I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
colon I-PAST_MEDICAL_HISTORY
a I-PAST_MEDICAL_HISTORY
los I-PAST_MEDICAL_HISTORY
46 I-PAST_MEDICAL_HISTORY
años. I-PAST_MEDICAL_HISTORY
El B-PRESENT_ILLNESS
año I-PRESENT_ILLNESS
1994, I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
los I-PRESENT_ILLNESS
51 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
se I-PRESENT_ILLNESS
diagnosticó I-PRESENT_ILLNESS
cirrosis, I-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
estudio I-PRESENT_ILLNESS
que B-EXPLORATION
mostró I-EXPLORATION
PCR I-EXPLORATION
positiva I-EXPLORATION
para I-EXPLORATION
VHC. I-EXPLORATION
Se I-EXPLORATION
realizó I-EXPLORATION
biopsia I-EXPLORATION
hepática I-EXPLORATION
que I-EXPLORATION
mostraba I-EXPLORATION
hepatitis I-EXPLORATION
crónica I-EXPLORATION
con I-EXPLORATION
fibrosis I-EXPLORATION
grado I-EXPLORATION
III, I-EXPLORATION
sin I-EXPLORATION
cirrosis. I-EXPLORATION
Recibió B-TREATMENT
interferon I-TREATMENT
con I-TREATMENT
persistencia I-TREATMENT
de I-TREATMENT
PCR I-TREATMENT
+ I-TREATMENT
de I-TREATMENT
VHC. I-TREATMENT
Evolucionó B-EVOLUTION
con I-EVOLUTION
complicaciones I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
hipertensión I-EVOLUTION
portal, I-EVOLUTION
iniciando I-EVOLUTION
controles I-EVOLUTION
en I-EVOLUTION
nuestro I-EVOLUTION
centro I-EVOLUTION
en I-EVOLUTION
el I-EVOLUTION
2007. I-EVOLUTION
Ese I-EVOLUTION
año I-EVOLUTION
se I-EVOLUTION
diagnosticó I-EVOLUTION
hepatocarcinoma I-EVOLUTION
que B-TREATMENT
fue I-TREATMENT
quimioembolizado. I-TREATMENT
Se I-TREATMENT
trasplantó I-TREATMENT
en I-TREATMENT
mayo I-TREATMENT
de I-TREATMENT
2008. I-TREATMENT
Post I-TREATMENT
trasplante I-TREATMENT
se I-TREATMENT
inició I-TREATMENT
inmunosupresión I-TREATMENT
con I-TREATMENT
prednisona I-TREATMENT
y I-TREATMENT
ciclosporina, I-TREATMENT
adicionando I-TREATMENT
micofenolato I-TREATMENT
por I-TREATMENT
falla I-TREATMENT
renal. I-TREATMENT
Se B-EVOLUTION
mantuvo I-EVOLUTION
con I-EVOLUTION
creatinina I-EVOLUTION
1, I-EVOLUTION
4-1, I-EVOLUTION
5 I-EVOLUTION
mg/dl, I-EVOLUTION
pero I-EVOLUTION
1 I-EVOLUTION
año I-EVOLUTION
y I-EVOLUTION
medio I-EVOLUTION
post I-EVOLUTION
trasplante I-EVOLUTION
tuvo I-EVOLUTION
alza I-EVOLUTION
hasta I-EVOLUTION
1, I-EVOLUTION
9-2, I-EVOLUTION
0 I-EVOLUTION
mg/dl. I-EVOLUTION
En B-TREATMENT
ese I-TREATMENT
momento I-TREATMENT
se I-TREATMENT
suspendió I-TREATMENT
ciclosporina I-TREATMENT
y I-TREATMENT
se I-TREATMENT
agregó I-TREATMENT
sirolimus. I-TREATMENT
Presentó B-EVOLUTION
úlceras I-EVOLUTION
orales, I-EVOLUTION
suspendiéndose B-TREATMENT
micofenolato. I-TREATMENT
Por B-EXPLORATION
estudio I-EXPLORATION
de I-EXPLORATION
falla I-EXPLORATION
renal I-EXPLORATION
se I-EXPLORATION
solicitó I-EXPLORATION
PCR I-EXPLORATION
para I-EXPLORATION
VHC, I-EXPLORATION
la I-EXPLORATION
que I-EXPLORATION
resultó I-EXPLORATION
negativa. I-EXPLORATION
Se I-EXPLORATION
solicitó I-EXPLORATION
carga I-EXPLORATION
viral I-EXPLORATION
en I-EXPLORATION
2 I-EXPLORATION
oportunidades, I-EXPLORATION
ambas I-EXPLORATION
negativas. I-EXPLORATION
Se I-EXPLORATION
interpretó I-EXPLORATION
como I-EXPLORATION
eliminación I-EXPLORATION
espontánea I-EXPLORATION
de I-EXPLORATION
VHC. I-EXPLORATION
<EOS> I-EXPLORATION
Paciente B-PRESENT_ILLNESS
femenino I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
41 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
con B-PAST_MEDICAL_HISTORY
antecedente I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
Diabetes I-PAST_MEDICAL_HISTORY
Mellitus I-PAST_MEDICAL_HISTORY
tipo I-PAST_MEDICAL_HISTORY
2 I-PAST_MEDICAL_HISTORY
tratada I-PAST_MEDICAL_HISTORY
farmacológicamente. I-PAST_MEDICAL_HISTORY
Ingresa B-PRESENT_ILLNESS
al I-PRESENT_ILLNESS
servicio I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
otorrinolaringología I-PRESENT_ILLNESS
(ORL) I-PRESENT_ILLNESS
del I-PRESENT_ILLNESS
Hospital I-PRESENT_ILLNESS
San I-PRESENT_ILLNESS
Juan I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
Dios I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
un I-PRESENT_ILLNESS
cuadro I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
otalgia I-PRESENT_ILLNESS
derecha I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
3 I-PRESENT_ILLNESS
meses I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
evolución, I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
inicio I-PRESENT_ILLNESS
insidioso, I-PRESENT_ILLNESS
el I-PRESENT_ILLNESS
cual I-PRESENT_ILLNESS
aumenta I-PRESENT_ILLNESS
progresivamente I-PRESENT_ILLNESS
llegando I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
una I-PRESENT_ILLNESS
intensidad I-PRESENT_ILLNESS
10/10 I-PRESENT_ILLNESS
al I-PRESENT_ILLNESS
momento I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
la I-PRESENT_ILLNESS
consulta, I-PRESENT_ILLNESS
según I-PRESENT_ILLNESS
la I-PRESENT_ILLNESS
Escala I-PRESENT_ILLNESS
Visual I-PRESENT_ILLNESS
Análoga I-PRESENT_ILLNESS
(EVA). I-PRESENT_ILLNESS
Al B-EXPLORATION
examen I-EXPLORATION
la I-EXPLORATION
paciente I-EXPLORATION
se I-EXPLORATION
encontraba I-EXPLORATION
afebril, I-EXPLORATION
sin I-EXPLORATION
embargo I-EXPLORATION
se I-EXPLORATION
evidencia I-EXPLORATION
otorrea I-EXPLORATION
purulenta, I-EXPLORATION
hipoacusia I-EXPLORATION
y I-EXPLORATION
aumento I-EXPLORATION
de I-EXPLORATION
volumen I-EXPLORATION
preauricular I-EXPLORATION
ipsilateral. I-EXPLORATION
El I-EXPLORATION
estudio I-EXPLORATION
del I-EXPLORATION
cuadro I-EXPLORATION
arroja I-EXPLORATION
como I-EXPLORATION
diagnóstico I-EXPLORATION
una I-EXPLORATION
otitis I-EXPLORATION
externa I-EXPLORATION
necrotizante, I-EXPLORATION
además I-EXPLORATION
de I-EXPLORATION
una I-EXPLORATION
mastoiditis I-EXPLORATION
ebúrnea. I-EXPLORATION
El B-TREATMENT
manejo I-TREATMENT
inicial I-TREATMENT
del I-TREATMENT
cuadro I-TREATMENT
consistió I-TREATMENT
en I-TREATMENT
la I-TREATMENT
hospitalización I-TREATMENT
y I-TREATMENT
el I-TREATMENT
tratamiento I-TREATMENT
antibiótico I-TREATMENT
con I-TREATMENT
un I-TREATMENT
esquema I-TREATMENT
empírico I-TREATMENT
enfocado I-TREATMENT
en I-TREATMENT
el I-TREATMENT
proceso I-TREATMENT
ótico I-TREATMENT
con I-TREATMENT
ceftazidima I-TREATMENT
más I-TREATMENT
clindamicina I-TREATMENT
endovenosa I-TREATMENT
y I-TREATMENT
ciprofloxacino I-TREATMENT
tópico. I-TREATMENT
<EOS> I-TREATMENT
El B-EXPLORATION
grado I-EXPLORATION
de I-EXPLORATION
compromiso I-EXPLORATION
es I-EXPLORATION
objetivado I-EXPLORATION
en I-EXPLORATION
las I-EXPLORATION
imágenes I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
tomografía I-EXPLORATION
axial I-EXPLORATION
computarizada I-EXPLORATION
(TAC) I-EXPLORATION
que I-EXPLORATION
muestra I-EXPLORATION
una I-EXPLORATION
franca I-EXPLORATION
zona I-EXPLORATION
de I-EXPLORATION
erosión I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
superficie I-EXPLORATION
ósea I-EXPLORATION
condilar I-EXPLORATION
mandibular I-EXPLORATION
derecha, I-EXPLORATION
con I-EXPLORATION
pérdida I-EXPLORATION
de I-EXPLORATION
capa I-EXPLORATION
cortical I-EXPLORATION
y I-EXPLORATION
destrucción I-EXPLORATION
hasta I-EXPLORATION
la I-EXPLORATION
medular I-EXPLORATION
ósea. I-EXPLORATION
Por I-EXPLORATION
lo I-EXPLORATION
anterior I-EXPLORATION
se I-EXPLORATION
interconsulta I-EXPLORATION
a I-EXPLORATION
cirugía I-EXPLORATION
maxilofacial. I-EXPLORATION
Al I-EXPLORATION
examen I-EXPLORATION
se I-EXPLORATION
aprecia I-EXPLORATION
el I-EXPLORATION
aumento I-EXPLORATION
de I-EXPLORATION
volumen I-EXPLORATION
preauricular I-EXPLORATION
derecho I-EXPLORATION
de I-EXPLORATION
límites I-EXPLORATION
difusos, I-EXPLORATION
consistencia I-EXPLORATION
firme, I-EXPLORATION
con I-EXPLORATION
aumento I-EXPLORATION
de I-EXPLORATION
temperatura I-EXPLORATION
local I-EXPLORATION
y I-EXPLORATION
eritema I-EXPLORATION
asociados. I-EXPLORATION
El I-EXPLORATION
examen I-EXPLORATION
funcional I-EXPLORATION
revela I-EXPLORATION
disminución I-EXPLORATION
considerable I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
apertura I-EXPLORATION
bucal I-EXPLORATION
de I-EXPLORATION
20 I-EXPLORATION
mm I-EXPLORATION
aproximadamente I-EXPLORATION
con I-EXPLORATION
movimientos I-EXPLORATION
de I-EXPLORATION
lateralidad I-EXPLORATION
conservados, I-EXPLORATION
asociándose I-EXPLORATION
a I-EXPLORATION
artralgia I-EXPLORATION
exacerbada I-EXPLORATION
por I-EXPLORATION
la I-EXPLORATION
función. I-EXPLORATION
Al I-EXPLORATION
examen I-EXPLORATION
hay I-EXPLORATION
ausencia I-EXPLORATION
de I-EXPLORATION
múltiples I-EXPLORATION
piezas I-EXPLORATION
dentarias I-EXPLORATION
posteriores I-EXPLORATION
tanto I-EXPLORATION
superiores I-EXPLORATION
como I-EXPLORATION
inferiores. I-EXPLORATION
La I-EXPLORATION
resonancia I-EXPLORATION
nuclear I-EXPLORATION
magnética I-EXPLORATION
(RNM) I-EXPLORATION
muestra I-EXPLORATION
cambios I-EXPLORATION
degenerativos I-EXPLORATION
y I-EXPLORATION
erosión I-EXPLORATION
a I-EXPLORATION
nivel I-EXPLORATION
cortical I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
vertiente I-EXPLORATION
anterior I-EXPLORATION
del I-EXPLORATION
cóndilo I-EXPLORATION
mandibular I-EXPLORATION
además I-EXPLORATION
de I-EXPLORATION
un I-EXPLORATION
proceso I-EXPLORATION
inflamatorio I-EXPLORATION
intracapsular I-EXPLORATION
diseminado I-EXPLORATION
a I-EXPLORATION
los I-EXPLORATION
músculos I-EXPLORATION
masticadores I-EXPLORATION
y I-EXPLORATION
al I-EXPLORATION
espacio I-EXPLORATION
temporal I-EXPLORATION
del I-EXPLORATION
mismo I-EXPLORATION
lado. I-EXPLORATION
Con I-EXPLORATION
los I-EXPLORATION
hallazgos I-EXPLORATION
clínicos I-EXPLORATION
e I-EXPLORATION
imagenológicos I-EXPLORATION
se I-EXPLORATION
plantea I-EXPLORATION
la I-EXPLORATION
hipótesis I-EXPLORATION
diagnóstica I-EXPLORATION
de I-EXPLORATION
artritis I-EXPLORATION
infecciosa I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
ATM I-EXPLORATION
por I-EXPLORATION
continuidad. I-EXPLORATION
<EOS> I-EXPLORATION
Luego B-TREATMENT
de I-TREATMENT
establecido I-TREATMENT
el I-TREATMENT
diagnóstico I-TREATMENT
de I-TREATMENT
otitis I-TREATMENT
necrotizante I-TREATMENT
y I-TREATMENT
mastoiditis, I-TREATMENT
es I-TREATMENT
ingresada I-TREATMENT
a I-TREATMENT
pabellón I-TREATMENT
por I-TREATMENT
parte I-TREATMENT
del I-TREATMENT
equipo I-TREATMENT
de I-TREATMENT
ORL I-TREATMENT
para I-TREATMENT
realizar I-TREATMENT
una I-TREATMENT
mastoidectomía I-TREATMENT
radical I-TREATMENT
modificada. I-TREATMENT
Posteriormente B-EXPLORATION
se I-EXPLORATION
realiza I-EXPLORATION
una I-EXPLORATION
punción I-EXPLORATION
intraarticular I-EXPLORATION
para I-EXPLORATION
estudio I-EXPLORATION
del I-EXPLORATION
contenido, I-EXPLORATION
donde I-EXPLORATION
se I-EXPLORATION
aprecia I-EXPLORATION
salida I-EXPLORATION
de I-EXPLORATION
contenido I-EXPLORATION
líquido I-EXPLORATION
turbio I-EXPLORATION
y I-EXPLORATION
seropurulento I-EXPLORATION
que I-EXPLORATION
se I-EXPLORATION
envía I-EXPLORATION
a I-EXPLORATION
cultivo I-EXPLORATION
bacteriológico, I-EXPLORATION
el I-EXPLORATION
cual I-EXPLORATION
resulta I-EXPLORATION
negativo I-EXPLORATION
a I-EXPLORATION
las I-EXPLORATION
72 I-EXPLORATION
h I-EXPLORATION
de I-EXPLORATION
incubación. I-EXPLORATION
Se I-EXPLORATION
realiza I-EXPLORATION
además I-EXPLORATION
una I-EXPLORATION
artroscentesis I-EXPLORATION
con I-EXPLORATION
doble I-EXPLORATION
aguja I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
ATM I-EXPLORATION
según I-EXPLORATION
la I-EXPLORATION
técnica I-EXPLORATION
de I-EXPLORATION
Nitzan I-EXPLORATION
et I-EXPLORATION
al13, I-EXPLORATION
realizando I-EXPLORATION
un I-EXPLORATION
lavado I-EXPLORATION
profuso I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
articulación I-EXPLORATION
con I-EXPLORATION
solución I-EXPLORATION
salina. I-EXPLORATION
La B-EVOLUTION
paciente I-EVOLUTION
posterior I-EVOLUTION
a I-EVOLUTION
estas I-EVOLUTION
intervenciones I-EVOLUTION
mejora I-EVOLUTION
su I-EVOLUTION
condición I-EVOLUTION
general, I-EVOLUTION
siendo I-EVOLUTION
dada I-EVOLUTION
de I-EVOLUTION
alta I-EVOLUTION
con I-EVOLUTION
disminución I-EVOLUTION
franca I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
sintomatología, I-EVOLUTION
del I-EVOLUTION
aumento I-EVOLUTION
de I-EVOLUTION
volumen I-EVOLUTION
y I-EVOLUTION
una I-EVOLUTION
mejoría I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
apertura I-EVOLUTION
bucal I-EVOLUTION
llegando I-EVOLUTION
hasta I-EVOLUTION
los I-EVOLUTION
40 I-EVOLUTION
mm. I-EVOLUTION
<EOS> I-EVOLUTION
Al I-EVOLUTION
control I-EVOLUTION
al I-EVOLUTION
mes, I-EVOLUTION
se I-EVOLUTION
presenta I-EVOLUTION
asintomática. I-EVOLUTION
Sin I-EVOLUTION
embargo, I-EVOLUTION
se I-EVOLUTION
aprecia I-EVOLUTION
la I-EVOLUTION
presencia I-EVOLUTION
de I-EVOLUTION
un I-EVOLUTION
ruido I-EVOLUTION
articular I-EVOLUTION
en I-EVOLUTION
apertura I-EVOLUTION
y I-EVOLUTION
cierre I-EVOLUTION
el I-EVOLUTION
cual I-EVOLUTION
evoluciona I-EVOLUTION
a I-EVOLUTION
crépito I-EVOLUTION
en I-EVOLUTION
los I-EVOLUTION
siguientes I-EVOLUTION
controles. I-EVOLUTION
Es B-DERIVED_FROM/TO
derivada I-DERIVED_FROM/TO
a I-DERIVED_FROM/TO
tratamiento I-DERIVED_FROM/TO
protésico I-DERIVED_FROM/TO
para I-DERIVED_FROM/TO
mejorar I-DERIVED_FROM/TO
la I-DERIVED_FROM/TO
estabilidad I-DERIVED_FROM/TO
oclusal I-DERIVED_FROM/TO
y I-DERIVED_FROM/TO
por I-DERIVED_FROM/TO
ende I-DERIVED_FROM/TO
disminuir I-DERIVED_FROM/TO
la I-DERIVED_FROM/TO
sobrecarga I-DERIVED_FROM/TO
articular. I-DERIVED_FROM/TO
Se B-EXPLORATION
pide I-EXPLORATION
TAC I-EXPLORATION
de I-EXPLORATION
control I-EXPLORATION
a I-EXPLORATION
los I-EXPLORATION
2 I-EXPLORATION
meses I-EXPLORATION
el I-EXPLORATION
cual I-EXPLORATION
confirma I-EXPLORATION
una I-EXPLORATION
regeneración I-EXPLORATION
parcial I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
cortical I-EXPLORATION
ósea I-EXPLORATION
condilar. I-EXPLORATION
Actualmente, B-EVOLUTION
cuatro I-EVOLUTION
años I-EVOLUTION
después, I-EVOLUTION
se I-EVOLUTION
encuentra I-EVOLUTION
asintomática, I-EVOLUTION
con I-EVOLUTION
dinámica I-EVOLUTION
mandibular I-EVOLUTION
conservada. I-EVOLUTION
Sin I-EVOLUTION
embargo, I-EVOLUTION
como I-EVOLUTION
secuela I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
otitis I-EVOLUTION
media I-EVOLUTION
y I-EVOLUTION
posterior I-EVOLUTION
mastoiditis I-EVOLUTION
queda I-EVOLUTION
con I-EVOLUTION
alteraciones I-EVOLUTION
auditivas I-EVOLUTION
a I-EVOLUTION
la I-EVOLUTION
percepción I-EVOLUTION
de I-EVOLUTION
ruidos I-EVOLUTION
graves I-EVOLUTION
además I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
persistencia I-EVOLUTION
de I-EVOLUTION
crépito I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
ATM I-EVOLUTION
derecha I-EVOLUTION
debido I-EVOLUTION
al I-EVOLUTION
daño I-EVOLUTION
irreversible I-EVOLUTION
de I-EVOLUTION
los I-EVOLUTION
tejidos I-EVOLUTION
intraarticulares. I-EVOLUTION
<EOS> I-EVOLUTION
Hombre B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
45 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
80 I-PRESENT_ILLNESS
kg, I-PRESENT_ILLNESS
talla I-PRESENT_ILLNESS
1, I-PRESENT_ILLNESS
72 I-PRESENT_ILLNESS
m, I-PRESENT_ILLNESS
IMC I-PRESENT_ILLNESS
27, I-PRESENT_ILLNESS
11 I-PRESENT_ILLNESS
kg/m2, I-PRESENT_ILLNESS
portador B-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
dislipidemia, I-PAST_MEDICAL_HISTORY
sin I-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
familiares I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
DM. I-PAST_MEDICAL_HISTORY
Inicia B-PRESENT_ILLNESS
un I-PRESENT_ILLNESS
cuadro I-PRESENT_ILLNESS
caracterizado I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
polidipsia, I-PRESENT_ILLNESS
poliuria, I-PRESENT_ILLNESS
cansancio I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
calambres. I-PRESENT_ILLNESS
Al I-PRESENT_ILLNESS
mes I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
evolución I-PRESENT_ILLNESS
consulta I-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
un I-PRESENT_ILLNESS
servicio I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
urgencia. I-PRESENT_ILLNESS
En B-EXPLORATION
el I-EXPLORATION
examen I-EXPLORATION
físico I-EXPLORATION
destacan I-EXPLORATION
piel I-EXPLORATION
y I-EXPLORATION
mucosas I-EXPLORATION
secas, I-EXPLORATION
acantosis I-EXPLORATION
nigricans I-EXPLORATION
en I-EXPLORATION
cuello, I-EXPLORATION
normotenso I-EXPLORATION
y I-EXPLORATION
pérdida I-EXPLORATION
de I-EXPLORATION
8 I-EXPLORATION
kilos I-EXPLORATION
de I-EXPLORATION
peso. I-EXPLORATION
<EOS> I-EXPLORATION
Se I-EXPLORATION
realizan I-EXPLORATION
exámenes I-EXPLORATION
y I-EXPLORATION
se I-EXPLORATION
hospitaliza I-EXPLORATION
con I-EXPLORATION
el I-EXPLORATION
diagnóstico I-EXPLORATION
de I-EXPLORATION
cetoacidosis I-EXPLORATION
diabética I-EXPLORATION
(CAD). I-EXPLORATION
Se B-TREATMENT
inicia I-TREATMENT
solución I-TREATMENT
solución I-TREATMENT
salina I-TREATMENT
0, I-TREATMENT
9% I-TREATMENT
1.000 I-TREATMENT
cc I-TREATMENT
con I-TREATMENT
cloruro I-TREATMENT
de I-TREATMENT
potasio I-TREATMENT
e I-TREATMENT
insulina I-TREATMENT
rápida I-TREATMENT
(IR) I-TREATMENT
8 I-TREATMENT
U I-TREATMENT
endovenosa. I-TREATMENT
A I-TREATMENT
la I-TREATMENT
hora, I-TREATMENT
se I-TREATMENT
continúa I-TREATMENT
con I-TREATMENT
el I-TREATMENT
aporte I-TREATMENT
de I-TREATMENT
volumen I-TREATMENT
(3.000 I-TREATMENT
cc) I-TREATMENT
e I-TREATMENT
IR I-TREATMENT
sc I-TREATMENT
(subcutánea) I-TREATMENT
cada I-TREATMENT
6 I-TREATMENT
h, I-TREATMENT
según I-TREATMENT
glicemias I-TREATMENT
capilares. I-TREATMENT
Se B-EXPLORATION
descarta I-EXPLORATION
foco I-EXPLORATION
infeccioso. I-EXPLORATION
A B-TREATMENT
las I-TREATMENT
8 I-TREATMENT
h I-TREATMENT
de I-TREATMENT
tratamiento, I-TREATMENT
al I-TREATMENT
revertir I-TREATMENT
la I-TREATMENT
acidosis I-TREATMENT
y I-TREATMENT
lograr I-TREATMENT
glicemias I-TREATMENT
< I-TREATMENT
250 I-TREATMENT
mg/dl, I-TREATMENT
se I-TREATMENT
inicia I-TREATMENT
terapia I-TREATMENT
basal I-TREATMENT
bolos I-TREATMENT
con I-TREATMENT
insulina I-TREATMENT
NPH I-TREATMENT
(Neutral I-TREATMENT
Protamine I-TREATMENT
Hagedorn) I-TREATMENT
e I-TREATMENT
IR I-TREATMENT
antes I-TREATMENT
del I-TREATMENT
desayuno I-TREATMENT
(AD) I-TREATMENT
y I-TREATMENT
cena, I-TREATMENT
más I-TREATMENT
refuerzos I-TREATMENT
de I-TREATMENT
IR I-TREATMENT
pre-prandiales, I-TREATMENT
lográndose B-EVOLUTION
una I-EVOLUTION
buena I-EVOLUTION
respuesta I-EVOLUTION
clínica. I-EVOLUTION
Al B-TREATMENT
alta I-TREATMENT
se I-TREATMENT
indica I-TREATMENT
régimen I-TREATMENT
con I-TREATMENT
180 I-TREATMENT
g I-TREATMENT
de I-TREATMENT
hidratos I-TREATMENT
de I-TREATMENT
carbono, I-TREATMENT
insulina I-TREATMENT
NPH I-TREATMENT
18 I-TREATMENT
U I-TREATMENT
AD I-TREATMENT
y I-TREATMENT
6 I-TREATMENT
U I-TREATMENT
a I-TREATMENT
las I-TREATMENT
22 I-TREATMENT
h, I-TREATMENT
con I-TREATMENT
automonitoreo I-TREATMENT
de I-TREATMENT
glicemias I-TREATMENT
capilares. I-TREATMENT
<EOS> I-TREATMENT
*HCO3 I-TREATMENT
Bicarbonato I-TREATMENT
de I-TREATMENT
sodio. I-TREATMENT
**HbA1c I-TREATMENT
Hemoglobina I-TREATMENT
glicosilada I-TREATMENT
A1c. I-TREATMENT
<EOS> I-TREATMENT
A B-EVOLUTION
las I-EVOLUTION
2 I-EVOLUTION
semanas I-EVOLUTION
el I-EVOLUTION
paciente I-EVOLUTION
se I-EVOLUTION
encuentra I-EVOLUTION
asintomático I-EVOLUTION
con I-EVOLUTION
glicemias I-EVOLUTION
capilares I-EVOLUTION
de I-EVOLUTION
ayunas I-EVOLUTION
70-110 I-EVOLUTION
mg/dl, I-EVOLUTION
pre-prandiales I-EVOLUTION
100-130 I-EVOLUTION
mg/dl I-EVOLUTION
y I-EVOLUTION
post-prandiales I-EVOLUTION
160-180 I-EVOLUTION
mg/dl. I-EVOLUTION
Dada B-TREATMENT
su I-TREATMENT
buena I-TREATMENT
evolución I-TREATMENT
se I-TREATMENT
disminuye I-TREATMENT
la I-TREATMENT
insulina I-TREATMENT
NPH I-TREATMENT
a I-TREATMENT
6 I-TREATMENT
U I-TREATMENT
a I-TREATMENT
las I-TREATMENT
22 I-TREATMENT
h I-TREATMENT
y I-TREATMENT
se I-TREATMENT
agrega I-TREATMENT
metformina I-TREATMENT
850 I-TREATMENT
mg I-TREATMENT
2 I-TREATMENT
veces I-TREATMENT
al I-TREATMENT
día. I-TREATMENT
Controlado B-EVOLUTION
al I-EVOLUTION
mes, I-EVOLUTION
relata I-EVOLUTION
episodios I-EVOLUTION
de I-EVOLUTION
hipoglicemias I-EVOLUTION
de I-EVOLUTION
60 I-EVOLUTION
mg/dl I-EVOLUTION
durante I-EVOLUTION
el I-EVOLUTION
día I-EVOLUTION
y I-EVOLUTION
los I-EVOLUTION
exámenes I-EVOLUTION
revelan I-EVOLUTION
buen I-EVOLUTION
control I-EVOLUTION
metabólico. I-EVOLUTION
<EOS> I-EVOLUTION
*HbA1c I-EVOLUTION
Hemoglobina I-EVOLUTION
glicosilada I-EVOLUTION
A1c. I-EVOLUTION
<EOS> I-EVOLUTION
Dado B-EXPLORATION
el I-EXPLORATION
inicio I-EXPLORATION
de I-EXPLORATION
una I-EXPLORATION
DM I-EXPLORATION
en I-EXPLORATION
CAD I-EXPLORATION
(sospecha I-EXPLORATION
de I-EXPLORATION
DM1), I-EXPLORATION
en I-EXPLORATION
un I-EXPLORATION
paciente I-EXPLORATION
con I-EXPLORATION
características I-EXPLORATION
fenotípicas I-EXPLORATION
de I-EXPLORATION
DM2, I-EXPLORATION
se I-EXPLORATION
solicitaron I-EXPLORATION
marcadores I-EXPLORATION
inmunológicos I-EXPLORATION
para I-EXPLORATION
diabetes: I-EXPLORATION
anticuerpos I-EXPLORATION
anti I-EXPLORATION
células I-EXPLORATION
beta I-EXPLORATION
(ICA), I-EXPLORATION
anticuerpos I-EXPLORATION
anti I-EXPLORATION
insulina I-EXPLORATION
(IAA), I-EXPLORATION
anticuerpos I-EXPLORATION
anti I-EXPLORATION
ácido I-EXPLORATION
glutámico I-EXPLORATION
descarboxilasa I-EXPLORATION
(anti-GAD), I-EXPLORATION
anticuerpos I-EXPLORATION
anti I-EXPLORATION
tirosina I-EXPLORATION
fosfatasa I-EXPLORATION
(IA2), I-EXPLORATION
los I-EXPLORATION
que I-EXPLORATION
resultaron I-EXPLORATION
negativos. I-EXPLORATION
El I-EXPLORATION
péptido I-EXPLORATION
C I-EXPLORATION
en I-EXPLORATION
ayunas I-EXPLORATION
fue I-EXPLORATION
normal I-EXPLORATION
(3, I-EXPLORATION
2 I-EXPLORATION
ng/ml). I-EXPLORATION
En B-TREATMENT
estas I-TREATMENT
condiciones I-TREATMENT
se I-TREATMENT
suspendió I-TREATMENT
la I-TREATMENT
insulina, I-TREATMENT
manteniéndose I-TREATMENT
las I-TREATMENT
medidas I-TREATMENT
no I-TREATMENT
farmacológicas I-TREATMENT
y I-TREATMENT
la I-TREATMENT
metformina. I-TREATMENT
<EOS> I-TREATMENT
El B-EVOLUTION
paciente I-EVOLUTION
continúa I-EVOLUTION
en I-EVOLUTION
controles I-EVOLUTION
periódicos I-EVOLUTION
durante I-EVOLUTION
24 I-EVOLUTION
meses I-EVOLUTION
post I-EVOLUTION
alta, I-EVOLUTION
lográndose I-EVOLUTION
una I-EVOLUTION
reducción I-EVOLUTION
de I-EVOLUTION
10 I-EVOLUTION
kg I-EVOLUTION
de I-EVOLUTION
peso, I-EVOLUTION
glicemias I-EVOLUTION
de I-EVOLUTION
ayunas I-EVOLUTION
inferiores I-EVOLUTION
a100 I-EVOLUTION
mg/dl, I-EVOLUTION
HbA1c I-EVOLUTION
5, I-EVOLUTION
9%, I-EVOLUTION
y I-EVOLUTION
perfil I-EVOLUTION
lipídico I-EVOLUTION
y I-EVOLUTION
presión I-EVOLUTION
arterial I-EVOLUTION
normales. I-EVOLUTION
<EOS> I-EVOLUTION
Hombre B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
42 I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
edad, I-PRESENT_ILLNESS
agricultor, B-PAST_MEDICAL_HISTORY
sin I-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
importancia, I-PAST_MEDICAL_HISTORY
consulta B-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
múltiples I-PRESENT_ILLNESS
ocasiones I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
3 I-PRESENT_ILLNESS
meses I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
evolución I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
cefalea I-PRESENT_ILLNESS
con I-PRESENT_ILLNESS
sensación I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
pesadez I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
mareos I-PRESENT_ILLNESS
sin I-PRESENT_ILLNESS
respuesta I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
analgésicos I-PRESENT_ILLNESS
comunes. I-PRESENT_ILLNESS
En B-EVOLUTION
su I-EVOLUTION
evolución I-EVOLUTION
presenta I-EVOLUTION
ataxia I-EVOLUTION
y I-EVOLUTION
lateropulsión I-EVOLUTION
derecha. I-EVOLUTION
Una I-EVOLUTION
semana I-EVOLUTION
previo I-EVOLUTION
a I-EVOLUTION
su I-EVOLUTION
ingreso I-EVOLUTION
presenta I-EVOLUTION
endoforia I-EVOLUTION
derecha, I-EVOLUTION
diplopia I-EVOLUTION
y I-EVOLUTION
postración I-EVOLUTION
en I-EVOLUTION
cama I-EVOLUTION
por I-EVOLUTION
vértigo I-EVOLUTION
intenso. I-EVOLUTION
Se B-EXPLORATION
realiza I-EXPLORATION
TC I-EXPLORATION
simple I-EXPLORATION
de I-EXPLORATION
cráneo I-EXPLORATION
que I-EXPLORATION
demostró I-EXPLORATION
masa I-EXPLORATION
en I-EXPLORATION
fosa I-EXPLORATION
posterior I-EXPLORATION
y I-EXPLORATION
hemorragia I-EXPLORATION
subaracnoidea I-EXPLORATION
por I-EXPLORATION
lo I-EXPLORATION
que I-EXPLORATION
se I-EXPLORATION
traslada I-EXPLORATION
a I-EXPLORATION
hospital I-EXPLORATION
de I-EXPLORATION
nivel I-EXPLORATION
terciario. I-EXPLORATION
Ingresa B-EVOLUTION
al I-EVOLUTION
servicio I-EVOLUTION
de I-EVOLUTION
urgencias, I-EVOLUTION
consciente I-EVOLUTION
y I-EVOLUTION
orientado, I-EVOLUTION
con I-EVOLUTION
cefalea, I-EVOLUTION
diplopia I-EVOLUTION
e I-EVOLUTION
incapacidad I-EVOLUTION
para I-EVOLUTION
la I-EVOLUTION
marcha I-EVOLUTION
por I-EVOLUTION
vértigo. I-EVOLUTION
Su B-EXPLORATION
examen I-EXPLORATION
físico I-EXPLORATION
sólo I-EXPLORATION
demostró I-EXPLORATION
endoforia I-EXPLORATION
derecha, I-EXPLORATION
marcha I-EXPLORATION
inestable I-EXPLORATION
y I-EXPLORATION
lateropulsión I-EXPLORATION
derecha. I-EXPLORATION
Se I-EXPLORATION
realizó I-EXPLORATION
una I-EXPLORATION
RM I-EXPLORATION
simple I-EXPLORATION
y I-EXPLORATION
contrastada I-EXPLORATION
que I-EXPLORATION
reportó I-EXPLORATION
imagen I-EXPLORATION
compatible I-EXPLORATION
con I-EXPLORATION
hemangioblastoma. I-EXPLORATION
En I-EXPLORATION
exámenes I-EXPLORATION
de I-EXPLORATION
ingreso I-EXPLORATION
se I-EXPLORATION
evidenció I-EXPLORATION
recuento I-EXPLORATION
plaquetario I-EXPLORATION
de I-EXPLORATION
10.000/mL, I-EXPLORATION
sin I-EXPLORATION
otras I-EXPLORATION
alteraciones I-EXPLORATION
en I-EXPLORATION
serie I-EXPLORATION
roja I-EXPLORATION
ni I-EXPLORATION
blanca I-EXPLORATION
por I-EXPLORATION
lo I-EXPLORATION
que I-EXPLORATION
se I-EXPLORATION
difirió I-EXPLORATION
manejo I-EXPLORATION
quirúrgico I-EXPLORATION
y I-EXPLORATION
se I-EXPLORATION
iniciaron I-EXPLORATION
estudios I-EXPLORATION
complementarios. I-EXPLORATION
El I-EXPLORATION
perfil I-EXPLORATION
de I-EXPLORATION
autoinmunidad I-EXPLORATION
(ANAS, I-EXPLORATION
ENAS, I-EXPLORATION
Coombs, I-EXPLORATION
inmunoglobulinas, I-EXPLORATION
anticoagulante I-EXPLORATION
lúpico I-EXPLORATION
y I-EXPLORATION
anticardiolipinas) I-EXPLORATION
infeccioso I-EXPLORATION
(VIH, I-EXPLORATION
Hepatitis I-EXPLORATION
B I-EXPLORATION
y I-EXPLORATION
C), I-EXPLORATION
pruebas I-EXPLORATION
de I-EXPLORATION
coagulación I-EXPLORATION
(PT, I-EXPLORATION
PTT) I-EXPLORATION
así I-EXPLORATION
como I-EXPLORATION
los I-EXPLORATION
niveles I-EXPLORATION
de I-EXPLORATION
micronutrientes I-EXPLORATION
fueron I-EXPLORATION
normales. I-EXPLORATION
No I-EXPLORATION
se I-EXPLORATION
consideró I-EXPLORATION
medición I-EXPLORATION
de I-EXPLORATION
dímero I-EXPLORATION
D I-EXPLORATION
y I-EXPLORATION
fibrinógeno I-EXPLORATION
ante I-EXPLORATION
ausencia I-EXPLORATION
de I-EXPLORATION
síntomas I-EXPLORATION
sugerentes I-EXPLORATION
de I-EXPLORATION
coagulopatía. I-EXPLORATION
<EOS> I-EXPLORATION
El B-EVOLUTION
paciente I-EVOLUTION
presentó I-EVOLUTION
deterioro I-EVOLUTION
neurológico I-EVOLUTION
por B-TREATMENT
lo I-TREATMENT
que I-TREATMENT
se I-TREATMENT
decidió I-TREATMENT
llevar I-TREATMENT
a I-TREATMENT
cirugía I-TREATMENT
urgente I-TREATMENT
previo I-TREATMENT
soporte I-TREATMENT
transfusional I-TREATMENT
de I-TREATMENT
plaquetas I-TREATMENT
para I-TREATMENT
resección I-TREATMENT
de I-TREATMENT
la I-TREATMENT
masa I-TREATMENT
en I-TREATMENT
SNC. I-TREATMENT
Por I-TREATMENT
trepanación I-TREATMENT
occipital I-TREATMENT
derecha I-TREATMENT
se I-TREATMENT
pasa I-TREATMENT
catéter I-TREATMENT
de I-TREATMENT
derivación I-TREATMENT
ventricular I-TREATMENT
externa I-TREATMENT
al I-TREATMENT
ventrículo I-TREATMENT
lateral I-TREATMENT
ipsilateral, I-TREATMENT
con I-TREATMENT
obtención I-TREATMENT
de I-TREATMENT
LCR I-TREATMENT
a I-TREATMENT
presión. I-TREATMENT
Se I-TREATMENT
identificó I-TREATMENT
tumor I-TREATMENT
en I-TREATMENT
fosa I-TREATMENT
posterior, I-TREATMENT
realizándose I-TREATMENT
drenaje I-TREATMENT
de I-TREATMENT
quiste I-TREATMENT
tumoral I-TREATMENT
aspecto I-TREATMENT
de I-TREATMENT
hemangioblastoma, I-TREATMENT
muy I-TREATMENT
vascularizado, I-TREATMENT
con I-TREATMENT
resección I-TREATMENT
macroscópica I-TREATMENT
total. I-TREATMENT
El B-EXPLORATION
informe I-EXPLORATION
de I-EXPLORATION
patología I-EXPLORATION
fue I-EXPLORATION
compatible I-EXPLORATION
con I-EXPLORATION
hemangioblastoma. I-EXPLORATION
Dada I-EXPLORATION
la I-EXPLORATION
asociación I-EXPLORATION
con I-EXPLORATION
el I-EXPLORATION
síndrome I-EXPLORATION
de I-EXPLORATION
Von I-EXPLORATION
Hippel I-EXPLORATION
Lindau, I-EXPLORATION
se I-EXPLORATION
consideró I-EXPLORATION
adicionalmente I-EXPLORATION
búsqueda I-EXPLORATION
de I-EXPLORATION
otros I-EXPLORATION
tumores I-EXPLORATION
a I-EXPLORATION
nivel I-EXPLORATION
abdominal I-EXPLORATION
con I-EXPLORATION
ecografía I-EXPLORATION
la I-EXPLORATION
cual I-EXPLORATION
fue I-EXPLORATION
negativa. I-EXPLORATION
<EOS> I-EXPLORATION
Es B-EVOLUTION
trasladado I-EVOLUTION
a I-EVOLUTION
unidad I-EVOLUTION
de I-EVOLUTION
cuidado I-EVOLUTION
crítico I-EVOLUTION
con I-EVOLUTION
excelente I-EVOLUTION
respuesta I-EVOLUTION
neurológica I-EVOLUTION
sin I-EVOLUTION
resolución I-EVOLUTION
de I-EVOLUTION
trombocitopenia I-EVOLUTION
–entre I-EVOLUTION
5.000 I-EVOLUTION
y I-EVOLUTION
169.000/mL– I-EVOLUTION
requiriendo I-EVOLUTION
en I-EVOLUTION
varias I-EVOLUTION
ocasiones I-EVOLUTION
soporte I-EVOLUTION
transfusional I-EVOLUTION
buscando I-EVOLUTION
recuentos I-EVOLUTION
> I-EVOLUTION
100.000/mL. I-EVOLUTION
El B-EXPLORATION
seguimiento I-EXPLORATION
tomográfico I-EXPLORATION
(Día I-EXPLORATION
2 I-EXPLORATION
y I-EXPLORATION
7 I-EXPLORATION
postoperatorio) I-EXPLORATION
demostraban I-EXPLORATION
hematoma I-EXPLORATION
subdural I-EXPLORATION
con I-EXPLORATION
signos I-EXPLORATION
de I-EXPLORATION
herniación I-EXPLORATION
en I-EXPLORATION
resolución. I-EXPLORATION
Es I-EXPLORATION
llevado I-EXPLORATION
a I-EXPLORATION
estudio I-EXPLORATION
de I-EXPLORATION
médula I-EXPLORATION
ósea I-EXPLORATION
(mielograma, I-EXPLORATION
biopsia, I-EXPLORATION
cariotipo) I-EXPLORATION
todos I-EXPLORATION
normales I-EXPLORATION
y B-TREATMENT
con I-TREATMENT
sospecha I-TREATMENT
de I-TREATMENT
púrpura I-TREATMENT
trombócitopenica I-TREATMENT
inmune I-TREATMENT
(PTI) I-TREATMENT
se I-TREATMENT
indicó I-TREATMENT
glucocorticoides I-TREATMENT
(hidrocortisona I-TREATMENT
50 I-TREATMENT
mg I-TREATMENT
c/6 I-TREATMENT
h I-TREATMENT
por I-TREATMENT
2 I-TREATMENT
días, I-TREATMENT
dexametasona I-TREATMENT
4 I-TREATMENT
mg I-TREATMENT
c/6 I-TREATMENT
h I-TREATMENT
por I-TREATMENT
10 I-TREATMENT
días) I-TREATMENT
sin I-TREATMENT
respuesta. I-TREATMENT
En I-TREATMENT
vista I-TREATMENT
de I-TREATMENT
riesgo I-TREATMENT
de I-TREATMENT
sangrado I-TREATMENT
intracerebral I-TREATMENT
se I-TREATMENT
decidió I-TREATMENT
aplicar I-TREATMENT
inmunoglobulina I-TREATMENT
IV I-TREATMENT
1 I-TREATMENT
g/kg I-TREATMENT
por I-TREATMENT
dos I-TREATMENT
dosis I-TREATMENT
espaciadas I-TREATMENT
una I-TREATMENT
semana I-TREATMENT
más I-TREATMENT
prednisona I-TREATMENT
a I-TREATMENT
1 I-TREATMENT
mg/kg/día I-TREATMENT
sin I-TREATMENT
mejoría I-TREATMENT
clínica I-TREATMENT
por I-TREATMENT
lo I-TREATMENT
que I-TREATMENT
se I-TREATMENT
programó I-TREATMENT
para I-TREATMENT
esplenectomía I-TREATMENT
laparoscópica I-TREATMENT
20 I-TREATMENT
días I-TREATMENT
después I-TREATMENT
del I-TREATMENT
procedimiento I-TREATMENT
neuroquirúrgico. I-TREATMENT
El I-TREATMENT
procedimiento I-TREATMENT
se I-TREATMENT
desarrolla I-TREATMENT
sin I-TREATMENT
complicaciones I-TREATMENT
y I-TREATMENT
presenta I-TREATMENT
recuento I-TREATMENT
plaquetario I-TREATMENT
de I-TREATMENT
165.000/mL I-TREATMENT
en I-TREATMENT
el I-TREATMENT
postoperatorio I-TREATMENT
inmediato, I-TREATMENT
con I-TREATMENT
bazo I-TREATMENT
histológicamente I-TREATMENT
normal. I-TREATMENT
Cuarenta B-EVOLUTION
y I-EVOLUTION
ocho I-EVOLUTION
horas I-EVOLUTION
después, I-EVOLUTION
el I-EVOLUTION
paciente I-EVOLUTION
presenta I-EVOLUTION
nuevo I-EVOLUTION
deterioro I-EVOLUTION
neurológico I-EVOLUTION
requiriendo I-EVOLUTION
reingreso I-EVOLUTION
a I-EVOLUTION
UCI. I-EVOLUTION
Recuento B-EXPLORATION
plaquetario I-EXPLORATION
126.000/mL, I-EXPLORATION
tromboelastografía I-EXPLORATION
con I-EXPLORATION
MA I-EXPLORATION
elevado I-EXPLORATION
sugerente I-EXPLORATION
de I-EXPLORATION
hiperagregabilidad I-EXPLORATION
plaquetaria I-EXPLORATION
y I-EXPLORATION
TC I-EXPLORATION
de I-EXPLORATION
cráneo I-EXPLORATION
con I-EXPLORATION
hematoma I-EXPLORATION
subdural I-EXPLORATION
derecho I-EXPLORATION
subagudo I-EXPLORATION
con I-EXPLORATION
efecto I-EXPLORATION
de I-EXPLORATION
masa I-EXPLORATION
y I-EXPLORATION
tendencia I-EXPLORATION
a I-EXPLORATION
herniación I-EXPLORATION
con I-EXPLORATION
hipodensidad I-EXPLORATION
de I-EXPLORATION
todo I-EXPLORATION
el I-EXPLORATION
hemisferio I-EXPLORATION
cerebral I-EXPLORATION
ipsilateral I-EXPLORATION
sugestivo I-EXPLORATION
de I-EXPLORATION
isquemia I-EXPLORATION
por B-TREATMENT
lo I-TREATMENT
que I-TREATMENT
se I-TREATMENT
lleva I-TREATMENT
nuevamente I-TREATMENT
a I-TREATMENT
cirugía I-TREATMENT
de I-TREATMENT
emergencia I-TREATMENT
–drepanotomía–. I-TREATMENT
El B-EXPLORATION
TC I-EXPLORATION
posterior I-EXPLORATION
no I-EXPLORATION
demostró I-EXPLORATION
cambios I-EXPLORATION
significativos. I-EXPLORATION
Con B-EVOLUTION
estos I-EVOLUTION
hallazgos I-EVOLUTION
se I-EVOLUTION
retira I-EVOLUTION
sedación I-EVOLUTION
del I-EVOLUTION
paciente, I-EVOLUTION
2 I-EVOLUTION
días I-EVOLUTION
después I-EVOLUTION
presenta I-EVOLUTION
hipernatremia I-EVOLUTION
y I-EVOLUTION
fiebre, I-EVOLUTION
luego I-EVOLUTION
de I-EVOLUTION
dos I-EVOLUTION
evaluaciones I-EVOLUTION
se I-EVOLUTION
declara I-EVOLUTION
muerte I-EVOLUTION
encefálica. I-EVOLUTION
<EOS> I-EVOLUTION
Paciente B-PRESENT_ILLNESS
sexo I-PRESENT_ILLNESS
masculino, I-PRESENT_ILLNESS
81 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
portador B-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
poliartritis I-PAST_MEDICAL_HISTORY
simétrica I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
manos, I-PAST_MEDICAL_HISTORY
que I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
un I-PAST_MEDICAL_HISTORY
inicio I-PAST_MEDICAL_HISTORY
fue I-PAST_MEDICAL_HISTORY
catalogado I-PAST_MEDICAL_HISTORY
como I-PAST_MEDICAL_HISTORY
artritis I-PAST_MEDICAL_HISTORY
seronegativa; I-PAST_MEDICAL_HISTORY
años I-PAST_MEDICAL_HISTORY
más I-PAST_MEDICAL_HISTORY
tarde I-PAST_MEDICAL_HISTORY
se I-PAST_MEDICAL_HISTORY
agregó I-PAST_MEDICAL_HISTORY
cuadro I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
dolor I-PAST_MEDICAL_HISTORY
urente I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
parestesias I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
extremidades I-PAST_MEDICAL_HISTORY
inferiores. I-PAST_MEDICAL_HISTORY
Se I-PAST_MEDICAL_HISTORY
repitió I-PAST_MEDICAL_HISTORY
el I-PAST_MEDICAL_HISTORY
estudio, I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
dado I-PAST_MEDICAL_HISTORY
MPO I-PAST_MEDICAL_HISTORY
(+) I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
biopsia I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
nervio I-PAST_MEDICAL_HISTORY
sural I-PAST_MEDICAL_HISTORY
compatible I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
vasculitis I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
vaso I-PAST_MEDICAL_HISTORY
pequeño, I-PAST_MEDICAL_HISTORY
se I-PAST_MEDICAL_HISTORY
estableció I-PAST_MEDICAL_HISTORY
el I-PAST_MEDICAL_HISTORY
diagnóstico I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
vasculitis I-PAST_MEDICAL_HISTORY
asociada I-PAST_MEDICAL_HISTORY
a I-PAST_MEDICAL_HISTORY
ANCA I-PAST_MEDICAL_HISTORY
(MPO I-PAST_MEDICAL_HISTORY
(+)), I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
compromiso I-PAST_MEDICAL_HISTORY
pulmonar I-PAST_MEDICAL_HISTORY
(Usual I-PAST_MEDICAL_HISTORY
Interstitial I-PAST_MEDICAL_HISTORY
Pneumonia I-PAST_MEDICAL_HISTORY
[UIP], I-PAST_MEDICAL_HISTORY
demostrado I-PAST_MEDICAL_HISTORY
por I-PAST_MEDICAL_HISTORY
tomografía I-PAST_MEDICAL_HISTORY
axial I-PAST_MEDICAL_HISTORY
computada I-PAST_MEDICAL_HISTORY
[TAC]), I-PAST_MEDICAL_HISTORY
articular I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
neurológico. I-PAST_MEDICAL_HISTORY
Además, I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
antecedente I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
cardiopatía I-PAST_MEDICAL_HISTORY
coronaria, I-PAST_MEDICAL_HISTORY
insuficiencia I-PAST_MEDICAL_HISTORY
cardíaca I-PAST_MEDICAL_HISTORY
CF I-PAST_MEDICAL_HISTORY
I-II I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
enfermedad I-PAST_MEDICAL_HISTORY
renal I-PAST_MEDICAL_HISTORY
crónica I-PAST_MEDICAL_HISTORY
(ERC) I-PAST_MEDICAL_HISTORY
etapa I-PAST_MEDICAL_HISTORY
3. I-PAST_MEDICAL_HISTORY
Desde I-PAST_MEDICAL_HISTORY
el I-PAST_MEDICAL_HISTORY
punto I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
vista I-PAST_MEDICAL_HISTORY
cardiológico, I-PAST_MEDICAL_HISTORY
el I-PAST_MEDICAL_HISTORY
paciente I-PAST_MEDICAL_HISTORY
había I-PAST_MEDICAL_HISTORY
presentado I-PAST_MEDICAL_HISTORY
un I-PAST_MEDICAL_HISTORY
síndrome I-PAST_MEDICAL_HISTORY
coronario I-PAST_MEDICAL_HISTORY
agudo I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
el I-PAST_MEDICAL_HISTORY
año I-PAST_MEDICAL_HISTORY
2012, I-PAST_MEDICAL_HISTORY
cuya I-PAST_MEDICAL_HISTORY
coronariografía I-PAST_MEDICAL_HISTORY
mostraba I-PAST_MEDICAL_HISTORY
oclusión I-PAST_MEDICAL_HISTORY
del I-PAST_MEDICAL_HISTORY
ramo I-PAST_MEDICAL_HISTORY
marginal I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
estenosis I-PAST_MEDICAL_HISTORY
no I-PAST_MEDICAL_HISTORY
significativa I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
vasos I-PAST_MEDICAL_HISTORY
principales. I-PAST_MEDICAL_HISTORY
Ecocardiograma I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
hipertrofia I-PAST_MEDICAL_HISTORY
del I-PAST_MEDICAL_HISTORY
ventrículo I-PAST_MEDICAL_HISTORY
izquierdo I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
leve I-PAST_MEDICAL_HISTORY
hipertensión I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
la I-PAST_MEDICAL_HISTORY
arteria I-PAST_MEDICAL_HISTORY
pulmonar. I-PAST_MEDICAL_HISTORY
Al I-PAST_MEDICAL_HISTORY
momento I-PAST_MEDICAL_HISTORY
del I-PAST_MEDICAL_HISTORY
diagnóstico I-PAST_MEDICAL_HISTORY
se I-PAST_MEDICAL_HISTORY
intentó I-PAST_MEDICAL_HISTORY
usar I-PAST_MEDICAL_HISTORY
ciclofosfamida I-PAST_MEDICAL_HISTORY
oral, I-PAST_MEDICAL_HISTORY
sin I-PAST_MEDICAL_HISTORY
embargo, I-PAST_MEDICAL_HISTORY
el I-PAST_MEDICAL_HISTORY
paciente I-PAST_MEDICAL_HISTORY
presentó I-PAST_MEDICAL_HISTORY
pancitopenia I-PAST_MEDICAL_HISTORY
severa, I-PAST_MEDICAL_HISTORY
por I-PAST_MEDICAL_HISTORY
lo I-PAST_MEDICAL_HISTORY
que I-PAST_MEDICAL_HISTORY
se I-PAST_MEDICAL_HISTORY
suspendió. I-PAST_MEDICAL_HISTORY
<EOS> I-PAST_MEDICAL_HISTORY
En I-PAST_MEDICAL_HISTORY
tratamiento I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
mantención I-PAST_MEDICAL_HISTORY
por I-PAST_MEDICAL_HISTORY
4 I-PAST_MEDICAL_HISTORY
años I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
prednisona I-PAST_MEDICAL_HISTORY
5 I-PAST_MEDICAL_HISTORY
mg/día I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
azatioprina I-PAST_MEDICAL_HISTORY
50 I-PAST_MEDICAL_HISTORY
mg/día. I-PAST_MEDICAL_HISTORY
Estable I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
asintomático. I-PAST_MEDICAL_HISTORY
Las I-PAST_MEDICAL_HISTORY
semanas I-PAST_MEDICAL_HISTORY
previas I-PAST_MEDICAL_HISTORY
a I-PAST_MEDICAL_HISTORY
la I-PAST_MEDICAL_HISTORY
última I-PAST_MEDICAL_HISTORY
consulta I-PAST_MEDICAL_HISTORY
se I-PAST_MEDICAL_HISTORY
diagnosticó I-PAST_MEDICAL_HISTORY
reactivación I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
su I-PAST_MEDICAL_HISTORY
vasculitis, I-PAST_MEDICAL_HISTORY
caracterizada I-PAST_MEDICAL_HISTORY
por I-PAST_MEDICAL_HISTORY
reinicio I-PAST_MEDICAL_HISTORY
del I-PAST_MEDICAL_HISTORY
dolor I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
parestesias I-PAST_MEDICAL_HISTORY
en I-PAST_MEDICAL_HISTORY
extremidades I-PAST_MEDICAL_HISTORY
inferiores, I-PAST_MEDICAL_HISTORY
intenso I-PAST_MEDICAL_HISTORY
livedo I-PAST_MEDICAL_HISTORY
reticularis I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
aumento I-PAST_MEDICAL_HISTORY
progresivo I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
VHS I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
PCR, I-PAST_MEDICAL_HISTORY
decidiéndose I-PAST_MEDICAL_HISTORY
inducción I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
la I-PAST_MEDICAL_HISTORY
remisión I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
rituximab I-PAST_MEDICAL_HISTORY
(no I-PAST_MEDICAL_HISTORY
se I-PAST_MEDICAL_HISTORY
tomó I-PAST_MEDICAL_HISTORY
nueva I-PAST_MEDICAL_HISTORY
biopsia). I-PAST_MEDICAL_HISTORY
Exámenes I-PAST_MEDICAL_HISTORY
previos I-PAST_MEDICAL_HISTORY
al I-PAST_MEDICAL_HISTORY
procedimiento: I-PAST_MEDICAL_HISTORY
Hemoglobina I-PAST_MEDICAL_HISTORY
13, I-PAST_MEDICAL_HISTORY
9 I-PAST_MEDICAL_HISTORY
g/dL, I-PAST_MEDICAL_HISTORY
glóbulos I-PAST_MEDICAL_HISTORY
blancos I-PAST_MEDICAL_HISTORY
12.300/mm³, I-PAST_MEDICAL_HISTORY
VHS I-PAST_MEDICAL_HISTORY
64 I-PAST_MEDICAL_HISTORY
mm/h, I-PAST_MEDICAL_HISTORY
creatinina I-PAST_MEDICAL_HISTORY
1, I-PAST_MEDICAL_HISTORY
39 I-PAST_MEDICAL_HISTORY
mg/dL, I-PAST_MEDICAL_HISTORY
nitrógeno I-PAST_MEDICAL_HISTORY
ureico I-PAST_MEDICAL_HISTORY
23 I-PAST_MEDICAL_HISTORY
mg/dL, I-PAST_MEDICAL_HISTORY
glicemia I-PAST_MEDICAL_HISTORY
101 I-PAST_MEDICAL_HISTORY
mg/dL, I-PAST_MEDICAL_HISTORY
albúmina I-PAST_MEDICAL_HISTORY
4 I-PAST_MEDICAL_HISTORY
g/dL, I-PAST_MEDICAL_HISTORY
colesterol I-PAST_MEDICAL_HISTORY
total I-PAST_MEDICAL_HISTORY
145 I-PAST_MEDICAL_HISTORY
mg/dl, I-PAST_MEDICAL_HISTORY
bilirrubina I-PAST_MEDICAL_HISTORY
total I-PAST_MEDICAL_HISTORY
0, I-PAST_MEDICAL_HISTORY
5 I-PAST_MEDICAL_HISTORY
mg/dL. I-PAST_MEDICAL_HISTORY
<EOS> I-PAST_MEDICAL_HISTORY
Se I-PAST_MEDICAL_HISTORY
hospitalizó I-PAST_MEDICAL_HISTORY
para I-PAST_MEDICAL_HISTORY
su I-PAST_MEDICAL_HISTORY
administración, I-PAST_MEDICAL_HISTORY
premedicándose I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
metilprednisolona I-PAST_MEDICAL_HISTORY
(125 I-PAST_MEDICAL_HISTORY
mg), I-PAST_MEDICAL_HISTORY
transcurriendo I-PAST_MEDICAL_HISTORY
sin I-PAST_MEDICAL_HISTORY
incidentes I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
enviado I-PAST_MEDICAL_HISTORY
a I-PAST_MEDICAL_HISTORY
su I-PAST_MEDICAL_HISTORY
domicilio. I-PAST_MEDICAL_HISTORY
Sin I-PAST_MEDICAL_HISTORY
embargo, I-PAST_MEDICAL_HISTORY
aproximadamente I-PAST_MEDICAL_HISTORY
a I-PAST_MEDICAL_HISTORY
las I-PAST_MEDICAL_HISTORY
24 I-PAST_MEDICAL_HISTORY
h I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
su I-PAST_MEDICAL_HISTORY
infusión I-PAST_MEDICAL_HISTORY
inició I-PAST_MEDICAL_HISTORY
fiebre I-PAST_MEDICAL_HISTORY
hasta I-PAST_MEDICAL_HISTORY
39, I-PAST_MEDICAL_HISTORY
8 I-PAST_MEDICAL_HISTORY
°C, I-PAST_MEDICAL_HISTORY
dificultad I-PAST_MEDICAL_HISTORY
respiratoria, I-PAST_MEDICAL_HISTORY
tos I-PAST_MEDICAL_HISTORY
con I-PAST_MEDICAL_HISTORY
expectoración I-PAST_MEDICAL_HISTORY
mucopurulenta I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
marcado I-PAST_MEDICAL_HISTORY
compromiso I-PAST_MEDICAL_HISTORY
del I-PAST_MEDICAL_HISTORY
estado I-PAST_MEDICAL_HISTORY
general. I-PAST_MEDICAL_HISTORY
<EOS> I-PAST_MEDICAL_HISTORY
Consultó B-PRESENT_ILLNESS
al I-PRESENT_ILLNESS
servicio I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
urgencias, I-PRESENT_ILLNESS
donde I-PRESENT_ILLNESS
se I-PRESENT_ILLNESS
evidenció I-PRESENT_ILLNESS
febril I-PRESENT_ILLNESS
(38, I-PRESENT_ILLNESS
3 I-PRESENT_ILLNESS
°C), I-PRESENT_ILLNESS
hipotenso I-PRESENT_ILLNESS
(PAM I-PRESENT_ILLNESS
49 I-PRESENT_ILLNESS
mmHg), I-PRESENT_ILLNESS
desaturando I-PRESENT_ILLNESS
89% I-PRESENT_ILLNESS
ambiental I-PRESENT_ILLNESS
y I-PRESENT_ILLNESS
polipneico I-PRESENT_ILLNESS
(FR I-PRESENT_ILLNESS
29x’). I-PRESENT_ILLNESS
Al B-EXPLORATION
examen I-EXPLORATION
físico I-EXPLORATION
se I-EXPLORATION
constató I-EXPLORATION
mal I-EXPLORATION
perfundido I-EXPLORATION
y I-EXPLORATION
con I-EXPLORATION
uso I-EXPLORATION
de I-EXPLORATION
musculatura I-EXPLORATION
accesoria. I-EXPLORATION
Exámenes I-EXPLORATION
de I-EXPLORATION
laboratorio: I-EXPLORATION
Hemoglobina I-EXPLORATION
14, I-EXPLORATION
4 I-EXPLORATION
g/dL, I-EXPLORATION
leucocitos I-EXPLORATION
5.200/mm³, I-EXPLORATION
proteína I-EXPLORATION
C I-EXPLORATION
reactiva I-EXPLORATION
177 I-EXPLORATION
mg/L, I-EXPLORATION
gases I-EXPLORATION
arteriales: I-EXPLORATION
pH I-EXPLORATION
7, I-EXPLORATION
49; I-EXPLORATION
pO2 I-EXPLORATION
53 I-EXPLORATION
mmHg; I-EXPLORATION
HCO3 I-EXPLORATION
19 I-EXPLORATION
mEq/L; I-EXPLORATION
SatO2 I-EXPLORATION
91%; I-EXPLORATION
PaFi I-EXPLORATION
254, I-EXPLORATION
lactato I-EXPLORATION
arterial I-EXPLORATION
23 I-EXPLORATION
mmol, I-EXPLORATION
troponina I-EXPLORATION
0, I-EXPLORATION
07 I-EXPLORATION
ng/mL, I-EXPLORATION
BNP I-EXPLORATION
254 I-EXPLORATION
ug/l, I-EXPLORATION
creatinina I-EXPLORATION
1, I-EXPLORATION
87 I-EXPLORATION
mg/dL, I-EXPLORATION
nitrógeno I-EXPLORATION
ureico I-EXPLORATION
33 I-EXPLORATION
mg/dL. I-EXPLORATION
Radiografía I-EXPLORATION
de I-EXPLORATION
tórax: I-EXPLORATION
cardiomegalia, I-EXPLORATION
hallazgos I-EXPLORATION
secundarios I-EXPLORATION
a I-EXPLORATION
UIP, I-EXPLORATION
sin I-EXPLORATION
signos I-EXPLORATION
de I-EXPLORATION
condensación, I-EXPLORATION
congestión I-EXPLORATION
ni I-EXPLORATION
derrame I-EXPLORATION
pleural I-EXPLORATION
evidentes. I-EXPLORATION
Electrocardiograma: I-EXPLORATION
ritmo I-EXPLORATION
sinusal, I-EXPLORATION
sin I-EXPLORATION
alteraciones. I-EXPLORATION
<EOS> I-EXPLORATION
Se I-EXPLORATION
volemizó I-EXPLORATION
vigorosamente, I-EXPLORATION
persistiendo I-EXPLORATION
hipotenso, I-EXPLORATION
por I-EXPLORATION
lo I-EXPLORATION
que I-EXPLORATION
ingresó I-EXPLORATION
a I-EXPLORATION
UTI I-EXPLORATION
para I-EXPLORATION
manejo. I-EXPLORATION
Se B-TREATMENT
tomaron I-TREATMENT
hemocultivos I-TREATMENT
y I-TREATMENT
se I-TREATMENT
inició I-TREATMENT
empíricamente I-TREATMENT
tratamiento I-TREATMENT
antimicrobiano I-TREATMENT
con I-TREATMENT
moxifloxacino I-TREATMENT
(completa I-TREATMENT
10 I-TREATMENT
días) I-TREATMENT
y I-TREATMENT
oseltamivir I-TREATMENT
(completa I-TREATMENT
5 I-TREATMENT
días). I-TREATMENT
Además, I-TREATMENT
se I-TREATMENT
inició I-TREATMENT
uso I-TREATMENT
de I-TREATMENT
vasoactivos I-TREATMENT
y I-TREATMENT
corticoides I-TREATMENT
en I-TREATMENT
dosis I-TREATMENT
de I-TREATMENT
estrés. I-TREATMENT
<EOS> I-TREATMENT
Evolucionó I-TREATMENT
con I-TREATMENT
requerimientos I-TREATMENT
de I-TREATMENT
noradrenalina I-TREATMENT
hasta I-TREATMENT
0, I-TREATMENT
1 I-TREATMENT
mcg/kg/min, I-TREATMENT
que I-TREATMENT
se I-TREATMENT
lograron I-TREATMENT
suspender I-TREATMENT
a I-TREATMENT
las I-TREATMENT
12 I-TREATMENT
h. I-TREATMENT
Se B-EXPLORATION
obtuvo I-EXPLORATION
muestra I-EXPLORATION
para I-EXPLORATION
panel I-EXPLORATION
viral I-EXPLORATION
y I-EXPLORATION
PCR I-EXPLORATION
viral I-EXPLORATION
(-), I-EXPLORATION
hemocultivos I-EXPLORATION
(-), I-EXPLORATION
urocultivo I-EXPLORATION
(-) I-EXPLORATION
y I-EXPLORATION
ausencia I-EXPLORATION
de I-EXPLORATION
leucocitosis I-EXPLORATION
en I-EXPLORATION
mediciones I-EXPLORATION
seriadas. I-EXPLORATION
TAC I-EXPLORATION
tórax I-EXPLORATION
no I-EXPLORATION
presentaba I-EXPLORATION
focos I-EXPLORATION
de I-EXPLORATION
condensación I-EXPLORATION
ni I-EXPLORATION
derrame I-EXPLORATION
pleural I-EXPLORATION
asociado. I-EXPLORATION
<EOS> I-EXPLORATION
Evolucionó B-EVOLUTION
con I-EVOLUTION
rápida I-EVOLUTION
remisión I-EVOLUTION
de I-EVOLUTION
todos I-EVOLUTION
los I-EVOLUTION
síntomas I-EVOLUTION
y I-EVOLUTION
en I-EVOLUTION
menos I-EVOLUTION
de I-EVOLUTION
48 I-EVOLUTION
h I-EVOLUTION
se I-EVOLUTION
trasladó I-EVOLUTION
a I-EVOLUTION
unidad I-EVOLUTION
de I-EVOLUTION
menor I-EVOLUTION
complejidad. I-EVOLUTION
<EOS> I-EVOLUTION
Mujer B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
62 I-PRESENT_ILLNESS
años, I-PRESENT_ILLNESS
con B-PAST_MEDICAL_HISTORY
los I-PAST_MEDICAL_HISTORY
antecedentes I-PAST_MEDICAL_HISTORY
de I-PAST_MEDICAL_HISTORY
HTA, I-PAST_MEDICAL_HISTORY
diabetes I-PAST_MEDICAL_HISTORY
mellitus I-PAST_MEDICAL_HISTORY
tipo I-PAST_MEDICAL_HISTORY
2 I-PAST_MEDICAL_HISTORY
y I-PAST_MEDICAL_HISTORY
EPOC I-PAST_MEDICAL_HISTORY
secundario I-PAST_MEDICAL_HISTORY
a I-PAST_MEDICAL_HISTORY
tabaquismo, I-PAST_MEDICAL_HISTORY
consultó B-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
su I-PRESENT_ILLNESS
hospital I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
origen I-PRESENT_ILLNESS
por I-PRESENT_ILLNESS
dos I-PRESENT_ILLNESS
días I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
evolución I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
dolor I-PRESENT_ILLNESS
abdominal I-PRESENT_ILLNESS
intenso I-PRESENT_ILLNESS
asociado I-PRESENT_ILLNESS
a I-PRESENT_ILLNESS
vómitos. I-PRESENT_ILLNESS
Se B-EXPLORATION
realizó I-EXPLORATION
un I-EXPLORATION
estudio I-EXPLORATION
ecográfico I-EXPLORATION
y I-EXPLORATION
tomografía I-EXPLORATION
computada I-EXPLORATION
(TC) I-EXPLORATION
que I-EXPLORATION
visualizó I-EXPLORATION
un I-EXPLORATION
aneurisma I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
aorta I-EXPLORATION
abdominal I-EXPLORATION
(diámetro I-EXPLORATION
de I-EXPLORATION
5, I-EXPLORATION
6 I-EXPLORATION
cm) I-EXPLORATION
y I-EXPLORATION
una I-EXPLORATION
UPAA I-EXPLORATION
no I-EXPLORATION
complicada, I-EXPLORATION
por I-EXPLORATION
lo I-EXPLORATION
que I-EXPLORATION
se I-EXPLORATION
derivó I-EXPLORATION
a I-EXPLORATION
nuestro I-EXPLORATION
hospital. I-EXPLORATION
<EOS> I-EXPLORATION
Ingresó I-EXPLORATION
a I-EXPLORATION
nuestro I-EXPLORATION
centro I-EXPLORATION
y I-EXPLORATION
se I-EXPLORATION
descartó I-EXPLORATION
que I-EXPLORATION
el I-EXPLORATION
dolor I-EXPLORATION
fuera I-EXPLORATION
secundario I-EXPLORATION
a I-EXPLORATION
una I-EXPLORATION
complicación I-EXPLORATION
del I-EXPLORATION
aneurisma I-EXPLORATION
abdominal, I-EXPLORATION
se I-EXPLORATION
realizó I-EXPLORATION
ecografía I-EXPLORATION
abdominal I-EXPLORATION
que I-EXPLORATION
sugirió I-EXPLORATION
proceso I-EXPLORATION
infeccioso I-EXPLORATION
en I-EXPLORATION
fosa I-EXPLORATION
iliaca I-EXPLORATION
derecha. I-EXPLORATION
Con I-EXPLORATION
los I-EXPLORATION
antecedentes I-EXPLORATION
reunidos, I-EXPLORATION
se I-EXPLORATION
catalogó I-EXPLORATION
como I-EXPLORATION
abdomen I-EXPLORATION
agudo I-EXPLORATION
apendicular I-EXPLORATION
y I-EXPLORATION
se I-EXPLORATION
realizó I-EXPLORATION
una I-EXPLORATION
laparotomía I-EXPLORATION
exploradora I-EXPLORATION
encontrándose I-EXPLORATION
tiflitis I-EXPLORATION
y I-EXPLORATION
necrosis I-EXPLORATION
intestinal, I-EXPLORATION
por B-TREATMENT
lo I-TREATMENT
que I-TREATMENT
se I-TREATMENT
decidió I-TREATMENT
efectuar I-TREATMENT
una I-TREATMENT
resección I-TREATMENT
e I-TREATMENT
íleo-ascendo-anastomosis. I-TREATMENT
<EOS> I-TREATMENT
Posteriormente, B-EXPLORATION
debido I-EXPLORATION
al I-EXPLORATION
tiempo I-EXPLORATION
transcurrido, I-EXPLORATION
se I-EXPLORATION
realizó I-EXPLORATION
nuevo I-EXPLORATION
Angio-TC I-EXPLORATION
que I-EXPLORATION
mostró I-EXPLORATION
UPAA, I-EXPLORATION
con I-EXPLORATION
paso I-EXPLORATION
de I-EXPLORATION
contraste I-EXPLORATION
que I-EXPLORATION
se I-EXPLORATION
extendía I-EXPLORATION
más I-EXPLORATION
allá I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
pared I-EXPLORATION
aórtica, I-EXPLORATION
sin I-EXPLORATION
clínica I-EXPLORATION
de I-EXPLORATION
SAA. I-EXPLORATION
Se I-EXPLORATION
efectuó I-EXPLORATION
estudio I-EXPLORATION
preoperatorio I-EXPLORATION
con I-EXPLORATION
coronariografía I-EXPLORATION
que I-EXPLORATION
no I-EXPLORATION
mostró I-EXPLORATION
lesiones I-EXPLORATION
significativas I-EXPLORATION
y I-EXPLORATION
ecocardiografía I-EXPLORATION
que I-EXPLORATION
demostró I-EXPLORATION
hipertrofia I-EXPLORATION
ventricular I-EXPLORATION
izquierda, I-EXPLORATION
disfunción I-EXPLORATION
diastólica I-EXPLORATION
tipo I-EXPLORATION
II I-EXPLORATION
y I-EXPLORATION
dilatación I-EXPLORATION
de I-EXPLORATION
aurícula I-EXPLORATION
izquierda. I-EXPLORATION
<EOS> I-EXPLORATION
Debido B-TREATMENT
al I-TREATMENT
alto I-TREATMENT
riesgo I-TREATMENT
que I-TREATMENT
representaba I-TREATMENT
la I-TREATMENT
UPAA, I-TREATMENT
se I-TREATMENT
decidió I-TREATMENT
cirugía, I-TREATMENT
que I-TREATMENT
se I-TREATMENT
realizó I-TREATMENT
5 I-TREATMENT
semanas I-TREATMENT
posterior I-TREATMENT
a I-TREATMENT
la I-TREATMENT
cirugía I-TREATMENT
abdominal. I-TREATMENT
Se I-TREATMENT
abordó I-TREATMENT
por I-TREATMENT
esternotomía I-TREATMENT
y I-TREATMENT
se I-TREATMENT
realizó I-TREATMENT
bajo I-TREATMENT
CEC I-TREATMENT
reemplazo I-TREATMENT
con I-TREATMENT
prótesis I-TREATMENT
de I-TREATMENT
dacron I-TREATMENT
Gelware™#26. I-TREATMENT
Se I-TREATMENT
observó I-TREATMENT
en I-TREATMENT
el I-TREATMENT
intraoperatorio I-TREATMENT
una I-TREATMENT
lesión I-TREATMENT
pulsátil I-TREATMENT
de I-TREATMENT
alrededor I-TREATMENT
de I-TREATMENT
dos I-TREATMENT
centímetros I-TREATMENT
de I-TREATMENT
diámetro I-TREATMENT
en I-TREATMENT
la I-TREATMENT
cara I-TREATMENT
anterior I-TREATMENT
de I-TREATMENT
la I-TREATMENT
AA I-TREATMENT
y, I-TREATMENT
al I-TREATMENT
diseccionar I-TREATMENT
la I-TREATMENT
AA, I-TREATMENT
se I-TREATMENT
encontraron I-TREATMENT
tres I-TREATMENT
úlceras, I-TREATMENT
una I-TREATMENT
de I-TREATMENT
ellas I-TREATMENT
a I-TREATMENT
un I-TREATMENT
centímetro I-TREATMENT
del I-TREATMENT
ostium I-TREATMENT
coronario I-TREATMENT
derecho I-TREATMENT
y I-TREATMENT
no I-TREATMENT
se I-TREATMENT
observó I-TREATMENT
disección I-TREATMENT
aórtica.. I-TREATMENT
<EOS> I-TREATMENT
La B-EVOLUTION
paciente I-EVOLUTION
evolucionó I-EVOLUTION
favorablemente I-EVOLUTION
y I-EVOLUTION
se I-EVOLUTION
dio I-EVOLUTION
de I-EVOLUTION
alta I-EVOLUTION
a I-EVOLUTION
los I-EVOLUTION
siete I-EVOLUTION
días I-EVOLUTION
postoperada I-EVOLUTION
difiriéndose I-EVOLUTION
la I-EVOLUTION
resolución I-EVOLUTION
del I-EVOLUTION
aneurisma I-EVOLUTION
de I-EVOLUTION
la I-EVOLUTION
aorta I-EVOLUTION
abdominal. I-EVOLUTION
<EOS> I-EVOLUTION
El B-EXPLORATION
estudio I-EXPLORATION
anatomopatológico I-EXPLORATION
confirmó I-EXPLORATION
UPAA. I-EXPLORATION
Actualmente, B-EVOLUTION
a I-EVOLUTION
un I-EVOLUTION
año I-EVOLUTION
y I-EVOLUTION
diez I-EVOLUTION
meses I-EVOLUTION
de I-EVOLUTION
seguimiento, I-EVOLUTION
la I-EVOLUTION
paciente I-EVOLUTION
continúa I-EVOLUTION
sus I-EVOLUTION
controles I-EVOLUTION
en I-EVOLUTION
Cardiología I-EVOLUTION
sin I-EVOLUTION
presentar I-EVOLUTION
sintomatología I-EVOLUTION
cardiovascular. I-EVOLUTION
<EOS> I-EVOLUTION
Paciente B-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
69 I-PRESENT_ILLNESS
a. I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
edad I-PRESENT_ILLNESS
con B-EXPLORATION
un I-EXPLORATION
PSA I-EXPLORATION
en I-EXPLORATION
el I-EXPLORATION
momento I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
consulta I-EXPLORATION
de I-EXPLORATION
22 I-EXPLORATION
ng/ml. I-EXPLORATION
El B-PAST_MEDICAL_HISTORY
paciente I-PAST_MEDICAL_HISTORY
tenía I-PAST_MEDICAL_HISTORY
una I-PAST_MEDICAL_HISTORY
biopsia I-PAST_MEDICAL_HISTORY
previa I-PAST_MEDICAL_HISTORY
por I-PAST_MEDICAL_HISTORY
sextantes I-PAST_MEDICAL_HISTORY
negativa. I-PAST_MEDICAL_HISTORY
Se B-EXPLORATION
practicó I-EXPLORATION
una I-EXPLORATION
E-RME I-EXPLORATION
que I-EXPLORATION
mostró I-EXPLORATION
inicialmente I-EXPLORATION
un I-EXPLORATION
nódulo I-EXPLORATION
situado I-EXPLORATION
en I-EXPLORATION
la I-EXPLORATION
base I-EXPLORATION
prostática I-EXPLORATION
del I-EXPLORATION
lóbulo I-EXPLORATION
izquierdo, I-EXPLORATION
morfológicamente I-EXPLORATION
sugestivo I-EXPLORATION
de I-EXPLORATION
hiperplasia I-EXPLORATION
nodular, I-EXPLORATION
pero I-EXPLORATION
el I-EXPLORATION
estudio I-EXPLORATION
espectroscópico I-EXPLORATION
mostró I-EXPLORATION
una I-EXPLORATION
alteración I-EXPLORATION
metabólica I-EXPLORATION
de I-EXPLORATION
este I-EXPLORATION
nódulo, I-EXPLORATION
con I-EXPLORATION
una I-EXPLORATION
importante I-EXPLORATION
elevación I-EXPLORATION
de I-EXPLORATION
la I-EXPLORATION
colina I-EXPLORATION
y I-EXPLORATION
una I-EXPLORATION
disminución I-EXPLORATION
del I-EXPLORATION
citrato, I-EXPLORATION
sugerente I-EXPLORATION
de I-EXPLORATION
neoplasia. I-EXPLORATION
<EOS> I-EXPLORATION
Un B-PRESENT_ILLNESS
paciente I-PRESENT_ILLNESS
varón I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
19 I-PRESENT_ILLNESS
años I-PRESENT_ILLNESS
acudió I-PRESENT_ILLNESS
al I-PRESENT_ILLNESS
Servicio I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
Urgencias I-PRESENT_ILLNESS
tras I-PRESENT_ILLNESS
un I-PRESENT_ILLNESS
accidente I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
tráfico I-PRESENT_ILLNESS
en I-PRESENT_ILLNESS
vehículo I-PRESENT_ILLNESS
de I-PRESENT_ILLNESS
motor. I-PRESENT_ILLNESS
No B-PAST_MEDICAL_HISTORY
presentaba I-PAST_MEDICAL_HISTORY
ningún I-PAST_MEDICAL_HISTORY